var title_f41_7_42096="Doppler interrogation VSD";
var content_f41_7_42096=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Doppler interrogation for ventricular septal defects",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Planes of Doppler interrogation for different ventricular septal defects as seen in parasternal short axis.",
"    <div class=\"footnotes\">",
"     PV: Pulmonary valve; AoV: Aortic valve; TV: Tricuspid valve; MV: Mitral valve.",
"    </div>",
"    <div class=\"reference\">",
"     Drawing by Emily McIntosh.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_7_42096=[""].join("\n");
var outline_f41_7_42096=null;
var title_f41_7_42097="Laparoscopic pyloromyotomy";
var content_f41_7_42097=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laparoscopic pyloromyotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intraoperative photographs of a laparascopic pyloromyotomy for an infant with hypertrophic pyloric stenosis. The pyloric muscle is opened using an arthroscopy blade and then spread open with a grasping forcep.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary L Brandt, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_7_42097=[""].join("\n");
var outline_f41_7_42097=null;
var title_f41_7_42098="CDC weight for age girls 2 to 20 years";
var content_f41_7_42098=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Weight-for-age percentiles, girls, 2 to 20 years, CDC growth charts: United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 689px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_7_42098=[""].join("\n");
var outline_f41_7_42098=null;
var title_f41_7_42099="Mepivacaine: Patient drug information";
var content_f41_7_42099=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mepivacaine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/55/40821?source=see_link\">",
"     see \"Mepivacaine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/5/20564?source=see_link\">",
"     see \"Mepivacaine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carbocaine&reg;;",
"     </li>",
"     <li>",
"      Polocaine&reg;;",
"     </li>",
"     <li>",
"      Polocaine&reg; MPF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F192932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Carbocaine&reg;;",
"     </li>",
"     <li>",
"      Polocaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691415",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to numb an area of the skin before care.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702468",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to mepivacaine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat while your mouth feels numb. You may bite your tongue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11559 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-B4DFEB0FC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_7_42099=[""].join("\n");
var outline_f41_7_42099=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192931\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192932\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025676\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025675\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025680\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025681\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025683\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025678\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025679\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025684\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025685\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/55/40821?source=related_link\">",
"      Mepivacaine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/5/20564?source=related_link\">",
"      Mepivacaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_7_42100="Vincristine (conventional): Patient drug information";
var content_f41_7_42100=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vincristine (conventional): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     see \"Vincristine (conventional): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/12/33993?source=see_link\">",
"     see \"Vincristine (conventional): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vincasar PFS&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10518612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vincristine Sulfate Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700620",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is given as a shot into a vein only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause tissue damage if the drug leaks from the vein. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to vincristine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697314",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have nerve disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness and tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698298",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698176",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       May not be able to get pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain in the upper, right side.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698558",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Some side effects may happen up to 2 weeks after the shot. Report them to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11143 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-6C4A3AC97D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_7_42100=[""].join("\n");
var outline_f41_7_42100=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234194\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10518612\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028597\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028599\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028598\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028603\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028604\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028606\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028601\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028608\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=related_link\">",
"      Vincristine (conventional): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/12/33993?source=related_link\">",
"      Vincristine (conventional): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_7_42101="Female perirectal perivesical sp1";
var content_f41_7_42101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Female perivesical and perirectal spaces",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A transverse diagram showing the relationships between the bladder and rectum.",
"    <div class=\"footnotes\">",
"     BL: bladder; VVS: vesico-vaginal space; VA: vagina; RVS: rectovaginal space; RE: rectum; RRS: retrorectal space.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_7_42101=[""].join("\n");
var outline_f41_7_42101=null;
var title_f41_7_42102="Ectopic pregnancy 1";
var content_f41_7_42102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Six week ectopic pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Aron Schuftan, MD. Copyright &copy; Aron Schuftan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_7_42102=[""].join("\n");
var outline_f41_7_42102=null;
var title_f41_7_42103="2D TTE Subcostal abdominal aorta";
var content_f41_7_42103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77731%7ECARD%2F77191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77731%7ECARD%2F77191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) from the subcostal view showing the abdominal aorta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The abdominal aorta (Ab Ao) can be seen in subcostal long (panel A) and short axis (panel B) views. The neural canal (NC) is seen through the intervertegral disc in this thin patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echocardiographic image of the abdominal aorta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 275px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAETAagDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooqxY2k9/fW9naRmW5uJFiiRerMxwAPqSKAK9FfSnxa8IaC/wANL3T/AA8dHl1bwZJClzJZf8fE0ZQRzmYbQdwmDHqcKO1fNdABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRXv3xp+E/hrwroGvXPh1r2S70e7toplN9HcbYpkBDzRhFaL5jtXk569+PAaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuo8P+FhrFms6XMyHBLKtuHxgnvvGelcvXoXgeRY9Lj3zJGN24hu4DGkwKd34EktbeKaW7cJJ0/cDI/8fqg/hq3XrfynjPFt/wDZ/X8q7HW9W89YIo44UVACZEBJf0zk4rCNxFufcXIPPygZJ9KVwVylH4OaTyxHcys0mSuLfggd87qqnw5EHK/bxkcf6sdf++q7sanZXL6eI82oSMrI7uSBx/X8a5e4aMXFwrPuUgqpAzj3ouJGSdAgDorX5AY9TD0/8eps2gRxLk3hxjOfK7f99VoMWyXxwMA9+RSAGRsM+G6DNGo9DPTQonYAXu0YBy8YX8vmp0Xh5ZF3LdsV6nEWSvXrz7GrVwfJxja/zZ4549P1qVndxGpyJc8kfdAz/Pmi7AzxoMJyFvHLAZA8jGf/AB6ux8B/CS68XTsItQe1tkHzztaFlB/uj5hk1B4W0ibXdZtYESZot2CY8AhfXPSvrXwXoVrodhHHoxubeNeTHN83zHqc45o1A8SX9mCQohPishm6L/Zh5/8AItP/AOGXZt23/hKH4HI/szn/ANG19Gxtcrvaa9L4ORhQF57c1oOtwyKY4wylcNzjBNO4HzD/AMMuzB1U+KSNwJ5030/7a1y3jj4Cal4ZsDfQaoL+zT/WOttsZPfG88fjX1nLbyrI8kolB6qFPJrDvbFFWcXzXEkFyOYpHAQ+3qAaLgz4am0IRKCbnJPby/8A69Vn01E6zt0Bz5fH869T+J/hVtDv3mjMItpmJRUmVyntXnErrDJ8qoxHHzA4yeKVwVmij/Z8WM/aePZOf50R6fExGbkhT38vJz9M1YkKhSY8sAQCenPpimNuR2+TO31J59RQBA1lHn5JyfXKYx+tBsUBbE+QDwQvX6c1KJEDKzDADc7epHf9KkAKrMpLcNkHI6Z4+vfpRcZCumqzhBMc7c/c/wDr0raYFBBn+cD7uz/69WFuWjlYruVzgkgYAOepH+FRfaMvvYZBBx9R/nimFiJtPQOF8846ZKYx+tSppIYkGfBH+x19utPaUsGLHczcg+hzQ0jscu+SuOp6Hvj9KVwOl1j4ejTvAvhrxINU85dZNyPIFvjyfJl2fe3/ADbuvQY965aXSlR2UXAO0ZJK4x7deteveNbhx8C/hkoVcOdUZgBjpdAYH5mvOrfSp9Qsbi5tlUpCQXLOq5GOwJyafURseKvHfivxRaXFlr2uiSC7dJLkR2MMBnKY2mQxqpfbgYDZxgVk6b4NTUHVbfUSdx+X9x1XP+919qnTwxqc7rGlv5spjDgxkN8vqcH3rZWDVNH0sS3FhAioxBkeXDkZ6bc5o1C5y2t+FW0q7NvLdEuBkhogpH5Map6boL397HbRykM7Y3eWSAPX6VZ1C4ke4Zt3zSckg569P8Km037bbXVvdWhljc/6lu5x2H40tRjbzwqLU3ga9Ja3YADySN368Vlvpiq4UTktySCmMAfjXS6jrUplvob+382e4wGdicxkDsP8apQ6RfyiNUh3/aF+T5h2PrninqxGR/ZkWdgu90mQAqx55z65/lmon08KCTI3HH3O/vzWjLbXUE80TwkniJzt6enPQVZXQr1Z1t2j2uyhkUuCCO/PT8zQBjxafE4y10F6dEJ/r1p40tCAPtPzZ5XZ0/XrUzq1rIYxtHGODwR/hninQId0ZA3kkqExkk//AK6WoCWGgvf3UVtbTF5pnCIuzqT+Ne26T+zPNdWcL3/iuC0uXALQrZeZtPpnzBn8q6T4GeAY9O2a1qsMU0xUeVB/FFnncfevecQKo7MFycDgdaEw3PnBv2XVAOPGSlumP7NA5/7/AFK/7LDj7vi9WGMn/iW4/L97Xv5v7SK58vdHvJySx5PtitQXEVxFjzVVj2Xn3ppgfNEn7LrxqpbxaMN0xpv/ANtrjPHfwPv/AAtbi4i1I6hCBlmS1KbR6n5jX2HJLBCcu7PHgg9ttY/iHV7SHTnidfMMgKgMQcg9sen+NF+4M+CpNHEbFTOxYDoEzz6dabJpkasFFyxJAzmPGD3716T8TfDMumSm9tgJLOdyQI+AjenrXnNwpGG+bIJDcjBPXt+FIE7kTadEOlyx5I/1fT9aVdMjY/8AH0AM4zs/+vSvcs4GMKw6BRx9frSeb5h8xsggEnHGen9aZVhH02JApN0MEZ4TkD86a1hEpx9oOO/7vkD160juWG9iFHZV4yfWgMC+XkUljyWyQO/OOtLUVgWzt2U4u/mAJx5fb8+tRT20ccbssxdlI42+vvmp/kKAPsUbySUPI/PtzUFy/mguzLu6YCmmDKlFFFMQV6v4Nayh8GwzGO1W42OGeaHzCx8xumenFeUV6L4OuJ4NAUx3xgRlZSuzI5ZuvFJiZBdSRJtPzNnOPmwAPTH1pbe38q1uBIqM3BDo2dvr0q+mnPLBGCwJwS27tn+hxVXzLhbYraKAJmCFFzlsf5/SkFxl4kL/AGVREIlMYO0Zwx9afpwTYHiiRmM4X5ejD0B9PSnAz6rfQxCWXy0G1AoBC+oH/wBeq1w89jNc2UkhZYjkptxlvXPbvQBq+IbaF50MRVFI5CIEyc4wF706xhhnFnmGNQ0rKzkZHGCM/wCFYN9eS3OHuZS/I4ds5HbP0AqRtTmKpGkjrFGPlAwNpxjPTBP5mgOhL4hkjfVD5SrJHt3BUIXcO/Tp0qKys2a+gjSVYwQreYmCFUjI9jjv+VVbi5uLxgGxJuIBfbgnjGOPxrb0i0ms723igeNJWYbi4yoB/Dp2pD2PoTwX8OrNdDtJ9JvfKc4cuBuDH6dq7AXHirSU8q6aC4jydkoBB/KvJtNv9e0EC3tLkXaP8zJC2drY7V6p4T1eWeyU391m5BBfcmffFHqIyZfiYdOkW31DTZNyMcsy7QD7ZHNT33xBUeS+yVPMGVAbAB45yPoePeuxe8gklKzw2rp/EWXnGOuCKpX8+hNphmlsrWW1HzPsX0PWnoPU83ufifexW7LbgtceYAsKjJbpz7Uy78Sy63b/APE5a7t5SuVUn5SR6jvVvxDF4YvA8lpp7x3GMgAFCB/ex1/rXMw6Lpt1cWluuqyxu2diJGenpyOtKxLZwniuwmnupXhtFhtGG5mbof8Aa56c155qlmtvKVWTzhkcqPwwO/4V7J41t9H05vLtbq5klDCKdZsAMT07Vyt3ommi23XGoOkiISIxETjPYnFMEzzbjBKBmmGMBF+/9aiYBmfc7bv4gT3q/e2z2kxaPcVbG07CMiqq+WrplWLAEuTgEqfTPtmixVyvsDHIwVzk9+3rUkalozwxxgjaOg55NIpZQpZz5ecnn8jn86Z5rbW8xt2BwO+Ovp75pj3CaPc4Us7OF6nqeO1JGMKWG5ivXJxtHOaFmbbtZmZSflULgg+o461p6faRTaPdPINs6kEHHbPNAN2MsTlQc5OVxwOR6Zp5STAXdlxwOcAepNNlSVwxZt3tj+v4U0RExMvrzkNwOAaGM9a8akD4FfCxmIIVtU6nr/pIrzi1nVLK4Dty5G0n+LnnFet6lCtz8J/hKjNGozqp+b7pxcr2rzvxLbQx6nIbcho2VT/d7gnA/wA9aRN+huaBrMWkXMV1BexO5tQg2nOG/un3xUnibVLPVtN3LcaaZ1JYmQ/vjk9B7GrWl2llG8XmT2jutszCU27ME4HBAHJ96x7mETLFCI4ZVnc5ZY9oHPb0HtQLS5yd05lusxqmQuBuPTjBJx0rUgISy09pLpY2WQ4jZzujXPDewz/KtvX/AA41pbyzSxxE4BxA4foevFc1qUBgW3O1cNEBlwSF5P8An8aATuP1xovttykcpmaRj+9Vvl9eD+tb+gX0Oktan7TaSwtGQ2ZMkMf79Zfhe0huYblrtokiOR0z8x6AZ6Vh3KtHIQrBArHp6igfkzp9W1qb7TcxmY/ZJ5o7iWNRhWZcgE+vBOPTNa11rOnyZtYU0xY3Q7RKcqpJB5OPvV5zIXeVxGSoB6E5z+NSR713BcksuGI7+opWBpEuoIr3EgjbGOM9FUCtzwMjf2xBP9jkuioDRxKCQX9ffH5VJ4e8Hanq6RXUNtNJaswQSKMLn8f/AK9e2eF/AWr6fbxR2T2yMMeYMEuF9AcYpib6B4L12/W9aK6trm0u3chPMLKWYDJABFd22oXrRt9r+0PPj/V9z7D/AD3pV0Zk08/Z0ntrm3O7zpwOvfJFRaRr6S372V39p8/JXzfJJVvpx0+tLbURSvNH1a/uIbuOBwv3QrScL7471ntpnjW1Nx9mspmK/cYHJ/wrsNS1W8sp0gjjeNdv+tTlRx3q/barJPbxtBK08ij5sDAJ/Gj1A80n0z4jalpwN08oVvmFuGMb/jjkVbsvDGu2emvcHzJdRYYzPIWWMenNejXWvfZHkFxbyoEUHdjK/mP61kazq9rJbBYL1POKk4TLdfpRoDPG/GXhvULKzI1i8STeSwVX2kdzx6V4rqltDBcS7JCRn5QerD0r13xfa3s0cqyQ3UsTNwz4Lk9sD0rzmfTpJJsSSC3kQ7mEowR0xximho5eWJI35cYABx15xnH5VGSW++wJPHLZ/wAir9/aeVM4E3mKTkkDrjvmqcjZO7aFYdxySc55FMtMhyc+uenFKo3FQzEA5+6Mn8vrUzvGygDgdSSDwT1x7Diotxzu6k88mgLCGGSIuHRwVOGGOh7U2YssOxlUd845P41JJMW2AKvBPGeufU9aZc8qdqhSv3sHPf8AlzTF0KlFFFAgru/DVxaroUUVwJ2JDcBgF4Zj+XI/WuEr0bwzFpEegafNqBuJHeOTKwgDBEjgA5I7c8etJgdDYaz5kccD2Uj2jExgxoN7Hvzjnr+tV7hNOPnWxt78SI26PdgEHphhit1otNaWzexjvUjKqWTgBiRzswev1q3ay6SsmoR3M89tOU2os8e9j06kd6RCZw0Bk06+jleKdVdTyvU57g/1rLvL0teSSIpUkkHdhjz3Fej6q0H27T00y3kZiMq5HL8dge1ea3fyXTq8YYlssCcc5PSiw1qVLdWELuYxOMkgsCAARjpjsSKdb2ckvlq2dsjEA4JUsOeD/hTfLIfbzuzyuepxXqPw68PWdlZw6zqly8M+c26ogkRef4hQVfsct4ds9MEbR6tFfNIzfu2jk2BT6kEV1mmeDrm5uFLJ/o7OBgyANtz/AA+9fQ1l4e0LUtHa6so7a4eVN27yhnOM+nFcnHZaTYxyXF4242+cxTJiRM/TqPxo8ydRPDfgiKK5a4tYGSNVBjZ5gWJ/CrWtXN1olwJ7PSobpZBtdRKN2f1q1YXGlyWUTf2bJKjtiPy5O34Hj8aoeJUtbyc250eQ2yfMJVfay/hnmgRkXVt4n1CJrxI3G75fs+d+F9hWpBcW+mW6veSrc3rAZhMO3aO4xmtLS9XhtbdRZySNABgyeXtVB+PJ/Ct66tRdWMD2xskkcZ82VMlhyeMUWHY4XxHfXUbRXtpaw3UUq5Eax/OjHuangt4rfSY7iWNodS2ZJkXLLnsorvP7IEllHIblW8gbjuBVe3pT9JtLK9gEjRRvIGIV1BOOfeiwrHzr8UpreeTSEg3XdzNeKWWSMoSF55/Ss/Q9AvNcila3jnt/LUlpnB2Lj+H2NfTmt2MV7LbRQWcEl1ZnzVmkUfuuMHHqSK4S11KUa1ex3ZuUSMcxeSAjEdTjHNIZ5SfAlzqFgxFrNOzfIZJH+Qk/3R6V5/4v8G6p4YuPK1K0dYmUmNzyrdeh9ea+sdPvzdwtJYwzTID93YIwT+OKwfFtprXi3RZ7C502ztVztjMzbmLeq4zVBdnyRZ2H2h8sqRptPDHgketRXenyaZLG0hDEqCCj/wCea6bxfoupeHppdNu4TFLG25xwQ/oQe9Z+nXccNsftyJcrD8yRPkgk+45pPQpPQw5beVQjYLRkbi8i8Enr9TXbrp1vF4U0u4AxNcs8bOTwcdPp1rLGpnWp/s0qRR7iFiVFwE57e31rY8XzxafpNtokUwn+ysXDg8DI6euaLh5HI3elXSbytuZI1AHmIu5evrU+m+HtQ1JZ2toViSIgsZjtC59zxU8fiC/giiSG4k2KpVRxwO9VJ9d1G4j2z3UjR9AvahBqex61pWz4U/C61a9SGeM6mFkij80c3AJIIPb9a8y8QW80Goy+ZPJOT8wl8rYWB7kHpXpF/rU+kfCf4VXIcqwbVWOACci5AHb3rzbxBrI1O+nuZJNzzctuHT6YoFYXQr/UzfLFYTvHJyA23IA75qa+1LVEnlgad28x921fXseKi8H63Ho+rtdvCkyqhXbIMqc8cgVr6l4zupL3fatHDbFg5iRFABAx3FIbWotgl9BdNEmqeS4jzODb79hPRcE81VuY9WurKC2nuonhmlaIKyAFSOSfYe1al14tSTV4b7+1JUmVOXWEAkf3MY+vNYkmrWt1AJXvXiuvtJkJKcKOx9zTJtctWXhq+Tz0trnfG0Y24h/1nt7Y9fpXD3qSCV0cjdnknvz1/pXqaeOI1MyT3bSKUCpM0eDJjtxjGa83v2imnkc7g5JwoIPega7lFVwpGAcjmur8BeFbnxNqXlw/LFGAXZVLED0x61n+HNJn1jVbWwtQFeY7Qx6AEg5r6g8PeAm0CK1fR5LZHjAy75Bdu5JobGzpPDGmW8HhZLAwPEscQUDbtxj2qzoWoXlrbPbrEBcRn5GlG3cPY+tbGjx6pvdryKBo+hWN88f4VNc6dFLcAyWfqVYMPypCOe1XWZp4prBYzHcSRkFmPGcdKybJb2QmWIt935iYTyfb1FdFrWi6db3f2uZHBXgqp5YfSmRQ28wlFtPLaQoM9OXPqAc4ApiM2NZLm5WJZJvNEYEmThAPQCtF4oLfyxOpU9BtbisONWSaWzgm+1XU3Jc8MtaVq0umBGmLXOSd0YYHYfXk+1IdwurSC5ikeUzfZ2GGQZG0dvrWX9k+y24fRrNdq4B8xANvvXTS3i30ab7NoVKkiYnp9eazBp8tkz+bJtsH5J++WPb6CmLc878YXWpKJ4rWFWuRg7uGZRx92uB1Twjqc7R3d8bc/aSA3mygPz1yPSvdb3U7H7ULSwtpp53xkRIMY/3jSQ6HetcJI1itlGX4Z2WRz+ByBTEeEaP8MZNQ1WSzuHC227/WIMkj0B/rWF46+GOq+FZ3lMYuLJgVW4C8YPY+/Nfbdnbi3hEabTtAydoFcz8Rrd73w9dW7QedBJGQSCAVI71Vh6o+CzaFAZEOCpzsPPGaW0tJL65SAuisVzlztC+gya0/EdnJp19KpjKSoxHJ6D/OayNqwyqskflkHJB546jP/wBap1LTutDan8HajASpMQYrkqCCQvX/ACabqOlWEeg3E8Vxm6hCbkOBuJYDj8M1nvOzqp3OzsMEsf8APb1qveuxhcMOw5BznkYouIy6KKKYBXb6FYT32j2P2VNojRi5eQKC3mNkgn/ZwMe2a4ivVPBsdvf+FrOzMgjcB2c7gDxIxyM+2KTEzJvZr21RDLcySFQvlbW/h6ZH0xj8KqyXczN5kkjSs7fP82S3rn9al1BFW5EaStLGnAII9egH1NU0hYl9oO4feAPP1/z60hlk3t021xM46qCCcqBjp6Y/xqBQZWYlxuyAS2cHtzUixlwFiViqKd3zZzjqcZ/CvUfgx4Bl8aahi9U/2Ragb3AK85yFGPfOaEhGF4Y8FXF0n2/W4pU0p8rFLjO9h6eo9/avcvglb6Neadc6TfQRvLExbDLnevA49K7H4haJAnhsWVlbojxL+5Ea8jA4AHpivKPAFpqei+Llm8idVfl8rj6/lTfkL1PfI9Gt9NES6fEIkX5QAOvsf8asaho9rewS77S3W4kGCwAP602e6uUhimiUyRs2CAORx/nrS2d1cPKwlhkVB/y0YHb2zTGcjN4bvtOtFFtDHHGh+7G2dw9wOKcfOeIh9MJjK5ExYfL6jmus1i4hFopaZ1BPQH271R8ttS0t4LaQrIR8rY+63XmpCxgRFXYRyxm4VD8qtF0/PrWs9vLdxq1vayK/8MWNqg/XtUNhpmqxwBbm0hnmQ4EgkI7dSMV1sUTpEDHGqsQMgsSKdgRzVrFfwXM32yBRbYHlxh84q5JqdnbxJHcwtHIzfLtUk5zxjitOS3lDFhh3Y5Oe3oPpUM9q0chkeEzOVONhGQPYfj+tOwFAK0wLRh4Qf4weD+FU47C4e6la6ME2R8jAYOPp1/8A11q2s5dXaWK4EYHCMoGPoBSIZwQy2h244cct9MdqLDMya1tpE8nUduAOFjzj8/wrFvp7PSox9ksbuUE7N8hIC/Qmrespr6yFtOntYIs9ZVyRz2Nc1q73c01ul8vmSRYYuJCEx6gD+tS7iOa+L3hmfxXa2yaXpBe9ByJydpxjpz2r5l13Rr3SL2W11C3kgmiJDRsMHP8A+rmvvj7WlrpH2hIc4Xq3Q/4186fG6bTtet4tRjeOPUIn2BejSCnogV0eAwXL2N0k8e9Spyh79OD+oNLJcSXD7pJOWyxOP54qC4O3cHywDjI+nv8AnUTuQcBVRQMYA4+uaRSXYstIoA3MNoU4Zerf54pIxujO89OmG4z06VWcp5YXGWHG78fSpk2+QoQ7SvLBgB+IPegGj2rWraK6+C3wtjnW4fMmp4aNwoA+09D7+n41xj6Nak3qi3vht5CnlojzyeORXqWneGp/EXwW+G8duqSSQtqDbTNsBBuTke54/CoZvhxrUNwzvawgMPLizdnOe2T3p2IbszzDTdAtbuW0itRMsskTMXZgAWHTFQ3+j22l2032yGZpH+WNlIwuB3GOa7vWPDl/4ZgjuJ4oPOtFZZNlxuOT3xXKHxNHKZ/tlrJNIEwjAjAOMcil1DfY4aWP96QNwwM/WkQJtywfjuO1aa2FzqF0qWtrJM54Kxg5FPn0TUILQzy2koiBKsSmFXHrTRXqZttC0xYRsfMAJUn5Rxjufr0qSC1ma8jis1M02fkCDJY/QVZs7K6uJfItLaaR+u0DJzj0rtNO8MeIvDa2WtTWF1agNujLRjHt9DRr0B2W51Pwz0q00kCLXtJvoNSBDidlIOOeBxxXt1h4j0+WxeFR5qH5SpBbafyrmdG1efXNIj/tO08m8VQyE9W9x/hXX6DIJLWOWzjh352urRhcmp6klzTbW5aCNre9YovPln5SM9Oaz72+1i21QpbzLPE5y0Vwcbfoe9brtPKr27IkTuMKr8HPsf6Vx50XxLp2qiaW4t9RtySVjLbWH445oDY6G/8AMeDzhKtypHyqkmADWFqNxrUCRtbadE0qjICyDAH1Irndb1zUJPEMdpJYLaR5G7BOz/PNdbq11cPDBbSJtjZM/aIz939aAK2i3DamTeXaR2s6ja6owOfrUl23+kIkGlFXOSZm5DfX1rlrLTirvDa3kl2WlAZIUyzg8nnt/wDqru49NNlE7IRNMMMkUzsSD6elCGUYpbqU7DF5MQPzBjkt9AOgrQurqC1RJp/lj7lTg/iKy9Y0rUpLmK6js7ZdwAkQSuM/55qa60v/AIljW+qfZo4WHHlM5P4k807CvcwdSv401CK7tZfKieTIdbgAN7bRXVJJe6itvN9uhS3j5IY5B9e9eNeKbCDRmjgsJEuYnfGGDHafau0stF1S2sY3XVTDHKoKxxW4wpx70tQPVbK+tLlNsU8c0qjBx1BrhfH3iW60hDYm2kuZ7gFYlTk1z3h+bUfBttc3d7GLt5HzJIZP5D0rg/iF4wN5qaX9jek3Ef8AAoGFFO4zE8YeC9TurV9WljaJgNxjkbng/wD1q8ons8XLFisaZySQQMHsB1/D0r2Ow1jU/FGnTPNfptB2+WT1b0+lcB4q0W802VpTJGVkUgYAIwfY0J3BOxy25TAjFhjJOz0+v5VXv8LC6/MPmG3P8Q7n/wCtT7hgZWUoISCQQCScYHrmoJJCbaUEnLYznBzz+dMqxRooopiCvQ/Aejy6pp+I4rqUbWUrCM/xd/bgflXnlegeDpdQh0qE20phgOdzeYU43Nn6/SkxM6XS/D1tJqghuYoncAfLNJtQ9cgn0/8Ar1qQaFZ3NlqUk9npUKxyeWWjnyV442c/MPWuYtb27W/ijG2VgxCrJwGHXLHPTrTbm+mt7owRw2wVm/1cOSmfr3paisd54J8AWWp+K7LT70wQkxeayXEgBlQfxKOpBNfWmgaPY6BpMVjptvFBbxglUjXaM+tfJ/hHStZTWrOWNbW6uQN3zvnandAe30r6p0uCdtNjDpHvA+ZGywB9j3pq+wKwty+nTTxPfQIrDKo79Pz6CotR0mwuBHtiBl5Zdjc++P0qj4hsbu5xFaoEmA38YYEdOhrT0QSxwRJdwHzk/jC9f8Keo9B6ve20Kqtn5oA5YShT+RpkN/M75axlSPGC7tjB9K2FKsCB24NUr6NJI9rNuXGdobGRRYZy/i3xGulxeZ/Y/wBsHZy4wPrU/hjV4tTtVlWK0hk3cxo+7b+VU7/S9Le5Ma30kTMTlA27cPxq3baHY6cGbT1WJzySEwWpW8w9TWYRxXfmRBWb1GcfifWtVZFMeYirMBgdua5q3eQPGk5kyxwyuoHH19a1fskQ2vExwDkgNgHnnp360AXWlBwGGxyMEbuaru6YI81QCcBlPIrLubS3F8JkS4eXOMhiR+OTV2+tI5LY7wq8YK5yM+1ADbtLUkK1z5Ejg9HGTVKG5/stZI57pGiC7lkkPzH61QuIbeCYXDqyqnAcAtx9DWF4min1R7Vzp4kVG3CRpdmAPYdfpSC9jq4NWsNRtkcGInON8mBn8/Wsm4jisL2S7jUXCEcRgjj6VBNZRyadt1C3DJ/CApGPxHuKy77WdE0+D7LDfA3ABxGAXYn0/Wi4bkXxB8WDT9CmkmeGObbgQLIN3Pr9K+TtZum1fVneYrEXbkt+deg+MPsd3LeXepSXRlZj5cEY4H+8TXketsgmzHkDrjJOR7/hSEtRmrW0EBUW77x/Fjp+JrGZONoT5ieMfqMVa+1BYChL8ncD6jpUbuVKFcqyHgsB/PvTLRHKpI34yp45OSPbNMTO5c5OPU80pb58ylvmJJwOpz3/ABpisVA2jJOfmp20C6Psv4TXcUHwS8HQPKiSzLfbUKbmbFy+Sv0z+orp7e6jtZl/tKNW3sUQ4zv4+nWvCdS1q/0r4A/DebT5rmCV5NQzLE4AGLo8H1zXM6R4y8Q3LXUr6peyOgJIRuV9G59PapbdyGj2n4nalZz6BqVh9pti5cBY/Lw6dOSe9eJeHRpVva3Ud5eKrGQ/L5W4SgD17VZGr6l4k+y2N1fXMsk+/ezEbWIHHase+0OPSEY3SztM2FRVbG0+p9aab3F5M6HT7yz+0XUaRTTidWdEtn2PjGOvanWepWKaWttLa3RuGdlZZpgyrGTnJGOtcfplg8+vm0W3upgiFgIn2u/fA9K0NA8J6trWqM8FlePp6SBXfk49Vz60rBotz2HwVoOntfR6oyS3Nm5KJJ5JU5Bx09B61vfEeCyGkxXS2N9Nbjh2SX5RzjpVzwZ/Z5t4rI6fLbRI3kzCWU5RORvHtuwD6A12Nx4aVbQ25t0miVuIiSVZf8aa1Cx4HbTalqdrJHoV8y20ZH7mYYZPoeley+BLuWGwiW4v4Zbsjac/eJ/z3rBvYPD+lMiLINLm34MZ5B5966TTLOwt1TUrWQyOuWDYHHFLS+gJsr+MNRSEsNa06covzLNGSNvvntXOaPNp/iGQynUDOFOFjlk2lPcg9a7Gw8Z6brz3GmvCW/gPmgbW/wA4qtY+HUsprmRrCyhiJyptzksPfNPRhbuRS6fdLFm5l042SfMUeEkEY7kmsHxB4xsbR4bb7LauiEYaHJG32AFQ+OpZ2097PTnv0KqFZWiyuMdc1x3hzxC661FbzTpOiLs2PagfqBmpA6u38Sizu/tyWNw8MmRhIwm0fjXRW3iyLVosrNLZqhO9Jkw3t2HFUl+zxLJcTpboZTgcEYHvnpTNb0gXds05kLW6rz5UmMj+7TsO9hmqeP7Gym+y3MjTkchlbg+2BXTaS32q1W+vZJAhG5IUICfj615VJZaVf6cyXNqbBoW+QEZY+5b0rQ8NXMek7vN1G61SIDi3txuCD3J6UeYF3WdRSTxhHNFKtqyZWOLyjIcevFbGohdduYIZ9XnQxYMhXgqPaseZLG81T7ZaBYvMTaI2y7j16966q3+x6XpIaCFYwB80lwACffvTVhHn/i1tD0uZnj1q+MaLtkRictx2z+Nef3viDSTZTW9tp8ZklchZZQCSPXoK6LxZZXviJZJrK7NwiEhibcKMegPeuQn8IapFaq+oRSQ2vUsVG4fTvTEmjm1mntr5DAqHBzlW+XPufSm6vd3lz5cl62/cvCr0X29qNWQKzHe7YcAfJ1Hv2yMDiqck8jxNCW3RsMnjGD34qSzKuLYlWkIUL0JxjvWfOq/ZtyAAAgEE888itok7YkC+WQNu4AkMcdTn+lUdUBa2PmD5kbHCgY9v500NmNRRRVCCvT/By2V94btLO5uIoCgdmMjbf+WjHg15hXQaTIRZRKGJOSRjPy8nikwtc9ItNPhXWbKdLzTJYnUKEllBGenzivZvAvwn0uSye91KSwubuVlZRbNujiH90da8l8EfDXWNftI9VjMaxhsCInDn/aAxXs3hDwZqGgXUckOsSJEf9bbupAP096EmidLndatoUAgaLRzYQ6mF/dyPwi9stjrj0q94V1zVUum0vxJBaJcgFoLu2c+TOg6EAklT/s5quxdSJTKkjDvt5PXqKrR/YriXJikinTJV45Ny9u30qWru9xqy6HR6r4htdNuI0eeFgeWJccev9TWvaXcN0oaGVJARnKnrXIW9jYrg3MH2gHlg8YZT65z0pzata6TcwrDpN2sXRWgiDL6etPUd+52cgYrhTzWBcWFzNqBKXMQQMHKPFz9P51DqfjfR9LiEmoPNApGctH1qvpfjbStamEVg8hlzx5se0H9aG0BtSaZbgAzr5qovRgMADpwB2/Oqp0/T/tUc1t5UVwMrkk5x6c1n6xa3d75bLqs1mVbhQvDc9D/KqF3qV1p9zDGbWKcH70u4Z/DvzQ2w0Osk8xisRYSKw5wMED1/z6U4xl0aNBtVcj51yD3zmsRb632Jm4nh3sDtLEjPXFPmmtrlkTcgQdTudfrxTAmNnfvytzbIgOf3aEnHcE5xWTceIItN1ER3EczY5U4wo9/ati4uobK1AQ7YtvJXPJ9PYVyWqeI9KggY3uoaYST8sbD5l/TNAjsI5J9Sg3rDbtAehZs/yrI1CymtjFgWkBRtw8vI3Ej0rn7XXtLCCS11A3BHRIpmYY9lHFdGZ5ryw3RafIwZf+W3BHHX1pboEZ3iA3raU0VlbXNw7j7scgQD3JNYNhY32m6a7zWVlbSY5ZnDE/U1fXxfJb3DWV5Z3ZmztzEoZf0ORXEfFbVbqPTTHbzC2V85DD5z9B2ouJ2uePfFbxDeXV15EtzB5YcgRwDgnPf3ryt2d2LN6kYycH0rU1wtJcuZZCzE54br0rJkwY3IU7MYDD7pPHOfypIpEJIZhsQjnGM5owD/ABfNjihm4xySM856/SkIc4PIRTgn0qi9hr4OcL1Oc9/pSA8AHj364P8AnFPPI6kiocEnI+b0pomWjue2eJ7u3g+AnwxE8Du7nVAhD4AAueQR3zx9K8+0/WYreeaSa03qykRjdjaenXvXX+OyF+BHwoJYj5tVwR/18ivMn2FOrEAZyRUsVjprbX4LZbNo7ZvNiL7nD/ez2/DitW38ZRs+by0ed9u1GMmADjHPr1rgF37wU9MZPA/KrUUMk0oSMMxPHA6UWBpI7iLWdJuNUSf+yLgK42TKtx94dMg44r6A+GnjnQo4bfSLGyNrGACvmPk577vU+9ch8LdI0m98HPpN1Zxpetlm3IA5PYgntXOar4G1rw9cm+WE3Forfeib5lHYmk02tCU0tz6M1jVdMS4iW4tImB5X5wpPuD3q5HqsdrAkzSbrYjkE8qa+XfE+vzzC1lkeWRF/vEjH1r074W69bazphsi7K4wDG54b6c/pRd31GttD1LU9N0XXYCbuzhnyAQWAOfxry3xR4em8P3zvpV9fWtnIeBANyp9R+VeuaVCyx+VJEHUAAdmA/rWrHb27DD26Mp4YFQSRVb7itbVHkfgnw7pvlT3V3qA1Iycll+R0+vcU7xKtvaWEjeHZ73UApO+MXHMf0OK9Mbw1pnmzPZWcETEdY/lz+ArgdY8CXFvrP2nTkuLeSQ/NJE3B+ozSs7Bc53wrc/arLzdTvdRiO7iF2JX8eKktntL/AFC5WOQWN4vEcy5G4euTxWze+Hbi2tJ9xvZ2PPkhuGP4GvMri/1zSdT3RWjxxBv+PdiScenP0pWaWgXTep6VbaM8mnTxalMLyI9BOOcd/m/rV+Kzkt9OSLRreC3iU/OGKkMPrmn+G9TXW9MRbnT5YY3XBSVuvrTL/wALaTa3a3UIcEHIi+0EI3ttzii+gW1Ob1ttQTVYITcP9lkwrRAo2R6D0rWTwtZrH51pBOspyWVpggk+tdXZQWDxMYrfypAONqKxz7frVK+0ZrxS0FxcRccs0fP5ZpryEcTaeCgLqXUBeQWs0jYSJpMlD6ZrtdO8K6TfRva61Kbt4mA/1vyvwCSB7dKy/wDhBLaSNpN1zNcA7gzswwfXANYsE0Xh66la61G1tZegWSTDEfrRqncaPTrjSdCtbOOJgiwR4KKOFX8PWsDXbrTIYjLOYXtk6K2MH8P6VQ0/xHp11YPdSxXJVQSZnbMZ+nNcfLqOleINbPlu8kaH51GdqjPb3ocrhZdDjfib4otLy2mtLOzt40JwGjQA49a8deIiIHAUE9c8/wD66+qNX03S9Qs5LaDTYpI1HOyNcn6mvHPGGmQxu8dvoc1tIOQ0hAH5UME7Hl06SscySYU4HLZz7fT/AAqHUVB04sE2HcNwGcHnj8gT69a7C08MXt3G880Qt7YHHmvwmPb1NZXiuCGLTZRArEKVHmEDB5HA9qZVziaKKKYBXSeHiFWBiqFQckdcnJ6/pXN1u6POyW6qoUk5xntznNJgfQPgbxvfWDR3FkA8ceA9v6jHUV6d4m8U2+peGHvbIMku3kdCh/xr5Z0PVLvTpo7m0l+dWJ/yK9Z8I/Ea1ncW2p20KrKMSqVGxvcVGwmnbQ674Y3/ANsecX+orP5hwEZsFareKfCOsWmrzXmnyXMlpnchglBkXPOdvUj+lcX4iudBtL3fplzNa7/nVozjYfzrc8I/EWHSrpF1a6NzhNiy7fnVfr3609F6BqdP4T8b6tpLINVEt7aD5HbZtkT3I/8ArV6hpet6Xf7bqKXeAeFUEEc8fX8K8i1eO08Szm/8OanHI/8AHarhXb1+tdL4Su7rSIg8dhHcRRgBsN8w9iMULyBu256Trd1pUujTTXyQyQIpJ8wdx/KvJLObS7iYXGj3kckiMSLVjgD2HQ9q7rUdb0rVdOktVtinmqciU7EyevNeYap8LNVjnWSxsHiAbcGiuOMfUc1WstEJ6anZad4ouNUmOn3wgtSe2ckj2rM8SX58P30N3ZmC7kY7TGkhDH/gJNZ8Xw4uXRLv+05YNQQcFpTIM49+a3tA0W90+YSeKYrPUEBBS5RBvH6UrMLnPDxJr+sa3bSRaNqSWacMsalc++TXqljJE1orTpdIyD7kmOMfhWpZ6cGEUsN0xhxlUGAKi1HTre5cLMhRD94u2Nw/P+dOyWqGcH4y8f6fpFk5guopJQeY2+bI9OK4SfxHbeJLUXB0O0u53OD5QZWUepJOMV6jfeEtHIYW1jaMz8bzEr49zkVxeueFr6OM2Vu7tGwLbbe3EQX2yopa9GJ+Zr+DLOC401RlLcnrFbsvy47E81s69bhtOeCO7upWxxFBKFdvxNeX6f4hPhGM6fcWqWSKed2Glf8AT61m6741ild59FN0bgphnjkPX6Dilq9GCtudNoVxq+iyOr6Xdx2pJJkuJkLMe+TWT8W9et7vw8Y5REkxGQC3zfpXG6rqN7dWqXPiDWr+3jJyluFYs/4kgYrmbvQ73VT9peG/az5PmzKQuPrTSfQLo4G6xK58pdzF8cA5Oa6HXfhv4w0LTzqOq+H9QtrOL78rx5Vc92x0HQVBqtvZ6dqEC2sjkKwLlxt7jn9K+gfiN498LalN8R7TSLy0hvZ9Mh8vUhqJmh1ABV3QpEfkVgMr8uT1PrRdLRl2b1R8wJot+9i93HZ3TWsThJZxExjQnoGbGFJ9zVFfkcNgfKe/t619VeC38MWvw60vwTq2vW1td+IrC4ubiJgHRZZcNAzS5xGyCIDaepP0r5cvYmimaMld8bFG2HIyPT8qSkpbFWa3KxG5iwGB1z0/SgLheeCvHvmkB4+UjPanA4jPzEL2HQEVQHqvjtgvwK+FBwAoOrH/AMmRivMCWUJuJJZeRwMH0r07x+C/wK+FLLkYbVsc/wDTyK8xTAKqwBYLkHHTvSJJI4yzKqhixOBgEmvdvhJp3hvSLIXN/cwT38w/eRPz5Qx2pnwQ8G2dxD/ak0ttd3uPkspFBKA45+v4V0XiCy0fS/EEN8lrHBNvxJBIg8sn1waPQh9jtzZ6VqtuphLW7KMxzw43IffrkVqaVoci6fLHf3rX6t1YcFfeptIutKisVurW3jgd1zswAjD29az7Txjpl9fyWr28luV48+IgqP8AexSutwscjrfh21tw1rcss1hKxEc7AHYfRvSqeh6FqnhNDPbC3vrUnJEfHHtzXoltodolxO8kq3VpP1VhlTnv/KqN54TsZInTTL2dYsZ8pJD8v09PpTuK3UgsPHX263YafIn2lBgwygofoDXT+HdT1u6kSe+jgjiAwEQ9OK8b1zUJtBvlhsZFlKY8xbhQWHPvXU+FPiBHDaSy3s0c9uh2sBGVKn29anZlJ31PWrvVQrqZBIjnHzRkcf5xUUfiKye6W3eeLc44jlbBPPbOMVR8PXWm3kAvrZXRJRuHnJzQ2leGtb1QtvtZb1TkgPnH4dqfzHqdBdQx3duZ7fZ5gGAucDPv9KgnsoZF2oLbzFPOdpx+FMksU0+IsFcRAdVkyB9RVKBraeQzwxRy5GCYjzVXsK1x19o0tzKkcRjeUnkowGwDqT/hUd1oUqQylkWaXbtAlIIB55qeOyluwzWMc1k/Utv278Z6+o5PX1qlfaZrisjy3gWMELlG3Fie+OxzRruFibQdFmWPc62sUjDny0IP862bfTZVPzXssiD+EAcD0ziqmixXdtIVvLu1mh5AGRkZq+dVsI5TGsyFxyQvNK/cdht1o9vNA6sZ8MDkiXb+uK4W78F6NG000ejpNJg4klJc13H9uWT71DBtvBAIrh/GXi22nWSytbmW2k4AMZ5p3S2E13OGstIvI7G9OoWczRRsfKU/IoXtgVlfDvRo73U7maSLo+CQ/bPTjium0TSdVuX33+o389sCCFcgBv1rZWMeH98qWMcUDH7xkwzfRcUuguoX2tWmhWMiWVg0O04ChD8x+tcNceH9U8VF9Q1OaBF5ZIEHOPQ/lXUap40jM0FrF9jEspHySjLJ+HSussLez/s4CbywzL88hG3P0pJoGj5/1oNGhsHQRiM7S0hyRjsqj/69cT460DULfwxPqFxuS23JtV+C2WHIH419DeLfDNlDbF9Bt4vt2d/mSpvPryTXgfxTv76LSJ9Pv8ysSv7xnzjDA8CqEjyGiiimWFb2kjdaJhVzyPc81g1v6QP9DXj15/E/40mBcUmJpGD7U6ZJ5X1yalt7lkAeMhtw3ZNRBSq4yM5644NI27GQQT0zilcC/JqsrLtuCrxheA3JHXkflVJbx2ZlD7VYbs54PX8jzVYHEjAAEMuzHXB//XQkSiNSQASSM9T160tLD5bbnT6Jdy2rpdW0ku2PnjPJ9OK9s8JfFfS1sUi1CX7PKnGZFJBx9B0+teB+HtYvdIkL25VkJ+6wzkVPqWsrf3fmmzhjwcsE4osJ7nvs3xRsricRy31s9sx+/FGQw/AivQPC/iHSH053sr+e8gcHMZk2nPsDg18n+H73w+soGrWc23jHlyYwM11Oq+IvCxtFj0iC8trhcbZBJuz9aQbH05D450Gx/dPa3MESjmR0BGffnNU774o6D9o8uKaOaE9irBifTkY5r5s8J+OrGw8yLXbFtRtXJDHzSj10eny/Du91CWS11HXbOW7IZYJMTRwnnhemBz+lO/dhqe/af4iswu+wKwLJyQwZjn8K5L4l+K/EGnWpm0+eSSDuqw4x+YrAtfDF1pkJuPD3iC6ukYbgMAkfhmqnh64v9R1prbxVr9xp7I/7oS2e+NhzncdwC/UjHvS6aiu9keY6j8RPFRnZp9UuIwTwrD/61a2gfGrXrDZC4hu0/iZkIOK9G8faVpRnlsbHWPCjyeSrGS/mWBiW5+VsFcYx3715t4d+GZvbnXp9Y1rS7aw0y2Fy5sruOcybt2wAhgACQRkn0FCjF7Am1uepeHPiDp3iiMtq+ladDbjA3XUgyfoOprs7LWfDml6cZNLg06NMZJiXivkXWLJUhikjkijO0HHnbu3pU9h4iIto7aSaWVFGAqjCn/PWqTa0uGj1PcfEHjJNXv2kaHTp7eFv3ZuTtRD6gDnNeVeMfE2rX1xIbo7rZTw9sCFFWV1nT7eyV9RukEuMraRxqOf9o1zHiTxHLexMFmjihH3YYFAX8cdaW4kcnqs8chaRXkVgx5fkk1nQSICplkO3HYH8vrTLhmcNkHOc0R208y7lB2AZGTgfhTLtoWZAk20QEqCc496hmt2iX592CM7jyGFEZa0f5gGIb0yB/jUst3JclfNLEYwpxjntQHoVJFdzvc/MFHGO3QUoXZy5yrEjI9v6UwsQcoxPJPI4+tKm1j87HJPTFAz1jx5/yQf4V8AEvqh6dP8ASK4vw9aeRqNrd6pYyy2JPG5TtPvmvYrbwy3iP4S/CpJObe2k1KSUZwWH2np+leh2en6Nquif2X9mQRxKY1iI+Zf60O3UzbPNdO0a5bVLa80S5a3gcgRzL/D7HvXrUml3N/piQeKrJLwADbcQL834ivJk1ufwB4gNjcRCXTiSwjPYZHSvf/A3ivSNatFe1lRlI/1ZblT6YpXs9QS0OA03V7bR9WbSRFNJBnKq6ZXH0xkV140/wvf4Fu8VlfEY3Rna3TrjvXRa7pVjcKZ4I4/OQZRgAD7CvMZdX0IauRrektDdQtt80Lj8aHoHkzoLGwXTLto578Sq53KTwCKr63aaTNcgTqI534jmhkOCR9KzPEi2M0K6roV2LhYcZXdvBA6jHasPVDZahHb6nbzqkqfeUEkflRe4WGXXgC717Vgk080cC4/esOo9iK6my8FW3hazeS3uXZRy6ykEN+ma2dH1p5dKSWzEM+B/yzcGvNPiL48umX7DqWkzW6BuJFcgMPyouCS2NC8+KGsaROIYILSZM7AjoQSM/lXaaV4st9Qt47mbRn07UCuSTH8p9PmrwWy8Qtc3cMdrpUOowIfuGNi+M+o7+9ez6PfWd3ZQvdeH9XgUDhGZytJeVx3Ojl8VxX7CO+aaJQBlCpKt9CKvR3NvFYCWDMK9SoUkgfhXO6x4q0mOyEQ0mdY+AN0e0Lz1zitvRNX02awTyLu3KkfcDhmA9D3o02BFvStWshEDuuhKOSZQyAf56VU8ReLrLSN906z3MoACoZhsGM9s/wCcV5T8TfE7G5MWmS3RePqpb5ev8q8bvdZvZ5WMknDEgpnIFA1qfRS/G7QpnRo7CSSdlIyuOB6c1E/xAfUYWj0uzglcZ3CWULgHn618y2hhty/2jLeXIw+V8e4/nWvo2pxtNJBBM9vG6H94RuYe9Fn3Gz3X/hMo4vMjlEVmigB5B8yn2HqauaX4o0K+3wafp73suDullCrn88V4lq0FhHAuNfkuW4YJj5fX1rtfCHhi5OnyXUF/b7pB9+X7o9qF5Mlmvf8AjbW9Ev5IdNtNPjDnhE+dh6c9Kht9bvJ7/wAzUoEuNQl5y0mQg9SB0rjPEVhrhvTEtzDw334flB/LpVjQ/B/iC4ZZoDPnH+tGQPrmqtcVzszb2/h2+bVrxIbm7PChnA2/RetdOniOe80s3NzaKkWC6vNgAY7AA/5xXndp4S1KC5c6vG5jx/rpW6+wrdvvCqX2nbr3Vb7y1HyoU2oopWdwVjVtp28VaW8ccU6kcF1JVOnY968V+Keg2ek6bfD+0DcXKlAqAHHLLnn2yR+FeqJql9Bpsel+H0McCDa00owW9a8r+KFrBDotw1zeebfkriNRnncucn1xTTBbnkFFFFUUFbel7Raxksc8kdDjk9qxK7LRdHvJ9Ct7uCFpIzuGVGSMMaTC9iqrHy3JXZxkHr70rIGGG9PU10+keCtb1axebT7CWXYTlVXqPYVh3mnXGn3EkN5byxSZ+dWBBH+FHKHNqZbq4OEGAM8lu1NjWSMgkH72Dg8ipwG3hlDgLjgtwR9TSXAMTkhd21vvc4IHbH9aSKvqMEoxhh0ORlqB+8ZWCEOc87u/+f6VCxUOVcZORyPSr+lpHNfxwSzfZ7Z5VVpXGRECcFzjk4HOPalawGvd+DtZ03w9p3iC8sZI9K1FittceYMORnPyg7h0OM9cZGao67pWo6LqTWWqWk1ndwgeZBKMMuRuGfqCDX0L4l8ceB/Eeh6r4ctb24t7ex+yLpsly37hxCwT90oAKkoWznr19qT48XujajoXiO+vJfDU9095bDRLnTJUkupFCgSmdhyVCggdgQvoDQpRkK0kz5iLNvXByw5wa0bNrqHdPDFIqpx5nJGT2J9faqoZGuOM5XkYHLHPSvqlPDtlafCe/wDAsVzpMurxaW2p3Fqsv+lfbAVl6YxgJtXIOT6Yp3XUbv0PnSDxRqqQqouZ1Q8Y3EYrV8NfEXV/Dl809vKkjvwfNG7g8d/zrr/FvwrsNI0vXkttbkn13QbeC51C1a12whZQOI5M8kA+nOO1eM3I23DYAwD0PSk4oSdz0PW/ijqOtK3n29oxYH5xFgismx8bT6b4W8R6JFbQOmtNbmWYEhoxE+8BR056GuLJOcrjr3HT8aJCCx2YQE5A64oskBK8ssrMcnk9jXp/w3+G7+I4FkuNQhtYT2Jyx/AV5ZFI6gqCwA9e5+n9a1tG16+06YG0uXjYkbmVuf0obfQTR634++FUOiWCy6fdvdTkYKsAOPb1ryyTQtReURCzkBbHGz2r2b4aS674muY2a6ItwMPc3Lg46cKDXquv+EdMFkZ9S1+4VYkJaO3cDeeuODmq0erJ95PQ+VIfhx4hu4gYLZWU/wB2QcfrWTqOl3+gB7a5QK5GMg5HXp6V7dean4a0mSWOzvLhzJ90F8qucEkt3NeceL9R0mW3kSK4+0St0bsv+NLmBNnnMuC4PUY/KnRZO0AbvYDvmknPzAgZzwCD1/zmtPw60Mdws12FeJPm8sn9KDToWbPwxdzae95LF5VsozvYdfbFYs0KoW8piQO59K6fxJ4sutRTyI9kVuvyrGpwOK5RnaTGCR1Jx3ouJX6n0fplxJa/Av4dGNW8stqAJHY/aTj+tT+HfE8cuoxRXa/Z75Wws4OA3sRS+HpLiL4NfDR7eESw79QEsZ6EG5ODSeIvC+n6zam80aYRXKctE2VIPt60WIb1HfGPT7e50xb9YHa7QffU5X6/SvHdE1y70a73W7yDsVDHPtXs/gzWwuNG8VW7PG3yJcMpK/jXPfEH4c/2dctqFoW+xOxKSRc7D1GfSjfcL8pztp8TvENm+23u5HiJ4RxmmRatrXi3VAZNn2hefvBCw9OePzrO0vTZ4ZFWS2W7gJ5I+8a6ZNF0M2he3vprW46+VPxg/UVNkhuRbv5ItFtz5hntbvbhkY5DfQjg1ythLDfX7CK7+zOTwsjHBNQ6s8t/drbSamJBHhV3NuB/GobvT3trcB7VpMdXQHH/ANanYSOqXUD4fLvHqccvXMbZIP0Irm/EOvw6nPG6ExNkAkMWH61SuWsDEsctnPDIB97fw3PfIrf8F+DE8QXkLwzwhN3zxyHbx7UIbPYPhFpYisLe9t7iCcuAWULhs56V67/a1nC4Sdnt7nGNr9/aud8L/D7SdOghaMXVpIF6xzEgn61b8S+HDNZkWt3MJx9x2jDkYppPcC9qzR6hbmOD7HvZcYnQ8/iK8Y8YeG9b8P3Ut/a6VZ3NquWzE+cd+mc13emw+IkgeCW3tbgqwQEtgtnvjt/jV+10bVoXlfXCBbnjyYmLjHvRr1Jduh83X/iyG5kdr3S4oSOoQtn+dVfCWiWvjDxhpum2TyRm8uArAKCVQcufwUE16/8AELT/AAZErSNAI7rnAVfvY9RXisWq32halcah4emSzdoZIPNCAnY4w2M9DjuORS9BrfU9R8afCXTrvxNDc6XbzeH/AA9Jp89/crNGzSxeS+2QqpOSWBRgCe5Nef8AiTwjbaDeadLaX5v9N1a2FxazmMxy7N2GDp2YEduPTNUNM+JHirT7Wzt7fU3aKzd5IvOXzT84w6MW+8hH8J4rP1/xBrfinVo9Q1OfzJ0jWCFIUEccca/dREHCqM9u+ad21sVZHf8Ag7SvCMJdtQYXNwxGFmQhVr01tKFxAhtbaKOHGAFlxgY446V534F8NeJtRsleSdbK2GMbotzHP4ijVdNurHWvsWqa1M+cAfu2OR9M8UO5Ghp69J4bsbpV1AXl3cpyEVhtB/CtGD4i6fCsUKl4IgOI1TgDPfPJqaw8G6DJbLJcrdTSkclIyufw5p1j4H0i9uWWzJtUU4Zrgb26dhmh69QRsW/ja3voWOnWU0s2MiSaPCCsm90xrqKW51nWGjEhyIvT2AArqf8AhDdNtbHbbGWWbH+teTYv1rnNStNKstNmilufMn27S0Z3sPxpIZw0n7yd7Hw/BczzOcNMSTj8+lcz8TNKstO8KXMTy7tRTYxHJz86g5J+prttJ1W10xZbcXsiIxy0kowfwHc1x/xO1LTZ/C2oR2MDyySFCbuVeTh16d6aYI8RoooqigrvfBmoPZ6UDDcbCpJZGPB59K4Kuq8OpaS2KiVisik7sjjqcf0pMD0LQfE+qJeK1tdG3bPIGMEceteuxnwh4wsE/tlgNSRSMFtrMee46187WqWtrIjTKZVJ4Kdfr+FW768gEkctrcSfKM4Y4I+n41O2sRNX3O8u/hLNqt7MPDnnlVPAuMAH2U9/xrmtb+FfinSoXkuNIudi5LsPnU9+g6VqeF/iJqllHHbLdE7gMNksV/Xivob4WeLJ9WsVS9v5DcIMMsinjr0J61UZLqhWa6nxteab5D7XjuEmRzlZFAXb2/HOeKpGDa/ykIScEkfdHrX6Bavo+laoxllg0+6kB+ZpIFYn2zXC6l8O/Ceqb0/shLaTkb4YwmP0qrR6MOaZ8YsssfzlwuehP06Ukky7mUAEY6gda+m7n4HaVNI8DTXKQ5JV1ZRz/u/gOfYVzes/Aq2i3Lpmuf6Q3SK5gIBzno2cUuVdw577o8BDfNkZ+g71atLyaMmRJ5FkHy5WQq3PGCRzjnGK7TxD8LPE2k7ybFpoguA9vlwfqBXF3GkX1u4WazuUCHo8TD+YocWxqa7nUaz8S/FWr6Eui6hq802nLsVojFGrSBPuB3VQzhfQk+9cXJJmQjkk89DzS7SroHygY/eI/mKY021juB4546VKSWxV2xxlEfAALHIHGajP3tpwrdRnoBTFlO7qDk8gCiUqdhx855O4nP5/rTHsORyrOC5OeNwGf505QivuQjJzkg/jTFnxG2T8noefzz1pA6qB8oI5yD29Of1pBozobXxJqFrZrBHdyxop+VUIFatt4kvkXbJObkk8RyMSPxri0YjaAzIpOCev04qxZTgHL9cc4+X/AD0pcq3BnT6yb97UPdeSoxlYxjOPfFcvLJ5jfORnpj2xSy3DSSMxyoBABzUExhCfKnzn8Bj/AD2poSQksqn5VXI45xyPpQGAjP3QwHyj19agJ6ZLccY6H/61OGMjacnjIx39B607DTWxMzqQQOSuTlh149v85qFCV5x90545x6UMxKDGOOPeiLODjqOTnGMenvRbQV9bHvuo6tLpHwL+GrwkhXl1IH1x9pNU7bxNeX9oJLaOKR4hu3Idr+vPtVu/hlm+BPwzkFmbyFH1HzVxnaDcHFZMPhaKW1+3+Hboi5Xk27HawPoD3pWIY8eI9Qupg1ukRl6PCy9R7VoWfjNEvtRsJJLi3a4jDyW0wBjyBtypPIJ49q59dRiu7nydUikhv1+UTA7WU+9M12S8jjVb6EXsaD5J15dQffr6UrBcx7i6vrDUSsdz5Y3ZXbz+Fab3V1rNs4YRyzgbcYw5PrxXHanMqyKVdyPR+2O38q19D8QJprxzW5aOVe5Ibd/nFG2pVrkF9pF/ZvvkglUA9T1FTWWuajb8pdFVTqWUNn8MV6Ha+LbPXoPnTZdAYLgcEZ54rmNTsdPkkeSOdYpeeCMZo0YtU7M6Hwv8QrmVPs17Y6Xdp0P2i3ALD6iuj0zWfD6amkk2lT6USQWWJt0R9xk5FeK3MZjuF8s4552j9cfjXtHwpXSvsRj1PU4p2kGPIuYiFX8TxRt1Fbsj2rRZrK6tEktL8+WQMCOYgj8DVm80C3vcSJqWoLMPmXDgjPvxiuA1nQ9NW28zStMtbgj5j9nuADnI9K2PBPjjSdLWOz1IXVjcEYxOpZAfrS21Y73dju9M0+ZQq3t0rMvWUIAxHp0x+PWtG8u9OgtiklzGgbJA3Fs9vrio11PTJ4Y52khdeoYEYrIvPEmhRystobaS5BywBAYU7rox2Zyviz4fWni6M/Z8RyZ3JIh69+9ee337POpNat9m1BQw/gfp9civb7Pxbo9zOsbXKwyg5EbDac/1HNXrvxTY2rfvhP5XaRI2ZffJxxTU1sJwZ4Fon7O8r7ft+qR7sfMqD+prpIfgZpeltHL9pi3K3/LSYgY7dK9esvEdhfxrJaSGVD6Hn8qTW7QXlqzJb27k/dMidarmvsJxseZXGmPYOqvq+n2tsB8yl25A61javeeDkkM0WoJcagq4BjPOfx4pPHugajc20pmG0Djy1bCdfp7V5fDo2mwuyXmpxRyN1it4Se397pU6p9hLXQ62HxLrltcSCyllugWwkT7DgfgKw77xJ4nDiW5P2aRiSAI14P8AWrejR+GNJ3TQSiSYD780o+XtnA5ri/Ed752oyNFcSyLuwMcAZ6UrIep2um+ILiZR/bFzNOx6LK4RB/3zXT2R0ye33PPAQOR5ZIUfUnk15DpVlLdsqw27CU/8tJZAB+dal5oqWVorTavFPJ1NujZyfT3pJW2B67neSDwkLz7RNcpd3H8KgkID6/X/ABrhPi5Bp7eGr+5tpHaQtHtVcbFG9c1Pp2v262621locBm6E+VvbP5VP8Q7SZfhdqs0mnG3AMJMki7W5lQcCqTYup890UUVRYVr2bsbe3CsMjKjjAA3E4PrzWRWnZqfswKKSRyT6YJpMDViuYlJSYFTnB2nPPqD6VJFMiTAowbBPbPH9KziC6q6gcg5VV7DqTj61LFE5QhSV42kjnJ5/Kh+QGxPLa+eGR2ilX7/HpivUPhb8RI9CeS31RjJGxwCAG6f0rx9YGTdJKpfdgg7c/wCev4Uj4+0FkjCZ5AiIVSMcfy5xUtAfY8HjfSr+Hz4YrhQBktGoJ6Z7GqkfjnR5pCLfVFaQZ+SQbHHXoe9fPXhrxNbWiKt+l3EMHEsD4wPy6iqeuT2s96Luw1HzSGyFdcMfr60tRdT3jUPiDo8UDfbbm4mkGRsf5WwOwIPP41zNn4q0LW9SPmy3FuqkBfOuXA/TNeS3V3DqNqBJ5KTg5EoNUNNmjt59t08/l9QYTk4osP1PqXSzHd/L4e8QyGbssg81PzIz7VT8UaX49eEJaaVp96G6yIgHH0NeO+Hdb1G0kA0nX54VJ/1c424/GvZvDmrajc2Eb3XiK6imHLNFIHQ/zoTt0/Qmx5P4j+Gfi/UbszXeiwQvnJCugHSuJ1n4beILBHe4skSFereYK+gr/wCLCaPeG2naHVgrbS6Aq30Oa2rTxrp2uCMHRraRnGSjsN4+i461Smn0DXofKi+A9ZkG9IIyCM4EgH6VgXulXNlIYLqIRvn77Z4x2FfT/iyTTd032XTpraUj7whcAH2wK8S8Q6Bq2pXe6NZ3RuQGUj8Oe1MObuzz0rjaGDAEZGRjI/zmjGDk8cce9dFfeGrnT4Q9xbqX7LvBxWHNaSxk5t2VT0yOn40y00RZPUYwQRg9KG4UMCD2Jz+dKEZnKHkg9AeffFPeKRCzx5CjBGOx9KQ7jppSdi4UMc5B6c9P8agJwzAbcY25H8+akdwVO1AoC4BA5Hrk/mKg28nHPHJFCFsI52nawO7r1p6uVdWjLK4IO4cYPtjpTdo6duecVIXdYtqkqjfNtHTOMZ/LvTEhhyPlwRkZx7U6PHOTwQc+3+TTTjA4ZWHOO2fp2pdoUkcHn+E9foaAW573ca7NoPwP+FtxEN8bPqQkTsy/aDxWfeJFr8J1Hw3MYbxBue3D7SfcVH4st3uv2ffhgi7PM83UiM8H/j4PT9K81s/temXKSRmTIOflJFS0J6mjqWq3guSuohhKgILBRlj3B9PrTD4mmgB8t22ns3PFW7/UbXWSG1JVjulH+uB6n/aFc5dWBErbWEo7MrAUaMa8y1c6jHPMkqxoGPJUDr6/1qixiky0ZwQBkdR+FWJdImjiEinK/hx61US33S8Db7HpQCsTWk8kMq4kZFzyQegrodNNzNKGcI46Zz/PNUra0+zOrywLNER0I56ckVrWc1m0m21sGdjyRuPWhibOzttOurmySS1sYb+AH5kQgMpqWx8PPfzrFbzjTpicNBPkD+VZGnW2t2FzHdafHcwRsR80bHI+oFep6PDrer28cq/Y5blRuWSVMPn3pa3JG2fhPxHosCXGg3dlNL/EASQT+IqlqXjjVbVHs9b0m0+0qMDCLnPrmtvUL7xXp1qRf6Fa3QwR5tscN9eOc14N4nvpJ9Sle4E1vLu+5k5H50NdbWCOvU6PXPGWsAbHLeQxyNp28Z9vSqlr43vtLTda6dEzNyZWLNn/ADmuHe6kuJQstwzAevOK0Y9Sgt4wJGmlHfDAD+VKyLsdNN4qudbuPMeeG0kAP3Mg/nVy38Y6tZOsE+ofa4JQFIDkkjn8q4Sa6spNzpCwJ6ksDj9KoRsBKpBcqPQ4BPpSaTGrn1R8P/HGg2MUUM32i1kPJ8zGD+vFenv470BLMuL+IKFwSz9OP1r4z8P6beai6eX5Eyg9Z3wMfnXrnh3TLa2gj+323hkgcMzOGY/+Pc09upLfkX/it41g1C2KaVeIMjOVZufavFT9rvS4echPUDrXq/iq30mWxkFlZacp28SIAgHPYnrXi+o3F1aXBRblCAeiNVegl5m3aaTcROj22m3d4W6MFwprT1TSr20tEuJNNuUlGevKkEfdI/WsSw8a65aIwtry7CFcBUbAFben+Ltav0FtMwkLH70rf40r+QNM417y7MjBmkA6gKSB/nFTJd36xApG0cOPvHsPr616dc+GtM8n7Rf6vFJOy7ikMeQpridVS0inYC4mvcgjYRhQKNB3J9A8UjTIQ1vHiQn7wUEk/WoPGmtapq3g7UTeTym33IQjdD+8Ws22uobYboLOMydi3QfhTfFl28vhu5E86F32EID/ALY7UWVwPN6KKKsYVo2TFoQrdB0/M1nVpafB5sRCsAxBHzDgcigCcMem/IUDgcHBPNTIWEzLGXVeeBzj2xSRQzorrhtu3aWAzlfTj3qUbomZooiBwBv6/X9KQJjReTedtZg27BKknGD71HNcM+V2oNpyOufwoklEqAbACOrY61CMYzwD0x+HWiwGumoQlBFIrFeASOB0qrNdmOTERBUjOD3qoFI+cKcYxk81FJuPIfaMHoPzosFh005bO1/vDPHGKmgujayHY5Dc4Oe9UCcEHd+K84oQeZJnOVJOT6+9Fimjr7DXt8YWeJJFBx8w7/Wtwa3d20W/T8wIRyFfI/I1wtrIYjvRSeCST6Crj6oZkVWclM7tvAPQ96Vu5Ja/tbzL/wA+6dw6tk4UdRXYL8VL+xVEsrW281PuyNEN4H1rzaSZTL8y7iOy54HqavW9pFcqC8iQgtxzyPak0B2t58VvE2o/J5qlW4JES5+lQR2l9PAb+/v4wOpiMxVj9AKztL8JS3Uu23uFTdyCW3f5Nei6B8J7Zo1m1jUpnXqFiT6468U7Ccjk7bUNKmt2S402VsHOROeapaj9hdCIdGumGP8AnoxWvWVPw+8P7rddMmmuFOC7oXJ/HpXJ+KPF1qdw0+S5ij67WQAAe3Ge9JNEnj19C0ZbZbtDk4wew9SSaz+XUgFsD16E49/pXT6s82o3H98E8sxxj/PFY0mnTxqDN/q16cjP0zVGiZRCFlYjlxnKc5+tNZw7bsL0HyoNueKeYSWIzhc7c/8A1qjKkDrnHcUxizbUbajFkOCpZQCRSDAY5LBunuKRjlmLHcx7mlA/vE4HGQaCeo35due/pTkIA6bu4FLtA+vsKeELgkOuffqeaBpW3PaPF6NN8CfhZ5LKp8zUT1/6bmvLtRF3ExWVSCOpB6n6161rtrLd/A74XBI/MdZdSYt3/wCPg/z/AKVzNxYJ5JS5BjOM/OeBUk3POdweU4bP8zU8KuzYjba2M9cVY1OwEN5nA2r0cHgVWMTRKHG7APB/rRsPzLn9oTRgwSNhhzjHUH+VCXRi2NJEGQj8KpSSPI258u5OSW9OKsWVq00R8yUHuADwv+fSiwF4aqjYCo+c4+Y8Cu58JS20CiVmB3dSccVh+ErW3kmH2iSzYH+C5U+3pjNej3Gl6bCiJd2yWgYcTQAtGffHJFDJbL+m6zZ292kpaC5iUjcpbYwHpgcV7P4V13wtfwwmwSJb6QbVhJCn3JPYDuefpmvAz8KtWvVFzod3DexnkRrKFbH410em/DLU47NGvRe2l1z8yuCP0pWlugTR7pqumRrpssgMUs5Uk4+6OOgz2/n3r5i+Kf8AZBPl3VmUuEG1ZIWBB+oNWvGEvivwvZiP+252tiCoy33favKta1Sa6P8ApUgkfH3iepo1W47KWqMC4ZXf9wCUzgmlW2ndWPlMEXqcZxVi0s5JSNhBIxtww/z1rUzfwJhTKOMHjNO9irmDMjfwRuqYHB/nTRJ8uDkY5GK6FN0qkXaM/OSQcVRubNPMCiNsk7eTyT/SjcE7DtGv1hYrOskgHJVZCv412Ol61okgCyaDlxxvE7lgfXHQ1xBt3gkXIA4POOtdFoPiWXRRiC0t5CBwZFJwfzpCa7G9rMGj3Fk7QDUkmb+B48IPxzXHrBJAzHah7jevJrpLrWL7XE8y4vYUH91eP89a56/tZRIc3CyZHrimStDe8P2dmymbVLkwxkcCIA9PrWlquoaTJbiDSopFfHEkjAFsd8VxAeSGModrAHj5s/pToZJjJ8m0EEbuOhzj8aNQsd3pXjCLS7QwvYxXD4yS3f2/nWPqHir7czqtlDEsgz8i49/Skg0nV76AGK0k+zjJDCM4x3rM1K0nsmPmW8m5Rj5l79x9KLD0KsNvcTy7obY5buT1OetP8S6W1t4eupp5lEmU2xqOuWHep9NOoXdwxjicuvP3CAKpeL7qRtPmik+98uR6cg0Bc4aiiiqGFaulm5EDeQzKpOCAOp9+9ZVali6C2UlVJU9/qe3ekwNAXsiIyxFWiZV3AdN2MnGO1SrcJLudcp32joKqGOIw7pUMb7VKFMBeg7DJycH0xkZpsMKMxUSjAzgdCTnjvigBjgbm6Dn1606KcBnDRKcAe2P8aBmEsCqMrDaecj9KimczFyEVSCWG04BI4yP0oHuTs3kgryGIPylvu4P/ANaq6MzKzdgcHaMj/PpTFAKrtcZHA9jnv6+tLDtRW3AiQ4ZScAEd8+9IGMxtIf5eDwODzjPPtREQJS7MucEnIIxz2xQ8f7xwpVj7GldFidfM24KDIUfX9aZRb/tNghUiORT3Kcj0qkzGRx8gLKfuqOPXOKWZ90mchzz82e5Oc5qNz+8AG1k4GOo6emfx/E0JEkvlhgrxEBeh56H/AAqxDHI8yyecq9ycY/LFVtwVmikChRjITnLevHGaQzHG0bixOSWOcfSgDptAWGS5CT6nNAAesQJyfzr1HSPD11qyRx2Oo63JEpxvwVQ9f9rmvELGQRuwDOqE4yOdvTGK9u+HnjLVLK2WK1t43jK4CIp3fnUtEs7ew8D3djbDzdcjjDAH5rZXbn3IrOk+HemajN5ureIZH9VEaR569Ks+JfEPijU7cxR2d3DE3B2wlj/47XO6P4X8W3UivZr9mVuWecAEfnzRqtiR2veFfBGhRtOi3V/LjPzzHZn3NeV+JbjT543Wwt/KP91XLYH417hqngvxBHaNJdzWF04AJMsm0L74715P41gk0yUrdeSxPeJMAew4/Wq1Gjzx4kQpuOzdl8Ae46ntxUEwCEhUyAThgTyD04qa7KltyqVB7g9B7/zqEytlXXKuhyG9PfNBfQjbJJLkk+pOc1KqgqMLnsxPXOf0pm9WceaTyOcYBPvmrVrb3EsR8tPk7k9KGCK7xFQeh7g561PBCA25nwV+6FHftT106W4lMUKSPKx4VRnJ/CvS/CPwi1/V7m3e8tGtLOQ8mTA4+mc9KBOSOh167ktfgT8NWglELNJqIGTkH/STxXGjX7ia2Nrex7kYEbyM5/GvYPjx4UsdG+F3g3SbJ1jSznuBEXfk7iWbB/3j/KvnW3leyuStyxI4GeoNJrqLcs3MHl/KW8yInvVa7VEhCRzDHJ+Yc/StO5uLOVQzfKMZBHr74rNe1t55MRzANzxjGKNgMwHapGF253E7efz649qs2UbyONhJUHBCnnHWku7d4ZTuAAzgEHOK0dHkENxG/wBnE6BuVC9aGM7nwxpfhe7MaajdakkpAyAoCqfz6V6bp3hTQPJL2OsTzQjny5ZMZ9utcTDqvh+8tRDd6fd6fIEBExUkE/lXIa672chNrfxzwn7pViP0pEn1F4a1fQNOPlSQi3YcbkORn/OK7v8AtDSb63+S4LoRw6v0/Kvg+DXL2FgRcHaQBjqDyOK6Cy16QKskNw8cvX5ZMY/Ci7HsfQfj7RPCtwsqXl6fPkGQrTHj6Zr5i8W6VBp+pSxwMkkIYgYPX61H4i1q4uZWZ55n7Decn6VzktxJKcuxzinqwStqWxJtm/dsBk88nj14r0T4fa9FNrOmaVdWFs0dzcR27SFQWAdwpIz35rzGJ1jAblpCT24q/aXUsF3HNE5hmjcPHIDyrA5B+oxn8Kl6FPXc+jvEHw38P6lqFsugC7sZk8QHRLl7hhIHAjMhkUdB0wB3rnvEtpoWm29s+k6DfzwCaW3kk1S2CYeM4yrrwc8nbjI4rl9C1i5dhNe+I7iJpLj7W5cO5ab/AJ6cfxY4z1rs9e8XJq1sv9oeItQ1CaMFUMUYQDPXjAHpVcz6mb7WPHPEs8cl/I6RiIA8gfdH41jFi7dsDI65Pp+VaviQj+0JnMvmRE7l3HkcDrjrWIsQVsO+1Vb7o/lmky47F2OELENs4U4HG7rSPFIi/OcZGM5zmprWOKQElSxx17c9qZJsE3KbfUE/zp2EMjRnZQMnnGa19Pt7hZg1uIVIbIJwRjH86xlkbYEXO3OcdPxp/myADLtx60WuM9CvPEepRWwjn8QRqMBQkQ6fl+VZ1hqVrNKv2iW4v3H8DcLmuYtdPur9/wB2vtuf5R+taX2C008DzL1ZZRyURSQD6ZpJCOq1zVpUsWjtxbQxsP8AVwgZI9zXmviC586zn+Vf4eQc9xWtJNKdsf7yRQPXOB9PypPENoieGbqWXMcg2bEbq3zjPT8etNAtDz+iiiqGFaVowWyZNhJk/iBzgdACPqOv86zav2jH7O0QCqGOWfHOB7/Wkxo2NNu0WFYyqbgpXawxjnn+tPeONsloFBHJKnGKyo027sIQG5x39zVmGachY0csWxnPGDjrQLYR0Ij3LuRSSFU1UULHNljmNR0wD19j/OpLmTz2KlTtUjb23Adc/U80DJkO4Kd3BJ7D1/8A1e9Fw2IxhLfftXOcZL529+n/ANemkKWc714PAAzkev04qXZGMKFTAbrzk/jVdlG08ZPTjpj1NBSYroquyxsNvYkY7eh79qezbjxgGTgEkDjPpTFO1g2M85x9KcpLhlXj5DnI7Zye360ARHHlkDOW6E/rx3+tNIK4VWIHUc/596kB2MOPmHfNIFRgeeRggY6mmIVUBKiPL59Op/Clj2iZfMUEDqB06U/ZKp+Vdv49KbsWM/OmTjgA8d6Q1Y6rQ59It5AZbeWYjk/Nwa9S8K+L9DsChh0Ri7fKHZxkcda8FWVkOV69R9c96IrmSNxyWx1B6UrMlxPqXWPi/JaWqpaWcEQ7EyAn/PSuEm+LOpy3u9o1mxzgy7FH5V5AdSXBHkKTyO/NVZrh5mDv90HoDj8KOUFE91v/AIuXLWvlpZ2xcnJP38HH8q8/17W112YtqN1LnqI1UYHsBXIJJkYUMc8Y5yP/AK9LtZChlXA46UWCxFeiAOfIL4IPJ71XihkmOFUkjPOK2WazaAkQ7D03Zz+lVBNKse1HIXuKeoCQWMNxc4klCEnlUX+Vel6J4QtvsaSX98LOJh8odclvwrhdK1uS2kUxx/NnIcAE10U3iy6iiEiREOcfO3Jaldidzqbq+t/D4A8OwW0jgfNcGEEn6Ht+FXIfiNr8zJDLqsdtGRt8xQMj3z9K80uvEF1fnErtknlVA5pLLT7y7mUiFljHzZP9aVgS7ntXxkmTU/hP4CeK5N35lxdsLmQ8thyD+Gf5CvB7/TrqFstgoQSD1Ar2P4tQy2fwT+HUbGNHS4vBsjOQSZCQff39zXlOjalgiKchoz1VuRT2AzI7K5kOyMBwecLUp0y+XDrC5AGC23pXTajbaeyC409JY5QPukjbn29s1LpPiGSKLDqN6D7xHygfSi4XMfTfDt3qilIp187OAjjjH+P/ANeuk0jw3faLceZqdpMsfbrtx9axtU1xftJeMeTKp6qCB+Vdl4V+I9xGsUV1MjKD1dCe2P5GgNTutOTSL6xCWt1Ak23BhuPnU+3PNeefEbR5bNy32K1Vf78B4NbGvav4evZlkeEwT93hbcrfWuL1zUopI5be3u5sMMBznIH0P+eaEyUtTkJgwXDKwAJU89utRLNIoB3E84z/APXq/dspk3O7Ocg7gOpxUMjxozF0BwOBg4IpbGm5BOzykEIxzkA9zUQhfJAUnHXFW12lTu4Ynj1xwaehGMgnGBgf1ppgVjJcBFPzbSM9c47f0qaEFMbozvbJJJ6VMMdR1HGcVPaXKQyD91HKc/dbvz/+ukJklmd3DTyRqO3arBltYlw8jyHHG7OBXYeH/FulLEqXfh7SpcDGXVs/zqTxPrHhu8tQLbw9YxS4wDEzgj8M0XuTdo8zvH3yYwNrHPDew4qJMwSbGySuMqwI/T6HNWpnhaQkpjc2ABk/h/Kq8W0sWdHL9+OgoLuXFdkJ8s7D3Ucg1Obv5GBhTccctzVToMHOMUiAKMD8adxWHZy27j+lOiAzlnUEc8jr9BTNwA5UnPtTgM5AAyuc8/5/yaNwJnkmBA3sU4II7+9XraVQhxGWYHq4xj8KzYVyxwcKvXPpWhbx2pUkuW54znC0AXH1CdExbLEuQP4eQe/NYniG8kn0+5SQsSNoyTnPzCuhjht2jYRRSMxAyWPHasTXbSGLQ7qQn98NoAUcffFAkcTRRRVDCrMDBU+ZmU4yuB1Of5VWqxGf3YC4znnPegCVHZTwxAHbNWFmG1sbfnULgjJBzzVaNMbsqQduVySMe9PhIcIFYDB47nvSY/UVt20bhuXGenQdKIdoLAkbiMAlsD8/WlnkRpCQxz6AcDrTXG1RkkfKMcZPT1oHcRmY7uMqQCe1I7LuIBXsQVNKIhHhlJII4IHfv1/GlO1dwYMTgLwAOP8AGjQNRkZ3bvvdMkAf54pyZOF+XJ7N1x/T/wCvToEwFcHbIsg2knr/AJOKjK4z8xz0AI5xQAjAgIWV9rDgnnJHpSbTtzghQOp6UAgE4OFPBJHH409lxIdxYxk8OM/NjqRTJ31EDMByWweR6daQszHlvbPp9KTIPA6/zo56ZOB17UDuIzcjPAPoOtKoJY4BPtSkqQMen/fRqSLylUOC4AbHODj0x/WgW7HAbAWdMp1HOcU4zoSNsWT2+v0qPJZCS5yWAx79/wAKYcZHBU+9IomW8k+VQVUDpgY/lWjp1g16BLcXUcKcY3v/AJ71jLgHPPXt1/zxViBWdXA3LjnIbGM/5/nRYS1RvX1lplrBlJ3nlOeOg/8Ar1jGMuhcxPjPAOfzzVtkihIaWUfLztUAcjvTLvVvMj8qJBtXgN68UhJFeO7aJdnlrGQfQH86mmupLqKYt/yzXcNxznBxgf57VUjjNyQUG0gDHq3PX2qxHbyBxHOCQQRjHHSgehNpzlJd4MZAGeT1rduNalMIit5BEOMc4GK5y3zCTujY4HRumauwD7UVSZQiAhTt6/8A6qQmeo+O2luvgN8NCzlpGl1H5jznFxivJprWe3+faykDOQOPzr2T4hpBF8DPhssHCLLfhST2845z+NeSm7IiMcbkEg9RTuCKSXkmT8xGOo7e4PvVqw1lra5BVVIB6EZBqpNEyfeUHJ4YdKjIDBsDIIGaLBodVe3+n6nHlbdYZSRkjp/Lisua1MWTbsrjGcKePc4rORjEy8gsWztPP61MZQGyxxkjB7Y6E4oaYWsP8545TkYwBtAPJ57Uk05DZ+frg5OOfelbZMhAfLdee1NX92h3qjbT8p6g0ikrjJWIRhISecAZ+nX9KgL5+/uI9jVy4wQ2VILDgnt/9eoZETbsR17nLDB+lERMihLbjsUsxBz/AI1YSVjGAo2/LkH1qtkbgFPy+pGKmttoPv0HPSnIaJTOqL8zBmz0B7fX86T7Qpc/ISxIx68dKrrHuVmOQB/D7f5xViKMMNynDNjBHrS0EIZ3QZQbOM9OQP8A9dNe7kYbXblehx+lSR7ZARIFORt4HHvTngUKwUA5bt/SmmD7EUcQlG4v82BkHn8etShCG3tL8oGCR/F9aa6+XsaNlAPTNSQsrIrYXqcjGBmpuNjgSMg8n0A5oJO046euOtPXGTu9OtINpfGcDPfk4p2YrjiR5anDKxHIz+tRRsfMc784IweMjip1jzFuDYwMlT/T2p0MbSyb8qMdT79sYpiH2sAkYfOAuOS2Vzn09vetiw01C6yCaJAwyD6gZGcfhVG1NqpLKWduVJb/AD/nNatvBGsayCZRGD/AMmgliy6bcOP3crlTzu6L/n/Gs3xOph8PXqNJFuJXKr14da2RfsXWKGI7wc5Jz6fhWJ4uST+yLp3weEJI93HHvzmgNTz6iiiqKCp4h8mSRg5GKgp6vgdM0AXMlow7ycsT947j25x2p6MG2ZPzD+L/AD+FU/Ox0X9aPPOOnP8AKlYrQsMzZbGPmyDxQrZ6nGOOnAPNQeefT+XT8qe10WYFlBAG0cDj9KAuiVSUd2cMpxwQOCf84NCnaRvBLYLEZ9KhNycEYbrkEtkjjpR9pK7tgxnrk5/XFAJkykgYJII4yx6ewodmkbG0h/4gTjNQPcBjkJgenofy6U8XYDKTEOMcA4z70WC63JURnJAYZUElWYLgDn8+enWgtGQPlkJ+tQtchmBaPIA45phnzxj5fTPaiwXH/TIpD15xgU0T44C8duelAnGSSmfxpk2XckLF1wfm6kD09amjeNSwMfOSeuTj0P061VM/Bwp5689frT1usA7kLHsSeRnr2pMZqw3duQha2L7RgEtjH0qd5tNIw1qwkzgZf+mKxReDr5fzdD83b06Uhuwc/uxz1560WEWrswMR5KbTwAB1qOOB2G5SFA7luR/nNQm6ViN0ZP0bH9Kc14NxKRbR2G7OP0osNM0V066JBjI+XgHpg9PzqtPazW5yy5bOelEerun8Lk/7/wD9all1gzKFkiLL6F//AK1CTBM39CuNOhaF79HlxxtQV1cmo2koSOy0aGJW48yQjdXmSamEUqkJA9Q/P8q2rDxVaWy/vtLkuG/2rrC/kE/rSsxNFvUtOee9PlnzZCchU+6e9V5dOvtPY70jgP3h82SO1LeeN5plVYbGK3QDGI25/PFY0utNNIXkhLE/3nz/AEosxHsPjzJ+BHw38wlm3aiMj/r5FePybiec8cYJrp9Y+Ih1HwB4d8MjTPKGkfaM3H2jImEsokwU2DGMAdTnrXHG+BOfJH0Lf/Wp9SkWSzEBdx246H+lNPJBOOv86jj1MR/8sF/P/wCtST6kZcfugAOnP/1qBE4BPORnqcUFSGAOPTPWqf204/1Yx9aet/gjMQOPU0alKxcUnAAVeORx3qSOUpjdk8nI/rWe2obsfuh0x1pV1AK4YQAkerUrXHdGmJI3RdxcHkYJ61CyNLKgjJcthcscDP1qpJqYbH+jqAB/epj6huDYiA3HJ5oSsK6LJQ89Pl645pyg+W2cdsHHSqX27gZjyR05qT+0RtA8kZ553U3cWhft8AoGAPORk4zxVkmPafu8DGOmPasc6iCFHk8A/wB7n+VPXVdoA8gEd/m6/pU2Y3Y0lG1sgAxE5zjof6UZlYgMFA65Hf0rO/tYf88Bn2alOr/9MP8Ax/8A+tRZiuaLHen7wYGcEdakC+wwOeKyv7X7+R/4/wD/AFqX+2Ov7jr/ALf/ANamo9wZqUBCCW2gZGAe+Kz49cCDH2Ueud/P8qBrg24NtnIIJ8zB/lRYRsRR/u3JdFUjr171FtO4KcZzgkc96y01woSVgHIIILAj+VPj15VLN9kG5sZIk/8ArUagaXlN5mxhgk4GR19xWvYKN4E0jYHXaOo9a5f/AISAbi32Xk46yf8A1quWXitbZ9zWAk7Eedj+lGoHc272cUOIbR5WA4djx/nrXO+L5ppNJuRIF2Ltxt4x84/OqR8brhQNNAx1/fnn/wAdqPVvGFvqGh3dgNLMcs+3E32jcEwwb7u3npjrTsSkcfRRRTKCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The abdominal (Ab) aorta (Ao) is seen from the subcostal long axis (panel A) and short axis views (panel B). In this thin patient the neural canal (NC) is seen through the intervertegral disc in the short axis view.",
"    <div class=\"footnotes\">",
"     RA: right atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_7_42103=[""].join("\n");
var outline_f41_7_42103=null;
var title_f41_7_42104="HSTCL bone marrow biopsy";
var content_f41_7_42104=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F72180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F72180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Hepatosplenic T-cell lymphoma with bone marrow involvement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 346px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFaAhwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDOi+/wck8k1aDASJknnGKrtH5UnGenarMeSFPOfTrXrn2cldXK2ox7t3JC4zg96dbAraKQcn0qeeLehLtwKZbHBI468DFIcfhsFspjT5x1pbKLM7McnvjHSpVjLYcsdjHpUsW2NXctsU8DPr2FITbaEuB6k9enpWQARdyE8Hbn3xWxON8Q4OenFZ7qDcM3OCmPrQiobFCAg2dyAeWcIPxNfQ/hm0FloVjCBjbEB7Amvn7w/AbrUra1GSZJ1JHsK+k4VMUSoccKFA6dO1YYl6JHh5zL34xHBcbc4ycUrAHkn/CnKGIAwGyPXGKkGMHPTOMDjNcdzwyJIyeMcn3pAuTlsYzye341PHuwSvGD6UwqN2RycdRSuOx4z4+X7B4illlDAGXzMqMlgRWjby2GmW7ajpEc9xqRG1IHIHlkjkn1Fa/xIt4he2rXAUQsefUcc1wF3Z+ZA6LK8SyZCyAEcdjXoxfPBHs4eMZ043LukahD4rkv5dR0+0bWbPmOUrtdx3B7cVi+IdOn1K4CTkMF+9EmBz61kQ6bd6R519ptw2oJHzMBxx/Ouu0KeDULIXcMTPMPvIf4ff14rWN6fvLYutToycoR0v0MXwr4bOl61Bf3M6wQ9FR/m3fUD+VZ3i3WdZutZm0zSBO6Bss0S8t+A6CtW9tdVbWIbwTNcxQNmGLbtBrF8XaPLDrK3y6pDYtOQdjOd0Z9MjtXRFqc+abu7Hmzg6NPlp33JdfvLZ4LW11mDzbjaN6qduDjGfY1pXCQ3Gjwx2MLwxAhiM9ce9Mu9M0y+toLmeXz7hFAkkQkh8dOazNG16e71xbCOGNLboqgZ2gdyam3NH3eh2e0VKac9HLRdy9qkF/P4ZUaWstxE52zIrfOh9/asjw5NF5V1owuHSdhvX5sqCByo966NtZstJ1kIJhFdS8bdmVb0yKx49Q8O2urmf7HJHcs+DKnzKDnk4NOndxat5kYiThUjUUl2fQq+Eze2lxdPqDvHp6cAyH+LPUVs6pdWGn6c+oWdyHdmwAOeTVzxhoF7rNy01s8SaZKFkhmY7FYY7+tYd/4ctLTS7TTJrzzLksZfORwYcn+Hp+tLmjJqTdvIqEXKPLBOT1abf4El/rt0dDsrvTRH5LsVlbG0DnkYq7JPcT6JdvYyYkaMMkgbgjuKsw+DS2hxWTmFYQ3nSuj58oe/qapJr2iaeq6bb7ntkJVm+9moUov4Vexr7N25bpX7d+pY8AQ6tq2k3n2yUSJEC0aTrkntxmrE048P2jFomeUqWmLDnPpUOkskGrLfJcf6Ao3QAdOOxHrW1qM9pragwxxzGXI2g8A+maiUrzu1oU6M6UORO78zlLTWbDWFY6motIQdomLcbvYd6l8OeA5X1CTV7m8trrR7c+YrwvzI3YY6isnxV4feDU7W0tVECNGP3UnBUk812/hK1h07SPs0k22NiWd5GAU47fnW9VqMOam9zz6bqV6nJUXwg0ksl1LcTBck5DRJhlHuaozaDbXN79tV5VwCSGPzMat+JVmk0G+/sphuUh8xMDle4GK47wTqd7daultPcSTwsvVjyhz61nThJwc09jpqTgqqpNbnuuiWbRaVaQC5jjDj5g3BJHYGtVbYzXhjaZiqpxKvzZJ/wA9KwxqRV47e4tknkUAoH5AFbTC5ae2FhCkEirl44u3P16e9ebK97k1IyvdnIfELfoc9rqNthU+5JtOA/rkZrlLXX5YorppVMVi6lvKV88Y9eteleLdGNz4fvoJnEt0E8xflwfwPevF5p00v7OLqJ5o5ovLdVT7ueOvrXXQSqRXkXQqKMZRfyN/wJrNj4kupLNIpbd7ciRS0uVZfcetcb4s/te08TXLyLcjEh27RkAVs6fp9v4J0i81MvJLcXB8uJWGNq9fzq34ovta1nRtOvdGTDNEPOfIDNxwcmuqFozvFXi+5x1JVJRTk2pLsZ2oxXetaJZXMswSWLKiK4yoYdiPepPDcGp2lhJbahcQ2tjM2I1lfbv+gPalSby9Kgl129T7RCfm9Ce3TvUnj7w/d+JYbHW9MuIJbUQBZULBfKx39hRzX/dvY3qRdGPt7Nt2v93VEsOj2+gmW5Z4kQn5j6VQvdQBjuDosMEt+uCCwBKqfSp9ENlrGjvYPdSTtEqrJuHBI/umqWohPDYj/si2ykp2yTn5yf8ACpSfM+bc7U4zgktI9+3yJdXu57fw6897bJd3SYAd0+6x/pVbwVf3Ot6ffW2oKZo1XOSMY+mOlXbvXfIt7NDboxuF3EHr+Va+iva3ZkNuIkMbBHSLjbUttRvYl0bVm7q2zXVmAzpYaNMlnDMsy5Jf19BRpdxq66Hb/Z47mR2JLgr79axvGmr3kXiK4t42aCKNtqxj+ddV4O1CR9FmmneTarbQQcKT6e9W/dim1cSqLEcypO1tLGX4ksr5LiO4nikzIowG4/CtbwpZ3M1vIJdkLNwm/qfpV271ERRsis8ku3OxuR+veq+h3omvz52fOXHlk9BSdRuFrCpYO03O56RoseLJULIDtIG4Y5HfirtuShZrqIDHREH+s9j7VjRXsMDeYlwplVM7S4Dn1GKo6P4pk1i8uIVt3WaHJWRz8o+ori9nKSbMJp81n1IPifpy6poAjgSVZCw+YjK4zx9BXF+E9Ci0Z7m5Ev2m52BFOMYJ9M16/LcWuo6Nd2sjiOeZeWz8oI5rzKTbbXSO6BVJwoyAGxWtCrL2bpl4fDQlV55LVGnua40aWKyvzFeg4Nux2gfj0z9KxraxkvEaz1m286FiAi/xqe5Vuwrj/GdxK2pmJ5Hij271UHAyf51teCLq4m0e9iuppHtImVopN+CG9FPpiur2Lpw57mf1mNerKhy6GrNqVvaPFpOnQCKyQlWLnLSH3x0rS0lpEiNujYld8qT2Fcpq9vdpOZoYcxlhh1O4n2PpXWeDYnu4HEsam4QgDBwW9zUVElG5007crVrWJtXsHfZumSPZ8zPwFJrjvEerCwultVtLeYR/MSRwCa9D17w5Frtk1h9sETDk+W3IxXmPjLSYtN1GCGZ7kgIAz8fvAO9VheST1+44MZVqKPKtNtTtvChbxBpCSQxrFEhKyRkYVR3bd6Vn6pqFt4e02eXw7b/bGV9k1xjgH6dhVfxNqupaL4T0/TdAieOwuIS9w6plsejHsKxfC2lLNoV41vdus0ybXG7K/TH9aagvjltfYFVnUcqUN118ypdeKbqCyt782dqbt5DtmMYPArVn1uXxX4eE1/CpvLVtuYVwXB9RUWn6Dbw2f2DVLiCfa2+KAOAc+3ep/Cmt2JS8sLKwW1uFzhl/iA65HrVtp6xWxKhKErVGrNfj8hNC0KG5s0uNWiMcKtlFkyCxpdQ1vV4LyT7Ige3TgRqx4/D+ldJp1rcarAFndSQ3AlIAGPcd64rxnaz6Zqq+UJMEnOASD+NKL552ZupRhC8tPQuaD/aT6hNdakkq6Y0ZMi9VxitF7Y3oSbQry2azKj7x2kN3GD+FZ1rdQWfh+WLXbiSL7Up2xDPmZ9SO30qXw1oFodLWQ3AmEjFgw3LgdMYH0q21u9DGVKXNyxv3v19DSuI/9r5vX1qS3XKrkAHNMeRQwwARyevSpYSCgOPfmuK59XZ8pPGhYMMKM8g+lUo1bzSWXbg4x/WrauQ5OBn37VFcKxbIAx9aVwhF3sMlJMqkHgfl9afuwQrE5PTHWmgBkDDt6dBSuqOn7wDgAjNFy3AsOgeDjjb71mID55GeoPetSL7jL1BHSsTbImpoFJGWxn60IS2Zo/D9FHjOz3dN5GCeM19DHkDAwPpx+dfMunTGx1iKZCQYZ1Ynpxmvpy2bfHE6n76g/nXNit0zwc5jaqn3QqkFMnoexHQ04JjBIyAeABSqBkEMACal2qRjHT17+tch41iMDjB9O38/ekZT/dOM5GTzU3CgMcjjnjimqoYjHY8gc5/GkOx478W9eNpqhsECFWQbgwzz6j0rgdQ8RzafqkUcDPcpEgypHyYxz1q98W5Jn8aszRl1cgDB5A7Vzeq6bfw3JIguGhkIkAiG7PHOQK96hSgoR5ux2OtUjTapLax1ulwKLWLXLe6i2XFyUa1HUBvUUmv3V74ag83S7YuWcu/l9QvbOO1ZWlWd3YaNcXc1tNH5aF41cY79DUXhvWW1S8Pno1sqn77NgPnqOeprPkfM3uken7SMoxu7Sa0Oy8L6lZ67YpqNvGd8C77y2U42f7SjuPbtXm/inUINb1RY44XRQ5QHdnv1xXYeG5INBnvIoVSJ7oMqmQ4BB9K57Vng0W5gu3sA+58l4m3YPrVUrRqOy9DmrUJzh7zVupasjFoEyWVlb+bPKAkhk5yfb0rd1S00vw/c7oJ4YZZ1BmEi8oCOVBFZniHX5LSziu9MiijkmI23Ui8rx156Viy211qyWur61dw2+3KyeaCfN9CAP507OXvPRP8AElRVOXK1e1mv+HL2m+HoLu5n1y61SJ7RH/cxgFi+O2e1XpNBsrjVgJLF3tWO8TI2B+VaHhTQ4tK8NXFxJqFpPHcTeagDfIq49/5CobvX7WytmO7CqfljUYz+FT7SbdoO/QPYQcW5q19XfU6DWls9VsYLJw8MFsmyPbKAMfTFclqegxSWqpA4EkZ/duCStcjqXiK/v5Hbe0UIGRHGcAUzSL7UZ7uOOOeV+eQxyoHvWscNOEb3M44ugpcsb6nZaXf6lpmtQW08RmszEUeRBjeD1BPrXNeKfBt9pmvGKwRrizn/AHkMuPuqf730rtFadVjIkPYEEZFdHtS9sfsuoqSqr8k8bhXQ46AdxWCrOm7peppWw3tUuZ6p3PPr2wurHSrexs0adLj/AFsic4b0x2NF3bv4X0qIMsyxFwZjtz9AD60l1aanpS3FzpNw91bYKuyHleerDqDTPAWo3t5rIt70ve2PLzJNyox3P0rd3UbrVLcinP2k+eT97pc3NZ0a71p7PVLYYxGoLPIExxxnPINUvFdvcWfhU+WzSurjzXXkID2zVbV7XVI/GJIZ5rKQ/KQCY1WrXiX+0/sSz6VJvhhz9oC8Bl/2h3FZwbvFXVjSUF7Oc43Uji9I1a902TfZ3DbiMsOo+nvXbwi3uLqAW3lQzygSuhXaAe/51gWt7oF1d2rQaU8EwwZMOTExHcDtVnV1t4hNcxzlp2kG3bzg5657CqqXlJK1rm2FcYUnKWrh1PWrjUFsvsqbY7iQqMoeSP611ujxQ6pZ/aLmEoUOAUYqRXEyW013o2lahDFJveHEs8KEtvHqe1X7HW3t0tlMKST7QjK5Jd89eK8ycbrTcU6ftYXgXtfh1Bp449PsyF25MqScOM964vU9Ea9ELzNs8lz5i5BVMH9a9UhsLmC1MsVzvLgNtkX5VB5wK8W8WaxNa3ksbW8whEpJdRwxz+lXh3KTtEzpuMk4vZC+OpgxtLBYzcxADgLgE/SqXjCa9i0GGGzTyBGqRN5IOEHer+k6omrSJE9rjyFLmQkkgnsKoN4igfWJLOJwrIPmHZm9D711RUk0mr2Np8soXhu9LmIdPl1LT2QoSuAfNlH3j6j0rb8OW0tjpAttUJMUqFWRW5OenNZfg+W+uPEF3Fe3hks0RpZXYYSNR6Zq7L44tZobqPRrKOS4i4t1kQMf94fzxVzU/gSJVek3zyerVmn1MrUb7T/DmoS6daxzF2AMkiuAVz0FdHBYM0SwW8csguFErLjp6nmq3h9bW+judd8RafFPe2qeY0oOBI38IZRwTWB/wmWrLq63ouTHDM5BjXAG3uB+FEoyqN8u63ChUeHhyTsl0/QueJYreDXIpJQZHiQKUZsKg7Yq/wCDLe2SOSZCyqzlnfd1NXPFMmj29tZ6neWCXEl0gaONm4PoWrOOv6hYRQXsX9npaNgrFHENuPTPXNNKVSFkc/to06l5tDfEVrpcMZvr7TWunZv9YshH/wCqpfDGtWN5ZlGhh0zTbVsF3YuCW9PVqNS8XX9rdMILaz8mRc7HiBABFZPim4Gr+HrJhbxwSB2Z1tlCqx/vbaFDmSjL8zSpKpSbqUrNdV1+80bjwxNJqrXWka7aXEErZCtkHb7A8GtXTNIh0lClwG88vw7ds9ayPCcccWkIbW5MyB926RdpiI6kDuK1tfu2vIFbfvBxlsVE5Svy9DooU7JNN69+hS1eAajrtvFDeNAyPh22lQw9/QV3GpSHw7pMaQ26G4lIPJ3ZXHXI9a4tdLvbq9FwyCRWwVKEdf8AarpZoLox2sd0ysYxsDbs4rKUr2TehtUoQummbCeI9PjsraCezt43cbmCtg7vbNcb4kkihv8AbHZeaAfMQk84P6CsnxHoF9f61Z7RsjU5LE9AP611+q6eifZpruJgqRqTxhmHvQ4xp2aerOelNc0k1bp6nJ3U0M8atc2cEzrwm9NxUVHHcvKrxzpi3BAYKoVV+mKkuUtZr2Z0WRADglXG0D1IqO+1TStGtIyyi9eTO2ONgo47sf6VvG8tErmc4xot1JLl8zFfXrqz1poLpVaEuEEfYLXqHgtc3KrJHGsbDI29/c/SvO4NR07XH3QaTFBqUa/umMpdX+oNdX4Fur6B5pdVieBFGSWHQevHQUsRH3drMqhU9pCV3e+3odrBp0lvfvNIBsQHb/tZ9fauV+JujG7NjdRqn7hircZ4rRuPEsEurRW/npsYgAFuSa37mIahp7p5sZIBDdCTjvXMpSoyUmYVYe1irvY8e1W8u9f8L3cNgu0Wzjeqtyyj2qT4faTPZ6RqE+qJLbJKFFuhUhpCDzx6e9ZumeJNQ0/xJNa29opDM0JQRfMR/e/rW9pGtXV7BfXuouftNshAEnGewFds1LltFaHNS9nKr7Tmu7GRrfha6sL19c1CY/ZS4kiTOXc9h7Cl8K6hb3epXjf2fbW00qH9+p+7ntyayLC5v9R1dBqkk80LvmVS3yge3pWxr2grqtzB/YJt4Yhw0CuSV9ye9aNOPuzZVONOUOeMXe70e5vXRuNC0OSaEmcBuTzxnrTJPGurzW1tNGQtq5AIMa5x6ZIrpdF02O30CNZp7a9uIkLNC8nOAOhrkNYu4PEGnm3tIEtZoTvCbQACO30rCMo1HZrrudSpyouUormiktCXxJ4Mn1aUawb2IWT7d7Pzs47Y6il0z+xrW28nT9XuJIFYjdtCgnvgGtDwpdWV/YLpkkZuZrdGcpEchx3/ACrMPw/hmd5LWS9jhZsqgI+X2q07XjUdrbHN7STfNTirPe25BfP5M0fHAwMitKB8qCMelZ+sr5kbHupGPWq8dy9vDGBkkjj3rmPsVDmijbKsX56k/nU7RfIF/Gs3TrpppFWQ4I6e9bDMDnnJFIxneLsUVBXerDg84p7AGPBOT05FOnXBLYyDUKZbAIP1HSgpu6uTxYCn7ufbsKy7j5dQiOec9elaYG1ipOMc81l6iwjuUPfI5IoQ4rVkNzDiW/B4YLmvonwlci88MabcK3LQg57ZxXz/AHXzXl0vOfL5HtXsHwbv4rzwfDAJQ00DMjp3UZ4zWOJV4XPGzmF4Rmd6g+bGOG59qRTyNvrg4OcUi54IOE9x+tOKgtlsdc89TXCfP+obuSo5I5xnpTHbZDI6kZVSRn9KkVSDzzjIye1RajD52nTqFYO0ZIwOc4oGtzwm+ni1ZLe4Kx+YZpG565DHOTWVult9RlUXIMjj92v8I/H1rkNZ1nUbBI4rWeS2EcrsGXgkhjWjrU2q6rpWlXsts63GMyuibd+ejED+le66Lja70Z30MVDaK1S1NLQI9ctPFivqkwNvcko6TSZSVT0GDWD8QND1XT9Ydrm2mihzmNgPkx2wRwas6lo+o3N/GQ2QUGN7HB9hXV6RcWNjon9ka1qDmR3EirM37tB6LnkVMpuMlNa+ht7K8GnfXv0KT3Nn/YWnPqg2TLANpj5kbPr2Bpl7qmlw28Dx2NzexycO5k27PZQB1+tJ4l0XS9K0mbU44L3UIFkCsscmFjJ/vEdqS2vdLk0G0nhC6ZBNlXSWXADj071CX2rXRr7SMl7GLtLqUvE63rXdt/Z8El1aSxhRE0eTntn1IrVbTm1HQ7dtf+z6cWxEEc5347gDlabpNlrM+t2xs9RYaUrg537gcVP8SLVi63Sr5omdkVkUgbh/WlzaqKNLKTalt/XU1YrW1tNNisrZ4Z7aH5UdGJB98VxNzoxn1iZLli0XXkcVseDLC5h06aS7DKp6bjgj8K1Z40UNNKAX24z3xTjNwbSdzOVCM0lbY47UdOg0XTLiVWEyzDYN45X6VD4LdGt7p5EVdrgb0GC3tUXid7m4u4LdEYo3Taeua29M0uS1hjtsBQo3ED19T610Slan7z1ZywgnX/drSJpiTJ4yMHjPrSeOtcn0LTbCWyCSNMMuXH3PbFTvaPb2Ul3IB5aNtGTwx9vpWlZXtre6YsV9YW7gvgOckt6VxppSTaujqqxm4NxdjmJ9WTTPC0Ov6dYgXV0f3qsxKAd+K1NKu4xocN9qMkemi9GBB912X1Bx0NS6zrmm6fJFby2QljBAePdhQM9BUfxPsrDXrzS5ItSgsZ3tgI4bkhEVR23dM1orSspK1+pxXqUXzx1VtvM0ri8Fnoy3scstypYpGVO5Np/kwpljcNeW2+3jDJ0yAMEd/rXKWeq3Ok3Vn4Z060GqWTMDcP5ZYOzdSp7ADvTfElz4j/4SNbWx057KGBtsJiX5GXuc1Lo9EdFPFxnLX0t5mjf+INO+3DTrezEtw3yM0UYAB9DU1t4UvpHgtdgcSPuY46D60zSvCbXV3LqFlJ87IWI6KH/iOa9B+G99/ZPhqe41i6yBLtSDO9gc/wBazqVOT+HqdM1L2DXW+x2Wk6a1hoUVoZUKom1gRgHNSwKsKWrxiGOJEO92xuX6NVLTvE0Op21ysEHlXkS7lgmbAkX1BrnfD2varrd5dTTgRaVaZ3xxoCrEduetcKhN3bPOVKeqlpY7W6CNbXMFoF3tukIGTknk/nXzvr+r6hZXN3poZJZ7ksI0ePnAP867DV/iakF9HbaZHFbup2F1HX/ezWtNoFn4n01dcjtSurIp5VcDOOorqoJ4f3qi0Y0vZxce5zHgCGW08P3k2sJHErfKr5G7d1Arkk0jTb/xwVS8aOVWDCJl4Y+uRWH4gtNUttQe2uIbnYDuZBnAOetdF4S0+6bUor66kUWyR7NpHze2fpXfOHInU5twoVIVGocuzNz4i6kvg+QWU9lbX4v4gGJBUeWOwx3561j+DPC2lSTRa3pv22c7N62j4Cwnp8z/AMQ9K0PGGp6bc2iW3iC1ub5Im/dXSj54l9KreN473TfDGkReF4mfSrlfMVoRufH+0PWsop8ijs316GdWmoVHVqq/La1v8jSW8Frf3Fpd21vZ6eIysxkGFYH19a5u58O6Mkyzw6k0li7ErFCA+R3IY9PxFZM2nXd54ctf7XnNniYnM5+Zl7AL1JqVbeXSsGAyvpqjZ8w5PufStFFx+F2ZrFxrSTqx91W12On12DStS0fTbWBilrB8kc0rjcT/AHSO9Uo/DEckca3erQFfvCFYSuQOgz0FR3/h6TxFp2nXOkXKeTG5WRWYBVb1yf5VBrN/d6VrsFk8LRxxRhfMPIf1IPSpjKVuWLNXh6E5u6tro+4viHTLu6laa2t4wqLtVQxbgdDnvWfo1neXt/bz6pEIbSyUsyDgvjt+NbV7dXlksN0s7ortuXI4I9PerF94i01NIEt1A0kl4fLDwjaDg9QKpTm0lYKtGNO7Uvl5mGvia5Fz5FtcmziYFxFbqAo9M8VqRazPc2Mks0SPJEdrGNQN3GckDvVez8NQSTFLbXIEVhuCSIBIR6DvWjoTLZpdWwQ2lrA/Lyx8v/tZ71VR07e6jnw8KyqWk7DPAOqXGovd7EcRxjIHXB74PrXT6PLHBeSlpC0bqXy5zsx3pnh7VLS8ju007ENvGSyBkA3sfWr+m2rGV/tDxwwyDDmTC7j7VxVGm3ZHqpyUf3mr/Mn0XVYb2X91FE5U4Zyudo9RU3xGuxpdrb3E48yERFGVRwQf5Ve8NWlhphkki2hGyGGcg1R8fGK50cll3RK2WJHGKyjZ1V2OOrJ8y5VseYRvDqEclvbq8fnr5Y2/e5/nWZ/wiEsMTrI8jFTy3l8L9a3PD19otxO8NkksV1G2VkBwCPX2qreaxdya8lvFI4iEgUAHIIzyTXoRc02o6Cryo1YxlLV7CaL4eTTv9JFx51wMlRswo+pNdFpF6skreffRBkX5oeMH2Nchf6rfw+JZommmkj84J5A4QofaoxawprTxQzyoxPR1zn2DVpKk5azfQ5qOJjG0aUdL2NbxRp9wuo/abWKNIAfMDEgYrofhab03twHLT2jjk7uhqHx/audLiRVdybZWIA74rE+Dr3kOrTGOSRIAoV1HTOaiX7zDtk07wr8ivZ/cdJ4p1228N3M8dzawRu2THIsWZHOO9ef2d1dwWF9qF3+9hnG2Ej7rMT1/Cu7+Knhn+3bm3ngvI4rhVKqkx+Vh359ay7XTdK0PQLayvtWiuZpJTJu2gKuRgqPX1zUUZxUFZXuO05VHze6lovM5DQ7lpJgrqSrnBxx17mvQ9Bg0e7328U0kMr4XfEAefpWfqVz4e0SVY0VW+0p8rIuGUHuaz7e+XwnqVrLYo8y3B3K2Q5z7e9VLmqL3dDtvRSSlq9vmReILnV9J1e707TlikS0ypPDMe+cZz/hWt4VtJdW0Ga9ltnhvvM2l9u1XHrVKHQrbSb668RSyy8uWhtnXDBm7sfSok8T3r3ixtfEMPmEe7AQd8jpWrjzx9xfM8ylVqU3au3r0Kdjqv/CFeIlkaJ5J0DKPKYKSCeprstV8QSedFJaRsUljEhAONrEnIPvWXfX+lXrwTT2wlvtpZWbBrn0ZJ90ouJBuYnGcVnJxm+aS1O6lgaig1GVl0t2N2dQ7MGHO3OKo3kYNnCxwCO9WpJFBYLxuXHPIqC4OLCJcZycfjXOfVU+gywjyUzzk8g96vi72XRjzx3FV7NSrRA44HXHSqNyxXV5N5AGAKC5RUnqdKn76NsHJHTiqke5ZOT1HT3pLK5YEnAZTx6Gkuj86lSCc80jFRs7FtSW2nbnnsaytZz5qHpzjirkT+gGSe1UtXQEl8k/MMkUJFRVpBNxeyhuMxcYNehfs/wBu3lanMQTGXx+Nedz86hIx5xF198V6P8A5SLXUYv4PM3AHmorfw2ebmy/cfM9cAHIHHHFPCkAZJYgenNIOfu847HmplHToT+eK80+WEwdvGMjuOtMzxnGcnJ9qeQQOevTI5xSMduNuSfWgR4JrvhmztPGU1nfQC5gkm86Iu2FUsc8+oql4ju7yy137Lu8uyhIPTCEdzXpfxO8Nx6np5vrdil5AAODjK968v8UaPPqujW8cN4jTxcMJXwG9Bz1r1aNRVLOTPQpOPJeK1MiDUzqXiUOTi0icO5i6BRWf8RNMni1WXVVT7Zpt7zDcQg+Wv+yfQj3q1f6N/wAItFDbalN5SzAPcSINyn0Ue1a2ka7Z2Vylt4emEunXL4uLWZd8brjl1XqnpXVFuPv09f67mWLqe1koNWOf+G97fJ4gs9PSSeWzu2Edxbj5lZfce1dD498Hga15UN3p0Fpbu3ySzquFP1Oc+1bfhPWtJtvFENr4c01FYMzXMoPAHdsnoBXHeLdA07VNZvdR/tCacNJt28ZJ9c+lYRm3V5vh0OypCclyqN9F1/U0vC1ukGnzWGk6lFdSoSzqjZyB6H/CrGtXN9c+E7mPTOLzeDIg68dxnv71U8BadYaXevJYN515jALuCEPfiuxtrF5fP/0e0c8s2DtkI9s8VE5qM77m8YSdPlnppbRnMeGYb+LRFm1AOJXwCW52n1J6VejZLhGhfCspwcVHq8mqJc282nNMdO+5LCo498r0NWLq1ijWKdHTHXa2UdOPTuKL317mzg4pO9yvHp0KuDIFbZyD6e1XIbR5J1MaZJIPHYVBc3ZgszcJbPNkZXb95j9K5fUNc16WKQxwvbwEYCgbXJpqLn1JlaKbS/zO9u7vStJimF3bi9vASQhf5B9RWV4e8T2HiGZ7C8sY7cMhWC5iwvlsO2K43S7y8t7Ey6pCRAAQRINpY/j1qOx1S003UDPbxARRMHJXkMx6Y/woVHdbsqUabitdzofF+k2Wh6YtxDfLqEvLSeWMAc+vrVLWtJh8TWmnyGZfJhUbDH82R6E/Wt7fYXFok97BCpujgxSMVMufU9BUPiDS5rTRJrDS4xZPIAyLGc4HpmnGo9E3qcqopKUWro5HXl1MyJDaSzLHFiNI426enSuxu9EluotJt2mkluJI1D8nINc7pN5NpGnRWtxGbufdvadTuCjP3c969C8EGJbn7ZuWU4faOpVj04pV7xVzWjVtC8enQ7vw3odvZ6WLV2XyXj2NHt2nPemtoGmS6a1l9lktUjcMHBG5jnrnvViwvzqGUnE0cqj/AFYGCSPU/wBKS+vksw80k0cc6KSrTggMPT/9VeZ71zgcpub11OF8Ra7beFby5tbDbI0g2vPOdxb2HoKu6LrthB4J1CaCDzZAp8wL0O7pXB+KYYPEerXV1qV1DBEz4VYzjb6/hXF69e3+mz/YNMlmWxGAhXJEvufU16dPDRqxSvr1KxNX2StUW/5mrp8Vhrc11LYW0v2mNifLAyCeua2dF+IN9pjDTmuHwGwPm/1ftWZa4s7S3itQLa/mUeYT8uc+tZM1jpFhq0t0upGe5DblhMfAc9ee9dTjCd1LVdDBynGzSuup7hNBbeLogOFv4k+aRVwkw9j0JrkreeLSLm9t4oI3v7YHbDPyH9a1/hdrc6CeS+A+zpgAqoHX0GKr/FXTyPFugavZRMi3T+XLxgtn1rghHlqOk9jT2yhJWWj0PNF1m71u7Fjq2mYR5dshgG3aM/rXZ6lY6zp3iGCxsYLlNI8oJBLGDgL6kjjNdoPC1rBpD3Tumm3DEbW3AFs9sV5bc+JPEGmXlzZWNzeNP5+yONd2GQ8VtGaqv3Ft3N+ms9V1t07E3jK2tLFra81cS3l2G+RAcbj2z6UzVPEthHawwtC0DXKBmiYbx7D6Vs3GjQanJAdZcNPEC7l5cYb+5WFc6Rpl1r0l6Y2dVwIowcYA6VSlDlSd7ouMK6nJpJx0GXcV/J4XFtbKIZzJvWNQF3Ieu2srRv8AiY2sukasZQLcmRJOGaMY5FdPGJ1vHW6tj/ZhGAwI4+h9axtKfQoNSuhp9zNcTndnzBwQeoB71UW0noOryVZpX0fTYpvqCazFFp1ij77YfKrcll6E5rN1AgTafYsu7yHyCOpyfSup0Lw0tnqLX7zMvnjYkbjG0HnNa+s29raSTRJPaidgBFNgAlj1ANN1lF8sSYUub3qis3+hyl7oy6TrC6zcXRSJXEnllPnJ/uiuhv7ptVjWaRxEs64ijZ+g9xVaRFbT4rbVpo5JCfkYtkL9a5zU7K8vfEVuVgkMClQkicrtH8qUV7TWT1Ro4rDO0VdN/nueieCvDc1vNLazsodwGRgvy4qTxbp97FqITyZJIiBs8sZA/Ct3SJk+0s8CkwlAm5uOfWti2Ie5+1S3EDxIdjsWzgeuO9cTqNS5mEqsoS9DF8OWktvZKlw+Q3zOCOAO1TeJIorjS2toiGnYZMZk5I/pWvqE0fk3KWKrOfLJTceM4/n7V4fZ3PiCfxUvn2t2shYq4CnaV7VdKDqXmnaxg6sZztPqM1iy03w/M8dk7GVuXy+CvtmrEdzdym1a3sxPIfvSoo27fUkVS8TaIuo6tI2nX8ElyThrWZtjgj0J4P8AOrM8994E0GG1l2fb7+TeyhtwiReMZHr7V3tKSTveRhRrqlzQa5YrZl9G+33c8l3ZBrpPlSdT27ZHT8a0LHRLKJonTz5J0YsRK/yA4/nVPTdQubzRnn09EiuSwAKrnOe2TVHxpq93pL21lHNskMQeRl/iJ6/SslzyfLFnZOnRpyvNW2dzsfF968Gj6aYrfdujAkZOeR2PpVjTZb9dBlk07T4TfMMxBgBu9zisbRvGNjBZaet9EJXnGxxjhj0z9fWu2hvbaW18xCI4kHA6YH0FYSvBJcpnKm/es9O/Y88+JEet3Og22+JjekKLgQDn6VyFn4PuH05b3WL6DT7ePhhMdzgewBruovEUPiW91PTY3ktpQrCBgfvkdjXAjT726S4s7lZTbhuDnLIw7+/vXXRcoqz0aPPxFFc197rTsdbe+H9G1Dw3banZX4uvsoEJXaQce5rLF3caFCL5YRM0h8qNn+by+M5A7VP4b0670rS57eCNLrzjznkN6ALWxEupi1Sa8t5LG3jXJEsYCL2B5qedrSTujrjS5XzaRe5hL40aV4dPe1a5hlO2XceWYnnArbHgvTWvSLe/8t9u50yGOPTNUbGOwu7ie5sJrG4njB3vGoVhnqR71PYaTFYCactLvcEbi2c/Q03JRXuaDVB1JKVS0vNFmPQre/1qP7I/2b7NhGJO4MB3471r/wDCKaeWZjAcsxPUf4VHpV1FZ2MskqCOGNSx9fx9a5v/AIWVEzMVsGK5+Ul+o9ayUKlT4DepiI0mqbZDeyCN89lA6VVnmLxoQOdwwTUuoQkW/nZO1uPx9Kquw8tMA5HGKhn01KzSsasEm6QEjAIx61n3wA1Y7cD1qxbEu8ak52jgCs7VHEd6WJwM5pN2Nbbm1G2xlKjtzVkbXXOwbjyKzbBlm2sjbieOKvoeTnPHJFBlJWY6M/MVGOvFQ6pEfLB35z27ZqbjdggA96j1JvMxxjkc56UE2s7la6bN6+DgeTk+3Fen/Am2ki02aZgAk3Kt7jqK8ynUC/YAgjyscd69R+Ad0W0G6t2PyxzMFNZ17+zdjzM3uqB6qgO3nIHqD0FTADaBjkjpTEYMW6fQVIDkbQe2frXnHyo3gE+vemsBzxnmpBwTyTxg0jjJGcY9DQMqXsX2m1miChmdNuCODXi8unCC/uYrxUkSAmTy8YDD09RXuDLj12mvCfiNrkWjeLbmzvBmGVdzOcZAPeunDXbcUduB+Jo5XW/FFtrN59jurZPJOIwkXJUDoay7PVdP0LU3NpZJckH52Zyhb1wKtweF5jqUd1poa5gkYSB15XB6nPWqtzpumXGssZRclkJwuMBuegr14OnH3ehValVqWlTS5kbPjO6h0Xw3anQozAdVi824mP3yrc7QfSsjQdJ/tjw1cW1xfJZM8itE7g7XwOh9K67xDb6Jq8VimtXo0u4gRY47WGPeSvYHJ4NP1HRIraztksXkmtNmVLjB/SsI1bR5evc1VJ9fn2POtUtZvB92sqPm4kj27o2yjD+v0rpPCHjovALe8tVSdjtFxD1Ye6n+ldLbeQ1ktveW0ExVv3QljD4P41lTeDoG1m3vBqEEduGDzCT5di56cCh1IzVqm/c2ScJ3Xw9l3NW6bUY7iEwTm6tXPHybSueoxUdxPbzSzw3BKsi7maZunoc1PJfMdYLWE6vpyvhNpwip3OPXHrXP+M9OudR0Vx4fnTURHIWmSBw0oTtleuKyh7zS2NajlS/eS1RW8LXmpXviVYIZ44o4syu+MqiLzmuqvPEmmahqkN7b+VIto5EyxABiOm8diKyL7S57b4e2NvawzRy3KlpXRMM5z91u+BXPeDvDesA6lI1lPAggIEpHykVp7OE4ube2hhWxdqiUY6D9b0S51e9uLzTtRW8ErcKG+ZB6Fe1aV54MjNpDaPdRwvFHuljiOF3EcZJ71wOhw38PiG2FqZY7lJwGk+7xnnJ7jFeoWPh29ur66h3vDNcSnyRM+M81pWcqTS5hYSdPEpuceVL8Tz3WNLv0uo7O1gurqBABHLyV9+Rx1r1K+sLiXRItLSVbfV5rbPJznA6fWuPuby4j1yHw3Z3vk3Mcu1ix/diTOSc+tdXqGt6E3iOCGO6D6xDF5UsiqFimcjkj3rKo5Sa08zbmp2sp3T09DhNPt9Q8O6dewagNpOWKg5PpXcfBw3d86TWluqWxfErNkhh357VkahLZLqDnU2jluphhAhLcZ6NXpvhi1OkeDZmsYXU3RJiiiJOxPYjvWeIqXhqtX9xnFSo0uVSv013Ok1jU20pkS1iWbepbOOI8dya8s8T69Nfu7XbGMAEkZJXjp9K3vtk0VhJbNDN5DnJ3jLj2Oa4LWoUuoZQpkjXPyl+ufc9/rWNCEU9QpwVLXdmabuyvpIcED5+Wx1q9ovhS8n8QLcw3yyIrGRYF69M4rlhZz20c8skbgQrkAHhyfet/4ea3fz6zHGCqyqceYuAMehr0JqcYtwehhJwrSUamktzj9Tub2TVLppDslEhURnrgHsKfqllLYapA0kZZ22vtB4BIr6I8Yf2Tpuhrrb6ZaXWoSDyxIY8DPct6/WvDta16O/u/M1WzjUg/L9n+U/lWmHxDq6qNkef7GST5pa3PRPhLqj3moT2ssKS7EwERTjA9PU/WvRPHcTR+DprhIizWu2VA3XAPT2NYPwhOlyaLnSrb7OwOHmQltx9DnvXb+KI1l8N3yy8q0RDcdeOwryK817fa2p0zcrxTPAvHeoalr8MNwJ7nywAY7dOxPvU2nTahb+GGs4bqO51nOWWMhnVewLdSfpWZrcWvW94qSW86acUxDiPAYd+f6VVurZbCxW60u6MN5KchWXv6EmvQcUoJaf13PQoOnOcuW+g+2nNgssd7dLHcSsW8qTnfmmaDbaksmpy3JaN51aK2RuQvHB+lO1fSF1PSodY1e5kt4IxslMabpJG9FzwKNO8UaZsto4lngEWI1LtvcjsT702tLxVyZ1eafspu1vxv/kZ3hC01uw1K4j1AyC02kyh23Kx9hU93pFj4XmbUIg99fv8APBashEcWeQzH+L6Vpztdy36SQiOVSchQ+Tj3pt/5OsO8ccqvMo3GNWyce3pRGbvdrTqS8ujyRTlqtmPh1O9bQYZL6Q3GpSksAeBGCe2Kxp9I1GWWC8nUTRJzCihuT/jV/Tp7EXltpUo2zbcRk+voTUMviq7tXntNLvbi2KE4dTjeR1AoSkm+RbnRJUYwjCUr28+qNOz8NT2EE+s+K5HtIJwDFEwBd/oOwrK1rVpL1Fh8MykWo/1h+7Ivp+H0rHtb+8166kttT1CWRp1O2SdywDDoD6A81b0W0l0q9ZpWBXGGK4KKuepNXyOGs3d9uhzQft9IaRfVafmdn4Su746MLeWWJZu+4bt3PTNdl4bhmjt2uTCodv4VHykeuaxfBdxp9/byyxLFNErYOwHGffNdeCn2cLbB7f5tuF5P5Vw1ZatWNqs7LkS7CLJGrusjeWD2VPT3pZLpyCzohLDapUDK/jTBJKz7tjtgHO7v/jSxOyAtAVIBzlVxx2B9qxaRiloeGeI9MlOtSx2+GPmMWXOWzWpa2UV7pBg1y2meCFsxY+Ug+m6tDxxoz/2lqVzDOsDTREo+f4uCentXK+ENSQbdI1aV3sLmTBcMS0ZPAI/GvUTlOnzdiUqUZqio6S18rnWWkkKWlu1mjRoh+VQf3aAevqfesPXrBPFF6J7a8gimT5XEjZAHqDXTalpttY6VPp+ZYYCWiMmQx+v41w1jNYaRK6w3Mk9wThNkeePp3pULu8o7mmNnCVqdRe4byeEIjY23n3MrG2BctEvDd8VqeGvEfmzxWMtsRbh9rMTyBnvT9L8SNDaRKlpNyfnEw27/AKCk1CaD7Qsukaa6mTnCfMcnrUTk37s1cuFHmleD91mDLqseneL7kW2iJG0U22Obe+evDY6Gurtb2ExzN9nVrh87jjC7/oPWsvxp4mXTJ7KzTSFlvkiR7hpkyufQjsar6/qwPh+4v9KEzXUuFMYUfuj6jHWlJObTta5lCVKnQcJauPX/ACOX0fUdZk8Xu1wtyBbFpZLdQQEVRnH06VseGPF9/wCJLm+0nXJnk0q6gcuM/wCoA6MM1S03W/EFx4flWe/kVPMCP5wUOy+m4jOParMV3HoUC/2e0dylyCs8ZjALqeq/St2r9NTgpUJ1ItynpbZ9bmR4fstLN7NaW2oStcSsEhkePajYPTrnJr1gwQhLa0KbvJX5ieWZvaub0Tw94XsVTWy8ifLu+yXGQqHPGD3rSXWIA6X0cqiINgAHOD6VlWl7R+7c3wkHShyz0aJ9ev7fSLB1vbMSRzAgIeprktNn8JS2+8aY6ZY8bs4+ldL4t0+18Q2KyRSeU/bBPX/CuPtBoGmxG2uFluJkPzyIpwT7U6Tiobu41Rq1q7vFNWNjVwf7JERiCouGTDdSO5rFePMCHnd6VrTlpI8Od5xgbv4RVG7XY0K5x/Ksmz6vCw5ULY58xc5HoR/WsbVyDeSDIYA9q14nDFQw4HoaxdQ5uWPXJrOWx1TXusfpM7292Cp+VuCK6gEAFsnJGOtcjbqVlGK6iNiETLHbj9feiLujLlH+YTntyMHpmlu2HlfKD2/GoZWUAsSR0IBNNvJGEaAEDPbNUOxHNLnUHwf4OgHTivUfgAy/2TfJjL+czY9s15CzbZpTgfdPAr2z4EWTW/hdpmTHnSMwJNZV3+7Z5OdO1FLzPUE+brnOOM1ID1/LNMjGfvnB68dKe3ynOcY9BXnnygoPY9uuKCy47n0pMFgDgc+9IueuPfJoADzgNwT0FfP3x48MXuq67Hd6fErNGmx13AF+eor34g7WOCD16dq4j4hI2IGVrZUVDJI03C8eprow1R06ikjajFTbhLZnja6J4g0nSdJhidomQb9sbfMGJzz6ijx3qF/p0ltd2ZjLgjzlVMjd9a6Ia7ZX/wBojsZ1mn8slRE2VUDtXMeF9deHUprK/i8yzkJysw3flXoxcm3KS2PV/wCXaguxVfQNR17VYNVjg3W+wNK0gO1Pqe1ejaVeQ32nSWUMHmC2GBMPu5749q4q08enU9ZfSbqFLbSJ/wB0iRDBXHTPsa6HTNKfSbq52XGwSLtVSQAw9TU1lK1qmltjGnUjVblDXXUYYykpMpVIwcb3OBn61zXifxI0WrxWNuWWLBWTcPvAiofGugeIdWusQTi5tF5VPOVVX3H+Na1v4Vs00+1utVZ7y8hjCCONs72HTOKqHs4WlJ3CrOo3yQVrdTm/CWkXU8WoCO6+yvMCqC4k2CT6e9afgDwdq1p4iiuZZI7FI/mGLhd0x9Bz3qTxJocmoiJoCLdFX5izbRH7c81iaTYzR6tALa6W6MR3L5eT8w9u1W5OUW09/IuMG6kafbqem6hNepYXsltc3EMp3MbZWGxm5wMV558OJtZfX5LiS8ljjjDCRJCdjeox0ruZ722lkuo7i6ZiEUyCMDAfuAe1R+H9X02BrorZf6PbxbmR+khPqa5Yyag1a9zonCMWpN99O5yeg+FbvXvGUyrfBLYSFxEoIZRnOMdqt+NvFU1l45hGgb41iKxqGPU8A4966f4f+MtN1HxQ1sbe2sJLjKRSxIVJPoCfWsHWX8Ef8JxNby6fqrXEUv8ABKuzcD19a0bl7X95F6I46crR5IS9P1RZ8RpYtrk9/ozWjawYQZYmjJ3EDnnoCaztL8NWM08fiG6Eq3GPO+xkDaHHv3rbuLezsb641eMlpXYtDAf+WZ7Mx/pSaH4hGuTpZ69Grl2xHdYCH0GexFSpzUfd/ryOt4Wk7aaLX59zJ8M7vEGtteNZyRt5u3DjGBnsP6V9DWltHFZpCsaoirs2+ntXD+DdOis9VkiADyIzESEduwH+NdfqepfYGjMqOFdsZP3frmuLET55JR2OTGTlNxgcB8a9VuNJ0pY7GBeSA0uec+n0FeM6F4quJ9Q+z3kJktypMpBJ24HXNe5+KfFvh20lS2vY4tVcqQ75GEz2NYF5qul6mB4d0PSLZY7uM+aYAGliXrnPpXVQqKFPllD5maw+K0nDReZ59YanpWrTPaQSlWlyFjmGA3tkda67wl4ct7S9t4fIMIlbg5zg+/tVTw78Hb+z1uC5NwI4kJeMsuSh9x3r2KDQLPygtwvmuQu7HyjcO496WIrwj7tN3QQxLteqveMm506ZAkVxafarN/3ZDthVXPHB6V5z498Eadp+rrHFI8ayjKlhny/b3r3OeJVtmWOFJpCuAsh4P1rwj4tW0uj6rEEmkMkpEm2MlhGPTn0qMHOTqWTsQpqppJHo/wAM9Ds9E0yW1tJpbgZDNKylctjpWv49vDp/hHUZUP70xFVPuaz/AIcX1xf+F7ZhIrqMhmIwfxrlvjp4kh0q1t7dWSS4Y/MnbJrJQlUr23dyZJKp7zskeaeHfGmqQulreCO/sbhyTbSnBjx3U9RV3xottLpU+oWqkTJ92EnKp7j1xVC02yab9thsIWuGwW8pMsR7e9aTQaiLiCHy1WJhv8t0+YZr0p8qnzRVj1aNCcoOLn7z6lHwpqc994eurTXIzNZkjYTwfqDWVo2l6JcagTbyXMmxvlSUDBx9O1dc9wvkTw6vDHDbuPLiKjlj3rM0/wAOroemXWpWLtdNIwTZj50Sn7S17O1+hz8kLxU1zNdfM5ybxCItRZoraPyVfGNxDYHoauaFr1rbazLqEVkn2mXI8rJwBjr+NbMfgc3tsLov9iWUE4kXlj7VY1LwJZw6SJNH1SGe42YkiK7ZAe+Kv2lB+73MKscRCzerXkZut6JbJdQa9dXLw2ThZUhiXfIW6kD0HvXNzQQyhtWikItDMcREZfd6Z/rXTWT3tjok1pr1ncGzTHlMThkz6H0rQ0rRtHm8PtDHDeMjPvj8zv6kn0qY1uTfXp8jWrhG1zJX6/MwvBVhpup3N1I1hcxmJS4Im6Z9OOtXvFGhefpj/wBjwssqn5oy+SR3+prYs1tLSJ7eCSJEHLKX5b61xmp6xrEniFoLBpBErjZGi5XHr0ojepU51+JnVtRpqnJ76aHa/CG3ksNOufNidGLA7XBz+XtXd+ewlJikw54O49P8a5vT9QjNvczM2HhAR3GRuPsDXJ6pqero7rZ+a8bnIYZyR9e1c/snVm29DabjCy8j06TMi/M7KByTjPH9KsCaIsiwPImQMk8/nXF+FLq7FxFFqEsux0JZd3RvQ110aI3fDqeAD/KsJx5XYuUba9DmfHcVnGhl1CUxs4wMfMoHr7j2rz2DwzJNcwT21zbNas4bzQ3AAPde1dd8UbRb6eC2EogdV3DcMKa4HUdK1XS7RbSFGuTcOGAtTvAx247mu+hG9L4jmdZ0p3lG67nca5qltd628USmQSYBP3RkDGQO9VjpttbRzrCRBMQR5m3JX1was6Lpj2mmwy6tPa2uqKBt81gWXjgkf3hSXL2VpZvPHcpqN05IVdpVSe+c9/asoyadondUhCUbuN0VrW2jsdBklkuHkTcMTzthc/Q81c8Taxd+H/A9jLol2Rc3ErefcooBHsD2FV5tBtPFOnW81zc3NhPDktAq5Rh/IfWtu2vNGuNFudDK2LrGheAFslXA79qpyXMm9ddTkqKpKnKMY2ta3dnGabrDX1vAuo/6U7KS0knZvXNb2hrBEzGKJg5xs3cgn0NchpljqtlHLPrBaLS413lyVZT6bcdzWlpNzBqFtIdHe5S9DDJd93Hbj1p1KdrtbGuHxCrOKas+3U0PFVhe36xz2MLSrk+ewG1UI9D3rnPCutaTa6jDb6vYm+XzMbi+AhJ6+9bFrq90niFdEjgupLKZxHOXyrMx6txwBTj4Z8N6V4rkj/tE3Jt23LEMMCfTHfFaJ2jyTOKpKSrN0dVd3v5FjxnpDax4pW0ttTiXToVG2JAf3R642+tc9JqVrpF4+ki0kki3gPI5Icn1AqZ7rTtJ8SXcy3VzLdSgksy7FQsKTwMGhvLjUdTmhnskBMm8eYzH29D71qvdjZ6pbHIo3tyvV6y6/I6+FYNOsZJEeWVFzlWHIGOn69az7PRNCu4fOivpI1c5KMMlT6c1XOteHtTKiWaeCZ2wigbhjtn0rVifTLJfJitvMxy7b/4u9c0k1ue1Ql7r5H9xhNMTMgBG0Hmquovm64zgH0606MYvSV2naM5J7026lDSoR3/nWTPqacUVd583HIHb6VUvWxMdw6VZuWCtuU9OtZ8zb9z889qh9gqysrF2HkKe2elbMmWhTlR2yD1rGsMGIfLkelbErjylHGAMj/GqjsDV0mRzYIG7DE/rSXzBQo4JGMVC7/KjJyTyOOlNufnCMCST19qdyuUgnkLeaflyy5r6O+FYjPg+wMfTaM184uiDzcnJxznoK9w+BF/9q8Lm2fBaKQrn2rDEK9M8DO4v2ak+56uMY4HT9KXAK885pkZIXDN/n0qRTnpwBXCfLiMMDHHsfSmFsnAIBxkD/Gnkjjpg8H3pGBK5UdP0NAEbYJ47/jxXBfFjTzrWgvaC5i00r8yXUxJQr3HHSu9ckHOB9K474kxyT6SlvChkE24PyOFA5wK0ou1RNG1GPNNI8k8CeGrTQdTtsX1tqZuHIeSEEIgA6DPWs7X9Y0bw5rr3C6R9tDyEESSELER1K469a6jwzpkOn6bGjNKMsfLx1cdx9K5/xNp2jWKvdatBcXMxYtFGxKpGPf8AvV6imp1Pe1ud/svZUnGGltjV0bwbo0t8NZnlMMBX7SgB6Z7H0qnZ+JLbW9YurWxka2aJD5Esj5D46jB6e1Yug+L1url7K4tkktplMZjK4IHqMVf0HQdK0CO61y9uWiCkpDE4yVPrj0pzhJX9o3foOjOMWpU7NPcydLd7yfVLnU5ZPsemqWkCnh2PQV0fgrxPp0mlXV1Lpw2QY2gueSfWqt1c6f4u0G4sNBlSC7d99wJU8vzCOh+mKb4D0qLT9I16Nbmz1e9WAN9lhO9VAPP1NXLlcHz6PTQ46lSp7VcrvF31NSW9s/E+l3e2M2pQYYjJAHbJ7VkeBWtNPurswXDvKIyFT++B2Ga5rSNY1i/1dLWytUtbRnxLbquEx0O4mull8NtDaai+n3KNfEAQiNgDjuOaJwjTTg3ZM0oVZVYqdruO/wDwDZ0m6sNZaR4g9u67kZo8HcR2x/jWRZ6/c397Pp97aBbFV8qRVQByvqcDrWXaaZcaH4XuLiXzI52kLTu4x16D3q58JbybWdUu7e6InZVDxN0Ib0J9KzcIpSlHVI9F1k1BVNG+hd0/wSNEuf7cs5p79IFMltB5XlnPqcnJA9utWLDzrqybxFrljELu5zHa+SAu8/3iPQVW8TWU8XiD+0JtRaK6T5RmTaIx7Adq6aMtrukpbpd2C3NuoEChwoOepOe5rOpObtKTuLD0qdBWS6mJBq9k2kXMEkqz3sbb2WBw2B6c0vgq3tNb1J5VtJPtkKF4IHbBPvjpXK6Zpdho/iYHWtRhin3FUSJNqSMTxuY8da67V/GNp4R1aBbGz8294FzMnGc9vQirnTfw09bkOu5JyejPQPCkkkeuNFdIEuefNDEHB9K6nVL2202N5dXureGzbKqsh+8fSvNItRuk12LUZZhJJdr5yoEAKrjoRSeKNP1Hx3e2sEV3a26qhIycEY5xjvXBKneV3sE8NzyjKTsranm2oW8eveJLpdFiC+bIW2FuBz1z9K7Hwj4Yjt/FdpdSavbRIj/vI9xEp44XPQ5rqNB8Gjw3p/2udIpJY1w8qEMuD3p/huxnvNYayleJrN3+1M6RDzODkKzdADWsqiadtjtq4mLptU3okekNaxPMkzLmSMYRueAf51IEGcnPYDuKxfF+rz6NpccttGHkdwgx/DT7XVJLbSbWTUhM80ihiVQZ59hXFyu1z5/2UnFS7lmxuJpr+7RwkcMRCpt659/8K53xd4atdauY4pbpYr3+8y8FfQCuvj2hFdE6ksR/X+VeJ/FPQ/GFz4ts30cXklhuBDofl9ea3w8OeekuUI1PZy5l6aHqnh3R4vDukmEzFo0UtK7fSvFPEk9v4k1m6Go2Ilso3aQT7tjRL7nv+Nek+Jbye20mx0uafFw8Qa5Gfv8A+ya8zmsTYwavqesX4uNOZTGlvAOXJ6degFa4daubep6WGh8U6ivzGZBq2mC+Npo8zl1TKPtxjFaUYd4Y5x5jO5IZ3bI+uKyvC0nh+4vUt7VrrzmBKAwhQoHJG7JzXVyR2kij7WgeNfmjRG2g+mRXTNq+iOznlTjaTOfNxf3Uc3k28kPkn5WmUYf3Gf5Vf8P6tqHkSR6p5RzlQUUB19Oe4pNV1JrgyPfeYIIkxHFGMKuPX1rkYvFlqFmIikBQZQk8Oa1hTdRW5TjrVYUnzTluS2Ju7rUrxWluUW3BYlicMfpRY2cupaqdQ0+8Nu+c3ETkhgFHUeua3/Dt2mqaWl5/qQpIZRz+tQS67p1qkzrGrgArJsQksPwqrtNqKIc3WUXUltqnsOtvFVjqt8dPaJ5VztV5B1NZc13qtl43Econ+z4ARYhlAuP5U/RINIe9GqWE8exMswPVD7g1sahJJr/h2f8AsK6864JMbKuAw/8ArGk1GMrJafkQ5VOVTk9VrZdUcz40jtE003Vm/nSNL5eVYbUHpkdSaz4td1XT5LG3sYInTYroxj3ls+9bHh3wutvp0tp4gnitZp3DRK3zFcdz2xXaxJo8GiPZWM8ct6ilY2dcFvUKabqKK5bXM+WVSXtea17aGfcwyzaU8ViALmchn3HJLf3RjoK3fB63ttaB9XMBKE/uwRlh/KsXS4byy0KMBtvz4ZlG4x/jW5Hpt1d6Qt5cvGSGKr55CMw7HHeuScrrlZ6EqUb819NirLrAFwsjWtu/mZ2LHkFfTca0tPu3nD5QI68HaeBn0NZFvbzSRyrIkjKSB5kScM3bBFaDXEWnJBAUWORwC6g5BP8Ate9TK2yNZQjtHcxvG1rDdzwiQohVNxYvtP09zVVHey0gjR5JLhy4Eku0Kc9gP8an8dRzXsNqtrt3gBmHQkelUVku9I0W6FrKgmdSWQ4Y9OMe4rSOqSKjaNLm6oyZNC1K+ui1teW092vzSW6yhpAPU+prM1eGDzba0t9Vga/hYs+44jDHtu9azfC73P8Awktj5G4ziTcxBwQO5JrT1/wmZr6a7s722lWSQs4zjyyeefSuxLknaTPPxFabp3pap79PuOh0/TtTn0W5jmvVknlUqDAQUUenFc5oPhm4s5by41BjBGI2UTsp2A+ue9a2hanaaVpnkRX6M8KHzAoyG9TU1/rVt4t8PSaVZyvHcxjcnm8A+wxUJTTa6BVqwTU46yS0Vy3oVhpOr6JdaVc63bM0q5DwKTsI5G4d/wAKo/DzUdJsDqemzacZSqnzL1yQ3HAwv8NVPBXh19EmnvtamigjCFAFO8qT3/CtfWNWi0nw+b/S44Loyy+WXYc8DqR3/Gi1701qmc825P61P3XbX8kZXiP7bf2Fnd+HlkV43bzlD/vWIPDfSs3T/D9rp8trrev6mYWaTc1uFy5cc8mrWjaVq/iCeHWo3SONXAk2nbgA9hWx420I6zBBHDKkM8bbvnXAf6+lU5KLULmLpSleuk273sczrug3Op382o2MsM2nzEtHK0oUD1B9xR4J0eS4v3BvFS0hUtOVO4EegHc1v+F9Ht7G2Nld3kdwxYtOqNwg9h1qDSPEmk2uqS2lraNFHI3lpcnrn6ehq3Uk4uKWpFPDQjOM5S36eZFIuiRfajpkYlulQkBhg5HselUdHtZpbFZLuSWSRyTkITgelbp0jTo9XfUJWkglTJmtk+fefUY6ZrpodRgWJVisWjjA+UBAOKzlOystTvw/xc9vkn+JxEjgzs4AA9B2qtKcuoyc+p9KvXUEMUIRgftJyd2cgj0rPG7cASTg9T0rnZ9dSmmrkF1lhyRwcVSkIIx2q/cD5cdfeqLRnYDgCs3uVUVy1ZqRG2D+NXMnaFzxUFpGfs+B1qZiFjwQTgflVLYpaJXGPlQCTj144p7nKg4Huc1WMmRgEnnHPNWA+IUGBkmmh3IXP+tyGyBXsn7Pif8AEmuXyeZWJA9q8bl5848nivYv2fAw0iZeceaxrKt/DZ4ud/wT2NunPQ08ehzyKawZsZGSOwNPB+XHc/nmuA+SF/w6mmuQBn8OafnjHGabkZ7nsMUCIyMZycZNZWt6f/aWntE3Ei8xPnBQ+2OtaxJ5yOnXHaogFzgE+4NJOzuiotxd0eX+E7Fb7WbizvmkYWuQq9NvPasP4629vax2yRRqwdcupOe+OPQ10WtytpnieeaxJS43jft5BB71yvinxboljq0NleWkGr6hOw8ySZsrHnoK9GkpOoppXPRqSuuZuyaOXn1m18FTW0fh3RIZ9RliUveXAMjZI6KDwK29ehu/Enh63snMdtcykzSHGBu96ZrNprH2ae6t7NhMOY5HUY2+i5qXw4l5JppOrbDOW5+bt+FdEpJpVFuvvJpUVFun0aOem8JXGgeFNQnsbmO9vpVAl8pv9UuegH9ag+F2i6hZvcahdW81rbzAQxu+UL9yV/xrtbSf+y9SW409lEq/fWQBg4PY57VifFDx5q9vqkFvbpFFsT5ZBGCDn+7npTVWrWbprW/Uyq4aOH5ZvSKMnUtWktfEEqz2e2N2wcA8DNdB4c8S6Tpmr4vbY3cR+SNTgsGPtUsOnaprmgWzytsuHjDO23JOfYciue07wZPba6F8h7m4iG/EYOT6HnoB60N0pq0tGjaMqiXLHZnV634j8PabqUtpqFrJdG84MJP7uEHnrVAXVrba5HY6fpi2Ky7DugyVZT7+lVvE/g+e5nt7nUSLOaMfO8silXHrx3xT/FerR6FoFu+mhJrsuFWfGRtA4NZ2hypQ1bN6MJ88nPZbPyDxLr2iza/c6VJZurIdrTpJnH0BrT0XwxJamHUEEc2nEbg7OAze2K5fTrTR/FtvaarqFpcRX6nbcrbsFSfb1fnofauleeS7vrqW3sbgWcEBEKYO1QOnFEtFyRdu448yanJb7Pujk/G/hLXPEHiVVsrSVLNUyZ3X5EHc/T6VufEG60PRpdLtpjdXN0luglmjQAMcdcHms3RI9diuItR1XW5RpULlngMjYIH8OPX2pPGujXHjK/XWfC11DqVpK4j8nO2WA+hU9R7iqSXMlJ6IyadNyqpe8+jO5igsptNsta0yR2hcDiVfmBHY47VduLF5LGa9zGQRuLr8rp7CsG1S50bTLDRhcLc3kZJlhiO5Uz/Cfet6yupbBkEuC5OXVsAY/u471yyTWx2qba0dyhoNxeaZqc0hvJ/7NZSPKD71z64+tbmma3HocP2rZbPBM3zxQJtdfc8108NppWvWMavbxqVHyhV2sn0xWBq3hBluX+yzx3EL8SxSEK659/SsueMnaRi69Ko+WorFT4keJ45PBkWo6YMx+aSxdclGHY1meFvFGseMfBN2ixRtqEDgB0XDMvfbnvXY6dpegWPh59LvZLaSDP75HbjJrmte8I3NncvH4ds2W0lUGGSBwqx+u7mrhKnycltb6M5qSXtbJ2itrlvwBdas2sSJcy38toq4cXZPyv6Cu71fUItM0+W7uOVjGcEk5PYCuf8AC+mXdjHOZ5Y3eQKAEOUTHU5964r4kXuqzz+RaFmgjOI0JyHPrWaiqtQqrCNetdbLsI13da3rV1d5hjYDO1nxtHt+VcxcTy61ZanpkMIWadsRYyQxHYe9XrWB4JFmuVYkwu8gQcjjpXEaZ4uhhv0itbEW6ylovOyTIm7jcM9xXbTptp8q2O6pOnTtG9uyNTwx4Vl0i/uJLy7ga6WEqtsjjfg8H8fbrVm2ub99bis47Jo7ELtlkmHCj1/CuZ8PrNpXi+a0uVeWZGLeZuzuHXP416jq9zYXOmtBaMltLeRlXy2T83pV1LwlaWtzJT9rSUoJ9dDjrexs9WkuV0jXRPLEGMsUg27l9s8EVX0vwVA8kc6zFlz80eMj6e1U5PAWoaVpFy8V1C9zc4RBHIAdmeQf0rpPBlrP4e0tra6IaWTkoTuC+4961lVcV+7kefSwzq+9ViXLbR4rbSZrW0QR9SASetZukeHpLK3c3M6SOW+6i7to7k101vH58EszTBtzKqHdzTdb0+4aAjTjHAVTcxUgbj6Vzqq/hvudapxi1J9DlbD4fSJY3+o/bDHbTgqsSjl+f0qroljp2m6VMRfpbyOShM5wQ1dpoEran4duggm+0RNiWFXwufUA9K8+8XeFb97BJ4YzLIjkmNfmJB71dOcpScJsVSFOFN1EtVt6GpDdWct8umXeXnSPct11DewFYuo2uqCQpptvcOWP+sRTyPStfw3btYWEF3r1m5mjUiBJFw3t+FY+uSeINV1wwW80ltbP8yMh2Ljvkj+VaLVuKegP9ylUa5m9j07wlazxaLBbSShJguZH3ZKn3rM1WSOW7xC/2rjYEdSoHuKuWcdxa6PDHbl34xI6Hlz/AIU+2hsNOkjuLpdtyxJ2MpcA+oWuLZtnZGVpOTNPw+z2lgsbzXEOP9Z8uYxzWfqOiXE+oPcpcLPE/wC8OV5b/CuObVtYi8TB7m6aS2LdjhHU9ABXQ6hfXMmv2cVj54VlzKiqeCex9qbg073Gqcoy507XE1kXH9oySRggRQgMoG7GfT3rLvdfittLVrHTUF2AVEkibj9T2qf4h63d+HlW409FxNgSMR0OOhH1pvh/WbjUdEt7j7PHHNMWyTjkDuBitlG0VNrQ4qdf2rdG+qOZ06CfWdMvka3SwMi/vLtIiGbnO3/9VR+GreyN01nao1ySMSnfycd/QCtq61XVJ9btLcvFJbh8OpYfKO4AFYTyw6ZrFzNY2U0VrzvXOWIroUna3fYp0XKfNZJJamq/hzT41uGFwyNdZjBZcheeelUzoQ8FCS/m26nuXaggJ2qD/ETU9lq2hfYPPmVo4QQXRSWYH0x/Wty41zT3s47m3iT+zR0klbIBHYj19qXPUTs9UTLD0bJwaUkt/IztJ8y/tYL64sppJJOAq8YHqfb3NWfN0fxGJdMtZ1jii4IWPC7vb1rE+IHia5P2O20nUVKyxZdbcYIz2+ntV34e2Edhp3mX0BhuHcn5hhiO2fajlcY8+z6GCrqtU9kldRWvmU/FkmqeE0tdO0ZN1vgSvMi5Lk9uK0kvL268Mpcxqg1FwSQ/GD9D3rS1i4S2FpcXAiiIyAwHQZ9e9Ub/AFvSY7sK1zFLMFLYQEFvr6mpTcraamnJyRk5T0f4HJaVdQ6NfMbkPdX03EvJwme3ua0tbg0Xw41rdRWE91c3CmZUmYbIvy60+ystO169GqJMLVFcb4mHLYNdJ4+ubaPSInj03c4XMUsgGPwA7VtKX7xK2+5zaqimnottL6GCg1C6xf2hFvJcoGxjO04roPDtnKumINS+e5LEkl+1cZ4L1m+upbm0mlMium5HxnyyPT2rYhubmIyJJN8wc9fm/KpqKSfIzowsY1F7Wm7XKCApdsMHA6A1LbIJCeSAB+FLKo+0M2McdetFm25/mI4GBjpXOfXeaKd9GN3yjPuKgkiAiHcnqK0ZkA68HOf/AK9NdAsO7AOeeOKVjVMgt02x+nHTvSFQ0ZLDav8AOrMDDywmOfSmXaEx/LwB1oSJnLlMiA/vD29Ktn+BT0ApdVR31QNFbeRblQEAHB4609gAyAjkdaHG2hlhqvtYcxXl5SUnpnrXunwMtkTw2ZFAyzEHivCJwwR+mO9e5/AacP4e8vOSGIxWFb+GzzM7v7LQ9Zi6KOozj6Up6559RimgA47/AIUqnd347+1cJ8mOJOcdx+lNxxgk568+lLkAZB49T3pPXPAPPPrSEMfAYt949xioyBgDBDAcYp5bAJ6n0FNyF4fPPTB6e1AHnfj22ittSiu1jJMx2vnue1fPuv6VE3j2dbm8itY5JldMAueTnAFfSnxMjDabbyqVDpJxu6Zr5wv/AAp4j1PXpmGn3EhZiwmRcrgdMGvWwLXK23Y3xD5qEbK+p0up+ILixuL6Sz1CK5Noufs0pJ3AcdKs+BfEc3iy6eG6ggikj+Y+QuAw+n4VzWmeCdR0+4e911VjsYgfPh3kysCOmO1dH8PI9J037dPps0tuFQl7mbBZPQCuioocrcdR0aldzs9EUPEvj6fR714bTw7HFGGx517l2lHt2FdJbtpvivRLJ79rW0m2iSLzztK/7O7uM1nwl3M+oWt7HqLR/PslQOFB74PFU/tdprmj3ba8RCLY/upI0AI9gBWcoJK8NGjelKUptVneLPUPD2g3sUPmwyLHMvCTk5Rlx0rifi1H4it9JtorVJJIZJGM8tpkl/TJHaofDesLqngzUtM0G8u3ntIvlil+84/vL/hWp8LrLxbp2nSS3zvBFKpaM3EoDD1+U81ioOlJ1JWuujHUn7T91F77M4rSZbibwrJour7ojdkmCSZsNu7AZrc8G+GL1LI6dq7RXVtcMPLVudnPNdJB4f0/X5pZ9TL32o226SBfuq2Bnk/WuL8KXutHxfPNciYNENqxYyvXpWjn7WMuXS2v/DHRGCoySe60v/mXZ9f060vTpOnaLaww20hVDuJY+p9/XFWdW8TarZT2ps5AqDGTHgg/h2+lW/Fh8LaJ4gaG4tZptTmKSyMpxHAW5wPX6Uap4rtrTXYLGTSbKSw3KNqx4fnoc/0qElo1G/qbSn7SKihfiDaw6t4f0xtS1y30vUnXeYXjLK6t0J2/dNL8P9Lt/CmlTXNhqA1CeZ/LjeBdqk+wPNZnxW8H6nfXct/pbSagJMFoI/mdFI4wB2rY+D/h/UrSxis9WDW7STfaFty2HjRe5HbNQ2vY/Fp2MJOKqXs9t+i8ij4w8R2fgy++zQQfaNccCWebd8sWedp9T61Fovif/hJI5Lm4s43ki+aRyxAT0wBS/ETw94a1zxZePZ+II7bUWIDwT5w7dyG7Vu+AvClr4eSWFrmC6e4iJmkjIZFXsvuSe1VJ0o0k9eYeHqVeduSXL+JN4e1gyRpLHJJCwbABPBrcv9Wa6hLwpicgbnVwQ2PWsDXNEuSsEenqvzdIF6+x4rEkttTgTy/LlEaNl2RMhcfyrFRjJ3R3+yp1FzXOX8TeIdbh1S4jtk/cqecpnP41u+DPFN1FILjU4W8hV4VnJUn6f0qPTPFGl6teSadcxyl/uh0AySPeodWu7bTGiW20cygPhTvLDnuR612StJcjjY56cPdcua8WdtceNrma4HmEx2wHIVCAB64qnq9/DqnlfZluJIGOGfGMn09qnt7uWyjkluI4/s6IspeaPlGI4A9RmvO/F3jTxDqOupbrI0dsjALCiBVkHqQKwp0ed+4rWF7SGHadvuOxj1O0stLWe/WVpYiVjjjlxjPX6/jWDZ674YlsX1hNHnE8c/lrauylXY85BxXda7pmiatpljprEabcSQb1nHZyOc1yd38NYodKi0jTtbsbvVhIZRDvCl//AK9OnKl9u6f6GeIrzcr01b1NPw14k0LxNfTRNoradqOBtbzNyyDpj2rgdbnuZPHa2kKyInmrEqE9u+Pau38I/DfV9HuJrm8e2tLmNCUUzKWc44PtUtqdHm1aO2vZ7aTV0b/W+X8pb+6T3qozpxnL2eqsRCL5Y+9r1sYfjTULLT7+0F9FM7odiBH549an1qXTRo1va3Fzc2Ml2QVlQbhz0z3xSeNPDdjdvFe63qh0tImIYMm4vnuorRS38L3GixatbPLq0digjEMgK/N2LYqouKUXr/wSa05Pnilpdfd1H6ZpS6JYw28s7XLjLFh/FkfLjPaotRuVkQoibRGvzqxyfrUS682ppiRjbKUyAsf3AOgPtXP634kuNLvYkgWJ5/kI+TOazUJSlruejRUYU03sdFbW+6yutsnlu2Dw2Qx9auTWt5FYxRWBWSdV3Fs5H5VPdiOeztpp444vOALIny7GI5ytZOv295a3VnFayPBCYl3tEpIxUJ3YSipO21yHX5ru00aF1gWa8ZvmLrvwPp2rmtd1i5jhtLF0SGV1V5W24bnoBXTanf3dreWpgeNGdQNzuFJHfg1W8f2Pl62t5OYxHcRoQZOO3OK6KVoNcxx13OqlSp99STxLqOq6Z4TtDoUcpmYgPKq7mUewq14Wh1m+0WO91Z4oLlcoPtDbGZex+tY+t+Jda0v7Nb6NbP5TqAJAu/PtXTz2Wp3sNpfzxO+Y8vHnG098iomuWKTtqRh9a8nz+Wpd0vQLa1lS/l23siknYc4J6krSWmrONRZlRF+0kkqnJX3z3rHsfH1tZ30Omm3RmXKmUDlfbNdc4sobSW9iS2jYrk9mY+tYTjKPxrc6Paaty1WyOd8R3Wmvc/ZtQnSQsd3kOgIY9sntXLp4sguNTOiy6VFD/wAsoHi48pu3HesTxtbxHVbfWZpvOt5CFkVDzkdvatrwN4eXUvEEGuJcyMhfdHEIzvz+Pb3ruVOnCnzS/pnlKrUlU5Yq1nr6Eeh/D/WJdWSe+M0RimD4A5fntXpWq6PcXNtJE2lt5LfO5WMb+nc/0r0bSdPMO2WdVE5546gY9fWtTDFTjJ7cda82pi5Tld9C3iuX3YrQ+XJ9BthPJpNpD5OTuYN1+v4ViWWo6ZZTRaVKk09lDOW3Fsbj349K9w+JKWdncNJdW8iiXKG4iUEqAPTv9K8rk8M+HIHi1LVNbHlTMTFbxQlXfHrnpXo4etGUbyuXUVSrGEoRVtn/AJGP4s0TT9I1KLWLS6klN03nW9kseSp7bm9Kv+DDOr3epa9KIYD1afI3N9KveNvEv9i3tpBp1vbBREp/exbm29sGnarpd34y0GwltmjspQ2+RJm2I3pgn8615n7Nc+z6nNSgo1Juk78vQv6hq2iXGnLNdlprNZNiBE+XPrk1xmpWOh2+qxa1FqX+htIP9FEJL7h2HbFdfJ4Kgu9HttItdasBLByx34UseuD3qhpfh7wxazf2Z4gkuLqTJZVhbAD/AF7ZqIThFaN+hpiKdScnaO2xVt7XT3shdRX9vBBdFmiZ1K4x1H1qjeazqVpp1xIq21/aREKu7Eiof72BTfE0llr1zB4f0GwjsI7VytvEGJVn7hmPJJ9a2PAfhaXR5pJLyVXumG0wRnKAejHuauUuVJzMoxnKUoLTz6HP2XiTVbHS2u5LW3RGbbFi3WMEnucdavaP4tu5LVmube0mk3nLtCMngVv6rpdzNcz/AG+BJdPClhGeB+AHSs2yv7W0h8q30e38sE4ypYn8aq8ZxulqXS54TtJ6WK0g+TduAJGMg5qO2U+UJV6KcEN/hTU3qoXOSOp6UkQO5txOf0NcZ9xZ6EjSK6/e2nsfWrLoWtSMcYB6cCqeMsCV+ntWjHzGE5KY7UjSRUtITuwnXFSTRlY2wc4I5PSrNoPnBPU0s+35lAIznAHNMznroHiO5t7g2i2SkLHEN5Pdj2rIKBnDHqe1TBF3Mq8g4IwKZKP3gwvIFIqhTVKCiijcKUhY4OO3+Ne0fASNk02X7uCT7c149d5+zNnHJ617L8Czu0uQtn73esq2lNnk53/CPXAfUEHNKQAAQRuz1Hc0gPy4JHXr7UrDnnk/nXnHyQdlYHkelI2BxkHNKMlQQe3JprkjqCQc9BzQAzBByTwe3vTSOQM/N3NHcdxnv3pG4OPU9+1AHF/FNvsnha8uWUyMkZbC9yDXlMnjD+zvDEd9aRYldBsTPys394/T0r3nXjbnS5lusCN0KnI3Zz2xXjUWjo4uLcR26WUZ4QkAfUV3YaUOS0l1O2gpSi0nocP4C1nVNU13ULvUbl5bGKB5rs7AQV9PSutttV0XVdO/syw02CKxkPzyqctKfc9vpS+IdP0uXwfLo3hQJZ3tw264DHAnx2B7VyGgaJrujW8LxC2hWSQiXzZAflHoK7W4VVzLTsTh4zpS5ay5tzvvD+m6P4ehvRbW3mIQXZ2k3ZQdQB2rnY/H+g6xcDRLrQEs7G5kEYuYXyynoDjFac2r6VFfR2F3E7eePLZo34Geo+lU9G+Hug2GuHUtR1sLp1s4kSIj594Odp+lRHkV5Vb36bhiYyjaNDZbmLc61b+APF50/R4fNjilC3E7n5mBPTHpzUXi+81GXx40i3Us0UoWSIhuiHoB/hXpXiHwJ4Q1/UB4ja/lW0kHmSeXgowHfJ6VbF/4b1CJZNCNldzWCBVbb8yr689cUliI/Fytu2pnTpzcrXt2MDxZZ3lj4Wne3mlS6mRXVjwwH92soeMLjwf4ft7hrWK61K5+RS44UDqx9Sa9B8ayTLDYzRI0rMgJzHu4x1I7VSvNC0jVvDkEfiCJHdm3oi/u3U9OKxp1Y8qVRXVzvqxnOm5p+89DmnsYviRbQataWKW14qj7RKzgKx9CfWtLU9LtrNreS6LG9gUANFhlkx059qy/jA83hLw3pOi6Aj21oV8yRl5LE+ppPhnBquvaJK3lM0sZDxnGF47DPc1bT9n7RO0eiIo105cj6I2bFLue4XYXSGQ/KHJXGexPXFUdSQaZYz3ml3LXkok/fhSWKj2PpWEw1TRfEly2r31w7STZS1znA9Ceg/Cr/gnRLrQfGFxrE9ykmjyI+bfd80m7+EqfTmk4pa3/AOCdXtKnKpcu78jKk8LP41s/+EnWaHRkibZcNdcLJj+JT6+1aFvevYaUieHr1LnyW3Oc/e564ql8WdS16+vRYadpE8WkQ8xpBCShJ78U7wlplx4P8LT614ij8u4uCPKtJRlzH6kds1o7yinJ+i/QmhWhRm4NavV9jV8X+NTpZ067isUGpyRB3O47fwFbOi+ItO8Q6ZeajPb3GmRR2+64eKTMbE8bdvvXHLc2PxHhmaeOLS7izYbPLBKNGf610Gq6BHL4C/sfQFmfzZVfzlwRNjscdKUqdOKjCStLr6GHtJy5pw1j0My00fwxYwx+IrdLpomYiNSwRC3v3H4U3RfiXp8GotBc6Uoi8whJJcOufUZ6Vk2UB0/wjc6R4luTY7bnfaxvGWbOMN9BV9NAsbzwwbtA2oQwyAEwKcgevqKuUIfbbfQunVc1bZbmvczyaj5yXtw8kLfOo6qAfT6VPeWdnBo8eo39k0jwSqjOPlZlx8uKwdG8Yy3Ou2+nnSopLEARIrKQ6r0zkV3UurW66m2j6jp+6x3Y8tOoUd89yB3rGcZU3Zo6frCqxvTW36Hn3jXVrUahC8csgZlD+QPmaNfQms650mXWLqHXNEuQYAwMnVXjI9q6HXfAFjf65O1jr8XnytmKIx7iynsD0qLVmTwN4blsrSeSO7CnzHYAkMewx2roU42jGluckVrJz+Fannl/LqsPiASSfawTKCqSFuRmu/h0q3fxPBPHMsDyyKQrjcSfT86yNM8YanpeiWt3qsMWqSsx+zG6jBMfrg10Orw2F7f6ZrMZNrqC7Z5YDnbHn0Ap1JS66b6oulyuTjFNve3a6M74i39prOqnTb+5mluoW+V/L2KPYD/GsHwTqbaJ4hWxsgbiK6kETJu4P/6q6PxhoGnz3k/iW11WOSMkFok6q+OhHpWJ4MtRrfia/wBRRFRbeMMR93c3Tj3IohKKpNdLfiKdO8otJKV9fQ9Iv7ATusUEkTHOGBPf0Iq1YaLpEcjC9a1ub1vuBRhE9t3rWRqAe1sp9QtrPykSIhQ/DSH2X29a8eF5rGoamqK9wszv8sakjHNY0qDqpvmtYrF4pUmqSu7nvniu2tbCHe8yrDJhvICbtuO+fTNcV4z1uWbw5BfWDFSreThT1weprfkht7jTLewvLp5LlUCvIkeeo6NXD+RdLqh03y2n04EkllB2n6VNCKWr6BUjNpQTs2cnqWi6xq0y6owSaGTbvcOD5X1XqPWu5sro6rJDol1ZtLbWkPFwxywOOv09qwT4Xl0LVp/EHiE3NpoyOTEI2AkuGPRAPT1PpWvqHjNbjw59s0C1+yYk2tG7Aqvv71vP33aKuceEl7Hmb0a1a6m/4dcWjIekPIIPRfr6Uy61zUZdVaNW3W4+QbWyNvuK57wnqVxrUsqzp5QPzA/cVz6n0rYh8O6hZ6vFOmDFIM792EHPU1k48knzbnqyUK1p3sacfgCwju01U3jLkBpIkGcg+vpVrxrHNJ4bezsJQt1cqEijTGQgPejV9QtraxmnZ2WFPvsvG76V57B4qur7XYJZI1MJYKU6YHbB7minTqVHz9jirezSVOo7JsyLO2bR78W+rKzIv37dhkH3r2/4bEf2hayusYjdCIVRdoQen1ryma/ttW1q5eWBmNrGzYHVtvTNangnxVLrF8bO6jS2mjBkhlg42Y7c104mnKpC9vU48NUgm6Te+3ofTqknHOOe/Q0NJHChkZtsaKSSRgY9a810v4lwyQGD91dXkPyyFGxyOp21i+I/G13rlu1rbkwRE7Tt4avIjhp81paCWHnLVbFXxz4tstV1G60+SFvKOVSZGwYyfbvXB+KNM02C104XuoSxxocRuVyZAewXt65rSOk2cl0rpOZCuGZlOefrVXxbYm7vdPkKJLsIKpjOzn2r1KcYwaUDqgpxhyzatdGz4ru9AtHsU1PS31K4SJcZO3jtnFZGveILLWNKFpaW09nNEQStsdyAdPmycj8K6PxroV3eXaXdmAYlhUzMBgKAOc155CduobtOshcBcb2d9u7B9PStKUISin1RyVK0oTb0V2LpXh/URrsQe6ia3H3jk9PTHaugvtUtLTUR9n00T3sa7DlwiqP9o+tVHuk8ldQtUeKRjtaJTnae/PcVVjt9Q1KSeXRIGuXOHlUKNyHpnnt71fIpvmmaSxLpx5aTffudf4IuPDOuamYbzRBputbSwulcsrEd8Hp9abq3iXSLBbiyjvEF6jElQnH0J9TVfwHpcljqcmpapC8bRRM20HO1cdTXFXOkaYDNrF5rG62aYkRLETJKSc4HaslTpyqN3dvvMatWpTUVorq7L2i+PprXVGkubYSwMduwcYHvnrXcpqFtLGkrpp9sHG5UkYbiPWvPF8NQay6Xvh9b2a0l6wLHueFu4J9Kf43sLe01O2gmt72SaO1jV2UcbufWtZ06cpJLQhYmrSpc1RXd9C+QFjBPOBxz1qOAMxLAngZxmnyNiIcdBnJ7U2FtsUu0447fzrjP0KOw+FjJjPrVrISJsg9MdeaoWwyQex5Aq3cMnknoOwHY0ge420mOe+30qRmyu/IwT1IqnYscEj6E9x71M0gI2DoB09KAcX0GREmVjgVHNx97BPJ47U+HcVY/KRz9KaygN16YHtQaWsVJlLwgDPt6V7F8A5hJp88IADKx+pFeRSbR0we+a9I+ATk6heBSBhjxn+tZ1lenI8fOl+5PdVOFGQSOlBByMZU9DQT8vHGPalGN3Tg8fWvNPjxrEb+c88cU1zkDA57DNA+8TnjpnHUUzOE5IGOPrQApJ244HfPWmlvvf3iBj6Uzcc7SvA5GOc0rPydvAoGZfiaHztJnYHDR4bOOOvNeV31rC2paibgqHWBTEB6k84FewXo32sqFS28bSFGfpXmvi3Tms9SgSKURyGLf5wGTHzjv2rpw8vsnfgpJvlbPM7WW4g1gSKGcbuuO9O8d2F5Jqlt5AyhjVgwHAr0qzh0r+wjNctE13ksJiPvY/vEcA1hXKvqCvJbB5VXC71P3R6/SuyNe0uZLY6pQVVtN2Rztjo6PBE720s8kf3njUk8etT+LfC+sa5ZWklijor5Ese3n6kVzl6niuXxLFb2X2yCKGQBWVikYHck9K7Xxx4wew8RaTBpd+HuvLWO7MYyrHHTFa2qRnFxab39Dlq1oTUoctltfuTDw7PafDWTw8Z1N8QJECt8smT93PY1geCfDGp6Q15qWrQLaxhFjWLeNzc55rpLq6uxe27sA0c2MsRzjpk+lQ+PtYvItDa0soiY25PGSSOlZwnUfufzPUHRhTamvsmTa+NtX1vxQ1h509qFmWNYkPG0H/Ctbxt8RII9Tl006MtzYwNte4Vyku4ddpxgfjT/DHiOO9trcWOlWUGtunlu+zMm48Fh+Fcn8RtP0qLWyYtWZZWwZ440J2vjB9jVQhTlVtKNhVpVHSjKL1PRNQ8a+Ebzwxp02tW9xPbuMRhlG8Edjg1LB4lh1/QLjTfBUp0u5jBKQugBlXHRWHevHPEkQ064sks1+02QgHkFlOHB6n2Oa2PhbcnTNaS7lgdiQ3lIvAXP1onhIRhzxe2yMITbnySR2+t65L4c8IafdrpcE2shCrvcwlmXHfmuT8D+M5/EOozab4gjWS2uDuBgATy8e3pW1e+LbrUNXePVwk0RbZ5YT+DpirFp4LtLHUmTSbJoTP92bJJ2nnp6VnaMItTWrPQoxlKUZJ2S3OvhhNjo0cnmXjI7FLW1glbLe/sO9ZviPwxcy6LcJq0D3azYZZPNLPF3259O1S3Wp/ZHfy1lmtrCP7MrRPs3P/ESeuO2BWBpHiDVr+68uHzreNT+7YMWUfUHrXPGM17y6G/JKWj2Zv+AvAmlw6JJ9ljlRp8lmZt3PTFUfEvhCbwfajU9E1CYWYkXzrdj9wn+Ifj2rptF1xtNllh1W2eF5PmURAsJAOpUf0qTxVetrfhu6+wgMuNyDu2PakqtT2l5PRnDKM6c/d2RxHiiytfHunWnmXYtNXthtVpELJIvviuK8XXd/4Ols9O025lt2t8FjGdodh1z61nWeu6zpuuL5ySGDdlxIMDHqD2rv9GtdN+Iui3qX1qRd2mTHcbscem71+tdzi6CXPrAuNSLUpUtJeZly+MFt9I0/VPsiLc3PzO0WFORx+db/AIM1i21bxLb3YiBWQ+WVkOSrEc5NZ58HaTJoKaTcXU1rdQyF4JbgDgHtx1GazLSyk8KmQ2V1FLqqsrRMo3Lxn5ie+c9Kzfs5pqG5vFTu1LaxL4t8P30WoahJpbH7RDIQuWwBznipvDmmvL4Rv9Q8RTxQ5kEQaXnkdwO9blvJLeaHCb7i8uHaWYqTlyfaua+JEF5PpcGneU6wQKHEcaEeYT29/rSjKUrQffcTi/iXTobHhzw6viSNvM1Ky+xwkeSWjByfUcioNS8NazpHiJFuGtpLKYhPPDcc9MjtXjkt3LaSi1jE8EcbZETMcq3evYvBPi+91Tw7c6fcad9sntIWdblzngdC3vVVadSm7p3RVOq5typy23Riaq1tp1rc20MP2mNpNpEgwM57V0fgvR4p9Mln0+2jtzw0nmSYB9cfSuYsrQ+JJiI4Ht7wvvkiHMbf7Y9BXomiSw6boElu0S3IDbDg4VqzqStDlW5vWUoS5k7t2OSu9E1dtQe9s7oXCQJwpJO73wa46yv/ABFc6vN5scqkttfagUKD74r1aFjMsxiU2pA+fYxYfQ5qFda0nUNLfTdNui98jZJ2gKx/xq4V3FO8bnHUpOdRatGbY23lXNsZ538xsBp2+6jDoOOx96xvFF7FpgnutLAurxD88anGweo9a6K0spEss3U5zK+I4h/EB1JJ5AFcSukwz+J3n0triVvNIkcvlT24/wDr0qVrtyOmqpT0g9uvYZFdN45snF+Wt44F3BHyyk+vrUlm/h7RvD3lXNlJdK0xDSAlWJHHHYCui1BovD8Ynd7MxFtqjeHMnqPasjVrnTLnTyUtBHbv1YuNobHatE+bp7pioaPlav3M/wAUXFlceHVuPDXmLDGy/alDZlAJ459PpW5pVw93otsrSSpEsYIL8sR/jWRoNpb6fZSi2YzGcY3EZBFdFs3WkMidR8pTnI/ClNpe6uhtCn1m73t8ipcW8Vzp9xaMWRZMFCT/ADribSxaw1yKJlYiKQNsfp9a6bUddtdKuFa73SuOkaYyua6XwRYWeua/ZXLWe22J3q75+cjnAFUpypxbezHL2Tbe7Ra8PfD6S6mmv4reS2S7Uj9+4xtPXCjk/jTB8LpvDSXV5pqm6fyz86sCYh6hDya9pTrwoxjipAwOM4weOPT3rg+u1b76HhyqJy5lGx8xeHPB9zYXs2p3N3DLI4ZlAyM7upo167ku9LSKDztwYqCV5Uev0q78Q9UuNJuJYtLbYJbiQIVPAXPTBrnZ7/V7vwzLNaRzSXMbbZpI1y6pjuBXpxlKo1OR3uKw9BuC0Sua2jafqNvpV4Ew9yImeJVGMjHX3rkfB97qDeJbWCfzpA0o3K2cpzyfauo+Gc+t3tldLczTjTgcCeZchG9ATXcWmm2b/vI1SSdBuBRc7sevOaUqvs3KLVzOFL23JWTsuxLbS3Ta3dW813DJpUqGPG7hiRya4nUfBM9nJM66hpxtV5WZpDlFzVzVLXUZrW7hguYoWdmYeXIMKPQY6UzStJhn8IanDq901xZwRBmMUm52YHPHoPrShJw1T3DFYaMbvqlfXqXtHsvD99o5toL86i0DeZK0Z2l2Pp7VieItWXTdOubHSJbW2JI3LDJmT6MaxPAus2EeuppWi6e0YvcxNcztvcHBxgdAKbp3gTX7TXwLm1XyIZA0lwSCjDP659K0jyxk+Z/I43UlPljBb7s6f4W6zqM9tq5vmebT7e2eRmK9SB93PpWV4M8RJr0d9o+v2cNxphha4jjjQK8bLzgH9K7DVPEGn6N4bv4ruGAWFz/o4Sx4Zjj9K4Hw7rGnaXcSf8I1pV3LJIuySachiqHsB2FEVzqUuWxnUTdb2bldWS+e+v4Gx4R1ltXEttpln/ZemQcqVl2r1/jbjJ71vXPmPKWcNcE/8tN+7P0PpWL8U9PabRdLn0mE29oE/e2sSbVV+5wOpJ9axvDeka2dMVmnltwzEqjtg4wOajljL31oenhpt/uaqvbqSw4mJDHt19fpSuViQp0BqrZqY9vB2jpznNTMRI57e47is2fWwT3ZJEB1B4HX/CnXJJjOT19BxToVGB0FLcxsQoXKk9qRp6le1J2uMAcYJzTJTtY4fkdcVLBD5aSMxwOlJc27QLC5bd5q7vpQHNG6QW7Dy/mPfJJpjyKRg5GaZNIVTavp2qLeX6E4HtzUm4TudnXnHBxXqf7PcRK38+OrkV5LIfkbnNet/s8u5t75SDsDk7gKzq/w5Hh52/3Vj2/HJz0PFNbkAsB1wM+lKo46e5B60ZAAAyO3XFecfICFjyBUMhweOOfWpGPUZA+tQs3PBw2cYHegYyXIbgY45Aph3CPJbcBzwP0pZH+cYA3D8fxpMfKCcjIHtQA4MAeGyTXmvi6CbxDqNzpiRkXYbYJQ/AjPXNejgDOeM45PQVh6ULO71q9urTa2weUWIOSe5HtWlKXI3JG1J8t2ZfhPwLYaFZrbzzSXoGDiT7mfXHf8a6hbK0EDIbWDymGNqoAMVKNyqCxGM4PP86lGACi4yevTiplUlN3kyHKRyHinwyJIfMsHCJGuGiIJ49RXnd34Th/tW3u3Dm4B+6q/fbHGM17plTne/BXJB6YxXlUl3NLLcQW7rIisQjIMlRnsfWuihVlZpM78NJ1Y8suhPpmnRvqEUDybMkHBHVvQ1s+Lb7SPCOliW6eJbiTO1mjDN74B7V5h8RdZ1Pw7bWKWLtFfHEhdRuK9wKueJdP1jx/4U0i8lkEuoxA7kQAE5HXHrXQqF3Gc37rIxFVym4w1sjq/DS6R4njW90K5tYtQjIkJjTYdw9V9K868c+DtTk1m6v8ATYhO0ud0cb8o/cr6jPpW94A8Pal4DuRe30PmX1wpEdux2gKOpJHevTNAWw1aC4uJUmkjlbY9vcAFY377SP50nW+r1HKm7olwlOjeqtPI8ksNR1Dw94Qt9JktI5bsgtI0qBzEG/hHpWlYT6L4e0gavqKLLqsp2wQk52f7WK2vE/ha7h8U6Xb6TeynTrjImgcg+XjnAbrj2rK+KXg+61+3tZtOt1jnsx5Xlw9GHbjrmrVSE2k3ZPVjUVGF4K7Es9f0TWPM1G0symp23zvC6hlkH94D+ldDpmsSP4dudQ8wz3DNsUMNuwnoFHtXnngHwpfaFdzahqcDiRY2jEcpID59u9dTd3UB0o21tA6XCEP5i8J7CpqwhzcsNUduHTlTvJWdyTxfYXfh/wALrd2txI0T/NJG2OGPJI7814/p+vagutpJbSlpHIAVc8V7zA66j4flh19pJISmS23OSeij3ridU8LaTZWE0+ixSLcY+YEgmNT0wR29avDVYxThNakV41pSUoy+E6y08T2Gt21rpt5dNHqyEGOYIBsf8P8AJrN8STy6f4fu9TJeWS3k8u6tM4Gc9R6A9a8x8A6Bq2o+IYJESSCGCQvJcsMBAOvNem/EDVbObydRsoZ32fublZF2pdRdM/UdfpSnSjTqKMXdEU6sqlNtRtucj4d8dwa1cf2ZrOgW7WsmQJbTPmRj1Oeoq74uvrPTvBx0zQZUi0x5f388ClZHfsG56D2rCTX9J8N+Jpo7jQxbRNEFJtZNwdSM7hmu5jtPCuneHIbjU55DBqWJIYZQVAOeje1a1LRkmou3Yzw9nFxlLmZn/Cu+/tLRWi1eG9uhbtst5YkLsFP8xVzUvCt9puuR3F/Pm3k+dAyEDHofQ/WuT8eaxqGmw6faabLDZWjZkD2BZFf0Oc88VtfDzx410G0PxjK0sNyNkVzMx4PYE/1rOUZ61Y7PodNnGShe9jrkvbSxCj7NCeR86zB29uOwrHv7ya41KKeRiY/MBVS3RQf5e1UdT0m08N6tOsrzzQv86KsZc49QRXSajo+jt4cS7Nrdi5lUGM8oQTznFZ+7Gz3uWnFWb3Z5Z4yl8PzeIppzaTzTN94o+xSe5x1NasVzd2sEH9jWn2WLA8sxEkkjux7/AENZWo6KZ592TFMCQ5deWH+NdDbx3F58P77S7NXWdJBi4TgOMcgntXXLl5YoxSqUee0fSxFd65fJmzu1t1uLlc7IYwpb6kdq6jw5cTWvhe4hlt13hTsWRcgn1PtXH+HXiukhWa2zd26Bd0TZLj0Oa1devjY6nbJaagj6qVCvYuSoJPbPTNYSipe6jtq3jFc/Uw/DGr6rd+IJ9PvJRE7A8DgAen0rotO8L3Phu/n1XWbyKHTk/eLGgz5jdcCt3RNOlEgvzpi2t6qbiHGWY+g965vx3Hba5JHFPrsy3Lt/q8YKA9Qw6flR7TnlyrRdTmlz6KOrRW1nW38R239o6ffMtqsm2QKmHU9lPovpWdcawmrS3Phy0lmtrpodwkAADEDLA49RUN5Np/w8ljsI7e8vpbhQ8kjuERh2xjrT9Qk0DRL628TPBcC6ul3pb5+6SME4rSMbbL0OWrXUqfI2tNJGNY6XYavZLo66my6nAzNGZIzskPdQc8H0rQsNFXTtHvbfX5vsls52h3XOG7bV65qzdTadqIN74ZKHVdu91C4dB3+tMkurbXrBLPxIZhcRZbzU5ZfrWzm9L6L8TGnRupOmk3b5Gxo1qLTwd9o0y8inaVzFHMgPyY65zVHR9V1a81p7do3ntIlxJOVw6H1z3qLwJrrRanLoBsx/Ye15Q8g+ZSoz5hP9Kx/EWpxagiy6ZfyG1LtGyoCoyPX61EYNycWvmaSxKjacnquhueIfBl1c3yyS3UChlDb+gYeoqBfE9x4U8TWRgjd7S0jCiJuBIO5FTeF74SeEJxq16LaytbjbDPMc7cjlfU1Dr4jk0u1vNJuYtatmcxb/AC8GJvQg8043k+SpqtinWhHWO73+Z9CeHPE2l67YRXNjcJHlN5jlO1kz1zntXM+Pfijo/h//AEGzm+26jKNpEHKxdsk/yArxjXLG51abT5Le/W2lhQK1vuwAR12jvWrNpugw6jDNqkqW9zMuxZJs/eA+9jtXNHCUoy5pNtdjmnh5uV0rJPqWdW1fw7eW8p1aVpYkUZRD+8z6j0NZGqakdM8PWt34CkuooJJSLl8+ZJkdA3HFU5/h+6tLI97FIjEshjYEvnuPWtCwkbwNokkdu+64vCPMkkX5FA6AD1rqUaaa5NfIupPETptVPdiV9abxnrukaZcTuYwuSYolERPP3mA6mtfwFZXsFze32oS/Z7WOIxtub77N2B7etN0jxDJrAZLsKJVHzKucN78U/wAb2l6NKt7Gyt2WJ18xQhyJM+9KTf8ADaSuaQoRhHng7mBrFwug2csZZ7o3BbDk/wCrB7jHU1s+A9M/svSby+u5hNZ3kezywpB+pzWRDos19osWlTSxm8U7lAILJ7E1qve/8IrHZaRNItxJIuDH1OT/AI023y+zibVKalP2lTa1lr+BS8QWWneEdKGqeH0Y3877TJIf9Sp5+Ue/rTT4i1bxF4IurgRyfaYJFRniBOQfatPTCvi63vNJ12yfTRGwZZowcceoP9K6/SYrbwRpFvYWMUbNPL+8kYbiVPr2FRKXs2k1eSPPUHPm5XaL2POdE8C6xqmhuL8/Y1ndZIDO4UsRx90nvV1NLi8GRtbO7y6hLgMcYUY6CsD4i3WrSeM7qO8nuMI4WEDKqF7ba3/FGqwzWmn6fPNJ/aaQr97qfqfU1s1OVrvR9gwsqcf3jjqtPNlvS9TnsbKe/wBYklaJv9XHnGSOgquni+3nHmTW0hkPXY3H5dqx7azvI7CY6zN9mtpTthS6OC7g8ED096z301rQ+XLaPI3XcJAAfp7UnTjc9GjWUve/A0dvyqwGW9jwKdCm0Adhyfaq4nHHQAdqcLn5xz+Ncp9ar2sXlAB3EHHpUo+YEnoODzzVF7gbCeMr6VVEznJQ47mhscUXGfeCC+0E9KZLI0xHmMcKuBk9KqhiWyCew5qZguwg5DZ6DtSuaKC3IXJZjzwPU01B1x+dJgFmxinoTu6A5pFFW7YhGJPzY7V798ArJYPCf2gDEk0hPIr5/vhlD6/d4r6l+GFvHB4O05YMY2A8evesq7tT9WfNZ7KyUTrPu9M4/wA/nSfwdskcEc/nTiOg6Ed8daa7Hb8uc+gHX/61cB8yMf5UGBz0PeoSMHO0Y657VLIAuQDxxyahlByCMHHr6+tMCDpLwOT2pwGQQevUZpFXHzYGMjHYZoXAODwScmkxiXHnfZ3+zlfOxhS33QfU+tcl4bnay1y6sLu5EjXRMsLYCfMPvAD+ldTd3sNoVEpjUOertjvXmPjeBbvxjB598NOtrZQ/2hBlk78Y71vRjzXi9mdNGLlGUT1PackNtGO1OGWHUc8/SvMdR+IK6XZD7HPNqSINvmXEIBYf3jt6/lWKfGd/4gAQapMkLttkSOPYcf3QBz+JprCza5uhdPCTk0pNK51vxA8a2mmadNCGKJJmPzkwXcd9g9O2TXkVnfRQXZvtPu9RNrKcGKVgzIx7jHBFR+L/AAzrd9dtfLHcXUCj5Yg3mMijoCM8VB4dm1DQbArLFDE8zbykyBiB7g9K9GlRhCl7ru2ax/dVPZqLsup6Nq+pWmsJCZra2aGJFjLyKd5I6nPYVxnxB1O78PtZwWYaASIJN+eMdgK7rwhDpmvIE1G3kt7i5XchD4jlYdQF/pWZ8RpILPUbK0OltqEQO1mdchcentWNGSjUULbdDbEqMockNGczZeJLgaZYy6uyOJG3BvM2kZ961/FfxPfQYLTT/DNvAsezeZGBYknrz3zXnXjxJF1p0MHlQrjyUKcbSKu6d4J1bXNEsLu2g/iMZDHaOvGDXY6NHSc9jz6latNOlBbHqOm+JrzUfBum6y8aicTuoA6KQMZNW9M8VpqkFyuoOsCpgb1XDSn2xUug+Hj4f8GnTb54btrKN7qVOsYc9E98d68jv/HGp6l9oWxJgmXLRrEi9B6DHFccKKquXItEztWIpxpqNRe8z0TV9RluWX7M9wXhwEZ+Dj8agm8QtZzW8mpwrLCM7lUgHB6n3Ncz8OfEV74ia5sdYUPNEm9LwLtIOfuuBwa09d0x7+0kjBV5lPysf5fSmoKMuWZvTq+1pc1Pc7U+II7HRRbyW/2ywnG+FxgADPHvkdKs6TZyxwtf6faXF1JKhKRKvIz254IrkfDkz2lrBayKHliUhiy5UYOc8/lXoVhrgbTludOmjjhgH763fJMf0HXHoelc9SPJpEcm4wXKtWRWek+JX0uSNxplmswO9DES2PQhePxrI0HSG/t2Gy1cLLAsb7EKY3DGMkHtXRaX4pEJk/taN13jfGUfcXz2A7Vxt1e6rqniRbyGZntt21No+7j27VMFJ3WwoSre9GSsn1E1bwV4fbUQmtK6+RgW7huGTP3D64rB8V6BdatqkUV1Ep02EgK6gjYvbHtXW/ETUnWO0S2y2owgBtvIPesnSp9YvtPli1BmZph8gPytmtoSmoqbY6UIq11vucnO/hzUrVfDE11PbTxSZguioZd/91h6fSorDwJa2GrxDVfEtnIkTBttvG7lhnpzwKX/AIQ2aLxXFczKIYEfdJI5+QH1Na8+hbb251BJfPtLfLu8LcEemeldD5VpGWj/ADE51OZzt1/A6XUdZs7fxTBDEs0zmJURUIBPHBOe1asIuZkmutTMscMY+UyHq3YAVxPw6hHiHxnda3dJiytV4PJCn0z+Ga0viNrF7q8L2WjsxXkRBTzIR6e9c8qX7xU182RGtJx22/I5LUrnzNbm+23cM0EzABDIfl/Su20HTWt4FL2QSxB3h1JG739xXk+j6Tr15qDacNOuDI7bmMiEbB3Jz2r2ieZrbwr9ktLiU3EabATIGDHHb24rfErktFO4qdb2kFKKsN8qztZ59QtooZZYj+5EY2hh3OB1rzzVtFt7nxda6pNcyW6yOsotiC8mR/DntXPX/jjxPYXQiXUZ4jG3EZRcZ9OnNenabqOh6p/Z0niGWO11a4RXwTtUN2DehPWp5J0VzdH2LdSEpuL1cf60OY8R61eR6rLfpNM0qtuQB+nt7VG2oWNzpFz4gMKfb2yBFOfkRvXjk1cuvDjtq135t3FLZtkkL6fj/Kq2pLpXhLwcsklj/a895IVRbjKxRj3xzWi5G0o6sxnUqUqTnLRDtKuP+Ep0GG91K0jvr+3z5IChAW7KP8Kp6VBc6/bSWviu1iiSJ8QsV/eRDsOOcCtLw5rUeoeCmubmyhs7e3n2RxWabV6dSTyaxR4hsdEmlbUBceffDKCI4MSdifUn0pe9dxS/4A7U1BVZvS23dlS21Pw94Y8SLNosc+p36ts2TJsiiPc+pruLmfRPEha/t4ora/jAWeM8RSZ9McisvSfDekJZyzQLDPc3CFhdM3G089Ox9xXI2OoW1yLzTNF82K/JO25fBSTHG3HUfWqko1NU3ddTlpylQlyvrrZfodJ4i1KXR/E66HaaVbwW0ygzysuSUI5w3piucs7/AMOI0mjxWbxwyyZ+079xDdAcelddpfh/xHJ4D1S38TxsbuV1W3M7L5iqPf0rF0rwXY6JCb7U2+3XsSmVYQ4WFeMgE9WPtSU4pWW/kOEZfHNJrq327FnXtFtf+EWOi2E0glhcXJeUbQzHtiszwn/xIEktNSvYIluWVhH97oMbvaqmk+P52nupNRtre5dj8gZfuj0rdgsvD3ii3fU3T7HeRY3RGTCOB2Aq7SStPb9RRnTlP2tPfrcqaxpjQeIYrue5iCR/vEjzhnA5yKw7qC78a61PNbBItoxiQ8D8q19b1LTJLdr/AE+OS41CyAjSI5KKOmT7CpfBV5qVzoesTXluluBt8q4EYjwxzke4q1NwV+uxnNqpLklqlrp/mbUbWmmRQR3E0ct3DGFKhuTgelV77WtNv9JH9oaY95au5y0b4eI/h0rkrfQNRjefUGmgmiGWLxzCQk++Oaf4d0nVpbxLtjHaxSHcVeQIXX/c7iq9lBXlfYv61OaUJR3NPxZpD6TpVm/h6G9EVwA8zltzA9hkcgVp6V47udJ0vT9K1CAzeWuHLgblB9M1htrtxonie5WW4eWJX2+Wpyq/ga6jVdO0nxBBDrIOLx1y8MPcjuR70SSslVV13IpxlKTlSfXVdjDn8Jzf2obm289beWTzllBI3KTkc9PzroNc0K1a4XWYY2ubyIBAhcjJxwSCOK2PCl3c3Nk9rfSeXA/yARgkADpWvFFb2OpCKW9yqr8yy9D/AIVyyryUtT0ZUYJclrNar1PMk8Oa9q+3Ubq78ls7vIQksoHQ4rWufFEkSm2uLWWYgbQxHJ9Tkdq7zU5ZvtKvAiJbj/nmPlYdxnrXKeJry3s9YhitLRkeUYaVfnGfYduaqNZ1WlJGVKlGknHq/wAy9Hdi+S3N3bozLGDG8sYcr7ZPWuY1hfDl9r8bXN2RqXCbACAD2zSa3qh0meBbyefdLwQhzgetVP8AhFILnWV1GzmM8BXzwuwhmYe1VGCjq3bsRVlZp07Oz1MXxzpWqDXZ5JoLie3RFEcoG5QmP0qFHu5YYjJu4QBcR7uB05plxLqs/iPzlW5E0suOM4x757dqfqfiJ7e9litbK0aJDjJyee9d0dUo72PJXPSvUu1dk+ASACDkZ61LGqYPzc4qnjJ6gU9W29815PN3P0tMsALnA78UqKOwGB6d6YHBHH4gipFY5I9eRxTNUI2FkyuM5xnpTSxPGfalYEk4AHFSIm3oOTxQMYigH5h+Hel2Djpk881MsXJz1wTinpDuYDr6cdaYnoZ1/Fti7e/519UeAY/K8J6cqHgRj+VfLupoAEjGQzuq9OTzX1d4Vi8nQNPQk4WIcEd8VhitIL1PlM9knKKRrEZHHf260w5HAxn1BxTzkc9ce9RnIXk/rXCj58imPXBwc1CcMxH8Q7e3vUsrbenQ54NRnhepLetMBMn1O36UDClv8KQ8HpyR27UJznkjHQA9KNhnO+NtN/tS2thuURW7maUc7sKM8V454ru2ub3zZ5XiiYkuqn73sPpXsfjORY7djApFyy4klGcLHnp6c15PqmjTa3cA6eu5l4+YjB967sK0km9j0sNG9NsydZ1DT7bRY2kVh5ihY7eMAAj1Y9qj0jxLo9kEaxtLmK6lXy3Mku4IfVT3rnvF1o8dyLYS+abb5JDGvyK3oTV3wtYaGz20V5eiS+DDbHkrGzHoN1d7hDkvqWpydRXtZfeakFhrtr4mgOkPcGNiJBKvTn+8K0/FusaOLrZqGnSm5j+WWaF1USN3JXHWqut+MrzR/EZ0vUJZFt4gIpI4QFjUdiB3x61D4jjsLdkullS/jZPMRdpxj/bHr7Vmk24uS+4qTcuZwlrc2LudFs47mydlh2qwQn5l44/Grf8Awks32u0PliUhBw67hnu2fQelch4a8Sapd6mrxWBngUjcqRHYF9D2ArY8Q62ula7ZwIkkVlcjEtugBCZ9CaiVFqXKzaliKcoc1ro7aPXPB+reWNYlt5LhWyWZcDI7AdhVjX9U0UWZNverFp6qQfJGdx9BjpXk134Nkkubm/0u9tr6xUlz5LZKj0Poav6fNBP4ba3Np5kTXB3FmIOccVlKjDRxbYUqCnK7+R7L4J1Ow13wtKljauIow0RDvkv9T714/q2haB4V8VFpNRUXDZItgN3lA+p/pXofhPUbTSdC0+GxtZIzNNiTjd5g71wPj3Q/DV74tmnuPEYs5Zmw0MkJbB9Cw4pYZWqSi7pPtqclaEqcnKMdn1Nrwzf6PqWuTaREsS7xuS4twFO7Hf1rQlsIVs1+1XltYXMhKoLh9nme5PYmuX0pPCngzxLYm/1OZ7hnUrLDGHiIPAJOcgZrmviP4f1htXu7zU2ne2dy8Lrlo9ueMHpWrhGU9G0rdS4VaiuopOSO+1QReEtFj1DULlJjJLtWOKQSfhkfnXAyy+IbfVk1DT555oZzhSeQVP8ACRV/TUsn+FpTxN50NvFcn7JLHy7k9Rg/zrtPCmp6dpnhq3SK0Z7Scjcbo7pZPcf3cVWtJPS7vYtudaVpdLPT9Su+uWvkLDeW+7UiA5ZZDlP9nH+FaWlan/Z8M88TeZPKclIzwB3Bz3rhPGlkdG1dp7dDc2l0BLDIBnAP8J9xVu6tr3Uvh2n2VWF/9o/eEDaRF9al0oySfRm3t2k42uW9c8Wafplwkt7FczXLodohIwnPf3rUj12BvD7a208+wAArOAHJPZSO1edaPq/2V2ttLkMAUkL8okaRu5JIOM13HxA0CZ/CmjylXE1whlkdeF3+h7DirlShGUYS0uYOvKpBzi79kWvB3ii38W3v9k3to4h67lf5sDpk9xXWavrcUmgzeHtNsFR5m+zpH0BXueK878HyxeEtKmlhtRd6xdcGY8JCvoPU1t+BfEVtB4ot7eby7i9kYo8jHiIHqF96yrUk5OVNaLYiLlyp1t+3mdKI7fwj4eGlwEGaZS0zrxt9hXkHizWdStNTh+yyNDGq70Yiuo8e61cahrd41lHI8Ak2M+MjA6CovDTRapfR2Gq2NtPZMpVXuF5Vu23v1/CtKKVNc8lfuTKM6tP3XZt3Lnw5vdQvlutQnuLgwmPyiVPVmrkPGmr31r4suYYJpLeK0YLCE9R3PrmvR9WsbzTprSzjZLG3iG5I41xvPbkcdfWk8TeELDXLCK4vrlbHVo1/fOBlJPcn1qI1oxnz20ZvOjGai27LyMaS5B0j7aNOtX1FoFcSlA43dyAeledy6BrMmv2tzexPGJ5FkMrsANpPLfSvYdA0i1mtmhhkEjmPYkr8kYHTiuN+Jdhe3MWkxW8cjusZhYRjO4g8VVGp7/Le1wxMYWva7TKnj28kttYRtJfGmQ43upznkZNHxA03X9a1TTItLgmm0uaCN4GiX92fUt9PesS8B0kwaDq6SGSYrI5ZtpiB6CuytUu7DVU06Ka5bTVjBEm8gBcdeOMVq37NRtqzD2f1vmXN7qffr2NG9sr+3/s6CxZEgjQI+5ABIR1Yjp1ql488E3PieNNV0aFZbi3jEU0SMAWUdGC+lXtIEJ0e7uXlkaJHIXfkdO4rCOoLCkeqaZqjRNCxRvLYgk9gR6VgudO63Xkbyo06keR+pa8NWdv4e0S3uNYLl3yix5Axk989quaHP4civp5dM0ktqGSyuX/dhh0JGKiAuPHXht7y8iEV9A+2SRvlVl/x+lZOj6ZdeGtafULXUprxZPl8oJkMPRvak1zX5nqW4WslHXy6aEeiy6uZ7++1V7plnY435Kqc9RntWjb6pZAR2t0nnCQFZFXrz6DtWj4g8eJA0SQaArIceaHJVQPT3qHRNMsfEdxNeWAjiQ/O65xsPoKtt255qyIhOHL7K3qcvb+FdGtb+5Q3kEinO1Q2XT8PatFfBkLCyhluAg3lgpIBkU9xzViLwlZ2Gsm4v9YsY4fMDbGfJHtxWF440TW7rxC8sUbXdo4AtZIGygXsB6VUZybspWJVGhaMYxudBp3hfRdE1O7eTVbiK8ClUgaDKjPYmnapFLrNi1hPcLCiA7DGvyk/7XqahGrvBb6baa3Gsl7HH5bMRlm9M464qldR6yNdtoViZbVmDtIwwuP6cURcm+ZvVCqUIU4qDWj0J9I0WHw5btJPd72lH3Qh2n0rl9dtb+PxEt0YzKJCHSQDKgentXYa3rWlarqh0+fcoGI0e3Yg5HepDLdaEzNqUcU2lxx5i80DIPrWlOpNSu92ZV6FJU4tNqzOf8dwabDBZXhtX/tCZQZMNhCOxx61HHNGlrZahZ2lw5RSiQI2FyeCTW1aa5pvi23mtdSBW5gXdG6x5V0B+7gdPrU32RAwk4t7CBR5cKkFiM9c0/aOKUJLVFYWgqkpVFonrodJo9w1tptuskaRyuoZ1c5OT2Hv71YnW3+0OCZo1YhWYqGw3pz2q3FJay6clzKuxWUeSZeMH2qlGQ9wLpyrKGyWfsf8frXF1udileTYkztZRR2zyt5R4YcZK9s+grC8W22qJo0o0jbLdRnnauXCn+6a39TtY3X7b9rgiglAErSHlcemOuawfGdja61YxjSdSNugI3MARuI6ZxV0viTOfEzbpuMNZPscl4VtJLuzdNbs5pFikyZJflKH05611urXl7pVlLe6WsReCLESLz+YrnrXV9V060mgcx3qRR9Jlz5h/riq7+NcxWzpYIbtiBP1CKB7V02lN3tdGNaMaUVC9m1uXLHxNeS2qDXjC0EwwpjQIyEn25rJv/DV0bp2t7dRE3K7iuT710mtz+GV0KXVorEyzcfu4mzGr+v0rzoazZzkyXEd2JGPRJMCqTvrFWChUpxk4VHqjTAweBTtnenYXHGRU6qQvGCc81yWPtYq5GkRwTjOelWEQnBPzdunWnxISAG+UdQanWI7gMZJ/WnY0VkQmPaBgtn0p0cRZssPYVaMASMbievNIpB4AHPOfWgSZCE3vkkgj0qeNQqs/b+dN+XnOQvYVDeTJFD8vUdMnp7UyZPqy94O0mTxJ4ytLZAdkbebIT0AH8q+praNYYVjXlUUAEivMPgboIsdJfUJ4dt1cfxEc49K9SRtqYB59R0rixM+aXKuh8NmOIdes30QjDD/ACnJB5GKiJ465Gcg+tK7A5xjJHb+VMd8LznI6Ad65kcA05GcnIJwPrUZ4z3JIAp5Gc84Pf8ApTJBvGMHHGQeuaaAQ5xncRzj8qpatqltpFuZrt+SpZE7tV3ICsdjNj5tq8k+wryfxxq1zrWqi1ijdLGAgeUw5Y9yfX6VpSh7SVnsdGGoOtO3Qh1HxRdX93Ncy2jrYXDfuod4XzMDqSegrzrV/EsttqKxojRbuCVfGB259K7+6Rr/AMp5o/MjgQhhGnI98en0rmdb8M6fe2UM0YWO4diNpByF7de9ehS5L2ex7dnSp/u1qZnjPw3JY2dnf232iaxvE8xmY5TefU/XtVTwHpMTXdzqN6oCWGGQY4Zz0/Ku28MXMlraxaTdlruzxsS2my4GP4sdRU85sp7eXSo41t4pSQfKUhd3uevFX7eSTh/VjGWFTtKcddzhbrTNK8UazPcp4jUXTtuaC4jIYgdQG6fhXQk6deFLeeGVEgAQvDguw6c1T0P4bXVtq/28XUd7aW7lgsCkswHYnGK7XSdDS8ie4t1i+Q5KNnJ9iRU1asVondIypXinKSSbetjHuANKW0ttMtJIbItuZQ2SP9psdSfyrjrTXbnW/ER0jULTMdw7RrKI8umf4q9MtJrC+1q3jgVY3BPmhm3CQAfdA964fxBr+vySXMOiaRHpiLKEaeCMCRlz6nnFFJ82lte7FUc0k4t+iVyt4fh1DwzrNzpenw3El75uNpXhl9SOlbVprl7rutix/s+C0EDgTKyBEkPQsfesnW/iHJar/Z8cKx6hgLLqCH55D6Z7D3FXk8T6xr+mS2F5pSmdEH79EAlf0J7mrkpS1lFX7jjytKMZWSdrLcZ4z8c3XhzxAunQWjwxIFwMYOPVazotUtPHbXcVxYRWt+p3CRP4x2J9DXaeA7aTSLQSeOJbaZIsi0iuY1eRR6c84qbxHoOk/wBm3mqeGYIbW6mIKsnqfas1UhB8qWvczvWlU1enYyrP4a2Oo6dHd6tMLOe3OxRI24S45GQOlZOhXV/o3iefSVkmvdLuFLSJcZ8pR3z7D2rc8LTnwBpL3XiW9+16pqHzJb79/lj1Oag8W+MLHRZbSe3s4bm01BN0gdPmx3A9PwprnlJx+JPYiNaMffkrMNfHhPXtBS2gubqCGzmKoqKCrk96lvDpl5DYWlt58jwpsiJUruPpt9arafoej+LNHnXw7c20bt+8FvGGEsTZzgg9R71mx+I9J0LVYrSX7bNqcYA+1x4AifsMHqPU0lH7Mb3XQ7adSmlzSe5o+I/GMnh6yttGudPtpnQZxMvzJn09KqaO0097/akl4f7PQcW4wdnHIx39M1btdY8P+OtX8jWtGka4/wBWNQhfacjuwPFT/bNJsb+TSdEaIwwnEjMMtJ7+1PSMeXltLqZ0ud1HKWz2IPDuj6NqWoTPo9hc2c4yWeWXcoXvtHapNc8ZLqnhvXNLt7Pyre1CrHKWJyQcZx6/Sti/R7CxR4UIaXCu+cYU9h/jWNp76a1reabNZqgmkBDk/wAX170oyUnzSV7WHUw6mrU3ZHCaZdXFvpc0zyySxcIhYdW7kf0q14O06Rrs6iN6scpCv8TueM/hmuw1TTLSOCG3WISxL/yyA5Jrfs9Mm8P2Vtez20ccj4CHr5IPoPWtZ4lcr5VqyVhVGUed3S2MBYrvQgRq5sLCxnGB9r5eR/Ud6r6doQ0x7nWb26FwkQaZdrZDADgrjtXKeN7DUb/xUz6hJcSwSECCVvmGw9l7V3mn2ukeCNCNp4lv1eS5BCwL/wAslPcj1qZ6JWd2+iJTnG86qSXQ5nwdrGr+J9a1O3iunmR4S0Ybj8Oa29G1e08PwPYa9M8pu/3WSd3lMeCefSr/AIes7TT2k1LQ7uyl09yFVLdfmLd93viuW1vwfc654jN7b3SyWQfzHVztcDvx3+opNwnNp6IuDmqNl7zYou9a8OeI7qC7lQ6ehGyU424P3SO9O8ZeNda0VNMGlyokM6GZpNgJc56Z7Vq+JtJsfFxtLW1ungltVAlyuQQOOT7VkR654Z0ycaTqlg94bAFVkl+6GHOB3q4WnZ8t31Rx4iThFwnK2uj6s3tmhapZ2l/44sHF/JEGiuIiQ7L15Hf61d8Squr2cX9jm4W3RBF5L4DnHr61jaPrNn4tWeRoGE9uudjYLDnjZ2A9q5/xTpuq3uoWMFiZjFw00gb5UOeST2wKzUPfs9Gu+x00oxjT51rd9DrbSaPTdPgsNQhkd0bBiBwST2+ta95oUFhpVxHDZReUyB5UkXLKx/hOPSrVnZW9uLa+1AtAy4jgd/vSsRgED+prgvE3jm80/wAQyW+nokwiO1i/IJ749amEJ1pWgXXxFOhZyOv0kr/Zssnkl4oeTFG2Ef0xVrQb+dtVVPssKowJEYABX8euKwrfxFJceHpNakVoLMnaREwRAe67PesnSviDaf2t5dnpzm3lwoZeCT+NL2E5J2RdTE0ublb1l0O08TwaY1w8dzG5Zl3NGiZ2Z9T/AIViLoq6XaEWMpYSnekg4I9vcV0l5pRvXjuEf7K7KFlVxnPocdqp+JY5tJsrUWpfdCwUn27GsoyatFMqEYOy6njOpeVNdXz3N3I0sbkeQo2lOevPBFdp4FhuIPC0lzcXM/2OVs+WP7o64J/pVS90vSJZkv8AWdQFvFcHfNBHy0hB7jtWr4ksrqSLT5fDYeTSfKwioOFI/vV6FScaijFaf1sedSjUouak7t6enmcva+NYLya7efQoWuLZWkgkVyoODxvHfHtXQeHPGN/qWlTX2vrE1rG5RSFCs2eyfSma4y6PbIbWzt1lkjXzcRgliRzuP+FJ4yt7CXwFpQnia3feZE8kcDPXPrWTdOVlbc6Y4evTjzuXN0s/zKGlX9rq2qSPo1rOjJkyebhjtHvik/t2z1O/m0i6gke2mHlyv5m0qQeoz6GlhnstH0SCPTOHukDSTLw7gdvpTdO1W3kS5lg0sT6pANwZU+8nf8apK70Xob1oWpL2trdfMn1bw5a6NYyxaILiUuB5l0wJbHoMdK6DwdZRG1kNyQ9zgblc5+X1x2rn7aK41vWbfU4muLXTwhDo7FBkdVI/rWv4Z1rRoLu6g06Z55XkCsWU7QM9RnrU1Iya7smhWioeyirdvM6Rp4NVnSzJlgEeXil4I49hXK+Ibh5kMFlPK0zOd22MqBj09a62+EWnFr2GBPMPG4rgKT3OKzLKKS/lE4bbkHcCcD6isaclH3rFVIOpGydkcgmmavfaayQu7KjZYFs8/St5NLm0bwy9xfxSzF3BMcZweBxWnoOn3VjrDyidHtS+QMgnNW/Hep21tZRTXisYi+59rH6VtKrKclBbHK4xp++nY5nRNcttct/sU2mtZTEFY5APmPfnPX60l/4b1DUNElt3JaAuHWZQO3rWDPqt3D4i+0iNItHx8khUKGQjrnrmt3wrfgm5/s26e7iYHMO7ATPfntWjhKHvRJlWjWjyW37+RQ8PW3h2OSbRTeS3LyKfOYJ+76cY78e1Ylx4La2uJYrPbcwhjtkWt268PW0KXctnvttRmDbX3fIM9h71V8M+FtUi05hdakYXMhO1ZC3GBzn86tTSfMnf1OR0KkmlKOtt1+Rz9vcI52ngnp61pQoMcAHnNeg/EP4Ui0jbUPDasYQCZIepT6V5VFdT2kgSdWG09+1cseWa5on1+Fx8aiubsUW5jnHSraxhQuSCMVn2t4k/RgD9KtNdqoUBhx0wetB335ldEswVwVHGKjGFDkgEj/PWqz3yoGO4ZI7VUuNQUxjncQeMU0hSqKK1ZaupVjUMzLx27U3w3ZPrfiO2h2Fod4LfQVL4a8M6p4pvVjijcRZ5cjivoLwR4JsfDNrGViVrsD5pD6+1RVqRpLzPGzDMVGLhF6nU6dAlpaQwxrtRVC4FTs+eeAB26fjRlUJAwCeefWmM3HUAnnNeZ5nyr7jCTnGST2I649KjyoDEggjpmguCM89ecVQ1PUbfTLMz3Uiqg6L/ABMfTFNJvRCLpwRnG1iep70m/arFjgKM5JAA/Go0uYlslupysaFA5LHoK+ePjD491LULgWOnSS2VrGTjDYab/a+lbUKEq0uVFW91yeyPUviV4pk0rR/s+mXES3VwMGbeP3a9yO2TXnfh+9u2t3YSRXksRI3mTfx/dzXI6LpuparpYku2ZioAO9ug9SKvWflaXI0JuVVScNEj/rXXGj7P3UfT4OlRp0E+/c7OfXBpuUuo52WZPvq+AinqVGOcVftSmoQW0llNFeRbtwWMH5dvZs9KyTEusaJLHdObZoV2xyv821T7VyS6zceF7ObyDKtuz7d6nBkb+n0pKm5Oy3HN040nUvaxs+L7+HTb1bm+umtpmflUXJY/h0FZ/i3xPeQ6dZ3GmPGbabOJxzuPfmq+syWHjDw7Fqd9IbKdTgtkfMe4C9PyrpPAWkLeWI0SCwWbTSQ7tOA7BvX2J9q6IqMEpSWx4lSvOd1F+61uaXhXxXfXXh2FVRELYjl2dMeo9DU3ifXINN0l/scro0nCohyWPpxXd2HgPRraLykhYxnqCf8ACuV+I/hiLRNJ/tWwiaRbUlvKxuOfWuOM6U6nuouM6bio31OH8O6XqXnm8uA0ZY712jDL/wDXre1FDdAG9ULOCCbgDlgexHrXD2PxFvGe3SeApuba2Djiun1G6juoZbO1uEjv2TckROSh65rpqQqKV5qx0YapDlvTd/zODnu9AsvGUseoadPq7LIEBMnlLu9lHJrqfI8Pw+J0mi1CW0mmACqDxCx6bsVl+H7Wxg1C5utc8u410HcoRsbeOpA6mm+DtAh1vxfKwSb7FEGnleQYUfU1u7K7beiOKEanxu12+vQ2rLwx4htPGiya4kkmmbgzyMcoy9iD6VF4z1TV9M8QGaF0fSw23yoOFx6gV6Td3A1LwhG1rPG0dhL5YCHcmz1Knn8a8r1DxhfKGawjiazjk2MDCHY+pPt7VhRc6srtLTQ6ZVo06d5N3v3NhvEdt4xjaOw0J7hbVQWaQZYn1DDoPY1R1DR7fXbyP7XC6y26eWLeM48uu4gu9NsPhnDqjJDpsUjky+Qu0OwPXjk59K8207VtOudY1DV9KF6hVcfOcbifWiF22oK1jL2kJWU9e5btHfwDr8MVnbPcrMQXz1YHsMV1GraHo19cya1IJbOOEeZKmBIST2B7fjVPw1cT6rA7IpGGO/fzj8a5W28ReI9K8aPZQxPdWk7FZLOSPcksff8A/XTalOXZrfzLdSOG95ap7eRNZ+NNJ0qbdoVg0c24kvcNuVs9cDFa+qxrZ2Mut2oWOSULKbdDuBY/xEUX3grw7d3q6hYTNawg759PZslDnkK3XFbEFmmoPM9k8P2eKMg2StkmMf7PfFKThe8L+Z0UZTcOapa/Qq/DzxZNrU1wmvx/a7S3jLYIxj0FcTqVzqOp+IpJRHJErS7bZF+6q54x+Hetua5tra0uYtKjeEO2JFJBJ9MHHStrQorfTbQ6lesstzjbbWzHBX/aqlai3JLcJwVa0m7enU2pZG0G2jfCTarKo2lxkRjHb3qXUr+8vvCxVSDcvliZT95uwFWdFutLuoJjdWTXNywzIGyxBxwQewrN1uUWKyTahEIbaMCUAHCovofeuVb2a1CdrvmPMYZtd0i5J+xXl1DE+759xjz9OgrqPiV4b1PXUtNftIWmeWNVltuhQ4/hHcU34e694p1HxWttZ6okukySlinylVX6EZrvFuI5dYvbcXUgDO0jFlLCIjsD6V0zrShUUkldfkcXso1qTjK9jyTQLq+8I6BqEt1Zsv2uVUWKTKkY6muw8EeMp7yzvBqcEEMBQpHIiYYHHTPpVrX4F16OKG4beiOclxnd6Y9KkuPD2n2thFBFa4gKBZX8zPPqAOlKpUhNe+tWdVGh7PlSeltjE+JVndSaLY3mgsPKlb/SfKOG3D19qwtKufD19fWVlrKStqrAQy3BHyFj0Bx1PTmun8aaLq+r+GdOtvD6ObizJV4oiFlkXs2K5+xsNI8J2sF54rTzNcVt6WkbbnJzkFz0FXSn7nKnr5bnJWjy1JSei89fuOx0bRNM8KXeoQ26ubhAAzSj5dpHGD361taZbRyE3U0R8uOMypGoOZtvb6VzPhnxDL4wv2a4t/KSH94VzuDY6A11X9kXc5muL24a1jkTgs3yqOu3A7VzVLp++9Tsp1FypJ2Ofv2PjBpL6cRWUlm42tETj6kZ7etcBr76NLrDSx2sjRk7WcvgM4HXHvXqegzWkk1w11JbxxxoYVUc7gfTj9K8z8U6Uuha/bfYJGu4JHDAYPQnof8ACujCtKTj9xONb5oxgvdR0firV9Ft/Dltot1aSW+9RIFTkrx1PrWToXhjS7RE1aG/e+gVfMVFGza3oaqePYrXV9XE+nXcMk/lqHgB5QgdBVjwfI1rMbH7SIi3+tjkAJb6A9K05eWl7rfdo5qFqtXmmvRmtpPjrUrvVVhvIswbgAFXHeu68Vz7raF3j4YAMo7D+tce9tDb3TXFtCBcs4QQj09AD3963tZmmNrFBI6kudy7yCVUdc1xzSlJOKsejKkoKLucD4n0Zr2SK4gBk3cFApynPeuo0m1k0nw4tvFO63MgJKxnOPqKz9I1W7m1CNlnLwxOFBGPm9vpXN3sHiGXxZdrbtdLI8o2KxyjLnt2xXQnKpHkbtYyqUvZVFNK/MdTfeG21Yx393dTJZIu6YD5S2BkgCsvTfE9t4qmTw9eaUbS1h3LZeTIWK+oYHrmtTWtbn0q+IiiMtpCNkkZ5Ut/EPpVexPhjURcy6bK+laxIhWAudyKx9GHrSUGleS9H2JqYm8k1LSOtu5qXngRtV0aGbRXWW4tP3UkQfkj29PpWTo2m3nhjVkv9Xt0s441IjWUj94x4A+lc9p/i7xN4a1saRa3DvOk3ly4XcZj/UelereK9C0bxDHZXfiTWPJkZARb/wAQbHPTpSmpU2ozd0+25FLGucJcuz79zA1qRvEOjbdEFlBfT5GyGQ/vPXg9PpXLWmiy+HLFZtSgX7R5oDKj/Mf8PrUHibRrvQtfS4WbbpClXimD8On+NT2eqaBfGW4u1mlJON7Sng9q0S5Y2WqLw15u60f6Hoen38N9ZxusmxZPu7iDn2ql4h3WuluYNyBiSSRjNVbGWwmgRWURQxjdEkXBZqvwaraXY+zSh5CONh5z7H/GudaO9tDepCVmlocD4B1K/uNanV3Lqp4x069BW142u5jaSLcKsiZIEZwRXZWtva2kafZLW3tTId7SAfdB71jeItM0e90+f7XrEEJBP78DCqP/AK9be1jOqpWsjibdOjZatHmsUMuvWW1FysKl2UcYA7/SpdGlitNJ1CGwEyXzDAkHIGD0FdhpGkQ6RoFy+l3EGp+aNjTwtyiH1Fc9deG7ixs/ttoZgAC0UUilWLew711KtCTcOnQ4p0JqPtWtWte/yMyDxJqenWAF8jTSyHESyDaQB3PtVKPUVud0tw96srMdwjkGK1NFsr3XkmTX0nKx8xTOnzofQe3tXWaV4O082MZuISJDknzH2k++KmpUVOR24WCqU1Ko9Oif5n0Iku9RjayEYIzwc+tcD4x+Gum64XnspBZTNyQR8pP9K7OzaCSzje3mDRyLkSBgd3vnpXBfGDxLN4e0eJLeVzcOMK4HX3JrxqCm5qMHZnDRqThK9M8o8QeBdX0KRwmJUHVo+RXOxWuozziNYZC5OBx3rpNA8WeJtTt7hCpnhQZLkYC/WpNT1+Ox02C4lQ/bSeccA16nJJe67Nnt0MbJ0uefQtaB8NtW1QobuQQRk9D1r0XSvhFp9r5bS3PmyDlgV4rC+HuuS6iq6hNeLBaqPmMz4ANdkPil4Wguxay6llgQvmKnGT3zXJW9te0PwPOq5hVm7xeh1ukaVa6XAIbSNEA68da0S+D8vJBqjYahb3sQltZkljP3CpyCKsMRsJkwqjnrxXA7397c4pScndkgckdsnrxTHfCkhsANyTxiq9xf2sCh554olx3cVwPxLf8AtrQluNK1hkgDFG8vIBPerp0+eST0Q4Qc3ZF3xP8AEnRdGDJBILy6zjZF0X6mud1J31e6hv7+X/RXQSbHOAFPavDbNVbXI7eaZ0R5djzt1Az1rbmbUbjxPPDZakNQsoEIGJBtZceleqsJGn8L+Z0xUKaSteR7MPH/AIXuYJtI1Gd7SPAVFClsgdDuFcX4u8CeH7w/2x/wkbW1m4AUXa7d3+6T1/KuV+G3h3UbrxG9xexf6Lao00okxlgOcLWH4v8AED+Jdb2uTBbK5RFZvlXnGcdqcKHJO1KTXcwc1ytTXXRM9NuPCt9b2qy6BdQTBLcOHibzI3HYZ9aw7K30mWWGPxDPapqDuF8qGF5GDZ4yeAKwrTxRN4c1Gz0zTIJp7WGRWyh+advb2ra+Kei38Wtw6zpthcwQXCCYps5jekoyUuST36ndGvB36tLoW9R1mSPWDp0cAKwOIizDnA6YHSovFN9pemRJbayrXccvzBIwMLj0qHxJd3EXhqHVbe3ZNRulAlmx/q+OWHua5zwgiarcGz1lDcWhJYTvnMR9j7+lUoLl530NnVnKXsYp6rdrQ6UWmk+KdLtl02VjDEcLbiPyip/u+hrvfAWu22jtLb3sRhQYGQQxTH94dce9eVxeDtSXxLbnQJv9DaYFNsmGwPUVb8aaI+h+J4tT1LUZbf5wQsSEscdVB6Gs5U41fc5tzCpKUKbVSFmvy7n0afEejfZjcf2lbiFeSwbP6V5/458VQ63Fbpo8sjwRuSXC4yfp6VzEEFvryXOr6deFgy4S3xtyfp0zWB4l1QeHLC3itEiF/Kct32J7/jWNLCLnstyYypYe1V3ZauvD2lXGtQ3s8kzyBlaWEAKM9cAHrVvWLOCTxRBqGnBYWtyHKOOWX+6xqNZZ9Z0uyv3Gy4ZcFmO07R/EPXFZev6qts721peL55x95fmJ+tbJT5rX8j0UqUqftF1N228L6bD4nbXrrUTDGj+YbYxFjk9Vz0I963PEWt2A0a40/RrdLSHUflMynJ+g9qz9MhzpEMusHaHTb87AeZWRrlzYeG7K1mRJZ0D5RDxtJ7ios6klfW2xhKlSjFt6LdozTe3Xw8i/ebr0Xw+Zc4Qr3H1rYXwzp+oeHYNe0G/m+xXT7Ws3XDRt3DEdRT7Xw9a+N421Kyumu7LAaWznba8LdCwPYU34iXGq+HE03w74Zh+y6TsEgZBuWRu5L9+a1dRyklF2l1OONO0k94dEtzS8PLfaj4R1zQrnTfPtYo2a3jAJxJ2rg/DGdB8P3UXiiGS2imk/cw+XiQ46kjriujm1K/bw/aG81FNLvI5d0kgbb5n5c1Y8Q6XDq11a66ssV5EI8NMsu8Bu4IP9aiMlFtS2fY6ng26nNHT1NbwE1udEe40q4EsU0mCsx2MpHbnrWd4h16Pw3qwl1yGaO4mU+WsCAsqdM8n0rh/EOp6j/acWj6QrKAwZViH3mP8ASvQ/EmlaN43t7WG41CW21qxhWNztysmBzTlTUJqVTZmEpTnzQorVaXOeSFZrZ9R0qc3lrPkLlSrDHUEetaXhHTp9F1R9RumIgZGUIvLNuGOlY6Xs/h6AaVpSYihJLTON25j39a7TwRe6zdaffzGOM3HklooXADOfVc806rko36G1PljGzWq+4xrLwwDqTTuJfs7NxEuASPXBq7e3vhh9XtoL6/WGVfkVVBcKfRiOAa8un1rV4tSkuZdRuIrtZCrxFv6eldXovhyLVrf+1dRvY7e2Vs77jAV29B6mrnS5dakvuIjWlVV6ask9bno2kINOvrm108mea4whlKcBT/SvOfix4ula8m8M+T9oihYJJct8rSHttHoKXx/qWoWcsVtpTyrE0QZZoMgSAd8+tdN4VsbfWvBseoeKbKK5vrdgtvPPlZM+5/irCMVTtVlr+fqPEUpVdI+V/M84+H97NoPiuKO0smmlkYJmUEbM98V6H4y8TWWj65Jb3MskM0gBkRF3KPXmsvxb411jR9QX+ytOtYtNhUK8ggBcn1LVkazoTeJ76x1q1LSw3ajzt2cqw61pK05KpNWVhUaU43pQeqfXsb95f6Tp9rb3JmZIrogoAc5PvVNY7jSr8ywTtLaXCeakgbGR9DWvrHg9dSawitX+0rbxBWgjU4X3Jro7DwbfSrBHLGqJGu0M38K+1YyqQS3O+FVU7udrHk99d6vNeMwaYvCco2c5HpntVq08Far4rvYrmO2lt0cgTO65X6gV7INI0nQWY3/lxAYKu+Dk+nHWmeItXns7W3vYJFNunMksa/Lt9/wpRxEr/u1ucdetGpFQ3SOU1Wwh8C6KlpZj99L96Vhgn2qld+I5ptEt2gRZZiMEKd233rM+IesWvjNIpdFuRLLAP3sQJDBfXHeneEPB2pX9kJbUeVEH6mT5iPStlGMYKVXc5qcnJvTQ6HRkN7p0czwLbXi5wwTaHX39PrXT2WgrqPh+7I8hrmYFUkK8I3Tg1j3elSQaEgd3lYS/v9p5CY6A9xnrisB7WSabztPJgtY127Gl25b+8AT29a52nLWLsegoe2p8rlY5O88H3Xg29XVvELW6RxSZSKF8vM3bA7D1rW0S28PeIrmTX3Se0lt2DPCTkNjvkV1XxP8ADE/iXRtNubO7tprlEVHzJ/rGx1B715/pn9m+Hhc6NqJlnv5sByh+WIntxXXGoq1Pmv73W3Y8yhCcZuCSstvU7W3mtNfu5LnR5PtagfIQBviPpWNaXv8AbWs6tcXryNaW8DREoOGKjkCreieEz4N0vULy1u2e5uE8uAZ6bv8AAVLpOjvZaK9tBiSSSM7s8Fy3VgO9Ypwiny/L9Ts/e1rRnpZfizktCvrLW9LurWztWsGtiZVLNnzB0x9a2PDty9nILYXzfaUP3CeQD3FR+DvDh0qG8le4ikLfwE42j8aoR6aLbUrq+vrqGOzAyrjhkNaNRnJ2OinN0aUYVPm+xf1HxDpOm3ctlrFpc6sjk7mjby+D/M1latZeF7X7LcWWtSWdpKS6W81qXdPYsOCPeuoudP0HVNIbUZdktvCmWuIn4P8AgfauT+zaT4nhmhtX8gWCFkcqW3L61dOSS0uu551WjzybUldar0OyikEtgJ4be2luliCxX6/f29jmuO8X3c9iunXFyjtcFzht2MY65+taPhLxBYSQxaRbNIcKVjZkBZj/AIVDrc0styIZ7FWEbDb5ibt1FNOM2mjWtGM0uR9vM2vGNu3ibwjYHTlMLWYBeF/mEgIznI6VzOhaMLKGZ7s53DJjCjBPbHrXU6fOU2u3ySADC5wuPb/CqeqM+qG40q2fyrx0zFMSMBuu0+mfWog2lyLY6IwjT5pxXvPsZngvWLnUdQ1G2XTx9qt7eSWAdOVHAIqv4W8Tz3d+0D2iw3i58zC8dec9wa6TwNofiHSdK1i61lvs5t4Ssbbgze+GH9a5XwxqmoXuo31q9wk+YWeOQouVYdPmxmr92XNaxjCpNTjJybVtU18zsNXkkumkt1uCjL02H73HQ1x3ivTtRfw3CqxSSL52ZZAN20AYAIHTnvVTTrfUrXUFv9aN1bW6SAvK6na/PT6VuSC+GvT3ME5ewmG9RC+FPtjvRy+zejN0/rNLklFpMyPh8NR0nUo7u4lmtrLOCq/8tPX8K29QtNeOvyag9wy6aXAVsFl9cAeuKfYG4vTezayRFbWy5JKbVA7c0zT1vrmVZzOz6T1CrJlTjsBVNO7bscylSjGMaV213/Uk8ca3qVtpGnTaMzyRyllkkaP51I7Y7fWr+i6/eR6ZANRs3e4xlvNJDD86wNUtdN13xHC2n6ibCSJQrW8yN82O6kcc12EUtzGgR9shXjc65P54pSUYpKxlRVafNJu138jN1XX7jwwjWdoZI5AcFVfMWB6D1roYJm8Q+H7IeIlV7IgsbnGSuB0qx4z8O6P4rs01PRWWN7Yfvyp2jGOpzXPaL4htLjQJ/C4XzBMCiyA/NnsRUpRqQUorXr5GXtpRdmkuxmad4ghumvtJ0qySS1iBfzFwNyDua4PV9fi1KNrd7NY/Kztffkn0Br0CPQYfh9psetC4lN7MxjVcYAX+tN0vS9A8URXGoWumx/aRkzrGxUn6p2+orXmgvfirruS3VmvZuSTfQ82i1m5utCWwSIR20L7iVzkk+tR6Xp9xqMnlwfNIp+6Op+lbsOkzvrMtlo1nL5LsAVKluPf2rvdFtE8EO141pLJMcfIEzt+lauappdWznWGm99kdb4LttT8K+EWe63PJwYo2GSp9TXPT+PNetdXkNyEms5esb9D/AIVoR/Eu9vL0WFtpoOeWlniOwe5qv4i8S6c9xDbO1iLpsB3ihAUE9gTya4oxkpN1I3bN4QVTTYuHXYrqKG0vNPg+0y4MawJ8qj8OSaw/iJfy6Xp62j3RtVBytuqgfhgd/rWzBPb6Lq9k9zPDbxEjyppcKHz3FZvxn0F7m+gubWIy21wA6zRjIVj1/ClDlU1fY7VK0uSna9jj/h1o9j4kn1OGeZRetEfJVvvA/wB4Dv8ATqKhsvh9q2kasXvbi3hT5lR0kzuJHBI6gU3TPDN9psn9pRrc7YD99UKnd2x7Vv37T3nhL7TDFOdRLFZJAxJI9QK3nJ8/uPRiWFlKHta6V12Oc0nU9Y8DTTz3EatJMTH5TvkOvc/Sty88GW/izSLTU/D9obO6uXIuI8kopPoDzzVjSdDu4PD3n6tHFNIwJie7wSg7YXqT9ag0b4j3+laimmJGZ7Zj5TOgAkBPGV7CqqXlrT+JHLGCiuap8L0s+52PhTR9F+H8UllNeQ6l4iCmVIyBtgYjoT2rA0eXxJqXiq5udUvZCShGxT8mO3HTFZOreCxaeJpJ49dieB28xmRt0uDzt9M+9dDeatHZ2kk1hazsltHkLvwXHck9652rfC+Zs66GG05nG3Ltrv8AIp+NVvZvDkC2bSpcrceWyRjcSD6Yrf8AAfhmV9KnTXEht7Z4w3nPhGDfTrXC23i++1eGS00mR7DUTk/K33k7gHHFTX+rQXng66sdOunfWEkXz0Q7mcdyvsPam6U+VQ21LWJhyucXr/WiQ22vdYtPG32d7Nm0pC8cbop2lcHD7hVDSvEct4l7YeJIH1TTiSYw5KtbNngof6V0Ph661Hw94BuJ7yQx3l1kW1vNw7L64PI9qs+Bby211/Ia3IaUMWUDncoyR071bfIm7XtpcIUo1felJ662f5Gj4bhsr7w7dafpumSoY4iYbhc5V8ZHNeZ2FlPceI7W2vbQ3W6Ty3iOctzycj0rVuvGviCw1Zktr17GG3mCraIu1WGeh7muo8b6/d2gtX0mC3sLy8h8yWSOIebg9dpNaQjUpysvteZwTnGom7NKJz3j64S28Q2xtbjyNM05hFDbICduOoz3z70WUFjruof2xp0bIElCyxMMAse59BU2jW9p4n0g2mquba6ibe1yV/1i9zgd6vaDq+n2mrx6VodtJFagEN8oZ5WHVnz/ACpTdo8q+JHThYS5+f7D/MZ8QtNvNc8LWrWCYl09yHtomJ3oejL61X8LaNJqPhBLbxOk0TxS5tfMbDMnoQew9TWV4svZodajnsby6juElUooBUYz0ruNZuV1OF5LtpLWeKIPKiZxL6Y+vpWD5owiv6R0/VoOvKb/AOAZOha3drql7o2k28cWipAyMY48MxA5JbqeayPC2pajY6o+kavI+oabIDJsdCfKPYqex+lHhrxBPfXE3kDyX3gCNeRj1PvXYLrMdrrEunTMGvYlEjvsH4gHvVTdm48vT+mOlQioxqKV9dP8jiviDo1+wsrwRSmF1O1CckDPHHWum+HMMuh6DK2ti3S2vmOLaYZbZjr/ALJqTxbo8PiiIzadcNHcxjd874Ut7HP6VnX8qQaTaRa1MguYuFWJtzMPpU/xIKPX8TdWU5Sm2k/PQ2fEWrWmk2lu+kQ20bSnyxcyqHaIHtkViWOt2unFp7qJXuem6MYBX+hpNDCFCLy4itzMGW2WfA3nHAx6VxOpJqQvmtblJkmDY8vbg89wO4qoUr+6xOdOCbi7o9Jv7zTL7Rv7YCRWpJILyHOMenqab8ONK/tDXINZ03U547VNxkeWP06rioLbR7J/BkejatNGt40hnWISBHz2Az3qt4Z1nVNL1W20g2RsNKcMnlxnJLYOCzfXrU8t4SjF6/oc03Pnat7v43Or8T694VGqzG60OzeXk7wvzn0JI6D2rh/iHqVhcppmkNC9lCCJ08gbljVvUZyTWXbaJqZ8RzS6qJY4UlLuzjAbngAdxXVeNNBXVNTstY01bcTxhFuIpGxux0IHp9KcYQozSv0JlzVaKjGLWqvfsXNb8SXfgjTNKsLSztJ7kwl4ru7TfiP/AGR71Z8MeLdQ8YyfZLi3tzd2ql1S1G1GUjkhfWrHjjRbHxxa6bDp2q6bHrenxeXLaPJtbnnAzVLwPoVp4N8QM+qXy3WrspiS2tgSIye5bpwKyvT9lqvfJpe0nWdRNNLoVvE32K4khs7kzwyAdRjb15B9q67wzotw2kGMvFbaVGA7y4ywA/u0lno2mXOL+7nWWG3Jee4dTgeiAD9a57WfiZaarK2jW1ultYudiTrnjsM+1RyzqrlgtFudFfEKHurdkniX4gnQ5ksvCcKrCPvyuoLSH15rqrf4gRWtlY3mojbLPEN8a9j649a8603Tzp+pO2oGyZF/ilIKg9jx/WtDxXojapolveLNaxqWMeWkCbxngqPStZ0qTahb5nNGk+Rzluze8V3cXjG4tFtLmOFkQttzjI9M+tOktLA+F7jw/qGopFdzgrHnkJnpk1ycSWfhDT7bULyRZIz8iBBuMh74PasDxJq2neImkuLNbqKaMbjBIMM6+x71UaDlZR+FdTGpOEF7Lr1Rc8P+C9b03UX8lFuTD8hMK5yv9Qa9Vs/EFlCkOhrA0DsQvnJgKJP93rivGPh1rN3aeKI5ILu6SzGRIhJbC+leoafcQjXmurPT5ZPLbeqTJzj+8DU4yMnO09TfCQjUpXtoYPxd0fU3vYEinll4BRYmwPfjrUXhC3a18PzS6ihd1cIFLfMGr1DVVi1nSrhol+yzyIAZ5hgLg9MHn8RXHWsuj+HNLkttTlt9TnnbO1T8inthu9ZRrylTVOxWHpxTdT7XYrWmm/8ACQtbxQzT2678PGeoPfBq3rXws0pr5L241eSBFOZRjBfArnbvV9aubK4j0UR2kUbgqkKcBT3LHkmrEFvNdWST3eob7rdhlaXr7Yp2nHaVjoqU3P3lp+Ze1a/gv7sF2W1sYx5cG/q2ONxHvUs9mZYdNOmXaqykkFjtyc+9ee+IIbl783TOfKLYwy9cdhT/ABxpGtTSaRNpK3X2dIwAysVMZJzlvatvZRSSTOSdWcI3Uetv+Cakt1NDdX66vAlrJExBdc7f/r1nw6K/iSF7ZNQE9o7DEsSljbt/tL1xVnxjNJrWmwXdu5mnswsV40Z3BsDG/FZPhm7az8QrqFkwit7dC11OpOwp6MPWtYQbhzrSRNTFv+DUV4nRXVrp2h+EJdA06VdVmaXfcOoKBiOwHtWTok8OnXkFtbaXLC10pWRC3Bzx3rb8Q3lnPoU2veFUxM8nLbOVPcgVQ8Gard3lreN4ilM0AG0TOQHUn0NZRT5G3/wbnTTqQXuwjtu/0JdJ0vQT4kK2NzHFeRoyfKTkN7A8fjWbeJe6Ml1fXEbTojExvI3ySH1x7U7U/h7qV0iXfhyJ7kSPkOsg4P17V2umWGjWVpFpnjC9c38yASRRtlFJ/vds03OK1T5u66mcqvK2lZaaWPLofEU+rxzW+sCF7Z/+ea7HT/dP9K35LGz0XSBqU8txckBUjKcMc9CW9Kt6r4D0Jda+yaT4hgjuSwAguYyOD/dY8Gp9UaytkTw5OGEIUoWkI3M/qPx6CtJThNrk2FhlVhC7+Pa/ci8EeL7y+urqy8mMiSJmAzzlRkZB6jtWd4d1WLUI9UlfSYNPniwfMtgQGJP3SD+dM8L6QdA8SIZ76CNlYqm4glgfb1NWrue9vbnUNPkiURM2EeNQOR3OKlqCk1FaOxr7CtUSqyfvW1Qa/FdXenRyzSSvaAZKvyCRTX1Rk0KS90+ON5YCFU7PkXj722r8VndW9hpywzbSjBJSwyDz0P51zOs6xfaZrdzHB+5jilKGKMAxMPQiqhT59F0Cti/ZpQatfS5Ld+Lp/EPh2fTtYMcTMwxdRJt3HPAIHGKdperWfh/w8piX7cxkKKW4G49Tj0FSa/r8cVppcP8AZNk5u1MkkezhucAqOxrcfTvDtxDa2TRwmRG8zyA+CM9RitHypJOOjOCK96TpNc6srso2GoRLbR3+oQqCSGjI+8f8+la1rrWnXEZl8+5VmYkghetZ2qQi8CR2MOxIPlVI1zj8Kh0vwvcNahp9ocn+Jtp/Kp5Yct3udkqtWVVp6JHoNhp+sWGpav4eliS4067j329xGAgb6tVP4f8Aw8udL8Si/vo3SOHJCt0BPf6VxviHxPrGkXenW9nqD28UcCuZGfOQfSvU4/HlkvgtNSS8R50jCs0vGSR+tYVPbRjaK+I82VNbXu99en/AIPjP4duNc0mwj0+FmaPdjAwMda5LwVoB+HWl3HiTxDvZpF8uG1UfeP8Ate1WPDfizXNZkkltry4k8yUCIRrkD1yD0GK6z4taLqeveHrWK0YNGh3TIOucdalSnTSw8mrPcuNOMpwcjxDUPHmptfXU9kIbVZ2JKog4HpXd+E7W51W2tbrW7lYA4yYw4DEduvTNcbL4RXQLRtT8RDCrzb256zN2yPSq8VxrNvOuomFwGIkUFcg+nFddSMZQtD7zbDxlOtL8Eey6nFbXFm9vlLV2G1ZHIG/0zXk914F1iXV5WuFJhBBMuMgD2r0nw3LPq/hmbUL61iS/jU7NsRx14OD3rjp/GV5ZSPb3rlIQcfKuWauehKpG6gVOnCXuy6M3/GGjx65odjp6TRrLaACMuuc+tck3jNtI1a30tHd7KIrG6tyM9D1r0W0W2isLbWrWVUiHzEOPlJ9/WoLfQvCer37+IHsFMsA3mBGxFI49z15qY1FFcs1dfqOVo+9Ttcp63Je2Fws8l4bDTnAYSsMhh6Y/pVJPifpQIgi0q51MghRtURKV/vA+tdTfJDfiObXTFcqcNFp6jMUXp9TXNa14T0zVJDczWZV1wPkfaMfQVNOVN/xEVUpVJr927MrXD2evTtdWctxEuDtgvUPy+24ZFY194Zub6Ivp9nb2knQx+apLe+Tiu20bTbLTlKWyKsXG08+lXbiS3aZkeIoiLnzX4B/ChVuWXuHUoycFCbuUtE8NS2/w7m060ks7rWWJbCupdM9ga8/s9M8U6APsd5YTiIsXZ5F3BR3Ga9GKQGUrFDG78EnIBUfh607Ufs/kmGWecs+AoEjAAenoaIVpQvdXuZTwvPJPmeh5/wCENOlGtPffYlWLn96y4BHoPX8K2PCnhK38P+M4tfgMlxpoDsiYGUc/wt+NHinTtQuJrcwyPLDHtjjAO0IfoP511h0qePSSPtUbTwgLIEHzOT/ER2xVVKl1e+4OjHmtNHl2oyan4p1PWbu+sJFlgYywlVIyQeF963Phzc62dPvLu4jWC5RTFZbk2bmPX610cM72VvcMLsTRhPn2DBH+yDVjStV+16Q0kSRv5QIhV0wu71yO/tROpePKo6FQocuqk2crpVtfXWn3cmsx2x1Ri2x2iy604aW+qacreI96TWKEpIBkOM8D2rMsvEniWPUp0vNPiba2BmM5YexFdWmn3XiHSL6G1Z45p0V4rSc4bI6jPoacm4u7aXoU0nS5lF28zyqLVryXUmSCdo0aQbFXgDmvU9L06VN0+Y7bV3hLRF1AMnuAehNcV4c8J61/wmGnxX2kTwxR3AklLRFVVAeu7ptrRvPC+tX3xBvb5zL/AGbuLm5LfIF7Bf6YrStGHNpLoZUMVOpBU3HqVNFg1y41p5tWxBbq+MSoN27PAA7mt3VNSkXTNTOlTjUdTx+8tpY8bEHoveoLm9k1i/urC+hdDBxDcNxz7+tX/DfhiDw4s2sXdxJc3pXCow+VVz1I6ms5SW8lr2Ohq1O0G9evX5GR8MZhqtxeRf2bDZziF3luIlKiLA+8Qf5VjeHLqC81e7FxfSyqcokix8jnqfavQNJ8VaKL6eziEUaXsTRPFGgDnPcc5/CuT/4QMaPrCTC5lMOd8UAXEjexHb8aamuaXNpfYmPOpRUdUvvNuy0+PR42tDPHcSO3m7wcg56CrMPh3RVJ1XxFerawZwB6t/MitHSdGAkafUdsSKu9wp4Qf41zPxFuIfGNrA3hq5i/0QbJbN3Acj++vqKzi3Kdr27sMRNxjywV2c14z8NarJ4jSaKMXVhMoa1mifcpT2PY10FhqSaXYySa7Kpnj+SGSQbip/ug9/r0rY8G6Pq1n4QWwuotwZjJF5h+aPPZfaq97pramkdhPoM0r2uQZWJH59q0lVUvdlsiKVN04vl0k9Xc5OLQLLWJbnV726lnUPuLbtnlY6D/APVXo/h2OxayF5IWmlK7Y4QvzcjALN9fSsTUtJhj8LtFZWRja1UySRxHf5nuR2rsfhpPZS+Gbe5u0VQAR8vO6sa07xuaPkpU3ZWfWwg0eQ24n1NRI7HJcn7o/GsW/ltYrxEgO0KR8oO49epHauo8Y6tG7R2emxzSmZcBYxk59xXB6P4Zl0K/uLnxDePHJMGCDbuOT0OPQVlT1V5P5BRlz+80JN4V0qHxmusyXVxbyP8AvvKjUMA2OWz1x7VV0jUtLvvFsz2motdagdwQNEVBPTJJrQiWCzgRtWuy8cuQZhhiyHgECs3w1oieHZbrUftH2y0OVt5UjCryeuTzxXRdOL5m29kOFOVKS9mkl10Og8RalbWVm2gxhyZI9spXgbv71cronw1v59RtrkPA9izhlkV+SP7u31rr4tEh8S3hvbC5E8q8Soo5Vq1NbXUfCulxizFw6HAZtvyg/wCNQqrpLkg7N7nK4xnK73OK+KGlTaPcwWtupYTDeWZcbx6fhXJeLorh9D0wu0gS3ODkdD6ivQLLxot1qsNtrdmL6B+hkHzoT3X/AArr9D8K2uoPc/2nF5lux+SCZCAinoQe5rVV3QUVNbfiYunCcJc7PHfCmj3Pi7SLrTpmdRDiSO4Zc7SO1dT4L+FF1DfRXl1exvH2Xb1U98d69TTSbDw1YuNPuobJGBYgKMsB6ZrzbxZ8SpbaKWDRkG5Tte53dfp6VCr1q7caWiZEnCNpJXkup2N94X0LRNNuFNxFbXEjCQOVDNx0GOuKyrG8/sW3udQVPtG5MJJtwuPp3ryXXP7QvNPgvZr2e8MwyJFzxz93iteKbVbXwBBYG6lF1LMXjgZvmVPXHXn0p/VtFzSvc1hVq2lGexmeIdc8Sa9qoecXITP7qNUwoX6V1fjzRJbjRdELNBDLDADI7Ns2g9MiuR0o30Go2klxcXGUkBZA2cc9KsfGqdZ/FSyWzym3eBBuHClsdPwraabnGEdkioclFc666nRaPcJB4fkisNRimZcGc2/zHB7HP9Kz7HS7trw3jSfuWb5R13e2Kx/g/KV8Q3aTBJLf7I5kXscdPxrq7fXtNvrsWAt2t5IPnQhiwfPpms5KVNuKR2QqU6vLJdSHVNR1G30fUItP2RXVsRKrPGCwU8EDPemaTqF7/YcGpa9dTG4lJVX6fL6FfT2q7eMjvLcSkCMoRLnkkdvxrN8N6xpfjW1n8O7JNP1EKRaysNyvjs3oalfDtp1MsS4U5c1/ea26HN6BqMNj4omewnZrG4DLJBIuVbPb867rW7SLXPDR0qF4dLXfvJWMgSem7vXP2nw91HTbCa9dUnuoidtquDuAOMmqer3TTrZPqU76bqEzbBCSQCBxk/3frWsv3kuaD2M1Tw6j7Gq99+xbmvYvBVvaaH5EF/FI/n3E0pIRyRwBjmrni60uNc8O2cmlpDauxJ+yQLtVsepPU0eI3gj1W3gvNLtrjyI1JuHJ6gdaINQfV5kNm0UPlPwo5x9BUKTVqi3LWHjWg6fS5zSw6hZ6ENPudSezvhJ5kcSuQP8AdLA1HqVlenWLLYk5mk2E8k7iMZyemKPiNpl9PLb6l5ZaJF8uU424IP3sH1rptPeXUfCpht7+SaWaEA8jCHHK10RqNRT7nnezXPJJWcSDxN4Zs9Z1Z7m08S2C3pwRbKxLKR6HpRf3umWniO0tdQuZL/UIkVGnwAA39fTmsHTdFvVureNrQW8MLgvM5xtxUtvPY+IPFjyWemyidJP9Y75V8d2HGKmUOXrdI66FWbqRVkm3f5HV3mhw3l8urbFURlX2M3zMB+ma5gnUx8QYnUy/Z2mG1cYBX0+tdF4jnnTWreTSXRkUAusT5QOBz1qfT7x7y4kunkhmVcdV+ZWPpWUW4q+90d7tXs9Uou/qReJNZsLESQTySb5Hy0UeMgVQ8Yro2jnT5b7S59QnuIRKsnnCIMvYNjqa5/U/DOs6j4hlmt7Oee2ZwTLj5VHuemK9Dk1SzK22kXbw3VzFGSqFd2zA9SOlWuWDVte5wVnUrx5F7rvvozEvtaiv/CVnfWmkwaeImMHI3sq9ipPP41xM8y/2hEsVqE2sNkoYljz1HvXb/wBp6JODZajPAmTiRdxDY9R2FJ4j0q20XSJb/RTcTuWCJO67iiY6pjj8a1o1Evdta5y4ui4NTUr23t3K/i/R9ZnubS5sLSQWaIrySRMcl8fxAcg8VLFc3Uyl54Szk8lQfyrl/C+q6hFqKSx3dzkktKRKeR6kelbgvri4klkhMioXOBilUvC0XY6stpfWLzu9TM0C6s9U0rbr9mbnyMR2xDYJx2PtXWG3h8T6LLpZtV0+OGMuDEpb7vrWzp/gXRjMlpa6lEkQPAXLSN6+1bp1Dwp4PUWMjS3l3KpRzgknPY+grKpVvL93e/QwhKCo8lRXkcn8MopbXUjpmhrIkeM3NxLg8ewHSva7S4/cF51MSocAOclvQ4968Dtfi6NJ1WW007RbGC0MhVnGQWHTnvXqPgfX38RWtzcpbsrgFhKZNyhvQDsK5cVTm3zyRlJwqL92rJHDeOEsvEXi7/TPtHlocRox4yPbsPauS1HVL1NQezgfakRxs28AV3XiPxf4Lg1cTXJe41WNtjrEvy7unLdKl8LeH9E1DXJdUtpkmAQypbSHLFgOhx2reM/ZxTnF2OmFSnNPldrEngXWb54/KvoBHBImxZpB9w/3uetc34q8FXV9r+Yik8UgD+fH91h9a4/xf4o1jUtYlt2mkiUSbVRBt78DHYVqaX4zHh25hs5AbhiVW4lLfKPUKK09jUi+eO7LjWjDmae29zZ8f6ta6TbWXh2KcNHbIBIRxz3rS8DX1pJ4K1CO3Jl2TAyKxG5Tnggelc38SfCl1c6x/aWnBblLnDbYzkjPQYrovCPhmfwrZSXOpFJJ7qLZJbg/cBHBPoaibgqSSerCnC7cpLtY6UJsCYGWwMqT0qXyZGDBGVmQAHPTntVGxmNxa73GdvyhT1/+vUrOeEiLrIem1sD61ynY4kdtdpbyFfLeaaMkgqMrz6+9U7q4k8yRbiQj5smI85z3PrVq9ZliYhFeNSpGOMkdifep4ibgwtGnJXBjIHH1PanpuXHTUjxHbvuVY0iYAh1b5hgdMHrQkqGFGDKVYn5RjJ96z7m2vp791ECywsAxGQAlXWeC2WK3hV2lUAj+6o7kZ60FtbEqgSMFZW2kY9//ANdVZbuXT9I1CSGB7m+QfIM8OP72PXtViHY4BWYlmPJIyf8A61SNcSWt9ALMReZMGiYyHAPH3hSIkjgfB+pm/wBVit/EEQtXupdkIKkF89gP61ueLdRt9Ju/selzMUh42r/C3v61z83h3VYvFaalLeQXEEE2+MsNzA+ntWkYtO1XVrq2Rnj1FQGkD/dJPcH0rrlyt3W1vkc8IzbvN6dO7+4uW/iNJLAyXECLdKvBjwgeubtJp/EF5NcQXjWy23zSRO5GweoxUt1p+gz3bWuqXs0VyjbAqgn9RUfiSC20fT5dL0VHDz/6x4zueRewPoKSjG9o7s6LzhHmaOo8V6zcy+EYYvD+oXNxdt8siztyf9pR3+lTeF7G8h8JpH4n1gW08j740mJHX+H/ACKyfBUEOh+El1TVZJFW3QttzkhjnA+tYuuw3fjWWzvtNvZLmDd8yyAqyMPakoaOC0jfc4rR9opR+O21zudUjtPCtu91dRG+uEUshY5QEjqfWvNNN8b6jPrcTrCjpLKFKsScgnpXqt7q8Wm+FrOLVbeC/eUlFikAyiDjlvX2rhPD50iTW3fTtFEMqgukkkpKRD+8fpToNKMnKN33FXVSc171u51aaRptl4kkmg06K61HO+JF/wCWbHu56YFauow/2Kpa7k+1atdNjaOvPQD2rjp/FazX/wBm0qQGxtzlnBw1zJ3dj3HpXUaP4Z1HUp4tVl1CCeKRhnD5cVjODjZ1GbwrJrm2X5mP8RXv7Dwja2FrFI1xduWuXH6KKz/hx4R+w2d1repxRE2qgpHKcICemfXHpVz4q+NNrf2fpoT9yQisfvZ9T71H8IdTluNK1r+150ZJF2o9w3DNnoAeKte0+r7WVzL3IVOd/E1+BFB411Sx1b7QttBd3ErbUYn5Ixn0/pUnxe8SatOLKGO5kt7OaINKbZSAXPY98Vu21pDpthcahfxRRCIbvITDCUds+g96zfCXxHTxLqP9ia/p9mLe4BSGZI9jRf3aI2T54wvy7hiFGVle1zhfA91q1lrkV5pRnkGQrblLK47hh3GK9Yvbs2cd61vZNEiAyR26LjA64wK4PxJJqej+I49H0a3vZSknJjU4k59q7K3/ALQvbG5uLtJba6tyFIlBBI9CKK75mp2Vmb04wasntpc88sPH+vXuuwRK8NvDJLgiGMA/ietel6jpthrdlJe61qo02ONgFdjkvj0Hp7VxuovoemaiNTkZWvB1t4iOvdj6VqayH1bw3bXMMbPDIMqqjcE/H1p1bScXFcoU6LhGyld33LmoaXZX+mPZ6TqNrqTMu5Z0AByP4SOxNcpeaqvhKxhh1KyjvJ3fDxMSCF/2fT3q94M8Mapp15NfBWhijHmt2Jx6DoKteOtM0PXTaatqmtGylkG0o8JYZ98dqIqKnyN3X6inOpyOzs33MqK+TRbqw8QaTqUlrZ3f7xbeTj6qfUCu/vfibYR6Ij6tapOZecpwrKepWuA1LRtG8RaXaaTomuLcX+nI3lAxEJKpOSF7jFPPgy4vPBemNfgx/YZGSQA/MyZ6D/PFVKNGdnU3/HyOKVOd2opeTOu0HXvDGpXHmaPo9yZsgZLgAE9K2/Gnjd/D0UdlIUs7l4soh/eMPT5jxzXid3qN1DMmn6GkltbBgAiLh5GzwWPU16X8UNNh8TWGl2E93BDr9pArSNIwUNkZx9awlTgqi5tjoqYecIx0uzgm8Y6zJqdpd30i/ZS5EkL8kD1x6VenPh3VrS/1CO3mcE7zEhG5MHnj0o0qCLSmfT/Fk9pH5sYiRnAaVfQgjnB96n1PSbrwbpjDR4kvGvjnzgCQIj2Hr7103i2oxVn+BUoRpvmvzW6bu5peEIdMuNMMOlyMkzfPFBNzkjtz39MVw2s6frOm+IZNSubG7co+5ZFycEdP/wBVdHZf2dYXtpLqMrLcyrkJgBEPfmrfiH7bc3ck73QVFBdJAx2uuOMGlT5oyfZl4rl0cXtr6Gui/wBpaBHqF5ZtHdkhmmUBdpPTcP61ylpFFql1f2RmnV4lMkgmAeJgOv0PvUXg7Vbq2v2fWdRjEVypjRJW+Vznj/8AXXSalLDouoSRvNZRS3SbCjOMSAj1696Ti6cnFamSnGrDmaSfmc94HuNLlu7nT9GlWK7lQqHkVvnUcnBq9pOn/wBnXt5dtcm5uWO0Dbwg9Bmks9MtdEsNR1HQrRJr6KIjZFJ5jxk/xAdgKpeA9SvryKQ6rORA0uA0gAIPfFOet5RehVCTjJU6ivK262Ru2ZUJ5UrhZ2OQCevfmuh8B6Fpo1G4vkiSK9mYrkL8yetZGq6PKJftCYZITuyvIK+uarS+J49GvLOazTz7ZxmSdSQSe/0x0rCSco+49y05Vbx69D2lbGKO2MaKcqDucjmvLPiF4N0y/kt9W1vU/sUMJ8vdGu9nXOQMevvXZr4xtZ7YNIWUOm4Z6kY9K8w+IGryeIvIsdNR3hjUhmUZBOaxwsKine9jz3QqS92Su7lPx3O7eTLpeJNMmj8sI3XgYz9a5ex1CLwtfK0Pn3E6bZNpOwJ7V1GtapN4T0rT7CewtLydo/MP2hCdpPQiqGj6S3ji6hublrO18ohJ9gC709h3Pau2EoqNpL3TujSkveTt/kdvqNpF468KwanKskUs4LC1LYLbeuz+8K820PX5DqzaFDZR2ttKxgLISJFPTcSas+INQ14ePIYdOF3bW9o4hsYlUhRGB19ORnNdCt1YS60bmWxWG9XhpVjAVj6/WnGLpxtut/Q82N675l7qu9O5zXhw3P8AaUmm/aWne2lLAMM5x3zXS65f/atNl0exjSO4lbMs8agbh7nrXLabaXUXj1ZIPMtbQTGVpe2zqcnpXZ6h4m0TUp5rextYlSfMS3cQ3bT7/WtKrtJNK5pSTnDle6v8zCsNLsPD+m3d9YXf2y8SNkdC42oce1WfDlpM+izagEVQ6qJMHCk+xqLRvDV/pelXsWp2du0Yy+B1de2R3NbXgvWm1PSZbKe2Flb27hl3cq2OxrOo3ZyWuu53UanJaOza27anReFddl0bSXQxTXMWDukRwBGfUL3x3qpqGlT3jwX14FK78Ryrzu3D069O1VbW1l1DWVsIZFiimk5WHlV77sHtXS+M/EGn+HP7IsdYu0MsWZN2NoPGAf1zXJtNKG7KxFSNN3W8jw+TRNPn8Q3dhuaRlkJDu23PqBW7onxAvbe9FnMEXTYf3BtZl3Iy9OfSrcOg20Gq3GrQTC5hkzPDjncDzyfrXHach1m/vbrUykFugMkkzIdqH0+tej7tRNvVI4YNU3CM7LdvTT5s9ZWGxvL2O1trS2js2iMz/Z02k46EnvzXGXvi+PSbqS1urSEyKcgydSOx4q1oV6+s+EtbtfDdxMl3bIGXdwzJ329xXEW2omFGj1rY92px/pIy4Hof1qaEFd85hicTKMlGhKy/Bn0pHoFpIJrH7RJE03MF3H95f9nPQ187+JbDxJY+MZbC6a8kvRNtifBPmDPBB7jFerajcHT45zcvKsFqcmRGOVPt2rY8DeMovFmnXFtETLeWykxzPF86r7++O9YUpzpJytdCr0ua3vWOJ8TeBPC/hjTYtZ1mS+uHmx/osbhVEncZ6/hWxoHxB8O2Xga7gsrSfT/MDRZzvZWI6+9YGueJtM1G8udF1uK5VEfgH5csTgYPWs6+tvDEsS6GbyeykV8RSY3pn3NbKnzxSqpt7mbgoXtJW/U4200q0vJ7qaC+eXyAZfKeMq0g7813fww1LVLnVVmsdOlRUIHmhfkxnkEn2ro/C3gDSPCMg1DXNXFxI6ExwxDaGWvQNOXT4NDn1XTrd5YUDOkbyDC4pVsRBpqKvfqKipQ628kecePrTw7aaw959mndlO6SVXAUt/sjHQe9clrejeF9MGnarealePFdjzktVhyzYPQt2FPvfG+ma/q7Qalpk4gkfar27gN19DVj4mNoUum6XZv9stJrdSE3IHO088gHpVQhKFou9zoq4n2sGov3V37lzwB4nv8AxL46EMqJBYOMt5K4WJF6ZPbjvSeP/Eslj4iey0p0u7bdtZgxYfnXWWnh8WPwot4vDMYu7qYBpZI1/eOpGenXAryVNLbQ7iO48QedDDMD+6T/AFrD156UqShUm2ltpYIVJxpqUpad+x1XhrxFcWge81cFLR3EKyLyAf730rvkYzIGhKyKwABXkfmO1cfZ6RZL4VgttFmkkF5llSYgAZ4JJP8AKmaPBa+FrCe1gn1L7cg3yRo4eIj129qynTjJvl3O5VpWjOVrPz2OzaMZKsu8dCc8/XHakSN4ADbjdIAflJwrZ6ZrmtA8b2eqXZtDBKJcZwAB09K6mwvtPu43+y3iSSbuEU4YfX0rGdOcHaSLhXjNe67lb7RO84hngEUuOYomG1vfIp0qEzEPGqSAcZOTj+VTSCOAh7hkRCemcEVmax4ms7KJmjX7QQBt2HAz6Emkot7I2jK7si5K8cVu880u2JerHgdKdpF1bajfQx7oWS4jKWzbt4VgOmAeM15LLr2o+IfEMFhfIrWc8ojZADhFzyQfarOoT/8ACN6rNY+HkMcMcm8zyf3fY10fV9OW+ph7dy5uy8upoT6nPost4NdjbDytGqJwcZ6nFal+sNv4Yxpc5OqXMReINgvsHv1+lRHRLTxLdLrX2lkitog0iMM7segqompaZ4g1tLeeOW3niTykugMIAvY1ejd0ttwd/hk/Id4O0lpNKW91gj7WshwZXxkdi3r9K7GLSLAwPqFxd2yzIuCqgEkenP8ASuWstK1DSdYN5dssekqgP7zr+A962ls08V6deTWJS0itl3S3UjYBH+NZ1FeXNfQftpUoezvqu5kz6Tf65eCN5Wk05zkqikoi/Qd/rVnWr5PDvhy7tfDVtm3jwJJm+8T7gVU0rWND0uBtOt9VnuHkyrybCE59Kf8ADXwhNpmu3mo6hqMEumqpEgViTNnkD61TsleWy2XcxlUlGSaje+77Fy/06HxL4f0jUbid4FtY1DRD5WLnnp3FYXiqW10iwW0jeT7RckNP5Y+Zh/d+grf8S+J7L7ZO8EQiih+ZIV7en41ieHdU03WY9STW9G86WzhN1C6TFJAc4wT6c06cZfE1oug61VU6fL9p/wBalfwT4aXxFKEsEnRmbBkcYSMV0d/4ii8HXsmmeGybyZf9bPdSbUJ9FAriJfFGrRPBLbTJaQRSDybeIAJ+GOT9T1rotZgstet0vNcePS9Zch/JH/LZTnkr1FXUh7/7zVdjnhKValzL3SGyvNK8TztY6tpgtrt5ci7tpSW3H2PWtHVvAOqoiafocLGON98ju4Gfc5NSeANGtLO6a4llQhTt3kZVT2PsPeoPiPqdze6sBBKFt4+FVP4vxrJSftbU9EdU4Pl5X7ztqdZpOjS6R4UuoNdmgaBvluFDbiD25Fcz4G8N6JD4kg1TT9QN5DbyZaGQBSnufWtD4e6RdatpV6l1NGsLLtCyS4IPYj1qzZeCv+Ec1G61aaTzbGaLy3EXqcAfTms3JR54uWr+4lRvJKVtPvKupfFPW5PELpYrZx2gbaqGIM2M9c113jHXrG+0i3stQvrfTL26jyGZSctjjnsPeuGm8GNBrjXcdyhhYeYpHUcdCKZ4t0yPxBZWM1wI7SOAGJZbh/LyfUZqVTpuUeXSxrUpQUE42TXmc9aeC7m7vlW9uwLUnL3QOQRWprvjWDTo4dK0CWeLTrFfLj2rxOR1Zj9a1dD8MXtr4XvrZL+3uGeJsGKQMQO351zPhXwVq+uSwQ6hafYdLt33T3M4IBUdh3JNdKlCV5VHexzVG1ywht1PTNK13UNR8EI9+IYZLomOBtu1TEoGWb/PNcFrmiXd3ZXC3DxzqnMDQndnn3ruNevkvr9YrOCT7DbwiGMHptFZMcBXayTSK6/dGOgrlptx1SsdtLlUXc8u0TT9RTXoRY2k8dxHID908c88966/xH8Q9RtNeZdPkjSOPAYSRhgx75Bqt8RvEOo6LfWEdhdOsgHmMx5H0HtU/iLwzptxpNnr2oajFZC9TeYGRmYnuQBXWlGVp1FuclatzXjH7Pc7bQ7238QeGxrLWUQvrdxvMaD5fQjFcS2vJeeLp5ZbfzbsuPvE8j0rqPA/iTRdF8PXGn+F5JtQ1SRDtWZNisfSuK0XV7jVPEDQy6La2V3IxiebLfu26d+lY06VnNtadBxxkozUYp/oN8UeGoL3xAb836MshBaIclMdj6VreLNWkga2t9HdjaxQhYoyT8pHUZPU5qjPpR8O3s99r10gTJWKKJgzSE/0FWrKwh1kLd2k/mwiQHytvzo2e1auytJ6pBFwnF04tRluVtCuLjVLbU21u0SVba2MokePmL2B9T0qh4S15PEckXh/UrUR28w2wyRuflbsDntWrZ6/4h0jWLuOK0ae2k/dy2skOVZPr61rWehadHv1bSrJra4yS6qxcRDvjPAPtRNqN21vtboc9P2tSXK37q3TW5z8mlIPENnp7RQpLaOD+8GflB5+tXvG/h24Gvya1Dbpd26gPIvJLADgKO1Ydh4n06HxFcsY58kFYjKvCv6nnNdloOrXmkXZPiWXyLWZC8cuM4JHDY7iplzwfNc6faRq2UVe3XzPN/DM2oRarfeIVnm0+KDqEzlyeiYPUetdtHrcPiLToryK2jhkRyjqqABj/e+tYGo69r9o1wdTlS+smJaNxgo/PBHFWPCOsHWI5tN1ERW5f95DLAm0jH8Jp1Fdc3UrD05Qkoq9rXen4tl6x1KGbUX0mZ50MsZVSSSrHqKwdFh1K51eWMB44I2KNGw4bn0pZ9UsRr0H2S0M5tifMJchhjvzXRaPr9xeagHitPMtpG2CRlG4fjTknBaLc3oSVSTcXezNTU9TtNFggknXMgwqFhuVD3GO9ZGq6vc2WoWb2+nJa2NyQ7yRKSGP1P3R7Vc1u2gvZo9pdUhlAYHocmu/8RpZ2nhw206l40jDCTup7D3rBSjBx0vcxrSdrydrs88+Jc1nqcNmswEVzsHlSnqw9DXKwW+oaVZ+TDbMRKwfeFPTtzXaeItOtdetLK5t7yMNCFDqQcEVjeO7PWIbqy0u18x7ExAh88MPXPatqMkkofmRUj7vu3b8jo9OvWdbL7RE2+NcM3Xtzg1i+OfCerawLS68OQtPbOD5qxuNyt6EVN4D0G/0y9klSbdbBSRHK3Ab1yai07TfF6eMlmlnRtORvMfZKpRkH8JxzmoTUJtwa0MsQueMYSVu+uw2Rz4Q0m20/VrUPPJFhwGyRntmq/hGLTLTF1ZWnmzXDnbFM3yRY9fX+VVtZ06/8Ra+8z2UxgDnHljIKjnIHrXRaDb2cFnGiI4jJYD7Um3B79Oac1Zb6vc68PKEo80lZ9O5m+JfGR8L+JjbeR9rkXBlZ24IPpW7ea9p72ttKlvHayv80fy9c9mFY2sw2M2reTNZQzyxnIdj7dvaudvr7UIPEItV05ZoQ25SUJJU9welONOM0rIwm6tJ80ne7002PSLTU5LCBbjEAk/hGTuJ+g7VyvinQLrxVqLeRqVpPfyYZkuJAGA9vSqK6o9zqzWsUYMPTb0YtWRpOjalp/jO2uv3jb5dxkAICr3zTjSdN817MU6qqrlUbp6Nm9YaY1hpj6R54luS7R5Rt23jnp0rnrG4v9K0i6hvbZbq0b5CM5HPrWx4z1u70rxjLHoUGLOQqS6At5vryOldlObedoWEQheaPfJEgyST6Cq53Baq9zJTVdc1rW0OY8Gw2Gj2txcAT2puYtrNu3bQaw7r4eTXlxJcafrWnz28h3K8zFXOfUYpLPxDPJ4ibTrnTgYHk8llcHzFGepq3eeNYtKu5rG2snEcLFOMc471ap1Luyvc5q9TDVEpN2S0Re8H3uqeI9V1KTUFaXRp42kmZvuoM8Y963NX1ax8E+DzF4Kh8m5uzia6c5cf5Hamqq2/whRoFETNNglBtzx7VyNr+98I3fm/PgnG7nFNRU567J2sRJfu7Pez1J/DWuDxLqcdp4jtlurlADHexoBIPZuxq74m8A2+kStqOo6uqWjtuijRS8rfhWz8ALeFprmRooy+R8xUZ/OtH48/I8BT5SsXBHGOacpuNf2cNEY07zoqM9banO63qVhr+m2Ftd29/AtshWO6cjMn+yQOldHZ/EbRNE8GRWlnavPEMw7W6H1rzjwwS9jYbyWzdDOec9aua5DEuhagFjQAXJwAo4qp0IStF7BTd/etqdd8PLHwh4jub24sLAWOpwqZV3SFgB3wDWfrMPhzX7mK3vGnt7yIlTJ1VhntWZ8Cv+Rlvh2+yvS6iq/8JY/A++B0rDlaqvV6HfQiqkNVudnJqmn6f4n0mTTLpraytoxFIclVbjn/APXWr418M6F47mOpWmqxPJEArhGznH9a8w8XfJY3Wz5fm7cVn/DIkahegE48vP60eyfL7VSs0KrSjTrKnFfEb/i7S78aabawSUQpjb5RyeOg4qz4AsblNNkfX45YrhTtgZ+GC4/iHf8AGtTRyQ12wOG39e9dFqH73R43k+d+m5uTWcqrtyHVKCjJTWjtY80vvD1hZtc3MU0jynJBUgLn+Yqv4WspUvTPOgmydzqhwoHue1dRcRobq3QqpU8kY4NW/FiLF4e/dKqbuu0Yzz3rX2srcr1uJ4empc6VrHNTaNaaZPc6prMpvLcHfBAsrGMDPGfWtKx1LS9dVbfULR1aRiyojhSBjp/9enlFbwjbqyqVKMSCODzXnfhon/hKsdsNTUfaJuT1QKaocvKviZs32qPbak2nRWhs5QxjgWIb2AJ4Lf3q7jU/CE96bRrmaxtIwivPbvKNw9yPeun0u0tm1Kzna3hM32YN5hQbs7eufWvKYJ5p9W1MzyySHceXYn+dZX5n7umhq5z5vZt3Ru6ncaoniK1ttOGzQ0X544QNrjHO41NB4UjtLl7rTfPdbtt+3qF9QKi8DsxvZUJJQykFc8dD2rvfBrMmmawUJUx/cIONvXp6VFSo4aIHaknO19bmF4i1Cw0vw9FDq8F1cJEuPJRgOPQk1iSXg1nwMNN8LWkltDNIXmQtl5PQfQVlanPNc+H9Ta4lklYM+C7Fj+tX/gl/x5yHvuk/lV8qhT5uqZgpc8k31T/Mw/DHhK5mvyb4pDHF1UHLE961PF2pyafAmn6Z8gb7zqOFHtXW6OqixuGCjd83OOaw9fYtp91uJOOme3FUqjnNOQ3Gy5I6X6mHomkabeeG72W+upBdhgwWLkoB0znrnrU3gDSy9/cTJFO8Ei7TKyY+Xv7VkeBeVmB5BPI9a6jVJ5oh5cUsiR4X5VYgflWlSTV433MYRs0VvEGm2OiedqNvZhnib9wJR0b+8R0965XTdJvvEWoo6h7i5dvMluH4IPsa9V0RFutIX7SomzIoPmDd296t+F40SaUIiqBIQMDHHpWUcQ4QbW50yw6qzTk9F0KNpDDpNrHb3+pW9iuMhGI3Mf6ZrSTRrW8iSW0eK5U8koM5A968g+ILNJ4pvxIxYAEgMc4rsfhRPKNGUCV8BuPmNKrQ5aaqp7mMcZKVZ07WOok0K3uz9mSaawB4RlO4K3ocUQzalAp0a+fekZOHPzFgBnH+FXVJ/wCErhTJ2eQjbe2fWmajz4l07PPysOfxrmTvozqvqmzym68ZajY66yM+LaN8GPALMPrWr4+t5/E9vaarpkkl3ZIgWSEHlGx6VynimNF1y82oo+Zugrr/AAezQ2MYiYoCoB2nGeK7ZNUkqkVqFagqt4SegeEIrvw1oN5dsZEvWZRBEvO1T1PNdDrtzIvk3t/fXEelRxpJNyQCx5246ZJrl9ZuJj8RdJjMsnltDgpuOD+Fdh4jRZfCuupKodFRSqsMgHPUCs56yjJ/aOKnNcklFW5TzLxJqkGrwvqltq7WTJLtSFSwx3HTqa9A0q8XUvD+l6iJklSRNk8h4JccGvLPGEEMPh7RzFFGhbzC21QMnjrXd6CAnw30HYNu6ZyccZOausrJRRnQqylVdyTxv4k8O2mqxWl34Zi1EQoP37SmNzn+dHjAaP4m0mzv4NS+xgoI47aVGKxEfwggfrWV45jR7uzZ0VmZOSRkmqNoS9mEclkWY7VPIH0qvZxjCM46NGuHjKdWUJyujovBfhpLHF5LewybRlSh6n2q/fTAXbvGq72bcWUYJqexUC1gAAAqgP8AWEdsnisW3KTcjsVNQ91FbX9Og1vT4oJH2TxsWikPO0HqPesu70jxHpdrZ/8ACNILnB3SLFgtuz6H+la6f6yX2FXdKJXUbcqcEOMEduarncVboTUw8ZJtaN9UaWoahFc2loNU1KDT7+SMCeNsg7sdM96fdxDRvByXTzi204Sh2uskvJ6BU71538V+PEcQHAHT2r1DxQom+BwaUByI0ILDOODWbppci6SZx1a0qcJSjujy671jwfc6lLfxwX0YDZZPKUbz7DPFauu6nB4y05P7HB22cODHIfmAHbH9a4TSI0bSNVLIpItwRkdDkVZ+H5K+JLTacZlQHHcZrrqUopXW6M8NjK3tYxm7r0NHwXJI98+n3Y8zTpFJeJuQrdiPQ1parcweD5I1t4Uk1R/3hBGURe2fX6V0LwQr42vgsUYHzHAUVxXxA51q4J64XmsopOaT2PUq1JuD5Hb8TV1afStU0OLVJbOHTJrhtkslqpIZvdf8Ko6lq/2TwTZW2j3LPGJ2SSQLtwT7VS18lPBOh7TtyXJxxnmtP4ZxpNZ6kkyLIgZTtYZGfpVpJK71szlkryVKOl0ndbk8t9KfDRttauYkvZWVoGTgtg8ZrpfEupX2reH7KMyM8kShJdvA+pNcr8QoozrOngouNmMY9619b+TwbIyfKwYDI44xUSXwMXJGUZykr8v6F6yCWGj5RhJsQsTH8xfj7tchdaz4j1Nw9pFcWlvGfkQ9B+fWl+G0jtqlwjOxTyGbaTxn1xXoGgEywN5vz4f+LmlzqnJ3V2XOg6qi+ZpWvY53xre6nB4G06Zl8l5nxLs4zx1FchoGp3trYarLHcygG3+9nGCTXd/E9mbTlUklUU7QTwv0rgbUY0G4xxmQZ/KujDpOmrrdnk1eZ1JalbRdX1SDUbZrS8uS4dcfMTzmvZvFWm32pTwS2u1pVjXzdrDh8A5Arzn4eRodWjYopPmDnFe56FGjQSkopJZskjr1rHGVOSd0tjooU7Uk5O/U4OSd0EdpIA0sS/M20buPQ9xWSupW99CypMQycFc8g/4Vc1b/AJG51/hDEAfhXH+FlH9s66MDg8cdPmqY004uR6CrNyhFLca9vctrgurdG8sMPnzW34lu72Wwto9LQyKZMXAQ4b/9VacKqbWQFRjPTFWmijEDARoBt7AU/aXabWxcsMopwT6mHp0R8P2uoaiFaW22hggO4q2On41z974p1mXw4l44aF5p2ijuF42KBnaP8a7vQPmHltzGZTlT06+lT+MbeFrW2iaGMxBj8hUY79qITXN7yuc2MoSu1CVkc34Tk1LXLezurq72zglTKyASSqD/AHu9dLrXhTSJr5nuLK2eQgZfzSC3ucd6l0+NEWVVRVVIhtAGAvHauB16RxdRYduYx39zTjzTno7GNeEKVNJq5//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow biopsy reveals sinusoidal lymphoma cell infiltration. Hematoxylin and eosin, 40x magnification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry and Immunochemistry for Hematologic Neoplasms, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_7_42104=[""].join("\n");
var outline_f41_7_42104=null;
var title_f41_7_42105="Epidemiology, risk factors, and etiology of hypertension in children and adolescents";
var content_f41_7_42105=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, risk factors, and etiology of hypertension in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/7/42105/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/7/42105/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/7/42105/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/7/42105/contributors\">",
"     F Bruder Stapleton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/7/42105/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/7/42105/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/7/42105/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has become clear that hypertension (HTN) begins in childhood and adolescence and that it contributes to the early development of cardiovascular disease (CVD). The supporting data include clinical studies that demonstrate cardiovascular structural and functional changes in children with HTN and autopsy studies that have shown an association of blood pressure (BP) with atherosclerotic changes in the aorta and heart in children and young adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=see_link\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43096?source=see_link&amp;anchor=H6#H6\">",
"     \"Risk factors and development of atherosclerosis in childhood\", section on 'Hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In hypertensive adults, multiple randomized trials have shown that reduction of BP by antihypertensive therapy reduces cardiovascular morbidity and mortality. The magnitude of the benefit increases with the severity of the HTN. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link\">",
"     \"Hypertension: Who should be treated?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these observations, identifying children with HTN and successfully treating their HTN should have an important impact on long-term outcomes of CVD.",
"   </p>",
"   <p>",
"    The epidemiology, risk factors, and etiology of childhood HTN will be reviewed here. The diagnosis, evaluation, and treatment of HTN in children and adolescents are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=see_link\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/42/2729?source=see_link\">",
"     \"Evaluation of hypertension in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=see_link\">",
"     \"Treatment of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neonatal HTN, including etiology, is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37833?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of neonatal hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, the following definitions based upon the 2004 National High Blood Pressure Education Program Working Group (NHBPEP) are used to classify blood pressure (BP) measurements in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/1\">",
"     1",
"    </a>",
"    ]. BP percentiles are based upon gender, age, and height (",
"    <a class=\"graphic graphic_table graphicRef63856 \" href=\"mobipreview.htm?7/45/7894\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52646 \" href=\"mobipreview.htm?7/46/7910\">",
"     table 2",
"    </a>",
"    ). The systolic and diastolic BPs are of equal importance; if there is a disparity between the two, the higher value determines the BP category. The age- and height-specific blood pressure percentiles may be determined using calculators for boys (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) or for girls (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=see_link\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal BP &ndash; Both systolic and diastolic BP &lt;90th percentile.",
"     </li>",
"     <li>",
"      Prehypertension &ndash; Systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;90th percentile but &lt;95th percentile",
"      <strong>",
"       or",
"      </strong>",
"      if BP exceeds",
"      <span class=\"nowrap\">",
"       120/80",
"      </span>",
"      mmHg (even if &lt;90th percentile for age, gender, and height).",
"     </li>",
"     <li>",
"      Hypertension &ndash; Hypertension (HTN) is defined as either systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;95th percentile measured upon",
"      <strong>",
"       three",
"      </strong>",
"      or more separate occasions. The degree of HTN is further delineated by the two following stages.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Stage 1 HTN",
"      </strong>",
"      &ndash; Systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP between the 95th percentile and 5 mmHg above the 99th percentile.",
"     </li>",
"     <li>",
"      <strong>",
"       Stage 2 HTN",
"      </strong>",
"      &ndash; Systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;99th percentile plus 5 mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44275598\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44275605\">",
"    <span class=\"h3\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of elevated BP &ge;95",
"    <sup>",
"     th",
"    </sup>",
"    percentile in children increased from the late 1980s through the early 2000s as illustrated by several large population-based and school-based screening surveys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. This rise in blood pressure (BP) was felt to be due, in part, to the increased prevalence of childhood obesity. However, results from the Bogalusa Heart Study showed that, from 1974 to 1993, mean systolic blood pressure (SBP) levels remained the same and mean diastolic blood pressure (DBP) decreased by 2 mmHg, while the rates of obesity increased from 6 to 17 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Obesity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a study of a large cohort of children of diverse race and ethnicity cared for in community-based practices from 2007 to 2009, the reported prevalence of hypertension based upon confirmed",
"    <strong>",
"     persistent",
"    </strong>",
"    BP &ge;95",
"    <sup>",
"     th",
"    </sup>",
"    percentile was 0.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/7\">",
"     7",
"    </a>",
"    ]. In this group of children, risk factors for hypertension included increasing body mass index (BMI) and age. Children who were black or Asian also were more likely to be at risk for hypertension compared with other ethnic groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44275612\">",
"    <span class=\"h3\">",
"     Other countries",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear whether childhood BP is increasing worldwide. In the United Kingdom, mean SBP has increased in children between 9 and 11 years of age from 1980 to 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/8\">",
"     8",
"    </a>",
"    ]. This increase was not explained by increased BMI. In contrast, an earlier report from Northern Ireland demonstrated a decrease in mean systolic and diastolic BPs over the 10 years from 1989 to 1999 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Switzerland, the prevalence of hypertension (HTN) in sixth-grade children after three repeated BP measurements was 2.2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/10\">",
"     10",
"    </a>",
"    ]. HTN was more likely in children with excess body weight, increased heart rate, and a parental history of HTN. In this cohort, 16 percent of the boys and 12 percent of the girls were overweight or obese.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44275619\">",
"    <span class=\"h2\">",
"     Prehypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Globally, the reported prevalence of prehypertension ranges from 9.5 to 24 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. In a study of 1010 adolescents who underwent BP measurements during three separate clinical encounters, about 20 percent of individuals had BP in the range of prehypertension at the first visit, 4 percent had persistent prehypertension defined as BP &gt;90",
"    <sup>",
"     th",
"    </sup>",
"    percentile or",
"    <span class=\"nowrap\">",
"     120/88",
"    </span>",
"    mmHg at all three visits, and 30 percent had a BP in the prehypertensive range during one of the three encounters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, 2.5 percent were hypertensive (BP &gt;95",
"    <sup>",
"     th",
"    </sup>",
"    percentile at all three visits). In this cohort, obesity was a risk factor for both prehypertension and HTN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of hypertension (HTN) in children may vary according to the patient's body mass index (BMI), gender, ethnicity, and family history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States and Canada, the rising risk of HTN is in part due to the increasing prevalence of obesity as demonstrated by the following observations in school-aged children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/3,5,11,16,17\">",
"     3,5,11,16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the previously mentioned report based upon the United States National Health Survey data, the risk of high blood pressure (BP) (defined as greater than the 95th percentile) doubled for every one unit of increase in the BMI z-score unit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a longitudinal adolescent Canadian cohort study, biannual blood pressure and anthropometric measurements were performed in 1267 patients who were in grades 7, 9, and 11 from 1999 to 2005 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/18\">",
"       18",
"      </a>",
"      ]. Multivariate analysis demonstrated that the risk of high systolic blood pressure (SBP) (defined as greater than the 90th percentile) was more than a two-fold increase in overweight children (defined as a BMI &gt;85th percentile) compared to non-overweight children (OR 2.63, 95% CI 1.75-3.92).",
"     </li>",
"     <li>",
"      A similar result was noted in a study of 1111 adolescents of a marked increase in the prevalence of high blood pressure on the BMI exceeded the 85",
"      <sup>",
"       th",
"      </sup>",
"      percentile [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 2002 school-based study of 5102 children (mean age 13.5 years), the prevalence of HTN rose with increasing BMI (2 versus 11 percent among those with BMI &le;5th and &ge;95th percentile, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of predominantly minority 8th grade adolescents, the risk of HTN increased with rising BMI (6.9 versus 24.6 percent among those with BMI &lt;85th and &ge;95th percentile, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/20\">",
"       20",
"      </a>",
"      ]. In addition, the risk of dyslipidemia increased with rising blood pressure and BMI. As an example, the prevalence of high triglycerides was 14.7 and 27.1 in normotensive versus hypertensive students.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relationship between elevated BP and weight begins in early childhood as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of primary care visits of 18,618 children between 2 and 19 years of age, systolic and diastolic BP increased with increasing BMI in all age groups including children between two and five years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study, SBP and weight-for-length were measured in 530 children from birth to three years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/21\">",
"       21",
"      </a>",
"      ]. An increase in the weight-for-length in the first six months of life was associated with higher systolic blood pressure at three years of life, particularly among infants who were thin at birth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, a report from the Bogalusa Heart study showed that mean systolic and diastolic BP levels did not increase despite a rise in the prevalence of obesity from 6 to 17 percent over the study period from 1974 to 1993 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/6\">",
"     6",
"    </a>",
"    ]. Nevertheless, within this cohort of 11,478 children, there was a positive correlation of BMI and BP levels. However, these results suggest that other factors may have ameliorated the expected increase in BP due to the increasing prevalence of obesity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32858?source=see_link\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37674?source=see_link\">",
"     \"Comorbidities and complications of obesity in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States and Canada, the prevalence of HTN and prehypertension is greater in boys than girls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/4,18\">",
"     4,18",
"    </a>",
"    ]. As an example, in the previously mentioned adolescent Canadian cohort study, boys were more likely to have high systolic BP (&gt;90th percentile) compared to girls in 7th (OR 1.29, 95% CI 0.77-2.16), 9th (OR 1.98, 95% CI 01.35-2.93), and 11th grades (OR 2.74, 95% CI 1.52-4.94).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;NHANES III showed that the incidence of HTN in adults was affected by race and ethnicity, being most common in non-Hispanic African Americans (",
"    <a class=\"graphic graphic_figure graphicRef81756 graphicRef58221 \" href=\"mobipreview.htm?1/63/2032\">",
"     figure 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/22\">",
"     22",
"    </a>",
"    ]. The age-adjusted prevalence of HTN was 32 percent in the non-Hispanic African American population compared with 23 percent in the non-Hispanic white and Mexican-American populations. African Americans also are more likely to develop hypertensive complications, particularly renal disease. In blacks, the relative importance of environmental and genetic factors has not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/58/11174?source=see_link\">",
"     \"Hypertensive complications in blacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children, data also suggest that the risk of HTN is greater in minority ethnic groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/4,5,24-26\">",
"     4,5,24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the previously discussed report based upon the United States National Health Survey data, the prevalence of high BP (greater than the 95th percentile) was 4.6, 4.2, and 3.3 in Mexican American, black, and white children respectively during the study period of 1999 to 2002 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 2368 girls enrolled at the age of 9 or 10 years in the National Heart, Lung, and Blood Institute Growth and Health Study from 1986 to 1997, the overall incidence of HTN based on two clinic visits was greater in African-American girls compared with Caucasian girls (5 versus 2.1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/26\">",
"       26",
"      </a>",
"      ]. The incidence increased to 10.5 and 3.8 percent in African&ndash;American and Caucasian girls whose BMI was greater than the 95th percentile and was lower in those with normal BMI (&lt;85th percentile, 3.5 versus 1.7 percent). Similar patterns were seen for prehypertension with incidences of 4.1 and 2.4 in African-American and Caucasian girls, 9.7 and 4.6 percent in obese African-American and Caucasian girls, and 2.2 and 2.0 percent in African-American and Caucasian girls with normal BMI levels. In the entire cohort, multivariate analyses adjusted for age and race demonstrated higher BMI and lower potassium intake were associated with an increase risk of HTN.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A family history of HTN is present in as many as 70 to 80 percent of all patients with primary HTN (also referred to as primary HTN), which has no identifiable underlying etiology, and in approximately 50 percent of hypertensive children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with primary HTN, elevated BP is thought to result from the interaction of multiple genes and environmental factors. It has been estimated that genetic factors account for approximately 30 percent of the variation in BP in various populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/28,29\">",
"     28,29",
"    </a>",
"    ] and as much as 60 to 70 percent of HTN in families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9159?source=see_link\">",
"     \"Genetic factors in the pathogenesis of essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best evidence for genetic factors influencing BP values comes from BP correlations within families:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The BP correlation is stronger between parents and children than between spouses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is no significant BP correlation between parents and adopted children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most studies in twins have shown BP correlation is stronger between identical (monozygotic) twins than between fraternal (dizygotic) twins or siblings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/31,34\">",
"       31,34",
"      </a>",
"      ]. However, the observation that the BP correlation is stronger among dizygotic twins than other first-degree relatives indicates a nongenetic environmental effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In both animal and human studies, a number of different genes have been evaluated but their role remains uncertain in the pathogenesis of primary HTN. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9159?source=see_link\">",
"     \"Genetic factors in the pathogenesis of essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Monogenic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, monogenic disorders can cause HTN and include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liddle's syndrome (MIM #177220), due to a gain-of-function mutation in the sodium channel gene, is associated with hypertension, low plasma renin and aldosterone levels, and hypokalemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25399?source=see_link&amp;anchor=H3#H3\">",
"       \"Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1\", section on 'Liddle's syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pseudohypoaldosteronism type 2 or Gordon's syndrome (MIM #145260) is due to mutations in WNK kinases 1 and 4, which result in increased chloride reabsorption with sodium. It is characterized by HTN, hyperkalemia, normal renal function, and low or low-normal plasma renin activity and aldosterone. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9930?source=see_link&amp;anchor=H13#H13\">",
"       \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\", section on 'Pseudohypoaldosteronism type 2 (Gordon's syndrome)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glucocorticoid-remediable aldosteronism, also known as familial hyperaldosteronism type I, is a disorder in which there is a chimeric gene formed from portions of the 11&szlig;-hydroxylase gene and the aldosterone synthase gene, which results in ACTH stimulating aldosterone synthesis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22615?source=see_link\">",
"       \"Familial hyperaldosteronism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital adrenal hyperplasia due to 11&szlig;-hydroxylase deficiency is a disorder that has been associated with multiple mutations of the CYP11B1 gene. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15878?source=see_link\">",
"       \"Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Syndrome of apparent mineralocorticoid excess (MIM #218030) arises from mutations in the gene encoding the enzyme 11-&szlig;-hydroxysteroid dehydrogenase. The defective enzyme allows normal circulating concentrations of cortisol (which are much higher than those of aldosterone) to activate the renal mineralocorticoid receptors resulting in increased sodium absorption. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40838?source=see_link\">",
"       \"Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence that breastfeeding may be associated with lower BPs in childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. This was illustrated in two prospective cohort studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first study, 7276 infants were evaluated at 7.5 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/36\">",
"       36",
"      </a>",
"      ]. Those who were breastfed as infants had systolic and diastolic BPs that were 1.2 mmHg and 0.9 mmHg lower than in infants who were never breastfed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/36\">",
"       36",
"      </a>",
"      ]. The reduction in both systolic and diastolic pressures was greater in infants who were exclusively breastfed, and the systolic BP reduction increased with the duration of breastfeeding.",
"     </li>",
"     <li>",
"      Similar findings were found in 7223 singleton infants evaluated at five years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/38\">",
"       38",
"      </a>",
"      ]. Those who were breastfed for six months had systolic BP that was 1.2 mmHg lower than in infants who had been breastfed less than six months or not at all [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     White coat hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;White coat or isolated office HTN is defined as office BP readings &ge;95th percentile but with normal values outside the clinical setting. Studies suggest a prevalence as high as 35 percent in children being evaluated for persistently elevated casual BP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/39\">",
"     39",
"    </a>",
"    ] and approximately 44 percent in children with a positive family history of primary HTN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/40\">",
"     40",
"    </a>",
"    ]. The prevalence of white coat HTN is higher when the office values reveal borderline or mild HTN, and much lower with moderate or severe HTN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that white coat HTN in children represents two populations: one that is destined to develop primary HTN (prehypertensive) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/42\">",
"     42",
"    </a>",
"    ] and one that remains normotensive outside the clinical setting. In adults, white coat HTN appears to be a prehypertensive condition with increased left ventricular mass and progression to sustained HTN. Similar findings were noted in a retrospective study of children with white coat HTN from a tertiary center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/43\">",
"     43",
"    </a>",
"    ]. About two-thirds of children with white coat HTN had either left ventricular hypertrophy (LVH) detected by echocardiography or systolic BP greater than the 95th percentile for age, height and gender during treadmill exercise. These observations have led to the concern that patients with white coat HTN are at risk for developing HTN and end-organ cardiac damage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link&amp;anchor=H11#H11\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\", section on 'White coat hypertension'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25943?source=see_link&amp;anchor=H3#H3\">",
"     \"Ambulatory blood pressure monitoring in children\", section on 'White coat hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prenatal and neonatal factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that prenatal and neonatal factors contribute to higher BP. There are data demonstrating a role for low birth weight in the development of primary HTN (discussed in greater detail separately). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39477?source=see_link\">",
"     \"Possible role of low birth weight in the pathogenesis of essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, a systematic review reported in utero exposure to preeclampsia was associated with an increase in systolic (mean 2.4 mmHg) and diastolic (mean 1.4 mmHg) BP as well as an increase in BMI (mean 0.62",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of childhood hypertension (HTN) are separated into two classes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary HTN &ndash; No underlying cause is identified.",
"     </li>",
"     <li>",
"      Secondary HTN &ndash; An identifiable cause is determined. In children with secondary HTN, the underlying disorder may be curable with complete resolution of HTN.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Primary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary HTN is the most common cause of HTN in older children and is a diagnosis of exclusion. It is more likely in children who are postpubertal, have a family history of HTN, are overweight or obese, or have only mild hypertension (blood pressure [BP] at or just above the 95th percentile). It is also more common in African Americans. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Secondary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of causes of secondary HTN (",
"    <a class=\"graphic graphic_table graphicRef73738 \" href=\"mobipreview.htm?27/60/28621\">",
"     table 3",
"    </a>",
"    ), and specific symptoms (",
"    <a class=\"graphic graphic_table graphicRef76420 \" href=\"mobipreview.htm?30/40/31372\">",
"     table 4",
"    </a>",
"    ) and findings (",
"    <a class=\"graphic graphic_table graphicRef76824 \" href=\"mobipreview.htm?31/61/32733\">",
"     table 5",
"    </a>",
"    ) may point to a particular disorder. In a Polish review, 351 of 636 children (55 percent) with sustained HTN had a known secondary cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/45\">",
"     45",
"    </a>",
"    ]. The most common were renal disease (68 percent) and endocrine and renovascular diseases (11 and 10 percent, respectively). Almost all children (98 percent) younger than 15 years of age had a secondary cause, whereas 75 percent of adolescents had primary HTN.",
"   </p>",
"   <p>",
"    In another observational series, 89 of 132 children (67 percent) with HTN had renal or renovascular disease, 30 (23 percent) had primary HTN, and 13 (10 percent) had nonrenal causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/46\">",
"     46",
"    </a>",
"    ]. Glomerulonephritis and reflux nephropathy were the most common renal cause of HTN in these patients.",
"   </p>",
"   <p>",
"    The following sections review different etiologies of chronic (persistent) secondary HTN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Renal parenchymal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of intrinsic renal disorders is associated with HTN and includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glomerulonephritis &ndash; HTN is a manifestation of both chronic and acute glomerulonephritis (GN). In children, the most common form of acute GN is post-streptococcal GN, which follows after a streptococcal infection. Henoch-Sch&ouml;nlein purpura (IgA vasculitis) can present with renal manifestations including HTN. In children, chronic glomerular disorders associated with elevated BP include IgA nephropathy, membranoproliferative GN, or lupus nephritis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35304?source=see_link\">",
"       \"Poststreptococcal glomerulonephritis in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1337?source=see_link\">",
"       \"Clinical presentation and diagnosis of IgA nephropathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link\">",
"       \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43833?source=see_link\">",
"       \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40729?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children with glomerulonephritis, the most common mechanisms of HTN are volume expansion (as in acute poststreptococcal glomerulonephritis) and activation of the renin-angiotensin system. Other common presenting features of glomerular disorders include hematuria, oliguria, peripheral edema, and an elevated serum creatinine or BUN. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=see_link\">",
"     \"Overview of hypertension in acute and chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal parenchymal scarring can be a sequelae of acute pyelonephritis and may be associated with vesicoureteral reflux. It is also seen in children with congenital anomalies of the kidney and urinary tract, and those with irreversible renal injury from hemolytic uremic syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/10/3242?source=see_link\">",
"       \"Presentation, diagnosis, and clinical course of vesicoureteral reflux\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30649?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\", section on 'Hypertension'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27674?source=see_link&amp;anchor=H20#H20\">",
"       \"Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month\", section on 'Prognosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Polycystic kidney disease &ndash; Polycystic kidney disease (PKD) is due to two genetic disorders, autosomal dominant and autosomal recessive PKD, that involve the formation of renal cysts. HTN is a common presenting sign in children with the recessive form of PKD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29913?source=see_link\">",
"       \"Autosomal recessive polycystic kidney disease in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic renal failure &ndash; Chronic renal failure (CRF) of any cause can be associated with HTN because of volume expansion. In addition, children who have undergone renal transplantation are at increased risk for HTN due to several different mechanisms including rejection or the administration of drugs that increase BP. A functional gene MYH9 that is expressed in kidney podocytes has been associated with nondiabetic end-stage kidney disease in African Americans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/47\">",
"       47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32026?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of the management of chronic kidney disease in children\", section on 'Hypertension'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22154?source=see_link&amp;anchor=H19#H19\">",
"       \"Complications of renal transplantation in children\", section on 'Hypertension'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H21\">",
"       'Drugs and toxins'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Renovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;HTN due to renovascular disease is due to a decrease in renal blood flow resulting in increased plasma levels of renin, angiotensin, and aldosterone. Children with renovascular disease generally have stage 2 HTN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definition'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Causes of renovascular disease in children include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fibromuscular dysplasia &ndash; Fibromuscular dysplasia is the most common etiology of renovascular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. It is characterized by arterial stenosis due to a non-inflammatory, non-atherosclerotic process. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/42/34471?source=see_link\">",
"       \"Clinical manifestations and diagnosis of fibromuscular dysplasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Umbilical arterial catheterization &ndash; During the newborn period, catheterization of the umbilical artery may lead to a clot in the renal artery resulting in renal arterial injury and stenosis.",
"     </li>",
"     <li>",
"      Other causes of renovascular disease include neurofibromatosis, arteritis, renal artery hypoplasia, and midaortic syndrome (segmental narrowing of the proximal abdominal aorta) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42105/abstract/49-51\">",
"       49-51",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=see_link\">",
"       \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/19/13624?source=see_link\">",
"       \"Clinical features and diagnosis of Takayasu arteritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=see_link\">",
"       \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Renal tubular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monogenic diseases in which tubular reabsorption of sodium or chloride is increased are associated with increased vascular volume and HTN, such as Liddle's syndrome, Type 1 pseudohypoaldosteronism, Type 2 pseudohypoaldosteronism or Gordon's syndrome. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Monogenic disorders'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Endocrinologic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocrinologic conditions associated with HTN include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Catecholamine excess &ndash; Catecholamine excess that results in HTN occurs in patients with pheochromocytoma and neuroblastoma, and those who use sympathomimetic drugs including phenylpropanolamine (over-the-counter decongestant), cocaine, amphetamines, phencyclidine, epinephrine,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/46/41696?source=see_link\">",
"       phenylephrine",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/51/25397?source=see_link\">",
"       terbutaline",
"      </a>",
"      , and the combination of a monoamine oxidase (MAO) inhibitor plus ingestion of tyramine-containing foods. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38121?source=see_link\">",
"       \"Pheochromocytoma in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/15/15609?source=see_link\">",
"       \"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Corticosteroid excess &ndash; Corticosteroid excess is more commonly due to exogenous administration of glucocorticoids and rarely due to endogenous production of either glucocorticoids or mineralocorticoids. In both settings, corticosteroid excess results in HTN.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Corticosteroid excess may be seen in patients with Cushing's syndrome due to hypersecretion of adrenocorticotropic hormone (ACTH). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/55/26489?source=see_link\">",
"       \"Causes and pathophysiology of Cushing's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mineralocorticoid excess that result in HTN may be seen in patients with congenital adrenal hyperplasia. Other rare causes of HTN due to mineralocorticoid excess include aldosterone-secreting tumors and the monogenic disorder of glucocorticoid-remediable aldosteronism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23369?source=see_link&amp;anchor=H11#H11\">",
"       \"Causes and clinical manifestations of primary adrenal insufficiency in children\", section on 'Congenital adrenal hyperplasia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22615?source=see_link\">",
"       \"Familial hyperaldosteronism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other endocrinologic disorders &ndash; Other endocrinologic abnormalities associated with HTN include thyroid disorders (hypothyroidism and hyperthyroidism), and hypercalcemia (eg, hyperparathyroidism). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical manifestations of hypothyroidism\", section on 'Cardiovascular system'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/33/23062?source=see_link\">",
"       \"Cardiovascular effects of hyperthyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33669?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical manifestations of hypercalcemia\", section on 'Cardiovascular disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coarctation of the aorta is the primary cardiac cause of HTN. The classic findings are HTN in the upper extremities, diminished or delayed femoral pulses, and low or unobtainable arterial blood pressure in the lower extremities. The diagnosis is confirmed by echocardiogram. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Drugs and toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of drugs and toxins can cause chronic HTN including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link&amp;anchor=H12#H12\">",
"       \"Major side effects of systemic glucocorticoids\", section on 'Kidney and systemic hemodynamics'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Oral contraceptives (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37859?source=see_link\">",
"       \"Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Arsenic (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8730?source=see_link&amp;anchor=H12#H12\">",
"       \"Arsenic exposure and poisoning\", section on 'Cardiovascular'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link&amp;anchor=H19#H19\">",
"       \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Hypertension'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/28/38337?source=see_link\">",
"       \"Patient information: High blood pressure in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/58/931?source=see_link\">",
"       \"Patient information: High blood pressure treatment in children (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertension (HTN) in childhood and adolescence contributes to premature atherosclerosis and the early development of cardiovascular disease (CVD). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43096?source=see_link&amp;anchor=H6#H6\">",
"       \"Risk factors and development of atherosclerosis in childhood\", section on 'Hypertension'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Since the late 1980s, the prevalence of childhood HTN has increased in the United States. This rise in blood pressure (BP) is associated with a concurrent increase in the prevalence of obesity.",
"     </li>",
"     <li>",
"      Children who are overweight (greater than the 85th percentile for weight) are more likely to have higher BP values (adjusted for age, gender, and height) and be hypertensive. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Obesity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of HTN and prehypertension is greater in boys than girls. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Gender'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, Mexican American and non-Hispanic black children compared to non-Hispanic white children are more likely to have elevated BP adjusted for age, gender, and height. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Ethnicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Childhood HTN is divided into two categories: primary HTN (no identifiable cause is found), and secondary HTN (an underlying cause is identified).",
"     </li>",
"     <li>",
"      A family history of HTN is present in as many as 70 to 80 percent of all patients with primary HTN and in approximately 50 percent of hypertensive children. In patients with primary HTN, elevated BP is thought to result from the interaction of multiple genes and environmental factors. Rarely, monogenic disorders, such as glucocorticoid-remediable aldosteronism or Liddle's syndrome can cause HTN. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      White coat HTN (defined as BP values &ge;95th percentile in a clinical setting but with normal values outside the clinical setting) is a frequent finding in children. Although white coat HTN appears to be a prehypertensive condition in adults, it remains uncertain whether white coat HTN is a marker for childhood HTN. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'White coat hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology of chronic HTN is separated into two classes: primary HTN, in which no underlying cause is identified, and secondary HTN, in which an underlying cause is identified. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common condition resulting in secondary HTN is renal disease (68 percent), followed by endocrine and renovascular diseases (11 and 10 percent, respectively). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Secondary hypertension'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/1\">",
"      Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/2\">",
"      Sinaiko AR, Gomez-Marin O, Prineas RJ. Prevalence of \"significant\" hypertension in junior high school-aged children: the Children and Adolescent Blood Pressure Program. J Pediatr 1989; 114:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/3\">",
"      Sorof JM, Lai D, Turner J, et al. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics 2004; 113:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/4\">",
"      Din-Dzietham R, Liu Y, Bielo MV, Shamsa F. High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation 2007; 116:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/5\">",
"      Muntner P, He J, Cutler JA, et al. Trends in blood pressure among children and adolescents. JAMA 2004; 291:2107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/6\">",
"      Freedman DS, Goodman A, Contreras OA, et al. Secular trends in BMI and blood pressure among children and adolescents: the Bogalusa Heart Study. Pediatrics 2012; 130:e159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/7\">",
"      Lo JC, Sinaiko A, Chandra M, et al. Prehypertension and hypertension in community-based pediatric practice. Pediatrics 2013; 131:e415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/8\">",
"      Peters H, Whincup PH, Cook DG, et al. Trends in blood pressure in 9 to 11-year-old children in the United Kingdom 1980-2008: the impact of obesity. J Hypertens 2012; 30:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/9\">",
"      Watkins D, McCarron P, Murray L, et al. Trends in blood pressure over 10 years in adolescents: analyses of cross sectional surveys in the Northern Ireland Young Hearts project. BMJ 2004; 329:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/10\">",
"      Chiolero A, Cachat F, Burnier M, et al. Prevalence of hypertension in schoolchildren based on repeated measurements and association with overweight. J Hypertens 2007; 25:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/11\">",
"      McNiece KL, Poffenbarger TS, Turner JL, et al. Prevalence of hypertension and pre-hypertension among adolescents. J Pediatr 2007; 150:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/12\">",
"      Falkner B, Gidding SS, Portman R, Rosner B. Blood pressure variability and classification of prehypertension and hypertension in adolescence. Pediatrics 2008; 122:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/13\">",
"      Chiolero A, Paccaud F, Bovet P. Pre-hypertension and hypertension among adolescents of Switzerland. J Pediatr 2007; 151:e24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/14\">",
"      Papandreou D, Stamou M, Malindretos P, et al. Prevalence of hypertension and association of dietary mineral intake with blood pressure in healthy schoolchildren from northern Greece aged 7-15 years. Ann Nutr Metab 2007; 51:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/15\">",
"      Acosta AA, Samuels JA, Portman RJ, Redwine KM. Prevalence of persistent prehypertension in adolescents. J Pediatr 2012; 160:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/16\">",
"      Paradis G, Lambert M, O'Loughlin J, et al. Blood pressure and adiposity in children and adolescents. Circulation 2004; 110:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/17\">",
"      Falkner B, Gidding SS, Ramirez-Garnica G, et al. The relationship of body mass index and blood pressure in primary care pediatric patients. J Pediatr 2006; 148:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/18\">",
"      Dasgupta K, O'Loughlin J, Chen S, et al. Emergence of sex differences in prevalence of high systolic blood pressure: analysis of a longitudinal adolescent cohort. Circulation 2006; 114:2663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/19\">",
"      Tu W, Eckert GJ, DiMeglio LA, et al. Intensified effect of adiposity on blood pressure in overweight and obese children. Hypertension 2011; 58:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/20\">",
"      Jago R, Harrell JS, McMurray RG, et al. Prevalence of abnormal lipid and blood pressure values among an ethnically diverse population of eighth-grade adolescents and screening implications. Pediatrics 2006; 117:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/21\">",
"      Belfort MB, Rifas-Shiman SL, Rich-Edwards J, et al. Size at birth, infant growth, and blood pressure at three years of age. J Pediatr 2007; 151:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/22\">",
"      Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/23\">",
"      Cooper R, Rotimi C. Hypertension in blacks. Am J Hypertens 1997; 10:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/24\">",
"      Voors AW, Foster TA, Frerichs RR, et al. Studies of blood pressures in children, ages 5-14 years, in a total biracial community: the Bogalusa Heart Study. Circulation 1976; 54:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/25\">",
"      Berenson GS, Voors AW, Webber LS, et al. Racial differences of parameters associated with blood pressure levels in children--the Bogalusa heart study. Metabolism 1979; 28:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/26\">",
"      Obarzanek E, Wu CO, Cutler JA, et al. Prevalence and incidence of hypertension in adolescent girls. J Pediatr 2010; 157:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/27\">",
"      Jung FF, Ingelfinger JR. Hypertension in childhood and adolescence. Pediatr Rev 1993; 14:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/28\">",
"      Hunt SC, Ellison RC, Atwood LD, et al. Genome scans for blood pressure and hypertension: the National Heart, Lung, and Blood Institute Family Heart Study. Hypertension 2002; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplan NM. Primary hypertension: Pathogenesis. In: Kaplan's Clinical Hypertension, 8th ed, Kaplan NM (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2002. p.58.",
"    </li>",
"    <li>",
"     Ward R. Familial aggregation and genetic epidemiology of blood pressure. In: Hypertension: Pathophysiology, Diagnosis and Management, Laragh J, Brenner B (Eds), Raven Press, New York 1990. p.81.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/31\">",
"      Havlik RJ, Feinleib M. Epidemiology and genetics of hypertension. Hypertension 1982; 4:III121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/32\">",
"      Biron P, Mongeau JG, Bertrand D. Familial aggregation of blood pressure in 558 adopted children. Can Med Assoc J 1976; 115:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/33\">",
"      Annest JL, Sing CF, Biron P, Mongeau JG. Familial aggregation of blood pressure and weight in adoptive families. II. Estimation of the relative contributions of genetic and common environmental factors to blood pressure correlations between family members. Am J Epidemiol 1979; 110:492.",
"     </a>",
"    </li>",
"    <li>",
"     Christian JC. Twin studies of blood pressure. In: Children's Blood Pressure, Report of the 85th Ross Conference on Pediatric Research, 1985. p.51.",
"    </li>",
"    <li>",
"     Feinleib M, Garrison R, Borhani N, et al. Studies of hypertension in twins. In: Epidemiology and Control of Hypertension, Paul 0 (Ed), Stratton Intercontinental Medical Book Corp, New York 1975. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/36\">",
"      Martin RM, Ness AR, Gunnell D, et al. Does breast-feeding in infancy lower blood pressure in childhood? The Avon Longitudinal Study of Parents and Children (ALSPAC). Circulation 2004; 109:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/37\">",
"      Wilson AC, Forsyth JS, Greene SA, et al. Relation of infant diet to childhood health: seven year follow up of cohort of children in Dundee infant feeding study. BMJ 1998; 316:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/38\">",
"      Lawlor DA, Najman JM, Sterne J, et al. Associations of parental, birth, and early life characteristics with systolic blood pressure at 5 years of age: findings from the Mater-University study of pregnancy and its outcomes. Circulation 2004; 110:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/39\">",
"      Oc&oacute;n-Pujadas J, Mora-Maci&aacute; J. White coat hypertension and related phenomena. A clinical approach. Drugs 1993; 46 Suppl 2:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/40\">",
"      Hornsby JL, Mongan PF, Taylor AT, Treiber FA. 'White coat' hypertension in children. J Fam Pract 1991; 33:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/41\">",
"      Sorof JM, Poffenbarger T, Franco K, Portman R. Evaluation of white coat hypertension in children: importance of the definitions of normal ambulatory blood pressure and the severity of casual hypertension. Am J Hypertens 2001; 14:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/42\">",
"      Matthews KA, Woodall KL, Allen MT. Cardiovascular reactivity to stress predicts future blood pressure status. Hypertension 1993; 22:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/43\">",
"      Kavey RE, Kveselis DA, Atallah N, Smith FC. White coat hypertension in childhood: evidence for end-organ effect. J Pediatr 2007; 150:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/44\">",
"      Davis EF, Lazdam M, Lewandowski AJ, et al. Cardiovascular risk factors in children and young adults born to preeclamptic pregnancies: a systematic review. Pediatrics 2012; 129:e1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/45\">",
"      Wyszyska T, Cichocka E, Wieteska-Klimczak A, et al. A single pediatric center experience with 1025 children with hypertension. Acta Paediatr 1992; 81:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/46\">",
"      Arar MY, Hogg RJ, Arant BS Jr, Seikaly MG. Etiology of sustained hypertension in children in the southwestern United States. Pediatr Nephrol 1994; 8:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/47\">",
"      Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/48\">",
"      Dillon MJ. The diagnosis of renovascular disease. Pediatr Nephrol 1997; 11:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/49\">",
"      Deal JE, Snell MF, Barratt TM, Dillon MJ. Renovascular disease in childhood. J Pediatr 1992; 121:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/50\">",
"      Piercy KT, Hundley JC, Stafford JM, et al. Renovascular disease in children and adolescents. J Vasc Surg 2005; 41:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42105/abstract/51\">",
"      Fossali E, Signorini E, Intermite RC, et al. Renovascular disease and hypertension in children with neurofibromatosis. Pediatr Nephrol 2000; 14:806.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6111 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-854D70C629-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_7_42105=[""].join("\n");
var outline_f41_7_42105=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44275598\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44275605\">",
"      - United States",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44275612\">",
"      - Other countries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44275619\">",
"      Prehypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ethnicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Monogenic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      White coat hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prenatal and neonatal factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Primary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Secondary hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Renal parenchymal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Renovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Renal tubular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Endocrinologic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Drugs and toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6111\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6111|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/12/17614\" title=\"figure 1A\">",
"      Prevalence of HTN in men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/46/19182\" title=\"figure 1B\">",
"      Prevalence of HTN in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6111|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/45/7894\" title=\"table 1\">",
"      Normal BP boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/46/7910\" title=\"table 2\">",
"      Normal BP girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/60/28621\" title=\"table 3\">",
"      Causes HTN children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/40/31372\" title=\"table 4\">",
"      History for hypertensive child or adolescent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/61/32733\" title=\"table 5\">",
"      Physical findings in the hypertensive child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27674?source=related_link\">",
"      Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=related_link\">",
"      Ambulatory blood pressure monitoring and white coat hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25943?source=related_link\">",
"      Ambulatory blood pressure monitoring in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40838?source=related_link\">",
"      Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8730?source=related_link\">",
"      Arsenic exposure and poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29913?source=related_link\">",
"      Autosomal recessive polycystic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/33/23062?source=related_link\">",
"      Cardiovascular effects of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23369?source=related_link\">",
"      Causes and clinical manifestations of primary adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/55/26489?source=related_link\">",
"      Causes and pathophysiology of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/19/13624?source=related_link\">",
"      Clinical features and diagnosis of Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/42/34471?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromuscular dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1337?source=related_link\">",
"      Clinical presentation and diagnosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43833?source=related_link\">",
"      Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/15/15609?source=related_link\">",
"      Clinical presentation, diagnosis, and staging evaluation of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37674?source=related_link\">",
"      Comorbidities and complications of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22154?source=related_link\">",
"      Complications of renal transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15878?source=related_link\">",
"      Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32858?source=related_link\">",
"      Definition; epidemiology; and etiology of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37859?source=related_link\">",
"      Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37833?source=related_link\">",
"      Etiology, clinical features, and diagnosis of neonatal hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9930?source=related_link\">",
"      Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/42/2729?source=related_link\">",
"      Evaluation of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22615?source=related_link\">",
"      Familial hyperaldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25399?source=related_link\">",
"      Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9159?source=related_link\">",
"      Genetic factors in the pathogenesis of essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/58/11174?source=related_link\">",
"      Hypertensive complications in blacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=related_link\">",
"      Overview of hypertension in acute and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/28/38337?source=related_link\">",
"      Patient information: High blood pressure in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/58/931?source=related_link\">",
"      Patient information: High blood pressure treatment in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38121?source=related_link\">",
"      Pheochromocytoma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39477?source=related_link\">",
"      Possible role of low birth weight in the pathogenesis of essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35304?source=related_link\">",
"      Poststreptococcal glomerulonephritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/10/3242?source=related_link\">",
"      Presentation, diagnosis, and clinical course of vesicoureteral reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43096?source=related_link\">",
"      Risk factors and development of atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30649?source=related_link\">",
"      Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=related_link\">",
"      Treatment of hypertension in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_7_42106="Treatment and prognosis of IgA nephropathy";
var content_f41_7_42106=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of IgA nephropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/7/42106/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/7/42106/contributors\">",
"     Daniel C Cattran, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/7/42106/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/7/42106/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/7/42106/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/7/42106/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/7/42106/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/7/42106/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgA nephropathy is the most common cause of primary (idiopathic) glomerulonephritis in the developed world [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Although this disorder was initially thought to follow a benign course, it is now recognized that slow progression to end-stage renal disease occurs in up to 50 percent of affected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/6\">",
"     6",
"    </a>",
"    ], often over 20 to 25 years of observation. The remaining patients enter a sustained clinical remission or have persistent low grade hematuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteinuria. The prognosis is difficult to predict with accuracy in individual patients, but important risk factors for progressive renal disease have been identified. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical predictors of progression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are two major clinical presentations of IgA nephropathy: the classic presentation with gross hematuria, often recurrent, following shortly after an upper respiratory infection; and persistent asymptomatic microscopic hematuria with or without mild to moderate proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/4\">",
"     4",
"    </a>",
"    ]. The diagnosis may be suspected in patients with the classic presentation, but must be confirmed by kidney biopsy, which, as described below, often provides prognostic information. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1337?source=see_link\">",
"     \"Clinical presentation and diagnosis of IgA nephropathy\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6\">",
"     'Histologic predictors of progression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The renal prognosis and treatment of IgA nephropathy will be reviewed here. The pathogenesis of IgA nephropathy and the outcomes in patients who undergo renal transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/48/20233?source=see_link\">",
"     \"Pathogenesis of IgA nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39367?source=see_link\">",
"     \"IgA nephropathy: Recurrence after transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RENAL PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with IgA nephropathy who have little or no proteinuria (less than 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    have a low risk of progression, at least in the short term. However, proteinuria and renal insufficiency develop in a substantial proportion of patients over the long term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. Among patients who develop overt proteinuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an elevated serum creatinine concentration, progression to end-stage renal disease is approximately 15 to 25 percent at 10 years and 20 to 30 percent at 20 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/2,3,10-13\">",
"     2,3,10-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of progression is typically slow with the GFR often falling by as little as 1 to 3",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per year, a change not associated with an elevation in the serum creatinine concentration in the short term. Thus, a stable and normal serum creatinine concentration does not necessarily indicate stable disease. The frequency with which this occurs has been evaluated in studies in which repeat renal biopsy was used to assess the frequency of progressive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In one report, repeat renal biopsies were performed at five years in 73 patients with persistent proteinuria and a normal or near-normal initial serum creatinine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/14\">",
"     14",
"    </a>",
"    ]. Histologic improvement occurred in only 4 percent, with 41 percent remaining stable and 55 percent showing progressive glomerular and secondary vascular and tubulointerstitial injury. An increase in serum creatinine to more than 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    was associated with major pathologic lesions.",
"   </p>",
"   <p>",
"    These observations and those in the following sections are generally from patients with biopsy-confirmed IgA nephropathy in which some factor other than hematuria prompted the biopsy, such as proteinuria or an elevated serum creatinine concentration. Patients with only hematuria are often not biopsied in many countries, such as the United States, but should be monitored periodically but progression to protein and impaired renal function can occur. (See",
"    <a class=\"local\" href=\"#H450429\">",
"     'Hematuria without proteinuria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The potential impact of biopsy criteria on prognosis was evaluated in a retrospective study that evaluated geographic differences in the clinical course of 711 patients with a biopsy diagnosis of IgA nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/6\">",
"     6",
"    </a>",
"    ]. Renal survival at 10 years was 96, 87, 64, and 62 percent in Finland, Australia, Scotland, and Canada, respectively. The better outcomes in Finland and Australia were largely, although not completely, attributable to the diagnosis of milder cases (eg, less proteinuria, higher creatinine clearance,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower blood pressure). This raises the possibility of lead-time bias influencing the prognosis, as opposed to a better prognosis in some geographic areas compared with others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/6,16\">",
"     6,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical predictors of progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in other glomerulopathies, patients who will develop progressive disease typically have one or more of the following clinical or laboratory findings at diagnosis, each of which is a marker for more severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/2,3,7-11,17-24\">",
"     2,3,7-11,17-24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated serum creatinine concentration",
"     </li>",
"     <li>",
"      Hypertension",
"      <span class=\"nowrap\">",
"       (&gt;140/90",
"      </span>",
"      mmHg)",
"     </li>",
"     <li>",
"      Persistent protein excretion above 1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453254\">",
"    <span class=\"h3\">",
"     Reduced GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reduction in glomerular filtration rate (GFR), as manifested by an elevated serum creatinine concentration at diagnosis or during the course of the disease, is associated with a worse renal prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/2,10,11,21,22,24,25\">",
"     2,10,11,21,22,24,25",
"    </a>",
"    ]. The magnitude of the effect of reduced GFR on prognosis was illustrated in a study from Japan of 2270 patients with IgA nephropathy in which the cumulative incidence of end-stage renal disease at seven years varied directly and markedly with the serum creatinine (SCr) at diagnosis (p value for the trend &lt;0.001) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SCr &le;1.25",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (111",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      &ndash; 2.5 percent",
"     </li>",
"     <li>",
"      SCr 1.26 to 1.67",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (111 to 147",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      &ndash; 26 percent",
"     </li>",
"     <li>",
"      SCr &gt;1.68",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;148",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      &ndash; 71 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452224\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;When present at diagnosis, hypertension or a significant elevation in blood pressure (eg, from",
"    <span class=\"nowrap\">",
"     100/60",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg) is predictive of a worse outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/9,19,23\">",
"     9,19,23",
"    </a>",
"    ]. The magnitude of this effect was illustrated in a prospective study of 332 patients with IgA nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/9\">",
"     9",
"    </a>",
"    ]. The cumulative incidence of dialysis or death was much higher in patients with hypertension (defined as",
"    <span class=\"nowrap\">",
"     &gt;140/90",
"    </span>",
"    mmHg) at disease discovery compared with those without hypertension (15 versus 3 percent and 41 versus 6 percent at 10 and 20 years, respectively).",
"   </p>",
"   <p>",
"    Similar findings were noted in a second prospective study of 542 patients with IgA nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/23\">",
"     23",
"    </a>",
"    ]. A higher mean arterial pressure was associated with a higher risk of progressive renal disease, an effect that was seen at all levels of proteinuria. However, as described in the next section, the degree of proteinuria was the most important predictor of renal outcome.",
"   </p>",
"   <p>",
"    It is thought that the adverse prognosis associated with hypertension is primarily related to its being a marker of more severe glomerular disease. However, if untreated, hypertension can directly contribute to progressive kidney disease. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Proteinuria and blood pressure goals'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H449899\">",
"    <span class=\"h3\">",
"     Protein excretion above 1 g/day",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relation between increasing proteinuria and a worse prognosis is related at least in part to proteinuria being a marker for the severity of glomerular disease. The rate of progression is very low among patients excreting less than 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and is greatest among those excreting more than 3.0 to 3.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/9-11,19,22-24,26,27\">",
"     9-11,19,22-24,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of the magnitude of proteinuria and its persistence on the course of IgA nephropathy was evaluated in the prospective cohort study of 332 patients (mean age 36&plusmn;15 years) cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/9\">",
"     9",
"    </a>",
"    ]. The incidence of dialysis and death was significantly higher for patients with protein excretion of 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    or more compared with those excreting less than 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (17 versus 3 percent and 41 versus 10 percent at 10 and 20 years, respectively). This study also confirmed the above observation that sustained proteinuria less than 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    could be used as a practical definition of partial remission in IgA nephropathy. Over the long term, the incidence of dialysis or death was much lower in patients who achieved a reduction in protein excretion to less than 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    with treatment compared with those with persistent protein excretion above this level (2 versus 29 percent and 2 versus 67 percent at 10 and 20 years, respectively).",
"   </p>",
"   <p>",
"    Similar findings were noted in the observational study of 542 patients with IgA nephropathy (mean age 38&plusmn;13 years) who were followed for a mean 6.5 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of decline in renal function was 24-times faster in patients with sustained proteinuria of more than 3",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      compared with patients with persistent protein excretion below 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      (0.72 versus 0.03",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2 per month), with a hazard ratio for the development of end-stage renal disease during the study of 10. Patients with protein excretion between 1 and 3",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      were at intermediate risk (",
"      <a class=\"graphic graphic_figure graphicRef65711 \" href=\"mobipreview.htm?31/47/32510\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients who presented with protein excretion above 3",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      who attained a partial remission (less than 1",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      had a similar rate of progression to renal failure as patients with sustained proteinuria from presentation of less than 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef78495 \" href=\"mobipreview.htm?35/15/36093\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The prognosis in patients who presented with protein excretion below 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      at presentation varied with the course of proteinuria over time. Renal survival was very high in patients who had a 1 to 2",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      increase in proteinuria and progressively decreased with greater increases in proteinuria (",
"      <a class=\"graphic graphic_figure graphicRef81522 \" href=\"mobipreview.htm?34/43/35517\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study from China, patients with less than 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    had significantly better outcomes than patients excreting 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/26\">",
"     26",
"    </a>",
"    ]. However, data regarding the effect of lowering proteinuria to different levels was not provided, in contrast to the above study (",
"    <a class=\"graphic graphic_figure graphicRef78495 \" href=\"mobipreview.htm?35/15/36093\">",
"     figure 2",
"    </a>",
"    ). Thus, the better prognosis in patients with protein excretion below 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    could simply have reflected less severe disease or better blood pressure control.",
"   </p>",
"   <p>",
"    Even the degree of proteinuria by dipstick at the baseline evaluation has predictive value. This was demonstrated in a report from Japan of 2270 patients with biopsy-proven IgA nephropathy who were surveyed three, five, and eight years after the baseline survey [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/10\">",
"     10",
"    </a>",
"    ]. The seven-year cumulative incidence of end-stage renal disease was 0.7 percent in patients who had no or trace proteinuria at presentation compared with 6.4, 18.3, and 30.9 percent in patients with 1+, 2+, and 3+ proteinuria at presentation. The urine albumin concentration ranged from less than 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    with a negative or trace positive dipstick to 300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or more with a 3+ dipstick.",
"   </p>",
"   <p>",
"    As described below, an ACE inhibitor or angiotensin II receptor blocker is the preferred initial drug to reduce protein excretion and slow the rate of disease progression. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Angiotensin inhibition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83037486\">",
"    <span class=\"h4\">",
"     Acute onset of nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrotic range proteinuria can occur in more severe IgA nephropathy and is an adverse predictor of prognosis. However, some patients have an acute onset of nephrotic syndrome and renal biopsy reveals only mild mesangial proliferation, with the most prominent finding being diffuse fusion of the foot processes on electron microscopy, similar to that seen in minimal change (",
"    <a class=\"graphic graphic_picture graphicRef58414 \" href=\"mobipreview.htm?20/6/20584\">",
"     picture 1",
"    </a>",
"    ). Furthermore, many of these patients behave as if they have minimal change disease, as remission of the nephrotic syndrome can be induced with glucocorticoid therapy. Whether these patients actually have IgA nephropathy is unclear. IgA nephropathy may also overlap with membranous nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1337?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical presentation and diagnosis of IgA nephropathy\", section on 'Minimal change disease and membranous nephropathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=see_link&amp;anchor=H445388995#H445388995\">",
"     \"Treatment of minimal change disease in adults\", section on 'Glucocorticoid therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450429\">",
"    <span class=\"h3\">",
"     Hematuria without proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have recurrent episodes of gross hematuria without proteinuria are at low risk for progressive kidney disease compared with patients who have persistent microscopic hematuria and proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/2,28\">",
"     2,28",
"    </a>",
"    ]. In addition, isolated persistent hematuria (ie, with little or no proteinuria) at presentation may be associated with progressive disease over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/7,10,11,29\">",
"     7,10,11,29",
"    </a>",
"    ]. The following observations are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study from China, 72 consecutive patients with IgA nephropathy who underwent renal biopsy because of hematuria with no or minimal proteinuria (defined as less than 0.4",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      were followed for a median of seven years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/7\">",
"       7",
"      </a>",
"      ]. Protein excretion above 1",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      hypertension, and impaired renal function (serum creatinine &ge;1.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [120",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      developed in 33, 26, and 7 percent, respectively.",
"     </li>",
"     <li>",
"      A study from Israel found persistent asymptomatic isolated microscopic hematuria (proteinuria less than 200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      in 3690 young adults (0.3 percent of 1.2 million eligible individuals) who were examined for fitness for military service [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/29\">",
"       29",
"      </a>",
"      ]. At a mean follow-up of 16 years, treated end-stage renal disease occurred significantly more often than in those without hematuria (0.70 versus 0.05 percent, adjusted hazard ratio 18.5). Four of the 26 patients had progressive disease had IgA nephropathy on renal biopsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients with isolated hematuria (ie, no significant proteinuria or renal dysfunction at presentation) undergo remission of abnormal laboratory findings, with reported rates ranging from 5 to 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/12,14-17,30\">",
"     12,14-17,30",
"    </a>",
"    ]. Remission appears to occur most often in children. This was illustrated in a study of 181 Japanese children diagnosed by renal biopsy before the age of 15 years; 30 percent had proliferative glomerulonephritis and were treated with immunosuppressive agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/17\">",
"     17",
"    </a>",
"    ]. After a mean follow-up of seven years, 50 percent had no manifestations of disease, 36 percent had persistent hematuria with or without proteinuria, and 14 percent developed progressive disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Acute renal failure with gross hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute renal failure can occur during episodes of gross hematuria in patients with IgA nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Renal biopsy in these patients reveals mesangial proliferation and segmental crescents in a small proportion of glomeruli (usually less than 25 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/31,33,34\">",
"     31,33,34",
"    </a>",
"    ]. These findings are insufficient to account for the acute renal failure, which has been ascribed to tubular obstruction by red cell casts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/32,33,35\">",
"     32,33,35",
"    </a>",
"    ]. However, the most common histologic lesion is acute tubular necrosis, which may be induced by the iron released from lysed red cells in the tubules, possibly acting via the local generation of toxic oxygen free radicals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/32,34,35\">",
"     32,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The serum creatinine concentration typically returns to baseline levels within several weeks to months, although dialysis may be temporarily required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/32\">",
"     32",
"    </a>",
"    ]. However, incomplete recovery of renal function was noted in 9 of 36 patients (estimated mean GFR after recovery 38",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    versus 89",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/35\">",
"     35",
"    </a>",
"    ]. Significant risk factors for lack of complete recovery included duration of gross hematuria longer than 10 days, age greater than 50 years, decreased estimated GFR at baseline, and more severe tubular necrosis on renal biopsy.",
"   </p>",
"   <p>",
"    One concern in such patients with known IgA nephropathy is that transformation to crescentic disease, which has a different prognosis and requires immediate therapy, can present in a similar fashion. We suggest renal biopsy if, at a maximum of one week, there is no clear evidence of reversal of the acute episode. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Crescentic glomerulonephritis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450116\">",
"    <span class=\"h3\">",
"     Genetic associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of genetic associations have been suggested to be prognostically important in patients with IgA nephropathy, but the data are often conflicting and may be confounded by the population studied (population stratification):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In some studies, progressive disease appeared more likely in patients with the DD genotype of the ACE gene, which is associated with higher plasma ACE levels, compared with patients who have the ID or II genotype [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/36-38\">",
"       36-38",
"      </a>",
"      ]. However, others have reported no correlation between genotype and outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The possible role of two other genes related to the renin-angiotensin system, the angiotensinogen and angiotensin II receptor genes, has also been evaluated. No relation was found with the angiotensin II receptor genes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/38,41\">",
"       38,41",
"      </a>",
"      ], while conflicting data have been reported with the angiotensinogen gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/38,41,42\">",
"       38,41,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 425 Chinese patients and their families, a polymorphism of the megsin gene appeared to be associated with a faster rate of rise in serum creatinine at two-year follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/43\">",
"       43",
"      </a>",
"      ]. Upregulation of megsin (a serine protease inhibitor predominantly expressed in the mesangium) correlated with mesangial expansion and hypercellularity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There were conflicting findings in two Italian studies as to whether or not familial disease is associated with a worse prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/24,44\">",
"     24,44",
"    </a>",
"    ]. The much larger series found no association between familial disease and renal outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/48/20233?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis of IgA nephropathy\", section on 'Genetic predisposition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At present, none of the genetic associations has proven utility in determining prognosis and making treatment decisions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450123\">",
"    <span class=\"h3\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other potentially modifiable risk factors for progressive disease include obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/45\">",
"     45",
"    </a>",
"    ], hypertriglyceridemia and hyperuricemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/46\">",
"     46",
"    </a>",
"    ], and smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Histologic predictors of progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although clinical features appear to be stronger prognostic indicators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/19\">",
"     19",
"    </a>",
"    ], certain findings on renal biopsy in patients with IgA nephropathy have been associated with an increased risk of progressive disease. These include both markers of",
"    <strong>",
"     more severe inflammatory disease",
"    </strong>",
"    , such as crescent formation and immune deposits in the capillary loops in addition to the mesangial deposits that are present in all patients, and markers of",
"    <strong>",
"     chronic fibrotic disease",
"    </strong>",
"    such as glomerulosclerosis, tubular atrophy, interstitial fibrosis, and vascular disease. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/2,11,12,17,21,24,28,48-50\">",
"     2,11,12,17,21,24,28,48-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several schema for classifying renal biopsy findings have been described that appear to correlate with prognosis; in multivariate analyses, the extent of glomerulosclerosis and tubulointerstitial disease are most commonly associated with a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/28,51,52\">",
"     28,51,52",
"    </a>",
"    ]. These indicators are typical of most glomerular diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link&amp;anchor=H7#H7\">",
"     \"Secondary factors and progression of chronic kidney disease\", section on 'Tubulointerstitial fibrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13649389\">",
"    <span class=\"h3\">",
"     Oxford classification of IgA nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A consensus on the pathologic classification of IgA nephropathy has been developed by the International IgA nephropathy Network Group working in collaboration with the Renal Pathology Society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. In order to develop this classification, clinical data and renal biopsies were obtained from 265 patients who were followed for a median of five years. Repeated analysis by several pathologists identified histologic variables that were consistently interpreted with a high degree of reproducibility. In a retrospective analysis, the following variables correlated with adverse renal outcomes independent of the clinical features at baseline and the degree of proteinuria and blood pressure control during follow-up:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mesangial hypercellularity",
"     </li>",
"     <li>",
"      Segmental glomerulosclerosis",
"     </li>",
"     <li>",
"      Endocapillary hypercellularity",
"     </li>",
"     <li>",
"      Tubular",
"      <span class=\"nowrap\">",
"       atrophy/interstitial",
"      </span>",
"      fibrosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Oxford classification has been validated in a European cohort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/55\">",
"     55",
"    </a>",
"    ], a North American cohort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/56\">",
"     56",
"    </a>",
"    ], and a Chinese cohort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/57\">",
"     57",
"    </a>",
"    ]. The predictive value of each of the histologic variables appears to be similar in adults and children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. A potential weakness of this classification system is that it does not include crescents or necrotizing lesions, as too few of these lesions were found in the data set due to inclusion and exclusion criteria.",
"   </p>",
"   <p>",
"    Based upon these observations, the consensus recommendation is that every biopsy report of IgA nephropathy should include numerical scores based upon the presence or absence of these variables. A suggested scoring system and the definitions of the above histologic variables are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1337?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical presentation and diagnosis of IgA nephropathy\", section on 'Oxford classification of IgA nephropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data on the utility of the Oxford classification, independent of clinical parameters (eg, reduced glomerular filtration and proteinuria above 1",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    for determining appropriate therapy. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Patient selection'",
"    </a>",
"    below.) It appears that the addition of a classification of glomerular pathology adds accuracy to prognostication, over and above clinical assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11169826\">",
"    <span class=\"h2\">",
"     Absolute renal risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;A scoring system that estimates the risk of dialysis or death at 10 and 20 years was developed in a prospective study of 332 patients with IgA nephropathy followed for a mean of 12 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/9\">",
"     9",
"    </a>",
"    ]. At the time of diagnosis, patients were assigned an absolute renal risk (ARR) score of 0 to 3 depending upon the presence of hypertension (1 point), protein excretion &ge;1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (1 point), and a global optical score (GOS) on renal biopsy &ge;8 (1 point). The GOS is a measure of the severity of glomerular, vascular, tubular and interstitial lesions observed on the initial biopsy; a value &ge;8 represents severe pathological lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/9,14\">",
"     9,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of death or dialysis at 10 and 20 years for specific ARR scores was [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ARR score of 0 &ndash; 2 and 4 percent",
"     </li>",
"     <li>",
"      ARR score of 1 &ndash; 2 and 9 percent",
"     </li>",
"     <li>",
"      ARR score of 2 &ndash; 7 and 18 percent",
"     </li>",
"     <li>",
"      ARR score of 3 &ndash; 29 and 64 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, as noted by the authors and described in earlier papers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/23\">",
"     23",
"    </a>",
"    ], reducing protein excretion and treating hypertension significantly improves outcomes. Thus, it appears that persistence of these risk factors is the most relevant issue for patient prognosis. (See",
"    <a class=\"local\" href=\"#H449899\">",
"     'Protein excretion above 1 g/day'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Proteinuria and blood pressure goals'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1205404\">",
"    <span class=\"h2\">",
"     Serologic predictors of progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with healthy subjects without IgA nephropathy, there is an increase in the proportion of poorly galactosylated IgA1 O-glycoforms in the serum. These poorly galactosylated IgA1 molecules are thought to be involved in the pathogenesis of IgA nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/48/20233?source=see_link&amp;anchor=H22581665#H22581665\">",
"     \"Pathogenesis of IgA nephropathy\", section on 'Poor O-galactosylation of IgA1'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of 97 patients with IgA nephropathy of varying severity, higher titers of autoantibodies specific for poorly galactosylated IgA1 corresponded to both the absolute renal risk score mentioned above and, consequently, to the risk of end-stage renal disease or death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/60\">",
"     60",
"    </a>",
"    ]. Thus, testing for autoantibodies against abnormal IgA1 molecules may prove to be a useful prognostic tool in patients with IgA nephropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     APPROACH TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to the treatment of IgA nephropathy is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. The slow rate of loss of GFR seen in many patients (1 to 3",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per year) hinders the ability to perform adequate studies. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Renal prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are two approaches to the therapy of IgA nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General interventions to slow progression that are not specific to IgA nephropathy, including blood pressure control and, in patients with proteinuria, angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). In addition, statin therapy may be beneficial in patients with chronic kidney disease and serum LDL-cholesterol concentrations above goal values. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Nonimmunosuppressive therapies'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Therapy with glucocorticoids with or without other immunosuppressive agents to treat the underlying inflammatory disease. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Immunosuppressive therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The general interventions are used in all patients at risk for progression (ie, with proteinuria), while immunosuppressive therapy is used in selected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient selection for therapy is based in part upon the perceived risk of progressive kidney disease. (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical predictors of progression'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with isolated hematuria, no or minimal proteinuria (less than 500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      and a normal glomerular filtration rate (GFR) are typically not treated and often not biopsied and therefore not identified as having IgA nephropathy. However, these patients should be periodically monitored at 6 to 12 month intervals since there is an appreciable rate of progressive disease as manifested by increases in proteinuria, blood pressure,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      serum creatinine. (See",
"      <a class=\"local\" href=\"#H450429\">",
"       'Hematuria without proteinuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with persistent proteinuria (above 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      or perhaps above 500",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      a normal or only slightly reduced GFR that is not declining rapidly, and only mild to moderate histologic findings on renal biopsy are initially managed with nonimmunosuppressive therapies to slow progression. Adding fish oil supplements at this stage should also be considered. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Nonimmunosuppressive therapies'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with more severe or rapidly progressive disease (eg, nephrotic range proteinuria or proteinuria persisting despite three to six months of ACE",
"      <span class=\"nowrap\">",
"       inhibitor/ARB",
"      </span>",
"      therapy, rising serum creatinine,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      renal biopsy with more severe histologic findings, but no significant chronic changes) may benefit from immunosuppressive therapy in addition to nonimmunosuppressive interventions to slow disease progression. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Immunosuppressive therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The Oxford histologic classification system may improve the ability to identify patients with the worst prognosis at the time of renal biopsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/58\">",
"       58",
"      </a>",
"      ]. This classification may also allow the identification of features that are steroid responsive. This was suggested in the original Oxford classification and also seen in the North American IgA nephropathy validation study, in which patients with endocapillary proliferation who received immunosuppressive therapy (largely corticosteroids) had a markedly lower rate of decline in glomerular filtration rate than those who did not receive this therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/53\">",
"       53",
"      </a>",
"      ]. However, such an observation does not prove cause-and-effect. (See",
"      <a class=\"local\" href=\"#H13649389\">",
"       'Oxford classification of IgA nephropathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Monitoring disease activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific markers to identify continued immunologic activity. As a result, clinical parameters are typically used, whether or not the patient is receiving immunosuppressive therapy. The major parameters that are serially monitored are the urine sediment, serum creatinine concentration or estimated glomerular filtration rate, and protein excretion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hematuria",
"      </strong>",
"      &mdash; Persistent hematuria is generally a marker of persistent immunologic activity, but not necessarily of progressive disease. Hematuria alone does not require any form of therapy but monitoring over time is essential since some patients develop proteinuria and progressive disease. (See",
"      <a class=\"local\" href=\"#H450429\">",
"       'Hematuria without proteinuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Proteinuria",
"      </strong>",
"      &mdash; Protein excretion above 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      is a marker of more severe disease and is a major risk factor for disease progression unless the degree of proteinuria is reduced. (See",
"      <a class=\"local\" href=\"#H449899\">",
"       'Protein excretion above 1 g/day'",
"      </a>",
"      above.) Because of the prognostic importance of the degree of proteinuria, we suggest an initial 24-hour urine collection for both protein and creatinine. The completeness of the 24-hour urine collection can be estimated from the rate of creatinine excretion. Normal values of creatinine excretion vary with age: in patients under the age of 50, 20 to 25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      estimated lean body weight in men and 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      estimated lean body weight in women; and, in patients between the ages of 50 and 90, there is a progressive 50 percent decline in creatinine excretion (to as low as 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      estimated lean body weight in men). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20663247#H20663247\">",
"       \"Assessment of kidney function\", section on 'Limitations of using creatinine clearance'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If the initial 24-hour urine collection seems complete, then the rate of protein excretion is probably an accurate estimate. In this setting, the urine protein-to-creatinine ratio on this specimen can be related to the total amount of proteinuria, and the urine protein-to-creatinine ratio on a random specimen can subsequently be used to monitor the degree of proteinuria, as long as muscle mass appears stable. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link\">",
"       \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Increasing proteinuria may be due to ongoing active disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      secondary glomerular injury due to nonimmunologic progression. It is often not possible to distinguish between these two possibilities, except for a rapid increase in protein excretion, which is usually associated with active disease. Issues related to secondary factors and progression of any cause of proteinuric chronic kidney disease are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link\">",
"       \"Secondary factors and progression of chronic kidney disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Protein excretion often falls with therapy with an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker and the degree of proteinuria is one of the major end points of such therapy. Protein excretion also may fall spontaneously, particularly during recovery from an acute episode, following effective immunosuppressive therapy, and perhaps in children. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Angiotensin inhibition'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Serum creatinine",
"      </strong>",
"      &mdash; The serum creatinine concentration, unless it is rapidly rising, permits an estimation of the glomerular filtration rate (GFR). As noted above, most patients with chronic IgA nephropathy have stable or slowly progressive disease. The rate of loss of GFR is often as low as 1 to 3",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per year, a change that may not raise the serum creatinine level to above normal values for a number of years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/11\">",
"       11",
"      </a>",
"      ]. Because of a compensatory rise in single nephron GFR among less injured glomeruli, a stable normal serum creatinine level or estimated total kidney eGFR does not necessarily indicate stable disease. (See",
"      <a class=\"local\" href=\"#H453254\">",
"       'Reduced GFR'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     NONIMMUNOSUPPRESSIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two main nonimmunosuppressive therapies in IgA nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB) both for blood pressure control and to slow progression of the renal disease.",
"     </li>",
"     <li>",
"      Statin therapy for lipid-lowering in selected patients (with elevated LDL cholesterol) to lower cardiovascular risk. No evidence is available to show that such therapy slows the rate of progression of renal disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fish oil (omega-3 fatty acids prescription strength and quality) has also been studied, but its role is less clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Angiotensin inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin inhibition with an ACE inhibitor or ARB slows the rate of progression of most proteinuric chronic kidney diseases, an effect that is mediated at least in part by lowering both the systemic blood pressure and the intraglomerular pressure, thereby minimizing both proteinuria and secondary glomerular injury (ie, not due to the primary glomerular disease itself). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link&amp;anchor=H3#H3\">",
"     \"Secondary factors and progression of chronic kidney disease\", section on 'Intraglomerular hypertension and glomerular hypertrophy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical trials supporting the efficacy of angiotensin inhibition in proteinuric chronic kidney disease in general are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H11#H11\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Effect of renin-angiotensin system inhibitors on progression of CKD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of diabetic nephropathy\", section on 'Preservation of renal function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94111424\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trial data supporting the efficacy of angiotensin inhibition in patients with IgA nephropathy are limited but it is presumed that the mechanisms of secondary progression (ie, progression not due to the activity of the underlying disease) are similar to those in other forms of proteinuric chronic kidney disease. ACE inhibitors and ARBs significantly reduce protein excretion to a comparable degree compared with placebo or the dihydropyridine calcium channel blocker",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/63,64\">",
"     63,64",
"    </a>",
"    ], an effect that is seen in normotensive as well as hypertensive patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/65\">",
"     65",
"    </a>",
"    ]. In contrast, the non-dihydropyridine calcium channel blockers",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    also lower protein excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/66\">",
"     66",
"    </a>",
"    ] and can be added if the therapeutic goals are not reached with angiotensin inhibition alone. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Proteinuria and blood pressure goals'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The antiproteinuric effect is mediated by both a reduction in intraglomerular pressure and improvement in the size-selective properties of the glomerular capillary wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/67\">",
"     67",
"    </a>",
"    ]. Angiotensin inhibitors also lower the blood pressure, and there is evidence that a goal blood pressure below",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg is associated with improved renal outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link&amp;anchor=H3#H3\">",
"     \"Secondary factors and progression of chronic kidney disease\", section on 'Intraglomerular hypertension and glomerular hypertrophy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best data supporting greater clinical efficacy of angiotensin inhibition compared with other antihypertensive drugs on renal outcomes in IgA nephropathy comes from a trial in which 44 patients with proteinuria (&ge;0.5",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    mean 1.9",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    and a serum creatinine concentration &le;1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    at baseline were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    or antihypertensive agents other than ACE inhibitors or ARBs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/69\">",
"     69",
"    </a>",
"    ]. The target blood pressure was less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg, and initially normotensive patients received a fixed dose of antihypertensive drugs. Blood pressure control throughout the study was similar in the two groups. At follow-up of about six years, renal survival, defined as less than a 50 percent increase in the serum creatinine concentration, was significantly more likely in the enalapril group (92 versus 55 percent) and a significant decrease in proteinuria was only observed in the enalapril group (2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    at baseline versus 0.9",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    at the last visit). The proteinuria decline after one year of therapy correlated with renal survival. Another small randomized trial showed benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    therapy compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another randomized trial, IgACE, compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"     benazepril",
"    </a>",
"    with placebo in 65 young patients (range 9 to 35 years) with IgA nephropathy, moderate proteinuria (1.0 to 3.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    per 1.73 m2), and relatively preserved renal function (creatinine clearance &gt;50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/71\">",
"     71",
"    </a>",
"    ]; patients were randomly assigned to benazepril (0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or placebo. Only five patients were hypertensive. At a median follow-up of 38 months, the primary end point (greater than a 30 percent decrease in creatinine clearance) was reached by only a few patients and significant efficacy could not be determined. However, benazepril therapy did result in a significantly lower incidence of the secondary composite end point (greater than 30 percent decrease in creatinine clearance or worsening of proteinuria until the nephrotic range was reached, 3 versus 27 percent) and a higher incidence of a partial (41 versus 9 percent) or complete remission of proteinuria (13 versus 0 percent). Although blood pressures were higher in the placebo group in the last one to two years of the study, the effect of blood pressure on outcomes was probably small, since differences were not observed in the first three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benefit from angiotensin inhibition was also seen in two observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. As an example, a report from the Toronto Glomerulonephritis Registry retrospectively identified 115 patients with IgA nephropathy who had proteinuria of at least 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and were followed for 3 to 121 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/73\">",
"     73",
"    </a>",
"    ]. The 27 patients who were treated with an ACE inhibitor, when compared with the 55 patients treated with other antihypertensive drugs, had the following significant benefits: a slower rate of loss of creatinine clearance (0.4 versus 1.0",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per month), a longer time to loss of one-third of creatinine clearance, and a higher frequency of remission of proteinuria (18.5 versus 1.8 percent). When compared with the 33 patients who were not treated with antihypertensive drugs, the patients treated with an ACE inhibitor had the same rates of fall in creatinine clearance and progression to renal failure and a higher rate of remission of proteinuria, despite having more severe histologic changes on renal biopsy and a higher initial serum creatinine.",
"   </p>",
"   <p>",
"    In contrast, angiotensin inhibition does not appear to be beneficial in non-proteinuric patients or those with low levels of protein excretion. This was shown in a trial of 60 Chinese patients with IgA nephropathy, proteinuria below 500",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    normal kidney function, and blood pressure below",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    (2.5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/75\">",
"     75",
"    </a>",
"    ]. After five years, there were no differences in the incidence of proteinuria or hypertension and no differences in the rate of kidney function decline. However, it is unknown whether or not a benefit would have been identified with longer periods of follow-up.",
"   </p>",
"   <p>",
"    The authors and reviewers of this topic do not agree on the level of proteinuria below which patients do not require angiotensin inhibition. Some would treat all patients with protein excretion of 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or more. Others would treat all patients with protein excretion of 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    or more, but not those with protein excretion below 1",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    This issue is discussed below. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Proteinuria and blood pressure goals'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Combination of ACE inhibitor and ARB",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of an ARB to an ACE inhibitor in patients with IgA nephropathy produces a further antiproteinuric effect in short-term studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/63,76,77\">",
"     63,76,77",
"    </a>",
"    ]. This finding is consistent with meta-analyses of trials in different proteinuric glomerular diseases, which found a significant 18 to 25 percent greater reduction in proteinuria with combined ACE inhibitors and ARBs compared with monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/64,78\">",
"     64,78",
"    </a>",
"    ]. As mentioned above, a more pronounced antiproteinuric effect to below 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    is a marker for better outcomes. (See",
"    <a class=\"local\" href=\"#H449899\">",
"     'Protein excretion above 1 g/day'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Despite these observations, the clinical role of combined therapy in the treatment of IgA nephropathy is uncertain for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most of the clinical trials of proteinuria, combined therapy was compared with the usual dose rather than a higher dose of a single agent.",
"     </li>",
"     <li>",
"      Despite the greater reduction in proteinuria with combined therapy, there are no randomized trials that have shown that this regimen improves renal outcomes in patients with proteinuric chronic kidney disease. The one trial (COOPERATE) that showed benefit from combination therapy has been retracted by the publisher due to concerns about the reliability of the data [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/79\">",
"       79",
"      </a>",
"      ]. This issue is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H21#H21\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Combination of ACE inhibitors and ARBs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the ONTARGET trial, which included 25,620 mostly older patients with vascular disease or diabetes, there was an increase in adverse side effects (including a possible increase in mortality) in patients who received combination therapy with an ACE inhibitor and ARB, compared with patients who received monotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/80\">",
"       80",
"      </a>",
"      ]. There was also an adverse effect on renal outcomes with combination therapy in ONTARGET. Although combination therapy reduced proteinuria, it was associated with a significantly higher rate of doubling of the serum creatinine or requirement for dialysis (2.5 versus 2.1 percent with monotherapy at a median follow-up of 4.7 years, hazard ratio 1.24, 95% CI 1.01-1.51) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/81\">",
"       81",
"      </a>",
"      ]; the increase in renal risk was much greater in the subset of 608 patients who, at baseline, had proteinuria and an estimated glomerular filtration rate of less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 (4.8 versus 2.8 percent per year with monotherapy, hazard ratio, 95% CI 1.05-2.51) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The applicability of these observations to IgA nephropathy is unclear since the patient populations are so different. ONTARGET was a trial of patients at high cardiovascular risk who had mean age of 66 years. In contrast, the mean age of patients with IgA nephropathy is much lower (eg, mean 36 to 38 years in two large series described above) and affected patients would usually be at lower cardiovascular risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/9,23\">",
"       9,23",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The ONTARGET trial is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=see_link&amp;anchor=H18#H18\">",
"       \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Combination of ACE inhibitors and ARBs'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H21#H21\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Combination of ACE inhibitors and ARBs'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H22#H22\">",
"       \"Treatment of hypertension in patients with diabetes mellitus\", section on 'ACE inhibitor plus ARB'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors and reviewers of this topic do not agree on whether combination therapy with ACE inhibitors and ARBs should be used in patients with IgA nephropathy. The authors of this topic suggest the use of combination ACE inhibitor and ARB therapy if the proteinuria goal of either less than 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or less than 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    is not reached with monotherapy at the maximum recommended dose. In contrast, the reviewers of this topic cite the potential harm and lack of evidence of improved renal outcomes and would add other antiproteinuric therapies (eg, sodium restriction, a diuretic,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an aldosterone antagonist) rather than combination therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H3#H3\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Effect of antihypertensive drugs on proteinuria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Proteinuria and blood pressure goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proteinuria and blood pressure goals with angiotensin inhibition and other antihypertensive therapies (drugs and salt restriction) in patients with IgA nephropathy are similar to those in other causes of proteinuric chronic kidney disease. These goals and how they can be attained are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H149378842#H149378842\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Proteinuria goal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IgA nephropathy has some relatively unique features that support attaining a proteinuria goal of less than 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in all patients, if possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/23\">",
"     23",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H449899\">",
"     'Protein excretion above 1 g/day'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The renal prognosis is progressively worse in IgA nephropathy when protein excretion exceeds 1",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      particularly if persistently above 3",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      (rate of loss of glomerular filtration rate 0.72 versus 0.03",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2 per month in patients with protein excretion below 1",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef65711 \" href=\"mobipreview.htm?31/47/32510\">",
"       figure 1",
"      </a>",
"      ). This is in contrast to many other causes of proteinuric chronic kidney disease, such as membranous nephropathy and primary focal segmental glomerulosclerosis, in which persistent subnephrotic proteinuria is a predictor of a relatively good renal prognosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of idiopathic membranous nephropathy\", section on 'Risk factors for progressive idiopathic MN'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of primary focal segmental glomerulosclerosis\", section on 'Degree of proteinuria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients who present with proteinuria of 3",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      or more, reducing protein excretion to less than 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      results in a similar rate of progression to renal failure as in patients with sustained proteinuria from presentation of less than 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef78495 \" href=\"mobipreview.htm?35/15/36093\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some patients, it is not possible to get below 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    with antiproteinuric therapy alone. The indications for the addition of immunosuppressive therapy are discussed below. (See",
"    <a class=\"local\" href=\"#H284610036\">",
"     'Indications for glucocorticoid therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The authors and reviewers of this topic do not agree on the degree of proteinuria that, independent of hypertension, warrants angiotensin inhibitor therapy. Some would treat all patients with protein excretion of 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or more to a goal below 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    as long the patient tolerates angiotensin inhibitor therapy (eg, absence of a substantial rise in serum creatinine or potassium or hypotension associated with the initiation of therapy). Others would treat all patients with protein excretion of 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    or more as tolerated, but not those with protein excretion below 1",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    However, occasional patients with protein excretion below 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    progress slowly over time. As a result, monitoring of the serum creatinine and protein excretion at yearly intervals is recommended. Angiotensin inhibition should be started if there is evidence of progressive disease (rising proteinuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serum creatinine) with a goal protein excretion of less than 500",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Independent of protein excretion, angiotensin inhibitors can also be used to treat hypertension.",
"   </p>",
"   <p>",
"    The issue of whether to use, if necessary, combination ACE inhibitor and ARB therapy or one of these agents plus other antihypertensive drugs that can lower protein excretion is discussed in the preceding section. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Combination of ACE inhibitor and ARB'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The adverse prognostic effect of high rates of protein excretion in IgA nephropathy applies primarily to chronic persistent proteinuria and not necessarily to patients with the acute onset of nephrotic syndrome in whom mesangial proliferation and IgA deposits may be accompanied by histologic findings of minimal change disease (particularly diffuse foot process fusion on electron microscopy). Such patients often go into remission with glucocorticoid therapy, a response similar to that with minimal change disease alone. (See",
"    <a class=\"local\" href=\"#H83037486\">",
"     'Acute onset of nephrotic syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H888784663\">",
"    <span class=\"h2\">",
"     Lipid-lowering therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic kidney disease is associated with a marked increase in cardiovascular risk, and is considered a coronary artery disease risk equivalent. The goal LDL-cholesterol is similar to that in patients with underlying coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link&amp;anchor=H12#H12\">",
"     \"Chronic kidney disease and coronary heart disease\", section on 'Statin therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although some studies suggested a possible benefit of statin therapy on the progression of chronic kidney disease, such an effect was not seen in a meta-analysis and a subsequent large randomized trial (SHARP) that included 6247 patients with chronic kidney disease not requiring dialysis. Statin therapy should not be used for this purpose. The supportive data are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30824?source=see_link&amp;anchor=H156847721#H156847721\">",
"     \"Statins and chronic kidney disease\", section on 'Effect on CKD progression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Fish oil",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible role of fish oil (prescription strength omega-3 fatty acids not over-the-counter food supplements) in patients with IgA nephropathy, which might act by antiinflammatory mechanisms, is not well defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/83\">",
"     83",
"    </a>",
"    ]. In addition to uncertain efficacy and consistency in omega-3 fatty acid content, there is an associated fishy aftertaste and eructations with this treatment that often limit patient acceptance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials evaluating fish oil in patients with IgA nephropathy have reported conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/84-91\">",
"     84-91",
"    </a>",
"    ]. A Cochrane meta-analysis of four trials including the two major trials discussed below showed no overall beneficial effect of fish oil on renal outcomes including serum creatinine, creatinine clearance, or change in proteinuria, although small benefits were possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/63\">",
"     63",
"    </a>",
"    ]. The two largest trials illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest and best quality trial from the Mayo Clinic, 106 patients with a mean baseline creatinine clearance of 82",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      and protein excretion of 2.5 to 3.2",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      were randomly assigned to therapy with either 12 g of fish oil or a similar amount of olive oil for two years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/84\">",
"       84",
"      </a>",
"      ]. There was no difference in blood pressure control and no significant effect on protein excretion during the study.",
"      <br/>",
"      <br/>",
"      At four years, patients receiving fish oil had a lower incidence of a &ge;50 percent increase in the serum creatinine concentration (6 versus 33 percent in the placebo group) and a lower incidence of death or end-stage renal disease (ESRD) at four years (10 versus 40 percent). With follow-up extended to more than six years, the benefits of continuous fish oil therapy persisted (15 versus 37 percent incidence of ESRD) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial by the Southwest Pediatric Nephrology Study Group, 96 patients (mean glomerular filtration rate [GFR] &gt;100",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 and estimated protein excretion from the urine protein-to-creatinine ratio of 1.4 to 2.2",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      were randomly assigned to one of three treatment arms: a purified preparation of omega-3 fatty acids (4",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      for two years; alternate day",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (60",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per dose for three months, 40",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per dose for nine months, and 30",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per dose for one year); or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/90\">",
"       90",
"      </a>",
"      ]. All patients with hypertension (blood pressure",
"      <span class=\"nowrap\">",
"       &ge;140/90",
"      </span>",
"      mmHg) were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      At three years, the primary outcome of a reduction in GFR to below 60 percent of the baseline value was observed more commonly in the omega-3 fatty acid treatment group (19 versus 9 percent in both the prednisone and placebo groups, respectively). This difference was not statistically significant (although the study was underpowered), and only baseline proteinuria was significantly associated with progression. It is not clear why these trials produced different results. One potentially important factor is that the positive Mayo Clinic trial evaluated patients with more advanced disease (more proteinuria and lower creatinine clearance at baseline). In addition, partial remission, defined by reductions in proteinuria, was not considered in these trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, a benefit from fish oil has not been clearly established. However, fish oil (3.3",
"    <span class=\"nowrap\">",
"     grams/day",
"    </span>",
"    or more) can be tried in patients with protein excretion above 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    despite three to six months of therapy with an ACE inhibitor or ARB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/1,92\">",
"     1,92",
"    </a>",
"    ]. Fish oil may have cardiovascular benefits and is unlikely to be harmful. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36330?source=see_link\">",
"     \"Fish oil and marine omega-3 fatty acids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     IMMUNOSUPPRESSIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal role of antiinflammatory therapy in IgA nephropathy is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. A variety of regimens have been used, mostly consisting of antiinflammatory doses of glucocorticoids alone or in combination with other immunosuppressive drugs. The available studies are not conclusive since most are relatively small and have limited follow-up, and the results are sometimes conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/2,3,92-95\">",
"     2,3,92-95",
"    </a>",
"    ]. For patients with stable or slowly progressive disease, angiotensin inhibition is initiated prior to immunosuppressive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284610036\">",
"    <span class=\"h2\">",
"     Indications for glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for the use of glucocorticoids alone or in combination with other immunosuppressive drugs in patients with IgA nephropathy are not well defined, and one must take into account the potential toxicity of these drugs. Most nephrologists do not treat mild, stable, or very slowly progressive IgA nephropathy with glucocorticoids or other immunosuppressive therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/96,97\">",
"     96,97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, we suggest antiinflammatory therapy with glucocorticoids in patients with clinical features supporting active disease and progression, which include hematuria in addition to one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increasing serum creatinine",
"     </li>",
"     <li>",
"      Persistent proteinuria above 1.0 to 1.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      after maximal antiproteinuric therapy",
"     </li>",
"     <li>",
"      Morphologic evidence of active disease based on kidney biopsy (eg, proliferative or necrotizing glomerular changes)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, we suggest",
"    <strong>",
"     not",
"    </strong>",
"    treating with glucocorticoids in patients with chronically elevated serum creatinine or histologic evidence of prominent glomerulosclerosis and tubulointerstitial atrophy or fibrosis. (See",
"    <a class=\"local\" href=\"#H888782229\">",
"     'Lack of benefit in chronic fibrotic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Combined immunosuppressive therapy can be considered in patients with more severe disease as defined by a more rapidly progressive clinical course",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    histologic evidence of severe active inflammation (eg, crescent formation). (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Combined immunosuppressive therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, patients with acute onset of nephrotic syndrome and diffuse foot process fusion on renal biopsy are treated as if they have minimal change disease. (See",
"    <a class=\"local\" href=\"#H83037486\">",
"     'Acute onset of nephrotic syndrome'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=see_link\">",
"     \"Treatment of minimal change disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H888782229\">",
"    <span class=\"h3\">",
"     Lack of benefit in chronic fibrotic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a chronically elevated serum creatinine level of 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (221",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    or greater and prominent glomerulosclerosis and tubulointerstitial atrophy or fibrosis on renal biopsy are not likely to benefit from immunosuppressive therapy and may be harmed from adverse drug effects. In a randomized trial of 32 such patients, the renal outcomes were not improved with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/25\">",
"     25",
"    </a>",
"    ]. However, such patients who have proteinuria may still benefit from angiotensin inhibition. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Angiotensin inhibition'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Histologic predictors of progression'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Glucocorticoids as sole immunosuppressive/antiinflammatory therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential benefit of glucocorticoid therapy in IgA nephropathy was examined in a 2012 meta-analysis of nine randomized trials including 536 patients with proteinuria (above 1",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    and relatively preserved renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/98\">",
"     98",
"    </a>",
"    ]. The primary endpoint of the analysis was a renal event, defined as a doubling of serum creatinine, a 50 percent decline in glomerular filtration rate, or end-stage renal disease, depending upon the study. The nine trials were heterogenous with respect to the glucocorticoid regimen (eg, high versus low dose, short versus long term), duration of follow-up (6 months to 10 years), the use of a placebo control, and concurrent therapy with ACE inhibitors. The major findings were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoid therapy significantly reduced the incidence of renal events compared with the control (2.4 versus 15 percent; relative risk reduction 0.32 [95% CI 0.15 to 0.67]). Glucocorticoids were also beneficial when only end-stage renal disease events were considered.",
"     </li>",
"     <li>",
"      The two trials in which glucocorticoids combined with ACE inhibitors were compared with ACE inhibitors alone produced findings consistent with the overall result (2.5 versus 19 percent of patients having renal events), suggesting that the addition of glucocorticoids to ACE inhibitors may be beneficial in patients with proteinuria and preserved renal function.",
"     </li>",
"     <li>",
"      The benefit of therapy was greater in trials that used higher doses of glucocorticoids and when treatment with glucocorticoids lasted less than 12 months. In contrast, baseline renal function (serum creatinine above or below 1.1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [97.2",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      and baseline proteinuria (above or below 2",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      had no apparent effect on whether or not glucocorticoid therapy was beneficial.",
"     </li>",
"     <li>",
"      Adverse events were more likely to occur with glucocorticoid therapy (24 versus 13 percent of patients experiencing an adverse event), although the majority of these adverse events were weight gain and cushingoid features.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the small number of events, the confidence in the findings of this meta-analysis is diminished by several additional concerns: eight of the nine trials used open-label designs; six of the nine trials failed to report that randomization was concealed; and four of the nine trials failed to use an intention-to-treat analysis.",
"   </p>",
"   <p>",
"    With the exception of patients described later who appear to have minimal change disease as the cause of nephrotic syndrome (rather than IgA nephropathy), we use glucocorticoids only after angiotensin inhibition has failed to lower proteinuria to goal. In addition, angiotensin inhibition is continued in combination with the glucocorticoids, rather than being replaced by glucocorticoids. (See",
"    <a class=\"local\" href=\"#H1392606\">",
"     'Patients with apparent minimal change disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1392575\">",
"    <span class=\"h3\">",
"     Glucocorticoid regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two largest trials included in the meta-analysis described above treated patients with glucocorticoids for six months and are briefly described here:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial from Italy included 86 adults with moderate proteinuria (1 to 3.5",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      and at most a mild reduction in glomerular filtration rate (median serum creatinine 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [88",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/99\">",
"       99",
"      </a>",
"      ]. The patients were randomly assigned to supportive therapy alone or glucocorticoids (1.0 g of intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      for three consecutive days at the beginning of months one, three, and five, combined with 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      given on alternate days for six months). ACE inhibitors were",
"      <strong>",
"       not",
"      </strong>",
"      used. At 5 and 10 years, the glucocorticoid treated patients had a significantly lower incidence of the primary end point, which was a doubling in the serum creatinine concentration (2 versus 21 percent at 5 years and 2 versus 30 percent at 10 years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another multicenter trial from Italy randomly assigned 97 patients with IA nephropathy, protein excretion greater than 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      (mean 1.6",
"      <span class=\"nowrap\">",
"       g/day),",
"      </span>",
"      and estimated glomerular filtration rate greater than 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 (mean 99",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2) to combined therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      and a six-month course of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (0.8 to 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for two months followed by monthly dose reductions of 0.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day during the next four months) or to ramipril alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/101\">",
"       101",
"      </a>",
"      ]. Prednisone therapy reduced the rate of the primary end point of doubling of the serum creatinine or end-stage renal disease (4 versus 27 percent) at eight years. Prednisone also reduced the incidence of end-stage renal disease (2 versus 14 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We agree with the 2012 KDIGO guidelines that either of these two glucocorticoid regimens is acceptable in patients with IgA nephropathy who are selected for immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1392606\">",
"    <span class=\"h3\">",
"     Patients with apparent minimal change disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a subset of patients with IgA nephropathy in whom glucocorticoid therapy alone is clearly beneficial: those with acute onset of the nephrotic syndrome, little or no hematuria, preserved kidney function, minimal glomerular changes on light microscopy, and diffuse fusion of the foot processes of the glomerular epithelial cells on electron microscopy. These histologic findings are characteristic of minimal change disease, and these patients behave similarly, usually going into remission with glucocorticoid therapy and occasionally requiring",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for frequently relapsing proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/102-104\">",
"     102-104",
"    </a>",
"    ]. Mesangial IgA deposits often disappear or are greatly reduced over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/104\">",
"     104",
"    </a>",
"    ]. It is possible that these patients have minimal change disease and that the presence of IgA deposits is unrelated, particularly in Asian patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/102,104\">",
"     102,104",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H83037486\">",
"     'Acute onset of nephrotic syndrome'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1337?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical presentation and diagnosis of IgA nephropathy\", section on 'Minimal change disease and membranous nephropathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=see_link&amp;anchor=H445388995#H445388995\">",
"     \"Treatment of minimal change disease in adults\", section on 'Glucocorticoid therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Combined immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined immunosuppressive therapy can be considered in patients with more severe disease as defined by a more rapidly progressive clinical course",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    histologic evidence of severe active inflammation (eg, crescent formation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Severe or progressive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have suggested a possible benefit from combined immunosuppressive therapy in patients with moderate to severe disease on biopsy; however, most of these trials did not include a comparison group treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/93,105-109\">",
"     93,105-109",
"    </a>",
"    ]. In addition, the studies were primarily performed prior to the widespread use of aggressive antihypertensive and antiproteinuric therapy with ACE inhibitors or ARBs. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Angiotensin inhibition'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Proteinuria and blood pressure goals'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are limited data concerning the effectiveness of cytotoxic agents in adults with progressive IgA nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/96,105-107,110\">",
"     96,105-107,110",
"    </a>",
"    ]. Two trials, which are discussed below, evaluated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/107\">",
"     107",
"    </a>",
"    ] or with azathioprine alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/110\">",
"     110",
"    </a>",
"    ]. Trials with more complicated regimens have been evaluated in children. (See",
"    <a class=\"local\" href=\"#H436408486\">",
"     'Severe disease in children'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1363959\">",
"    <span class=\"h4\">",
"     Glucocorticoids plus cyclophosphamide followed by azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of initial therapy with glucocorticoids plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    followed by maintenance therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    was evaluated in a single center study of 38 patients with IgA nephropathy and initially impaired renal function (but no crescents on biopsy) as defined by an initial serum creatinine concentration between 1.5 and 2.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (130 and 250",
"    <span class=\"nowrap\">",
"     micromol/L,",
"    </span>",
"    respectively) that was declining at a relatively moderate rate (by at least 15 percent over the year prior to study entry) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/107\">",
"     107",
"    </a>",
"    ]. Mean baseline protein excretion was 4.0 to 4.5",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    patients were given antihypertensive therapy as needed (but not specifically ACE inhibitors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ARBs) and randomly assigned to no further therapy or to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (40 mg per day tapered to 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    by two years) plus low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for the initial three months followed by low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for a minimum of two years (some patients were given azathioprine for up to six years). Blood pressure control was similar in both groups, and immunosuppressive therapy was associated with a low incidence of adverse effects.",
"   </p>",
"   <p>",
"    Compared with the control group, the patients treated with combination therapy had a significant reduction in protein excretion during the first six months of therapy that persisted during follow-up (eg, reached 1.8",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in treatment group versus unchanged at 4.4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in controls at one year). Renal survival was significantly higher in the treatment group at years two (82 versus 68 percent) and five (72 versus 6 percent).",
"   </p>",
"   <p>",
"    These findings suggest that patients with severe or progressive disease (eg, rising creatinine, nephrotic range proteinuria,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    marked proliferation without crescents) who do not have significant chronic damage on kidney biopsy may benefit from combined immunosuppressive therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early therapy is important because improvement is rare when the baseline serum creatinine concentration is greater than 3.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (265",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in the absence of crescentic glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/92\">",
"     92",
"    </a>",
"    ]. In addition, immunosuppressive therapy is not indicated in the spontaneously reversible acute renal failure that may be associated with gross hematuria. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Acute renal failure with gross hematuria'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1363966\">",
"    <span class=\"h4\">",
"     Glucocorticoids plus azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    does not appear to provide further benefit compared with glucocorticoid alone. This was shown in a multicenter randomized trial in which 207 patients with a serum creatinines &le;2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and protein excretion &gt;1.0",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    were treated with glucocorticoids (a three-day pulse of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    in months 1, 3, and 5 in addition to oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every other day) with or without azathioprine (1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for six months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/110\">",
"     110",
"    </a>",
"    ]. At a median follow-up of 4.9 years, there was no difference in renal survival time, defined as the time to a 50 percent increase in plasma creatinine from baseline. Protein excretion decreased in both groups from a median of 2.0 to 1.3",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    during the first year of follow-up but there was no between-group difference. Major side effects were more frequent among those who received azathioprine compared to those who did not (17 versus 6 percent, respectively).",
"   </p>",
"   <p>",
"    This trial is limited by the fact that fewer than one-half of patients were treated with an angiotensin converting enzyme inhibitor or angiotensin receptor blocker at the onset and therefore were not receiving the current standard of care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/111\">",
"     111",
"    </a>",
"    ]. In addition, there was no run-in period during which supportive therapy was optimized. Thus, low risk patients who may have responded to nonimmunosuppressive therapy may have been included in the trial, possibly obscuring a potential benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    in patients who were at high risk for progression.",
"   </p>",
"   <p>",
"    The role of combined immunosuppressive therapy in the treatment of severe or progressive IgA nephropathy is summarized below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H436408486\">",
"    <span class=\"h4\">",
"     Severe disease in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two trials from the Japanese Pediatric IgA Nephropathy Study group evaluated children (mean age 12 years) with newly diagnosed severe disease defined as diffuse mesangial proliferation on renal biopsy, with crescents in 22 percent of glomeruli and sclerosis in 5 percent of glomeruli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. Despite the marked pathologic changes, the mean creatinine clearance was normal (approximately 150",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2), mean urinary protein excretion was approximately 1.2",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    and the mean blood pressure was",
"    <span class=\"nowrap\">",
"     115/65",
"    </span>",
"    mmHg. Both trials supported a benefit from combination immunosuppressive therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first trial, 78 children were randomly assigned to heparin-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      alone or with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      for two years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/108\">",
"       108",
"      </a>",
"      ]. The outcomes at the end of the trial were significantly better in the children treated with the regimen that included prednisolone and azathioprine (group 1) compared with heparin-warfarin and dipyridamole alone (group 2): mean urinary protein excretion and serum IgA levels fell in group 1 but was stable in group 2; and the percent of glomeruli with sclerosis was stable in group 1 and increase in group 2. The blood pressure and serum creatinine remained normal in all but one patient. In a 10-year follow-up study that included 74 of the 78 children, end-stage renal disease had developed in fewer patients who received prednisolone and azathioprine compared with control therapy (5 versus 14.7 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/112\">",
"       112",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the second trial, 80 children were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      or to prednisolone alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/109\">",
"       109",
"      </a>",
"      ]. At two-year follow-up, patients treated with combination therapy had a significantly higher rate of achieving the primary end point of disappearance of proteinuria (less than 0.1",
"      <span class=\"nowrap\">",
"       g/m2",
"      </span>",
"      per day; 92 versus 74 percent) and had no change in the percentage of sclerotic glomeruli compared with an increase from 3 to 15 percent with prednisolone alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Crescentic glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of crescentic, rapidly progressive glomerulonephritis in patients with IgA nephropathy has not been evaluated in randomized trials. Observational data suggest possible benefit from regimens similar to those used in idiopathic crescentic glomerulonephritis: intravenous pulse",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    followed by oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , intravenous or oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    plasmapheresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/113-117\">",
"     113-117",
"    </a>",
"    ]. Glucocorticoids may act in this setting by diminishing acute inflammatory injury rather than by correcting in the factors responsible for IgA production and deposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/118\">",
"     118",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18231?source=see_link\">",
"     \"Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One report evaluated the efficacy of aggressive combination therapy (including pulse",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and plasmapheresis) in six patients with crescentic glomerulonephritis due to IgA nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/115\">",
"     115",
"    </a>",
"    ]. After two months of therapy, there was substantial clinical improvement characterized by reductions in the serum creatinine concentration and protein excretion. However, repeat renal biopsy showed persistence of florid crescents and one-half of patients had progressive disease after therapy was discontinued.",
"   </p>",
"   <p>",
"    A more prolonged course of aggressive immunosuppressive therapy was evaluated in 12 patients with crescentic IgA nephropathy who had a mean serum creatinine concentration of 2.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (240",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and protein excretion of 4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/117\">",
"     117",
"    </a>",
"    ]. The treatment regimen consisted of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for three days)",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for 60 days, followed by 0.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for 60 days, and 0.3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for 60 days; all patients were on 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      at the time of repeat biopsy).",
"     </li>",
"     <li>",
"      Monthly intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (0.5",
"      <span class=\"nowrap\">",
"       g/m2)",
"      </span>",
"      for six months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After the six month course, there were significant reductions in the serum creatinine concentration (2.7 to 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [240 to 133",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    and in protein excretion (4 to 1.4",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"    Repeat renal biopsy revealed the absence of cellular crescents and endocapillary proliferation in all patients.",
"   </p>",
"   <p>",
"    Throughout the three-year follow-up, all patients continued",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day), and the blood pressure was controlled to a goal of less than",
"    <span class=\"nowrap\">",
"     130/70",
"    </span>",
"    mmHg with ACE inhibitors and other agents as needed. Compared with 12 untreated historic controls (matched for age, gender, baseline serum creatinine concentration and histologic severity), the incidence of end-stage renal disease at three years was significantly lower in the treated group (1 of 12 [8 percent] versus 5 of 12 [42 percent]).",
"   </p>",
"   <p>",
"    These limited data suggest that patients with crescentic glomerulonephritis who do not have significant chronic damage on kidney biopsy may benefit from therapy that initially includes intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . This is consistent with the benefit noted with a similar regimen in other forms of crescentic glomerulonephritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18231?source=see_link\">",
"     \"Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of combined immunosuppressive therapy in the treatment of crescentic IgA nephropathy is summarized below. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Unclear role for other immunosuppressive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the above regimens,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    have been evaluated for the treatment of IgA nephropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H436409221\">",
"    <span class=\"h3\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data concerning the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) in the primary treatment of progressive IgA nephropathy. Three small, prospective placebo-controlled randomized trials evaluated the efficacy of MMF therapy; the patients were also treated with ACE inhibitors. The trials had conflicting results, ranging from no benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/25,119\">",
"     25,119",
"    </a>",
"    ], particularly in patients with advanced fibrotic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/25\">",
"     25",
"    </a>",
"    ], to a reduction in proteinuria and a decrease in rate of decline in GFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/120,121\">",
"     120,121",
"    </a>",
"    ]. Additional trials are ongoing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/122\">",
"     122",
"    </a>",
"    ]. Some of the authors and reviewers of this topic would consider the use of MMF in selected patients and some would not use it in any patients. In addition, the KDIGO clinical practice guidelines do not recommend the use of MMF as first-line therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MMF is associated with increased fetal risk and should",
"    <strong>",
"     not",
"    </strong>",
"    be used in women who are or might become pregnant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=see_link&amp;anchor=H7#H7\">",
"     \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    has been investigated in a small series of patients with IgA nephropathy. Although proteinuria may be reduced, the use of cyclosporine has been limited by the associated nephrotoxicity, leading to a rise in the serum creatinine concentration that is greater than that seen in untreated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/123,124\">",
"     123,124",
"    </a>",
"    ]. In addition, relapse occurs soon after the drug is discontinued.",
"   </p>",
"   <p>",
"    Based upon the available data, we do",
"    <strong>",
"     not",
"    </strong>",
"    use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    for the treatment of IgA nephropathy pending further studies showing benefit. The observation that cyclosporine appears to be effective treatment of nephrotic range proteinuria in Henoch-Sch&ouml;nlein purpura (IgA vasculitis), where the renal biopsy findings are those of IgA nephropathy, provides indirect evidence of possible benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/125,126\">",
"     125,126",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis?source=see_link&amp;anchor=H8#H8\">",
"     \"Renal manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\", section on 'Renal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     OTHER POSSIBLE INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other interventions that have been evaluated in an uncontrolled fashion include tonsillectomy, a low antigen diet, intravenous immune globulin, and wormwood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/63\">",
"     63",
"    </a>",
"    ]. Other drugs, such as vitamin D analogs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/127-129\">",
"     127-129",
"    </a>",
"    ], phenytoin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/63\">",
"     63",
"    </a>",
"    ], antiplatelet agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/63\">",
"     63",
"    </a>",
"    ], and danazol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/130\">",
"     130",
"    </a>",
"    ] have also been evaluated but data are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Tonsillectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tonsillitis has been associated with hematuria and proteinuria in IgA nephropathy. It has been proposed that the tonsils are a source of abnormal IgA that forms immune complexes and deposits in the glomeruli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/131,132\">",
"     131,132",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/48/20233?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathogenesis of IgA nephropathy\", section on 'Source and regulation of pathogenic IgA synthesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several retrospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/132-135\">",
"     132-135",
"    </a>",
"    ] and at least one prospective study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/136\">",
"     136",
"    </a>",
"    ] suggest that tonsillectomy, usually in combination with some immunosuppressive therapy, is associated with improved renal outcomes in patients with IgA nephropathy and relatively mild renal injury. However, other studies reported no benefit following tonsillectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/137,138\">",
"     137,138",
"    </a>",
"    ]. Randomized trials have not been performed.",
"   </p>",
"   <p>",
"    In the prospective study of 55 patients, the effect of tonsillectomy plus pulse glucocorticoid therapy was compared with pulse glucocorticoid monotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/136\">",
"     136",
"    </a>",
"    ]. The patients who underwent tonsillectomy did so after receiving a consultation from an otolaryngologist stating that tonsillectomy was indicated. Mean baseline protein excretion was 1.0 to 1.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and the mean baseline creatinine clearance was 95",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patients who underwent tonsillectomy had significantly higher rates of remission of proteinuria and hematuria at two years after therapy (77 versus 41 percent, and 79 versus 18 percent, respectively). The beneficial clinical effects of tonsillectomy on proteinuria persisted through a mean follow-up of 54 months.",
"     </li>",
"     <li>",
"      In 18 patients who underwent a repeat biopsy at two years, mesangial proliferation and IgA deposition were reduced to a significantly greater degree in the patients who underwent tonsillectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of four case-control studies, including this one from Japan, demonstrated a lower rate of end-stage renal disease among patients who had tonsillectomy plus glucocorticoids compared to nonoperative therapy with a pooled odds ratio of 0.22 (95% CI 0.11-0.44) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/139\">",
"     139",
"    </a>",
"    ]. The rate of clinical remission at 5 and 10 years was higher in the tonsillectomy group.",
"   </p>",
"   <p>",
"    These findings provide some evidence supporting the efficacy of tonsillectomy in patients with \"chronic tonsillitis\" and significant IgA nephropathy (ie, proteinuria &gt;1",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"    However, aside from such patients who require tonsillectomy for conventional reasons, tonsillectomy should",
"    <strong>",
"     not",
"    </strong>",
"    be routinely performed in patients with IgA nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials are required to confirm that tonsillectomy is effective in slowing progression of IgA nephropathy and to clarify the role, if any, for tonsillectomy in the absence of other indications for this procedure, since the improvements observed may have been due to glucocorticoid therapy rather than removal of the tonsils.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Low antigen diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low antigen diet consists of avoiding gluten, dairy products, eggs, and most meats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/140\">",
"     140",
"    </a>",
"    ]. The rationale for this regimen is that dietary macromolecules may be responsible for activating the mucosal IgA system. When given to 21 consecutive patients with IgA nephropathy, protein excretion was markedly reduced or fell into the normal range in 11 of the 12 patients whose baseline rate was more than 1",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    In addition, repeat renal biopsy showed significant reductions in mesangial IgA and complement deposition and mesangial cellularity.",
"   </p>",
"   <p>",
"    The benefits in the above study have not been confirmed and a report using a gluten-free diet alone for several years did not demonstrate improvement in either proteinuria or renal function despite a reduction in the level of circulating IgA-containing immune complexes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/141\">",
"     141",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least part of the rationale for intravenous immune globulin (IVIG) therapy in IgA nephropathy comes from the observation that partial IgG deficiency, which could be corrected with IVIG, may predispose to infections that could trigger flare-ups of the renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-dose IVIG has been tried in severe IgA nephropathy, characterized by heavy proteinuria and a relatively rapid decline in GFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/143\">",
"     143",
"    </a>",
"    ]. Eleven patients (nine with IgA nephropathy and two with the related disorder, Henoch-Sch&ouml;nlein purpura [IgA vasculitis]) were treated with IVIG at a dose of 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    for two days per month for three months followed by an intramuscular preparation given every two weeks for another six months. IVIG therapy was associated with a reduction in protein excretion (5.2 to 2.3",
"    <span class=\"nowrap\">",
"     g/day),",
"    </span>",
"    prevention of a continued reduction in GFR (loss of 3.8",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per month prior to therapy versus stable GFR after therapy), and decreased inflammatory activity and IgA deposition on repeat renal biopsy. The benefit of IVIG needs to be confirmed in a larger number of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1783026\">",
"    <span class=\"h2\">",
"     Budesonide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glucocorticoid",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    (8",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for six months) was administered to 16 patients with IgA nephropathy (median proteinuria 1.5 grams per day) using a specialized enteric formulation that releases the drug in the ileocecal region where Peyer's patches are located [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/144\">",
"     144",
"    </a>",
"    ]. At six months, proteinuria significantly decreased by 23 percent, and serum creatinine significantly decreased by 6 percent. However, 8",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of budesonide is roughly equivalent to 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and it is therefore unclear that the effects were attributable to the specialized enteric formulation rather than systemic absorption of the glucocorticoid. In addition, the study was not randomized, and long-term outcomes were not assessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is generally well tolerated in patients with IgA nephropathy and a normal or near normal glomerular filtration rate (GFR). As with most other chronic kidney diseases, the risk of worsening renal disease with pregnancy is increased in women with an initial GFR below 70",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    uncontrolled hypertension, or severe arteriolar and tubulointerstitial disease on renal biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/7/42106/abstract/145,146\">",
"     145,146",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11241?source=see_link\">",
"     \"Pregnancy in women with underlying renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Angiotensin inhibitors and some immunosuppressive drugs (particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil) should be discontinued at the earliest indication of pregnancy or prior to attempted conception because of risks to the fetus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     END-STAGE RENAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who progress to end-stage renal disease can be treated with dialysis or transplantation. Issues related to recurrent disease in the transplant are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39367?source=see_link\">",
"     \"IgA nephropathy: Recurrence after transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/62/12257?source=see_link\">",
"       \"Patient information: IgA nephropathy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12140441\">",
"    <span class=\"h2\">",
"     Background",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgA nephropathy is the most common cause of primary (idiopathic) glomerulonephritis in the developed world. Slow progression to end-stage renal disease occurs in up to 50 percent of affected patients, often over 20 to 25 years of observation. The remaining patients enter a sustained clinical remission or have persistent low grade hematuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      proteinuria. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical predictors of progression of IgA nephropathy include elevated serum creatinine, hypertension, and persistent protein excretion above 1000",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      Patients who have recurrent episodes of gross hematuria without proteinuria are at low risk for progressive kidney disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical predictors of progression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Histologic findings on renal biopsy in patients with IgA nephropathy have been associated with an increased risk of progressive disease. These include both markers of more severe inflammatory disease, such as crescent formation, and immune deposits in the capillary loops in addition to the mesangial deposits that are present in all patients, and markers of chronic fibrotic disease such as glomerulosclerosis, tubular atrophy, interstitial fibrosis, and vascular disease. The Oxford classification is a pathologic classification that identified several variables that correlated with adverse renal outcomes independent of the clinical features, including endocapillary proliferation. It has been validated in numerous cohorts. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Histologic predictors of progression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute kidney injury can occur in patients during episodes of gross hematuria. This is usually due to acute tubular necrosis, and the serum creatinine concentration typically returns to baseline levels within several weeks. However, acute kidney injury can also represent transformation to crescentic disease, which requires immediate therapy. Among patients with IgA nephropathy who have an acute deterioration of renal function that does not improve within a maximum of a week's observation, we suggest a repeat renal biopsy to exclude crescentic disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Acute renal failure with gross hematuria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19826620\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are two major approaches to the therapy of IgA nephropathy (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Approach to therapy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nonimmunosuppressive therapies to slow progression, including blood pressure control and, in patients with proteinuria, angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), and fish oil. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Nonimmunosuppressive therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunosuppressive therapy with glucocorticoids, with or without other immunosuppressive agents, to treat the underlying inflammatory disease. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Immunosuppressive therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with isolated hematuria, no or minimal proteinuria (less than 500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      and a normal glomerular filtration rate (GFR) are typically not treated and often not biopsied and therefore not identified as having IgA nephropathy. However, these patients should be periodically monitored at 6 to 12 month intervals since there is an appreciable rate of progressive disease as manifested by increases in proteinuria, blood pressure,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      serum creatinine. (See",
"      <a class=\"local\" href=\"#H450429\">",
"       'Hematuria without proteinuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with persistent proteinuria (above 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      or perhaps above 500",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      a normal or only slightly reduced GFR that is not declining rapidly, and only mild to moderate histologic findings on renal biopsy are",
"      <strong>",
"       initially",
"      </strong>",
"      managed with nonimmunosuppressive therapies to slow progression. The sequence of nonimmunosuppressive therapy is as follows (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Nonimmunosuppressive therapies'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Angiotensin inhibition with either an ACE inhibitor or ARB. The goals of therapy with an ACE inhibitor or ARB are a urinary protein excretion below 500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      and a blood pressure less than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Angiotensin inhibition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Proteinuria and blood pressure goals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fish oil (3.3",
"      <span class=\"nowrap\">",
"       grams/day",
"      </span>",
"      or more) can be tried in patients with protein excretion above 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      despite three to six months of therapy with an ACE inhibitor or ARB. Fish oil may have cardiovascular benefits and is unlikely to be harmful. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Fish oil'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest antiinflammatory therapy with glucocorticoids in patients with clinical features supporting active disease and progression, which include hematuria in addition to one or more of the following (see",
"      <a class=\"local\" href=\"#H284610036\">",
"       'Indications for glucocorticoid therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Glucocorticoids as sole immunosuppressive/antiinflammatory therapy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An increasing serum creatinine",
"     </li>",
"     <li>",
"      Persistent proteinuria above 1.0 to 1.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      after maximal antiproteinuric nonimmunosuppressive therapies",
"     </li>",
"     <li>",
"      Morphologic evidence of active disease based upon kidney biopsy (eg, proliferative or necrotizing glomerular changes)",
"     </li>",
"     <li>",
"      However, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      treating with glucocorticoids in patients with a chronically elevated serum creatinine or morphologic evidence of prominent glomerulosclerosis and tubulointerstitial atrophy or fibrosis. (See",
"      <a class=\"local\" href=\"#H888782229\">",
"       'Lack of benefit in chronic fibrotic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Either of the following two regimens is acceptable in patients with IgA nephropathy who are selected for glucocorticoid therapy (see",
"      <a class=\"local\" href=\"#H1392575\">",
"       'Glucocorticoid regimen'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , 1.0 g, for three consecutive days at the beginning of months one, three, and five, combined with 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      given on alternate days for six months.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      , 0.8 to 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, for two months followed by monthly dose reductions of 0.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day during the next four months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combined immunosuppressive therapy can be considered in patients with more severe disease as defined by a more rapidly progressive clinical course",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      histologic evidence of severe active inflammation (eg, crescent formation). Various combinations of immunosuppressive drugs have been used in such patients. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Combined immunosuppressive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a subset of patients with IgA nephropathy who present with acute onset of the nephrotic syndrome, little or no hematuria, preserved kidney function, minimal glomerular changes on light microscopy, and diffuse fusion of the foot processes of the glomerular epithelial cells on electron microscopy. These histologic findings are characteristic of minimal change disease. Such patients with acute onset of nephrotic syndrome and diffuse foot process fusion on renal biopsy are treated as if they have minimal change disease. (See",
"      <a class=\"local\" href=\"#H83037486\">",
"       'Acute onset of nephrotic syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=see_link\">",
"       \"Treatment of minimal change disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are no specific markers to identify continued immunologic activity in IgA nephropathy. As a result, clinical parameters are typically used, whether or not the patient is receiving immunosuppressive therapy. The major parameters that are serially monitored are the serum creatinine concentration or estimated glomerular filtration rate, and protein excretion. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Monitoring disease activity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/1\">",
"      KDIGO. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 2:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/2\">",
"      D'Amico G. Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membranoproliferative glomerulonephritis: survey of the recent literature. Am J Kidney Dis 1992; 20:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/3\">",
"      Alamartine E, Sabatier JC, Guerin C, et al. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis 1991; 18:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/4\">",
"      Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002; 347:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/5\">",
"      Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int 2004; 66:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/6\">",
"      Geddes CC, Rauta V, Gronhagen-Riska C, et al. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant 2003; 18:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/7\">",
"      Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001; 110:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/8\">",
"      D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 2000; 36:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/9\">",
"      Berthoux F, Mohey H, Laurent B, et al. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 2011; 22:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/10\">",
"      Wakai K, Kawamura T, Endoh M, et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant 2006; 21:2800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/11\">",
"      Rekola S, Bergstrand A, Bucht H. Deterioration of GFR in IgA nephropathy as measured by 51Cr-EDTA clearance. Kidney Int 1991; 40:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/12\">",
"      Johnston PA, Brown JS, Braumholtz DA, Davison AM. Clinico-pathological correlations and long-term follow-up of 253 United Kingdom patients with IgA nephropathy. A report from the MRC Glomerulonephritis Registry. Q J Med 1992; 84:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/13\">",
"      Chacko B, John GT, Neelakantan N, et al. Presentation, prognosis and outcome of IgA nephropathy in Indian adults. Nephrology (Carlton) 2005; 10:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/14\">",
"      Alamartine E, Sabatier JC, Berthoux FC. Comparison of pathological lesions on repeated renal biopsies in 73 patients with primary IgA glomerulonephritis: value of quantitative scoring and approach to final prognosis. Clin Nephrol 1990; 34:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/15\">",
"      Hotta O, Furuta T, Chiba S, et al. Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis 2002; 39:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/16\">",
"      Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J Nephrol 2005; 18:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/17\">",
"      Nozawa R, Suzuki J, Takahashi A, et al. Clinicopathological features and the prognosis of IgA nephropathy in Japanese children on long-term observation. Clin Nephrol 2005; 64:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/18\">",
"      Lau KK, Gaber LW, Delos Santos NM, et al. Pediatric IgA nephropathy: clinical features at presentation and outcome for African-Americans and Caucasians. Clin Nephrol 2004; 62:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/19\">",
"      Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis 2001; 38:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/20\">",
"      Hall CL, Bradley R, Kerr A, et al. Clinical value of renal biopsy in patients with asymptomatic microscopic hematuria with and without low-grade proteinuria. Clin Nephrol 2004; 62:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/21\">",
"      Ikee R, Kobayashi S, Saigusa T, et al. Impact of hypertension and hypertension-related vascular lesions in IgA nephropathy. Hypertens Res 2006; 29:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/22\">",
"      Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant 2002; 17:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/23\">",
"      Reich HN, Troyanov S, Scholey JW, et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007; 18:3177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/24\">",
"      Izzi C, Ravani P, Torres D, et al. IgA nephropathy: the presence of familial disease does not confer an increased risk for progression. Am J Kidney Dis 2006; 47:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/25\">",
"      Frisch G, Lin J, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 2005; 20:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/26\">",
"      Le W, Liang S, Hu Y, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant 2012; 27:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/27\">",
"      Maixnerova D, Bauerova L, Skibova J, et al. The retrospective analysis of 343 Czech patients with IgA nephropathy--one centre experience. Nephrol Dial Transplant 2012; 27:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/28\">",
"      Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 1997; 29:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/29\">",
"      Vivante A, Afek A, Frenkel-Nir Y, et al. Persistent asymptomatic isolated microscopic hematuria in Israeli adolescents and young adults and risk for end-stage renal disease. JAMA 2011; 306:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/30\">",
"      Ibels LS, Gy&ouml;ry AZ. IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine (Baltimore) 1994; 73:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/31\">",
"      Bennett WM, Kincaid-Smith P. Macroscopic hematuria in mesangial IgA nephropathy: correlation with glomerular crescents and renal dysfunction. Kidney Int 1983; 23:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/32\">",
"      Packham DK, Hewitson TD, Yan HD, et al. Acute renal failure in IgA nephropathy. Clin Nephrol 1994; 42:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/33\">",
"      Praga M, Gutierrez-Millet V, Navas JJ, et al. Acute worsening of renal function during episodes of macroscopic hematuria in IgA nephropathy. Kidney Int 1985; 28:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/34\">",
"      Fogazzi GB, Imbasciati E, Moroni G, et al. Reversible acute renal failure from gross haematuria due to glomerulonephritis: not only in IgA nephropathy and not associated with intratubular obstruction. Nephrol Dial Transplant 1995; 10:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/35\">",
"      Guti&eacute;rrez E, Gonz&aacute;lez E, Hern&aacute;ndez E, et al. Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy. Clin J Am Soc Nephrol 2007; 2:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/36\">",
"      Harden PN, Geddes C, Rowe PA, et al. Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 1995; 345:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/37\">",
"      Yoshida H, Mitarai T, Kawamura T, et al. Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995; 96:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/38\">",
"      Hunley TE, Julian BA, Phillips JA 3rd, et al. Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 1996; 49:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/39\">",
"      Suzuki S, Suzuki Y, Kobayashi Y, et al. Insertion/deletion polymorphism in ACE gene is not associated with renal progression in Japanese patients with IgA nephropathy. Am J Kidney Dis 2000; 35:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/40\">",
"      Schena FP, D'Altri C, Cerullo G, et al. ACE gene polymorphism and IgA nephropathy: an ethnically homogeneous study and a meta-analysis. Kidney Int 2001; 60:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/41\">",
"      Frimat L, Philippe C, Maghakian MN, et al. Polymorphism of angiotensin converting enzyme, angiotensinogen, and angiotensin II type 1 receptor genes and end-stage renal failure in IgA nephropathy: IGARAS--a study of 274 Men. J Am Soc Nephrol 2000; 11:2062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/42\">",
"      Pei Y, Scholey J, Thai K, et al. Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. J Clin Invest 1997; 100:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/43\">",
"      Xia YF, Huang S, Li X, et al. A family-based association study of megsin A23167G polymorphism with susceptibility and progression of IgA nephropathy in a Chinese population. Clin Nephrol 2006; 65:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/44\">",
"      Schena FP, Cerullo G, Rossini M, et al. Increased risk of end-stage renal disease in familial IgA nephropathy. J Am Soc Nephrol 2002; 13:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/45\">",
"      Bonnet F, Deprele C, Sassolas A, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001; 37:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/46\">",
"      Syrj&auml;nen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000; 15:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/47\">",
"      Yamamoto R, Nagasawa Y, Shoji T, et al. Cigarette smoking and progression of IgA nephropathy. Am J Kidney Dis 2010; 56:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/48\">",
"      Daniel L, Saingra Y, Giorgi R, et al. Tubular lesions determine prognosis of IgA nephropathy. Am J Kidney Dis 2000; 35:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/49\">",
"      Lai FM, Szeto CC, Choi PC, et al. Primary IgA nephropathy with low histologic grade and disease progression: is there a \"point of no return\"? Am J Kidney Dis 2002; 39:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/50\">",
"      Weber CL, Rose CL, Magil AB. Focal segmental glomerulosclerosis in mild IgA nephropathy: a clinical-pathologic study. Nephrol Dial Transplant 2009; 24:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/51\">",
"      Lee HS, Lee MS, Lee SM, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee's glomerular grading system. Nephrol Dial Transplant 2005; 20:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/52\">",
"      Manno C, Strippoli GF, D'Altri C, et al. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis 2007; 49:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/53\">",
"      Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/54\">",
"      Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS, Cook HT, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/55\">",
"      El Karoui K, Hill GS, Karras A, et al. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies. Kidney Int 2011; 79:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/56\">",
"      Herzenberg AM, Fogo AB, Reich HN, et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int 2011; 80:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/57\">",
"      Shi SF, Wang SX, Jiang L, et al. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the oxford classification. Clin J Am Soc Nephrol 2011; 6:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/58\">",
"      Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Coppo R, Troyanov S, et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int 2010; 77:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/59\">",
"      Edstr&ouml;m Halling S, S&ouml;derberg MP, Berg UB. Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification). Nephrol Dial Transplant 2012; 27:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/60\">",
"      Berthoux F, Suzuki H, Thibaudin L, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 2012; 23:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/61\">",
"      Barratt J, Feehally J. Treatment of IgA nephropathy. Kidney Int 2006; 69:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/62\">",
"      Appel GB, Waldman M. The IgA nephropathy treatment dilemma. Kidney Int 2006; 69:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/63\">",
"      Reid S, Cawthon PM, Craig JC, et al. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev 2011; :CD003962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/64\">",
"      Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/65\">",
"      Maschio G, Cagnoli L, Claroni F, et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant 1994; 9:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/66\">",
"      Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/67\">",
"      Remuzzi A, Perticucci E, Ruggenenti P, et al. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 1991; 39:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/68\">",
"      Kanno Y, Okada H, Saruta T, Suzuki H. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up. Clin Nephrol 2000; 54:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/69\">",
"      Praga M, Guti&eacute;rrez E, Gonz&aacute;lez E, et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/70\">",
"      Li PK, Leung CB, Chow KM, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006; 47:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/71\">",
"      Coppo R, Peruzzi L, Amore A, et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007; 18:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/72\">",
"      Cattran DC. Is proteinuria reduction by angiotensin-converting enzyme inhibition enough to prove its role in renal protection in IgA nephropathy? J Am Soc Nephrol 2007; 18:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/73\">",
"      Cattran DC, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994; 23:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/74\">",
"      Kanno Y, Okada H, Yamaji Y, et al. Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation. QJM 2005; 98:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/75\">",
"      Li PK, Kwan BC, Chow KM, et al. Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor. Am J Med 2013; 126:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/76\">",
"      Russo D, Pisani A, Balletta MM, et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/77\">",
"      Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001; 38:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/78\">",
"      Catapano F, Chiodini P, De Nicola L, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008; 52:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/79\">",
"      Retraction--Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2009; 374:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/80\">",
"      ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/81\">",
"      Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/82\">",
"      Tobe SW, Clase CM, Gao P, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011; 123:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/83\">",
"      Donadio JV, Grande JP. The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy. Semin Nephrol 2004; 24:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/84\">",
"      Donadio JV Jr, Bergstralh EJ, Offord KP, et al. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 1994; 331:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/85\">",
"      Alexopoulos E, Stangou M, Pantzaki A, et al. Treatment of severe IgA nephropathy with omega-3 fatty acids: the effect of a \"very low dose\" regimen. Ren Fail 2004; 26:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/86\">",
"      Donadio JV Jr, Larson TS, Bergstralh EJ, Grande JP. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol 2001; 12:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/87\">",
"      Donadio JV Jr, Grande JP, Bergstralh EJ, et al. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol 1999; 10:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/88\">",
"      Bennett WM, Walker RG, Kincaid-Smith P. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trial. Clin Nephrol 1989; 31:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/89\">",
"      Pettersson EE, Rekola S, Berglund L, et al. Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study. Clin Nephrol 1994; 41:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/90\">",
"      Hogg RJ, Lee J, Nardelli N, et al. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 2006; 1:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/91\">",
"      Ferraro PM, Ferraccioli GF, Gambaro G, et al. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. Nephrol Dial Transplant 2009; 24:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/92\">",
"      Alexopoulos E. Treatment of primary IgA nephropathy. Kidney Int 2004; 65:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/93\">",
"      Strippoli GF, Manno C, Schena FP. An \"evidence-based\" survey of therapeutic options for IgA nephropathy: assessment and criticism. Am J Kidney Dis 2003; 41:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/94\">",
"      Laville M, Alamartine E. Treatment options for IgA nephropathy in adults: a proposal for evidence-based strategy. Nephrol Dial Transplant 2004; 19:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/95\">",
"      Ballardie FW. IgA nephropathy treatment 25 years on: can we halt progression? The evidence base. Nephrol Dial Transplant 2004; 19:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/96\">",
"      Floege J, Eitner F. Present and future therapy options in IgA-nephropathy. J Nephrol 2005; 18:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/97\">",
"      Locatelli F, Del Vecchio L, Pozzi C. The patient with IgA glomerulonephritis--what is the role of steroid treatment? Nephrol Dial Transplant 1999; 14:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/98\">",
"      Lv J, Xu D, Perkovic V, et al. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol 2012; 23:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/99\">",
"      Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999; 353:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/100\">",
"      Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/101\">",
"      Manno C, Torres DD, Rossini M, et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 2009; 24:3694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/102\">",
"      Lai KN, Lai FM, Ho CP, Chan KW. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 1986; 26:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/103\">",
"      Mustonen J, Pasternack A, Rantala I. The nephrotic syndrome in IgA glomerulonephritis: response to corticosteroid therapy. Clin Nephrol 1983; 20:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/104\">",
"      Cheng IK, Chan KW, Chan MK. Mesangial IgA nephropathy with steroid-responsive nephrotic syndrome: disappearance of mesangial IgA deposits following steroid-induced remission. Am J Kidney Dis 1989; 14:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/105\">",
"      Woo KT, Lee GS, Lau YK, et al. Effects of triple therapy in IgA nephritis: a follow-up study 5 years later. Clin Nephrol 1991; 36:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/106\">",
"      Walker RG, Yu SH, Owen JE, Kincaid-Smith P. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial. Clin Nephrol 1990; 34:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/107\">",
"      Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/108\">",
"      Yoshikawa N, Ito H, Sakai T, et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol 1999; 10:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/109\">",
"      Yoshikawa N, Honda M, Iijima K, et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol 2006; 1:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/110\">",
"      Pozzi C, Andrulli S, Pani A, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 2010; 21:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/111\">",
"      Floege J, Eitner F. Combined immunosuppression in high-risk patients with IgA nephropathy? J Am Soc Nephrol 2010; 21:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/112\">",
"      Kamei K, Nakanishi K, Ito S, et al. Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol 2011; 6:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/113\">",
"      Welch TR, McAdams AJ, Berry A. Rapidly progressive IgA nephropathy. Am J Dis Child 1988; 142:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/114\">",
"      Lai KN, Lai FM, Leung AC, et al. Plasma exchange in patients with rapidly progressive idiopathic IgA nephropathy: a report of two cases and review of literature. Am J Kidney Dis 1987; 10:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/115\">",
"      Roccatello D, Ferro M, Coppo R, et al. Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy. Nephrol Dial Transplant 1995; 10:2054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/116\">",
"      McIntyre CW, Fluck RJ, Lambie SH. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment. Clin Nephrol 2001; 56:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/117\">",
"      Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant 2003; 18:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/118\">",
"      Galla JH. IgA nephropathy. Kidney Int 1995; 47:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/119\">",
"      Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004; 65:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/120\">",
"      Chen X, Chen P, Cai G, et al. [A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy]. Zhonghua Yi Xue Za Zhi 2002; 82:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/121\">",
"      Tang SC, Tang AW, Wong SS, et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 2010; 77:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/122\">",
"      Dal Canton A, Amore A, Barbano G, et al. One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomised, controlled study. J Nephrol 2005; 18:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/123\">",
"      Lai KN, Lai FM, Li PK, Vallance-Owen J. Cyclosporin treatment of IgA nephropathy: a short term controlled trial. Br Med J (Clin Res Ed) 1987; 295:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/124\">",
"      Cattran DC. Current status of cyclosporin A in the treatment of membranous, IgA and membranoproliferative glomerulonephritis. Clin Nephrol 1991; 35 Suppl 1:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/125\">",
"      Shin JI, Park JM, Shin YH, et al. Cyclosporin A therapy for severe Henoch-Sch&ouml;nlein nephritis with nephrotic syndrome. Pediatr Nephrol 2005; 20:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/126\">",
"      Park JM, Won SC, Shin JI, et al. Cyclosporin A therapy for Henoch-Sch&ouml;nlein nephritis with nephrotic-range proteinuria. Pediatr Nephrol 2011; 26:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/127\">",
"      Szeto CC, Chow KM, Kwan BC, et al. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Am J Kidney Dis 2008; 51:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/128\">",
"      Fishbane S, Chittineni H, Packman M, et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009; 54:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/129\">",
"      Liu LJ, Lv JC, Shi SF, et al. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 2012; 59:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/130\">",
"      Tomino Y, Sakai H, Hanzawa S, et al. Clinical effect of danazol in patients with IgA nephropathy. Jpn J Med 1987; 26:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/131\">",
"      B&eacute;n&eacute; MC, Faure GC, Hurault de Ligny B, de March AK. Clinical involvement of the tonsillar immune system in IgA nephropathy. Acta Otolaryngol Suppl 2004; :10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/132\">",
"      Xie Y, Chen X, Nishi S, et al. Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney Int 2004; 65:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/133\">",
"      Hotta O, Miyazaki M, Furuta T, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis 2001; 38:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/134\">",
"      Xie Y, Nishi S, Ueno M, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 2003; 63:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/135\">",
"      Akagi H, Kosaka M, Hattori K, et al. Long-term results of tonsillectomy as a treatment for IgA nephropathy. Acta Otolaryngol Suppl 2004; :38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/136\">",
"      Komatsu H, Fujimoto S, Hara S, et al. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol 2008; 3:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/137\">",
"      Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol 1999; 51:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/138\">",
"      Rasche FM, Sailer LC, Czock D, Keller F. Tonsillectomy, high dose immunoglobulins, and cyclophosphamide in progressive IgA-nephropathy. Acta Otolaryngol Suppl 2004; :32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/139\">",
"      Wang Y, Chen J, Wang Y, et al. A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy. Nephrol Dial Transplant 2011; 26:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/140\">",
"      Ferri C, Puccini R, Longombardo G, et al. Low-antigen-content diet in the treatment of patients with IgA nephropathy. Nephrol Dial Transplant 1993; 8:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/141\">",
"      Coppo R, Roccatello D, Amore A, et al. Effects of a gluten-free diet in primary IgA nephropathy. Clin Nephrol 1990; 33:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/142\">",
"      Rostoker G, Pech MA, Del Prato S, et al. Serum IgG subclasses and IgM imbalances in adult IgA mesangial glomerulonephritis and idiopathic Henoch-Schoenlein purpura. Clin Exp Immunol 1989; 75:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/143\">",
"      Rostoker G, Desvaux-Belghiti D, Pilatte Y, et al. High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Sch&ouml;nlein purpura. Ann Intern Med 1994; 120:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/144\">",
"      Smerud HK, B&aacute;r&aacute;ny P, Lindstr&ouml;m K, et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant 2011; 26:3237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/145\">",
"      Abe S. Pregnancy in IgA nephropathy. Kidney Int 1991; 40:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/7/42106/abstract/146\">",
"      Abe S. The influence of pregnancy on the long-term renal prognosis of IgA nephropathy. Clin Nephrol 1994; 41:61.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3039 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_7_42106=[""].join("\n");
var outline_f41_7_42106=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RENAL PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical predictors of progression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H453254\">",
"      - Reduced GFR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H452224\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H449899\">",
"      - Protein excretion above 1 g/day",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H83037486\">",
"      Acute onset of nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H450429\">",
"      - Hematuria without proteinuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Acute renal failure with gross hematuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H450116\">",
"      - Genetic associations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H450123\">",
"      - Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Histologic predictors of progression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13649389\">",
"      - Oxford classification of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11169826\">",
"      Absolute renal risk score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1205404\">",
"      Serologic predictors of progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      APPROACH TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Monitoring disease activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      NONIMMUNOSUPPRESSIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Angiotensin inhibition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H94111424\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Combination of ACE inhibitor and ARB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Proteinuria and blood pressure goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H888784663\">",
"      Lipid-lowering therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Fish oil",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      IMMUNOSUPPRESSIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H284610036\">",
"      Indications for glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H888782229\">",
"      - Lack of benefit in chronic fibrotic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Glucocorticoids as sole immunosuppressive/antiinflammatory therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1392575\">",
"      - Glucocorticoid regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1392606\">",
"      - Patients with apparent minimal change disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Combined immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Severe or progressive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1363959\">",
"      Glucocorticoids plus cyclophosphamide followed by azathioprine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1363966\">",
"      Glucocorticoids plus azathioprine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H436408486\">",
"      Severe disease in children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Crescentic glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Unclear role for other immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H436409221\">",
"      - Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      OTHER POSSIBLE INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Tonsillectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Low antigen diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1783026\">",
"      Budesonide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      END-STAGE RENAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12140441\">",
"      Background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19826620\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3039\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3039|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/47/32510\" title=\"figure 1\">",
"      Magnitude of proteinuria on renal survival in IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/15/36093\" title=\"figure 2\">",
"      Reduction of proteinuria on renal survival in IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/43/35517\" title=\"figure 3\">",
"      Renal survival in patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3039|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/6/20584\" title=\"picture 1\">",
"      Electron microscopy in minimal change disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1337?source=related_link\">",
"      Clinical presentation and diagnosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36330?source=related_link\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39367?source=related_link\">",
"      IgA nephropathy: Recurrence after transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18231?source=related_link\">",
"      Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/48/20233?source=related_link\">",
"      Pathogenesis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/62/12257?source=related_link\">",
"      Patient information: IgA nephropathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11241?source=related_link\">",
"      Pregnancy in women with underlying renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis?source=related_link\">",
"      Renal manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30824?source=related_link\">",
"      Statins and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=related_link\">",
"      Treatment of idiopathic membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=related_link\">",
"      Treatment of minimal change disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=related_link\">",
"      Treatment of primary focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_7_42107="Enteric pathogens";
var content_f41_7_42107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Enteric pathogens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Pathogen",
"      </td>",
"      <td class=\"subtitle1\">",
"       Small bowel",
"      </td>",
"      <td class=\"subtitle1\">",
"       Colon",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bacteria",
"      </td>",
"      <td>",
"       <p>",
"        Salmonella*",
"       </p>",
"       <p>",
"        Escherichia coli&bull;",
"       </p>",
"       <p>",
"        Clostridium perfringens",
"       </p>",
"       <p>",
"        Staphylococcus aureus",
"       </p>",
"       <p>",
"        Aeromonas hydrophila",
"       </p>",
"       <p>",
"        Bacillus cereus",
"       </p>",
"       <p>",
"        Vibrio cholerae",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Campylobacter*",
"       </p>",
"       <p>",
"        Shigella",
"       </p>",
"       <p>",
"        Clostridium difficile",
"       </p>",
"       <p>",
"        Yersinia",
"       </p>",
"       <p>",
"        Vibrio parahaemolyticus",
"       </p>",
"       <p>",
"        Enteroinvasive E. coli",
"       </p>",
"       <p>",
"        Plesiomonas shigelloides",
"       </p>",
"       <p>",
"        Klebsiella oxytoca(rare)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Virus",
"      </td>",
"      <td>",
"       <p>",
"        Rotovirus",
"       </p>",
"       <p>",
"        Norovirus",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Cytomegalovirus*",
"       </p>",
"       <p>",
"        Adenovirus",
"       </p>",
"       <p>",
"        Herpes simplex virus",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Protozoa",
"      </td>",
"      <td>",
"       <p>",
"        Cryptosporidium*",
"       </p>",
"       <p>",
"        Microsporidium*",
"       </p>",
"       <p>",
"        Isospora",
"       </p>",
"       <p>",
"        Cyclospora",
"       </p>",
"       <p>",
"        Giardia lamblia",
"       </p>",
"      </td>",
"      <td>",
"       Entamoeba histolytica",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Can involve both the small and large bowel, but are most likely to occur as listed.",
"     <br>",
"      &bull; EPEC, EAggEC, EHEC, ETEC may all contribute; routine laboratories and cultures will not differentiate these from E. coli which are normal flora.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_7_42107=[""].join("\n");
var outline_f41_7_42107=null;
var title_f41_7_42108="Warfarin drug interactions";
var content_f41_7_42108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medications that interfere with the effect of warfarin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Increased warfarin effect",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acetaminophen",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Allopurinol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Anabolic steroids",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Aspirin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Amiodarone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Capecitabine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cephalosporins",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cimetidine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ciprofloxacin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Clofibrate",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Clopidogrel",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diclofenac",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Disulfiram",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Erythromycin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fluconazole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fluorouracil (5-FU)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Selective serotonin reuptake inhibitors (eg, Fluoxetine)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Glucagon",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Influenza virus vaccine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Metronidazole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Macrolide antibiotics",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Omeprazole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulfamethoxazole/trimethoprim",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tamoxifen",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Thyroid hormone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tolbutamide",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Decreased warfarin effect",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Azathioprine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Antithyroid drugs",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Carbamazepine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Dicloxacillin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Glutethimide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Griseofulvin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Haloperidol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Nafcillin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Oral contraceptives",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Phenobarbital",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Rifampin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Vitamin K",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     This is only a",
"     <strong>",
"      partial list",
"     </strong>",
"     . Please refer to the warfarin drug information topic for additional drug interactions. Some drugs may have multiple, opposing effects on warfarin; in such cases, the drug may increase or decrease the effect of warfarin, depending on which aspect of the drug interaction is dominant in that particular patient.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_7_42108=[""].join("\n");
var outline_f41_7_42108=null;
var title_f41_7_42109="PMN granule contents";
var content_f41_7_42109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Content of human neutrophil granules",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Granule",
"       </td>",
"       <td class=\"subtitle1\">",
"        Azurophil",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gelatinase",
"       </td>",
"       <td class=\"subtitle1\">",
"        Secretory vesicles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left topBorder_single\">",
"        Marker enzyme",
"       </td>",
"       <td>",
"        Myeloperoxidase",
"       </td>",
"       <td>",
"        Lactoferrin",
"       </td>",
"       <td>",
"        Gelantinase",
"       </td>",
"       <td>",
"        Alkaline phosphatase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left topBorder_single\" colspan=\"1\" rowspan=\"2\">",
"        Membrane",
"       </td>",
"       <td class=\"topBorder_single\">",
"        CD 63 granulophysin",
"       </td>",
"       <td class=\"topBorder_single\">",
"        CD15,CD66,CD67",
"       </td>",
"       <td class=\"topBorder_single\">",
"        CD11b/CD18",
"       </td>",
"       <td class=\"topBorder_single\">",
"        CD10,CD13,CD45,&nbsp;CD35 (CR1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD 68",
"       </td>",
"       <td>",
"        CD11b/CD18",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        CD11b/CD18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"1\" rowspan=\"9\">",
"        Oxidase receptors (R)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"9\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td>",
"        Cytochrome b",
"       </td>",
"       <td>",
"        Cytochrome b&nbsp;",
"       </td>",
"       <td>",
"        Cytochrome b&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rap1A",
"       </td>",
"       <td>",
"        Rap1A",
"       </td>",
"       <td>",
"        Rap1A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FMLP R",
"       </td>",
"       <td>",
"        FMLP R",
"       </td>",
"       <td>",
"        FMLP R",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C3bi R",
"       </td>",
"       <td>",
"        C3bi R",
"       </td>",
"       <td>",
"        CR 1R",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibronectin R",
"       </td>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        C3bi R(CR 3R)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laminin R",
"       </td>",
"       <td>",
"        CR 4R",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitronectin R",
"       </td>",
"       <td>",
"        C1q R",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        FcGammaIII R",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasminogen activator R",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"1\" rowspan=\"2\">",
"        Signal transduction",
"       </td>",
"       <td>",
"        Thrombospondin R",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Diacylglycerol deacylating enzyme",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Decay accelerating factor",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gi2 protein subunit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"1\" rowspan=\"2\">",
"        Others",
"       </td>",
"       <td>",
"        NB antigen",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9 kd and 155 kd&nbsp;proteins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\" rowspan=\"1\">",
"        Matrix",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"1\" rowspan=\"11\">",
"        Microbicidal",
"       </td>",
"       <td class=\"topBorder_single\">",
"        Myeloperoxidase",
"       </td>",
"       <td class=\"topBorder_single\">",
"        Lactoferrin",
"       </td>",
"       <td class=\"topBorder_single\">",
"        Lysozyme",
"       </td>",
"       <td class=\"topBorder_single\" colspan=\"1\" rowspan=\"11\">",
"        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitric oxide&nbsp;synthase",
"       </td>",
"       <td>",
"        Lysozyme",
"       </td>",
"       <td colspan=\"1\" rowspan=\"10\">",
"        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lysozyme",
"       </td>",
"       <td colspan=\"1\" rowspan=\"9\">",
"        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BPI protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Defensins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serprocidins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Elastase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cathepsin G",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Proteinase 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Azurocidin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (CAP 37)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"1\" rowspan=\"6\">",
"        Hydrolases",
"       </td>",
"       <td>",
"        Acid beta glycero-phosphatase alpha",
"       </td>",
"       <td>",
"        Gelatinase",
"       </td>",
"       <td>",
"        Gelatinase",
"       </td>",
"       <td colspan=\"1\" rowspan=\"6\">",
"        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mannosidase beta",
"       </td>",
"       <td>",
"        Collagenase",
"       </td>",
"       <td>",
"        Acetyltransferase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucuronidase beta",
"       </td>",
"       <td>",
"        Histaminase",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        &nbsp;",
"        <br/>",
"        &nbsp;&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glycerophosphatase",
"       </td>",
"       <td>",
"        Heparanase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N-acetyl-beta&nbsp;glucosaminidase",
"       </td>",
"       <td>",
"        NGAL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sialidase",
"       </td>",
"       <td>",
"        Sialidase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"1\" rowspan=\"3\">",
"        Other",
"       </td>",
"       <td>",
"        Acid mucopolysaccharide",
"       </td>",
"       <td>",
"        Beta-2 microglobulin",
"       </td>",
"       <td>",
"        Beta-2 microglobulin",
"       </td>",
"       <td>",
"        Plasma proteins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heparin binding protein",
"       </td>",
"       <td>",
"        Plasminogen activator",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Vitamin B12 binding protein",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Borregaard, N, Kledsen, L, Lollike, K, et al, Clin Exp Immunol 1995; 101:6.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_7_42109=[""].join("\n");
var outline_f41_7_42109=null;
var title_f41_7_42110="Metabolism of tryptophan";
var content_f41_7_42110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F77541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F77541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    Metabolism of tryptophan to melatonin in the pineal gland",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 487px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Zhdanova, IV, Wurtman, RJ. In: Endocrinology: Basic and Clinical Principles, PM, Conn, S, Melmed (Eds), Humana Press, Inc, Totowa, NJ, 1997. p. 281. Copyright &copy; 1997 Humana Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_7_42110=[""].join("\n");
var outline_f41_7_42110=null;
var title_f41_7_42111="Chilblain lupus";
var content_f41_7_42111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chilblain lupus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 192px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chilblain lupus characterized by reddish-blue nodules (in this case, on the fingers) occurring in cold weather. The lesions improved after the administration of nifedipine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Samuel Moschella, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_7_42111=[""].join("\n");
var outline_f41_7_42111=null;
